{"93137037ac3f5cbc25549ce22a87fa47bd7e25fc": [["IntroductionCoronavirus disease 2019 (COVID-19) has been regarded as a global threat, which has attracted much attention since 2019.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31]]], ["However, Italy, which located in Europe, is in a serious stage of epidemic spread.", [["epidemic spread", "PROBLEM", 66, 81], ["serious", "OBSERVATION_MODIFIER", 49, 56], ["epidemic", "OBSERVATION_MODIFIER", 66, 74], ["spread", "OBSERVATION_MODIFIER", 75, 81]]], ["Fundamentally, due to the long incubation period of the virus, the difficulty in identifying symptoms, negligence in the prevention and control of returnees, and the relatively low number of sick people, Italy and the whole of Europe have not been highly vigilant, which has brought an opportunity for the spread of the virus [1] .IntroductionVarious mathematical models are being used to conduct a variety of studies to analyze and predict the evolution of this epidemic.", [["people", "SPECIES", 196, 202], ["the virus", "PROBLEM", 52, 61], ["symptoms", "PROBLEM", 93, 101], ["this epidemic", "PROBLEM", 458, 471]]], ["Reference [2] based on the SEIR kinetic model, taking into account the propagation mechanism, infection rate, and isolation measures of COVID-19, established a SEIR +CAQ propagation kinetic model, which can be used to predict the trend of COVID-19 in China, and to provide epidemic prevention and help with decision making.", [["infection", "DISEASE", 94, 103], ["the SEIR kinetic model", "TREATMENT", 23, 45], ["infection rate", "PROBLEM", 94, 108], ["COVID", "TEST", 136, 141], ["a SEIR +CAQ propagation kinetic model", "TREATMENT", 158, 195], ["COVID", "TEST", 239, 244], ["epidemic prevention", "TREATMENT", 273, 292], ["infection", "OBSERVATION", 94, 103]]], ["Reference [3] used the least square method of SEIR partitioning and Poisson noise to estimate the basic reproduction number of COVID-19 in Japan as R0 = 2.6 (95% CI, 2.4-2.8).", [["SEIR partitioning", "TREATMENT", 46, 63], ["Poisson noise", "PROBLEM", 68, 81], ["COVID", "TEST", 127, 132], ["R0", "TEST", 148, 150], ["CI", "TEST", 162, 164]]], ["The experimental results show that the epidemic of COVID-19 in Japan will not end quickly, and it is ridiculous to think that COVID-19 will disappear in summer spontaneously.", [["COVID-19", "CHEMICAL", 51, 59], ["COVID", "TEST", 51, 56], ["COVID", "TEST", 126, 131]]], ["Therefore, it is necessary to propose a COVID-19 prediction model based on time series.", [["a COVID-19 prediction model", "TREATMENT", 38, 65]]], ["Reference [4] proposed the ARIMA model that is useful to predict the spread of COVID-19, and then continuously improved the model by updating the data set.", [["COVID", "TEST", 79, 84]]], ["The experimental results show that it has good consistency with the actual epidemic spread.IntroductionBased on the ARIMA model, we perform the simply model on the epidemic data from February 24 to March 30, 2020 in Italy and then predict the epidemiological trend of COVID-19 in the next 5 days.", [["COVID", "TEST", 268, 273]]], ["Table 1 records the source of the original data and the description of the data set.Data valueThe data are reliable and represent a true epidemic situationData descriptionThe data used in this paper are sourced from the statistics of the National Health Commission(http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml) and then compiled by the website (https://news.sina.cn/zt_d/yiqing0121 ).", [["Data value", "TEST", 84, 94], ["The data", "TEST", 94, 102]]], ["Here, the cumulative number of confirmed diagnoses, new diagnoses, deaths, and cures were counted in Italy for 36 days from February 24, 2020 to March 30, 2020.", [["deaths", "DISEASE", 67, 73]]], ["A time series database was established using Excel 2019 [5] .", [["A time series database", "TEST", 0, 22]]], ["We apply the ARIMA model to predict the cumulative number of diagnoses and the number of newly diagnosed patients [6] .MaterialsARIMA models include Autoregressive models (AR), Moving Average models (MA), Autoregressive Moving Average models (ARMA), and Autoregressive Integrated Moving Average model (ARIMA) [7] .MaterialsThe basic model expression of ARIMA (p, d, q) is:MaterialsThe Augmented Dickey-Fuller (ADF) unit-root test helps in estimating whether the time series is stationary [8] .", [["patients", "ORGANISM", 105, 113], ["Augmented Dickey-Fuller (ADF) unit", "DNA", 385, 419], ["patients", "SPECIES", 105, 113], ["the ARIMA model", "TREATMENT", 9, 24], ["MaterialsARIMA models", "TEST", 119, 140], ["Autoregressive models (AR)", "PROBLEM", 149, 175], ["ARIMA (p, d, q)", "PROBLEM", 353, 368], ["root test", "TEST", 420, 429]]], ["Log transformation and differences are the preferred approaches to stabilize the time series.", [["Log transformation", "PROBLEM", 0, 18]]], ["Wolds decomposition theorem and Cramers decomposition theorem construct the theoretical basis of ARIMA model fitting stationary sequences [6] .MaterialsParameters of the ARIMA model were estimated by autocorrelation function (ACF) graph and partial autocorrelation (PACF) correlogram.", [["the ARIMA model", "TEST", 166, 181]]], ["We use R to statistically analyze the fitted predictions of the cumulative number of confirmed and newly diagnosed COVID-19 in Italy, and the significance level is set at =0.05 \u03b1 [9] .", [["COVID", "TEST", 115, 120]]], ["Steps: (1) Establish the observed time series database;Materials(2) Check the stationarity of the observation data.", [["the observation data", "TEST", 94, 114]]], ["If the sequence is not stationary, perform a difference or logarithmic transformation until it becomes a stationary time series;Materials(3) Calculate the ACF and PACF of the stationary sequence, and use ARIMA model to identify preliminary values of the autoregressive order, p, the order of differencing, d, and the moving average order, q.Materials(4) Perform model tests, including the significance test of the model and the significance test of the parameters.", [["logarithmic transformation", "PROBLEM", 59, 85], ["the stationary sequence", "TEST", 171, 194], ["ARIMA model", "TEST", 204, 215], ["model tests", "TEST", 362, 373]]], ["(5) To predict the epidemic situation in the next 5 days.Parameters and testsThis paper counts the epidemic situation in Italy from February 24, 2020 to March 30, 2020, and the time span is 36 days.", [["tests", "TEST", 72, 77]]], ["We can clearly see that the sequence is non-stationary because it shows a clear upward trend.", [["a clear upward trend", "PROBLEM", 72, 92], ["clear", "OBSERVATION", 74, 79], ["upward", "OBSERVATION_MODIFIER", 80, 86]]], ["In view of ARIMA modeling requires a stationary sequence, it is necessary to perform a difference or logarithmic transformation on the sequence.Parameters and testsAlthough the second-order difference of the sequence shows stationarity.", [["a stationary sequence", "TEST", 35, 56], ["a difference or logarithmic transformation on the sequence", "PROBLEM", 85, 143], ["tests", "TEST", 159, 164], ["the sequence", "TEST", 204, 216], ["logarithmic transformation", "OBSERVATION", 101, 127]]], ["Overfitting leads to less-precise estimators, and adding more parameters may fit the data better but may also lead to bad forecasts.", [["Overfitting leads", "PROBLEM", 0, 17]]], ["So, in this paper we first perform a logarithmic transformation on the cumulative confirmed original sequence, and then performs a first-order difference based on the logarithmic sequence.", [["a logarithmic transformation", "PROBLEM", 35, 63], ["the logarithmic sequence", "TEST", 163, 187]]], ["The differential logarithmic sequence is shown in Figure 2 . .", [["The differential logarithmic sequence", "TEST", 0, 37]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20058636 doi: medRxiv preprint Figure 3 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["Correlogram for the cumulative logarithmic differential logarithmic(which was not peer-reviewed)The ARIMA (2,1,0) model was constructed to fit the logarithmic sequence of cumulative diagnoses, and the residual sequence after fitting was tested to be a white noise sequence, that is, the model was significant.", [["a white noise sequence", "TEST", 250, 272], ["significant", "OBSERVATION_MODIFIER", 297, 308]]], ["Logarithmic cumulative confirmed sequence prediction is shown in Figure 4 : It is known from Figure 4 : The logarithm of the cumulative number of confirmed diagnoses of COVID-2019 is in a gradual phase, that is, the growth rate of the cumulative number of confirmed diagnoses is slowing down.", [["COVID", "DISEASE", 169, 174], ["sequence prediction", "TEST", 33, 52], ["COVID", "TEST", 169, 174], ["slowing", "OBSERVATION_MODIFIER", 279, 286]]], ["This is a very important signal that Italy is now at a very critical point.(which was not peer-reviewed)The same method is used for the newly confirmed number of patients.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170]]], ["The original sequence and the differential log sequence are as follows: Figure 5 Original sequence of new confirmed diagnoses .", [["differential log sequence", "DNA", 30, 55], ["The original sequence", "TEST", 0, 21], ["the differential log sequence", "TEST", 26, 55]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20058636 doi: medRxiv preprint Figure 6 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["medRxiv preprint Figure", "TREATMENT", 274, 297], ["med", "ANATOMY", 99, 102]]], ["Differential logarithmic sequence of newly confirmed diagnoses(which was not peer-reviewed)The ACF and PACF diagrams of the differential logarithmic sequence of newly diagnosed people are as follows: Figure 8 shows that the difference between the number of diagnoses on the day and the number of diagnoses on the previous day is not a continuous growing process [12] .", [["ACF", "CANCER", 95, 98], ["people", "ORGANISM", 177, 183], ["ACF and PACF diagrams", "DNA", 95, 116], ["people", "SPECIES", 177, 183], ["The ACF and PACF diagrams", "TEST", 91, 116], ["a continuous growing process", "PROBLEM", 333, 361], ["ACF", "OBSERVATION", 95, 98], ["PACF diagrams", "OBSERVATION", 103, 116]]], ["The number of newly diagnosed patients has now reached a flat period, which indicates that the current prevention and control in Italy has been effective.(which was not peer-reviewed)Based on the ARIMA model established above, the cumulative number of confirmed diagnoses and the number of newly confirmed diagnoses in the next 5 days are predicted.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["newly", "OBSERVATION_MODIFIER", 14, 19]]], ["The 95% confidence interval data prediction is shown in Table 2 .(which was not peer-reviewed).", [["confidence interval data prediction", "TEST", 8, 43]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint .Conclusions and recommendationsR statistical software was used to construct a trend-fitting forecast based on the ARIMA model.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["From the perspective of statistical analysis, although we need more data to make more detailed predictions, in fact, the number of confirmed new coronaviruses in Italy is still increasing, and effective prevention and control measures are still needed.Conclusions and recommendationsThe growth rate of newly diagnosed patients in Italy has slowed down.", [["coronaviruses", "DISEASE", 145, 158], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 318, 326], ["statistical analysis", "TEST", 24, 44], ["new coronaviruses", "PROBLEM", 141, 158], ["control measures", "TREATMENT", 218, 234], ["new", "OBSERVATION_MODIFIER", 141, 144], ["coronaviruses", "OBSERVATION", 145, 158], ["increasing", "OBSERVATION_MODIFIER", 177, 187], ["growth", "OBSERVATION_MODIFIER", 287, 293]]], ["Before the turning point of the epidemic comes, we must not relax our vigilance and continue to carry out various government-prevented measures strictly, such as strengthening the work of regional isolation, doing effective personal protection, and organizing existing medical forces for rapid treatment.Conclusions and recommendationsAs for the government, the most important thing at present is to greatly reduce peoples contact and implement isolation policy.", [["regional isolation", "TREATMENT", 188, 206], ["rapid treatment", "TREATMENT", 288, 303]]], ["China has done very well in restrictive and preventive measures.", [["preventive measures", "TREATMENT", 44, 63], ["restrictive", "OBSERVATION", 28, 39]]], ["It is hoped that the \"City Closure\" decree issued by the Italian government will go in the right direction, because this is the only way to curb the spread of epidemic.", [["epidemic", "PROBLEM", 159, 167], ["right", "ANATOMY_MODIFIER", 91, 96]]]], "PMC7316645": [], "2d9440ba65195b7530e44f7a6b9fe824a5706d68": [["Correspondencewww.thelancet.com/microbe Vol 1 July 2020 e105CorrespondenceThe role of oral bacteria in COVID-19CorrespondenceWe read with interest the Corre spondence by Michael J Cox and colleagues, 1 highlighting the relevance of coinfections in the clinical outcomes and mortality of patients with coronavirus disease 2019 (COVID19).", [["oral", "ANATOMY", 86, 90], ["coinfections", "DISEASE", 232, 244], ["coronavirus disease", "DISEASE", 301, 320], ["oral", "ORGANISM_SUBDIVISION", 86, 90], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["oral bacteria", "PROBLEM", 86, 99], ["coinfections", "PROBLEM", 232, 244], ["coronavirus disease", "PROBLEM", 301, 320], ["coinfections", "OBSERVATION", 232, 244]]], ["We believe the role of oral bacteria in facilitating coinfections in COVID19 is pertinent, yet overlooked.", [["oral", "ANATOMY", 23, 27], ["coinfections", "DISEASE", 53, 65], ["COVID19", "CHEMICAL", 69, 76], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["COVID19", "GENE_OR_GENE_PRODUCT", 69, 76], ["oral bacteria", "PROBLEM", 23, 36], ["bacteria", "OBSERVATION", 28, 36], ["coinfections", "OBSERVATION", 53, 65]]], ["We concur with the need for wholegenome metagenomics to capture the data relevant to coinfections, but this should also warrant consideration for the bacterial species comprising the oral microbiome.CorrespondencePoor oral hygiene is considered to be a major ecological pressure that steers complex microbial communities in the mouth into dysbiosis.", [["oral microbiome", "ANATOMY", 183, 198], ["oral", "ANATOMY", 218, 222], ["communities", "ANATOMY", 309, 320], ["mouth", "ANATOMY", 328, 333], ["coinfections", "DISEASE", 85, 97], ["dysbiosis", "DISEASE", 339, 348], ["oral", "ORGANISM_SUBDIVISION", 183, 187], ["oral", "ORGANISM_SUBDIVISION", 218, 222], ["mouth", "ORGANISM_SUBDIVISION", 328, 333], ["wholegenome metagenomics", "TREATMENT", 28, 52], ["coinfections", "PROBLEM", 85, 97], ["the bacterial species", "PROBLEM", 146, 167], ["dysbiosis", "PROBLEM", 339, 348], ["mouth", "ANATOMY", 328, 333], ["dysbiosis", "OBSERVATION", 339, 348]]], ["Ecological shifts in a dysbiotic ecosystem favour an increased prevalence of pathogenic oral bacteria.", [["oral", "ANATOMY", 88, 92], ["oral", "ORGANISM_SUBDIVISION", 88, 92], ["Ecological shifts", "PROBLEM", 0, 17], ["a dysbiotic ecosystem", "PROBLEM", 21, 42], ["pathogenic oral bacteria", "PROBLEM", 77, 101], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["pathogenic", "OBSERVATION_MODIFIER", 77, 87], ["oral bacteria", "OBSERVATION", 88, 101]]], ["Daily activities such as mastication, flossing, and tooth brushing can induce bacteraemia, which facilitate haematogenous dissemination of oral bacteria and inflammatory mediators, inducing systemic inflammation in some patients.", [["tooth", "ANATOMY", 52, 57], ["oral", "ANATOMY", 139, 143], ["bacteraemia", "DISEASE", 78, 89], ["inflammation", "DISEASE", 199, 211], ["tooth", "ORGAN", 52, 57], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["flossing", "TREATMENT", 38, 46], ["tooth brushing", "PROBLEM", 52, 66], ["bacteraemia", "PROBLEM", 78, 89], ["oral bacteria", "PROBLEM", 139, 152], ["inflammatory mediators", "PROBLEM", 157, 179], ["systemic inflammation", "PROBLEM", 190, 211], ["bacteraemia", "OBSERVATION", 78, 89], ["systemic", "OBSERVATION_MODIFIER", 190, 198], ["inflammation", "OBSERVATION", 199, 211]]], ["Individuals with periodontal disease show microulcerated sulcular epithelia and damaged periodontal tissues, and thus seem more susceptible to bacteraemia.", [["periodontal", "ANATOMY", 17, 28], ["sulcular epithelia", "ANATOMY", 57, 75], ["periodontal tissues", "ANATOMY", 88, 107], ["periodontal disease", "DISEASE", 17, 36], ["bacteraemia", "DISEASE", 143, 154], ["sulcular epithelia", "TISSUE", 57, 75], ["periodontal tissues", "TISSUE", 88, 107], ["periodontal disease", "PROBLEM", 17, 36], ["microulcerated sulcular epithelia and damaged periodontal tissues", "PROBLEM", 42, 107], ["bacteraemia", "PROBLEM", 143, 154], ["periodontal", "ANATOMY", 17, 28], ["sulcular", "ANATOMY_MODIFIER", 57, 65], ["epithelia", "ANATOMY_MODIFIER", 66, 75], ["damaged", "OBSERVATION", 80, 87], ["periodontal tissues", "ANATOMY", 88, 107], ["bacteraemia", "OBSERVATION", 143, 154]]], ["Good oral hygiene is therefore essential for controlling the total bacterial load in the mouth, maintaining or reestablishing the oral symbiotic equilibrium, and preventing the dissemination of oral bacteria to other sites in the body.", [["oral", "ANATOMY", 5, 9], ["mouth", "ANATOMY", 89, 94], ["oral", "ANATOMY", 130, 134], ["oral", "ANATOMY", 194, 198], ["sites", "ANATOMY", 217, 222], ["body", "ANATOMY", 230, 234], ["oral", "ORGANISM_SUBDIVISION", 5, 9], ["mouth", "ORGANISM_SUBDIVISION", 89, 94], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["oral", "ORGANISM_SUBDIVISION", 194, 198], ["body", "ORGANISM_SUBDIVISION", 230, 234], ["the total bacterial load in the mouth", "TREATMENT", 57, 94], ["the oral symbiotic equilibrium", "PROBLEM", 126, 156], ["oral bacteria", "PROBLEM", 194, 207], ["bacterial load", "OBSERVATION", 67, 81], ["mouth", "ANATOMY", 89, 94], ["bacteria", "OBSERVATION", 199, 207], ["body", "ANATOMY", 230, 234]]], ["2 Metagenomic analyses of patients infected with severe acute respiratory syndrome coronavirus 2 have frequently reported high reads of cariogenic and periodontopathic bacteria, 3 endorsing the notion of a connection between the oral micro biome and COVID19 comp lications.", [["oral", "ANATOMY", 229, 233], ["acute respiratory syndrome coronavirus", "DISEASE", 56, 94], ["patients", "ORGANISM", 26, 34], ["oral", "ORGANISM_SUBDIVISION", 229, 233], ["patients", "SPECIES", 26, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 49, 94], ["Metagenomic analyses", "TEST", 2, 22], ["severe acute respiratory syndrome coronavirus 2", "PROBLEM", 49, 96], ["cariogenic", "PROBLEM", 136, 146], ["periodontopathic bacteria", "PROBLEM", 151, 176], ["the oral micro biome", "TREATMENT", 225, 245], ["COVID19 comp lications", "TREATMENT", 250, 272], ["infected", "OBSERVATION_MODIFIER", 35, 43], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome coronavirus", "OBSERVATION", 62, 94]]], ["Evidence suggests that period ontopathic bacteria are involved in the pathogenesis of respiratory diseases, such as those implicated in COVID19, and are associated with chronic inflammatory systemic diseases including type 2 diabetes, hypertension, and cardiovascular disease.", [["respiratory", "ANATOMY", 86, 97], ["cardiovascular", "ANATOMY", 253, 267], ["respiratory diseases", "DISEASE", 86, 106], ["systemic diseases", "DISEASE", 190, 207], ["type 2 diabetes", "DISEASE", 218, 233], ["hypertension", "DISEASE", 235, 247], ["cardiovascular disease", "DISEASE", 253, 275], ["COVID19", "GENE_OR_GENE_PRODUCT", 136, 143], ["period ontopathic bacteria", "PROBLEM", 23, 49], ["respiratory diseases", "PROBLEM", 86, 106], ["chronic inflammatory systemic diseases", "PROBLEM", 169, 207], ["type 2 diabetes", "PROBLEM", 218, 233], ["hypertension", "PROBLEM", 235, 247], ["cardiovascular disease", "PROBLEM", 253, 275], ["period", "OBSERVATION_MODIFIER", 23, 29], ["ontopathic", "OBSERVATION_MODIFIER", 30, 40], ["bacteria", "OBSERVATION", 41, 49], ["respiratory diseases", "OBSERVATION", 86, 106], ["associated with", "UNCERTAINTY", 153, 168], ["chronic", "OBSERVATION_MODIFIER", 169, 176], ["inflammatory", "OBSERVATION_MODIFIER", 177, 189], ["systemic diseases", "OBSERVATION", 190, 207], ["diabetes", "OBSERVATION", 225, 233], ["hypertension", "OBSERVATION", 235, 247], ["cardiovascular disease", "OBSERVATION", 253, 275]]], ["These diseases are frequently reported comorbidities associated with an increased risk of severe complications and death from COVID19.", [["death", "DISEASE", 115, 120], ["These diseases", "PROBLEM", 0, 14], ["severe complications", "PROBLEM", 90, 110], ["death", "PROBLEM", 115, 120], ["COVID19", "TREATMENT", 126, 133], ["diseases", "OBSERVATION", 6, 14], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["complications", "OBSERVATION", 97, 110]]], ["Suggested mechanisms that might explain the role of oral bacteria in the pathogenesis of respiratory infections are via the aspiration of oral pathogens into respiratory organs, the alteration of the respiratory epithelium by periodontal associated cytokines, and oral mucosal surfaces rendered to promote the adhesion of respiratory pathogens.", [["oral", "ANATOMY", 52, 56], ["respiratory", "ANATOMY", 89, 100], ["oral", "ANATOMY", 138, 142], ["respiratory organs", "ANATOMY", 158, 176], ["respiratory epithelium", "ANATOMY", 200, 222], ["periodontal", "ANATOMY", 226, 237], ["oral mucosal", "ANATOMY", 264, 276], ["respiratory", "ANATOMY", 322, 333], ["respiratory infections", "DISEASE", 89, 111], ["respiratory pathogens", "DISEASE", 322, 343], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["oral", "ORGANISM_SUBDIVISION", 138, 142], ["organs", "ORGAN", 170, 176], ["respiratory epithelium", "TISSUE", 200, 222], ["oral mucosal", "TISSUE", 264, 276], ["periodontal associated cytokines", "PROTEIN", 226, 258], ["oral bacteria", "PROBLEM", 52, 65], ["respiratory infections", "PROBLEM", 89, 111], ["oral pathogens into respiratory organs", "PROBLEM", 138, 176], ["the respiratory epithelium", "PROBLEM", 196, 222], ["periodontal associated cytokines", "PROBLEM", 226, 258], ["oral mucosal surfaces", "TREATMENT", 264, 285], ["respiratory pathogens", "PROBLEM", 322, 343], ["respiratory", "ANATOMY", 89, 100], ["infections", "OBSERVATION", 101, 111], ["respiratory epithelium", "ANATOMY", 200, 222], ["respiratory pathogens", "OBSERVATION", 322, 343]]], ["4 Numerous studies 5, 6 report that oral hygiene interventions in patients with pneumonia have substantially improved clinical outcomes and reduced mortality.", [["oral", "ANATOMY", 36, 40], ["pneumonia", "DISEASE", 80, 89], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["Numerous studies", "TEST", 2, 18], ["oral hygiene interventions", "TREATMENT", 36, 62], ["pneumonia", "PROBLEM", 80, 89], ["reduced mortality", "PROBLEM", 140, 157], ["pneumonia", "OBSERVATION", 80, 89], ["improved", "OBSERVATION_MODIFIER", 109, 117]]], ["One in ten pneumoniarelated deaths of older nursing home residents (\u226565 years) are considered preventable by improving oral hygiene.", [["oral", "ANATOMY", 119, 123], ["deaths", "DISEASE", 28, 34], ["oral", "ORGANISM_SUBDIVISION", 119, 123]]], ["7 Improved oral care has been shown to significantly reduce the incidence of ventilatorassociated pneumonia in patients in an intensive care unit.", [["oral", "ANATOMY", 11, 15], ["pneumonia", "DISEASE", 98, 107], ["oral", "ORGANISM_SUBDIVISION", 11, 15], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["ventilatorassociated pneumonia", "PROBLEM", 77, 107], ["ventilatorassociated", "OBSERVATION_MODIFIER", 77, 97], ["pneumonia", "OBSERVATION", 98, 107]]], ["8 Further metagenomic studies and clinical trials are required for the characterisation of coinfections in COVID19 and the potential connection between the role of the oral microbiome and complications arising from the virus.CorrespondenceThese data are vital to ascertain whether poor oral hygiene is a modifiable risk factor for COVID19 complications and if there is a place for the promotion of good oral hygiene as a preventive public health intervention during the pandemic.", [["oral", "ANATOMY", 168, 172], ["oral", "ANATOMY", 286, 290], ["oral", "ANATOMY", 403, 407], ["coinfections", "DISEASE", 91, 103], ["COVID19", "CANCER", 107, 114], ["oral", "ORGANISM_SUBDIVISION", 168, 172], ["oral", "ORGANISM_SUBDIVISION", 286, 290], ["oral", "ORGANISM_SUBDIVISION", 403, 407], ["Further metagenomic studies", "TEST", 2, 29], ["clinical trials", "TEST", 34, 49], ["coinfections in COVID19", "PROBLEM", 91, 114], ["the oral microbiome", "TREATMENT", 164, 183], ["complications", "PROBLEM", 188, 201], ["the virus", "PROBLEM", 215, 224], ["poor oral hygiene", "PROBLEM", 281, 298], ["COVID19 complications", "PROBLEM", 331, 352], ["a preventive public health intervention", "TREATMENT", 419, 458], ["coinfections", "OBSERVATION", 91, 103]]]], "0bf4618d8aea8295bb7d4fbfa9dc33c54971b3db": [["HIV protease inhibitors are being considered as potential treatment of COVID-19, the disease caused by Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2).", [["Acute Respiratory Syndrome coronavirus", "DISEASE", 110, 148], ["COVID-19", "CELL", 71, 79], ["Severe Acute Respiratory Syndrome coronavirus-2", "ORGANISM", 103, 150], ["SARS-CoV-2", "ORGANISM", 152, 162], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 103, 148], ["SARS-CoV-2", "SPECIES", 152, 162], ["HIV protease inhibitors", "TREATMENT", 0, 23], ["COVID", "TEST", 71, 76], ["the disease", "PROBLEM", 81, 92], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 103, 148], ["CoV", "TEST", 157, 160], ["Severe", "OBSERVATION_MODIFIER", 103, 109], ["Acute", "OBSERVATION_MODIFIER", 110, 115], ["Respiratory Syndrome coronavirus", "OBSERVATION", 116, 148]]], ["In particular, the use of lopinavir/ritonavir has been supported by in vitro data, animal studies and clinical data in patients with other coronavirus infections, specifically SARS and Middle East Respiratory Syndrome (reviewed in [1] ).", [["lopinavir/ritonavir", "CHEMICAL", 26, 45], ["coronavirus infections", "DISEASE", 139, 161], ["SARS", "DISEASE", 176, 180], ["Middle East Respiratory Syndrome", "DISEASE", 185, 217], ["lopinavir", "CHEMICAL", 26, 35], ["ritonavir", "CHEMICAL", 36, 45], ["lopinavir", "SIMPLE_CHEMICAL", 26, 35], ["ritonavir", "SIMPLE_CHEMICAL", 36, 45], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["lopinavir", "TREATMENT", 26, 35], ["ritonavir", "TREATMENT", 36, 45], ["animal studies", "TEST", 83, 97], ["clinical data", "TEST", 102, 115], ["other coronavirus infections", "PROBLEM", 133, 161], ["SARS", "PROBLEM", 176, 180], ["Middle East Respiratory Syndrome", "PROBLEM", 185, 217], ["Middle", "ANATOMY_MODIFIER", 185, 191], ["Respiratory Syndrome", "OBSERVATION", 197, 217]]], ["However, early experiences with the use of lopinavir/ritonavir in COVID-19 patients provided conflicting results.", [["lopinavir/ritonavir", "CHEMICAL", 43, 62], ["lopinavir", "CHEMICAL", 43, 52], ["ritonavir", "CHEMICAL", 53, 62], ["lopinavir", "SIMPLE_CHEMICAL", 43, 52], ["ritonavir", "SIMPLE_CHEMICAL", 53, 62], ["COVID-19", "ORGANISM", 66, 74], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["lopinavir", "TREATMENT", 43, 52], ["ritonavir", "TREATMENT", 53, 62]]], ["Indeed, Ye, et al showed that, compared with treatment of pneumonia-associated adjuvant drugs alone, the association with lopinavir/ritonavir had more favorable effects in lowering the body temperature [2] .", [["body", "ANATOMY", 185, 189], ["pneumonia", "DISEASE", 58, 67], ["lopinavir", "CHEMICAL", 122, 131], ["ritonavir", "CHEMICAL", 132, 141], ["lopinavir", "CHEMICAL", 122, 131], ["ritonavir", "CHEMICAL", 132, 141], ["lopinavir", "SIMPLE_CHEMICAL", 122, 131], ["ritonavir", "SIMPLE_CHEMICAL", 132, 141], ["body", "ORGANISM_SUBDIVISION", 185, 189], ["pneumonia", "PROBLEM", 58, 67], ["adjuvant drugs", "TREATMENT", 79, 93], ["lopinavir", "TREATMENT", 122, 131], ["ritonavir", "TREATMENT", 132, 141], ["pneumonia", "OBSERVATION", 58, 67]]], ["Conversely, Cao and co-workers, in a prospective, randomized, open-label trial, reported no added benefit of lopinavir-ritonavir in hospitalized adult patients with severe Covid-19 treated with standard of care [3] .", [["lopinavir-ritonavir", "CHEMICAL", 109, 128], ["lopinavir", "CHEMICAL", 109, 118], ["ritonavir", "CHEMICAL", 119, 128], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 109, 128], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["lopinavir", "TREATMENT", 109, 118], ["ritonavir", "TREATMENT", 119, 128]]]], "PMC6781508": [["IntroductionAccording to data released by the World Health Organization (WHO), infectious agents causing lower respiratory infections, diarrheal diseases, and tuberculosis were ranked in the top ten causes of death worldwide, resulting in 5.7 million deaths in 2016 (1).", [["respiratory", "ANATOMY", 111, 122], ["lower respiratory infections", "DISEASE", 105, 133], ["diarrheal diseases", "DISEASE", 135, 153], ["tuberculosis", "DISEASE", 159, 171], ["death", "DISEASE", 209, 214], ["deaths", "DISEASE", 251, 257], ["infectious agents", "TREATMENT", 79, 96], ["lower respiratory infections", "PROBLEM", 105, 133], ["diarrheal diseases", "PROBLEM", 135, 153], ["tuberculosis", "PROBLEM", 159, 171], ["lower", "ANATOMY_MODIFIER", 105, 110], ["respiratory", "ANATOMY", 111, 122], ["infections", "OBSERVATION", 123, 133], ["diarrheal diseases", "OBSERVATION", 135, 153], ["tuberculosis", "OBSERVATION", 159, 171]]], ["It is clear that we need to improve our understanding of these diseases and pathogenic agents in order to develop more effective drugs and vaccines.", [["these diseases", "PROBLEM", 57, 71], ["pathogenic agents", "TREATMENT", 76, 93], ["effective drugs", "TREATMENT", 119, 134], ["vaccines", "TREATMENT", 139, 147]]], ["To this end, we need a suitable animal model that can most accurately mimic the pathogenesis of infection as infection usually induces a complex process of host immune responses that in vitro experiments are unable to simulate.", [["infection", "DISEASE", 96, 105], ["infection", "DISEASE", 109, 118], ["a suitable animal model", "TREATMENT", 21, 44], ["infection", "PROBLEM", 96, 105], ["infection", "PROBLEM", 109, 118], ["host immune responses", "TREATMENT", 156, 177], ["infection", "OBSERVATION", 96, 105]]], ["Only in vivo models can accurately assess the complexity of host responses and allow the efficacy and adverse effects of drugs or vaccine to be evaluated.IntroductionThe Syrian hamster (Mesocricetus auratus) has been used as an animal model to study human-associated diseases for over 60 years.", [["Syrian hamster", "ORGANISM", 170, 184], ["Mesocricetus auratus", "ORGANISM", 186, 206], ["human", "ORGANISM", 250, 255], ["Syrian hamster", "SPECIES", 170, 184], ["Mesocricetus auratus", "SPECIES", 186, 206], ["human", "SPECIES", 250, 255], ["Syrian hamster", "SPECIES", 170, 184], ["Mesocricetus auratus", "SPECIES", 186, 206], ["human", "SPECIES", 250, 255], ["drugs", "TREATMENT", 121, 126], ["vaccine", "TREATMENT", 130, 137], ["The Syrian hamster (Mesocricetus auratus", "TREATMENT", 166, 206], ["associated diseases", "PROBLEM", 256, 275]]], ["A number of studies have documented that Syrian hamsters represent better models for analysis of viral infections compared to murine models as the similarity to humans with regard to disease symptoms, pathognesis and immune responses is greater (2\u20134).", [["viral infections", "DISEASE", 97, 113], ["pathognesis", "DISEASE", 201, 212], ["Syrian hamsters", "ORGANISM", 41, 56], ["murine", "ORGANISM", 126, 132], ["humans", "ORGANISM", 161, 167], ["hamsters", "SPECIES", 48, 56], ["murine", "SPECIES", 126, 132], ["humans", "SPECIES", 161, 167], ["Syrian hamsters", "SPECIES", 41, 56], ["humans", "SPECIES", 161, 167], ["Syrian hamsters", "TREATMENT", 41, 56], ["viral infections", "PROBLEM", 97, 113], ["disease symptoms", "PROBLEM", 183, 199], ["pathognesis", "PROBLEM", 201, 212], ["immune responses", "TEST", 217, 233], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infections", "OBSERVATION", 103, 113], ["greater", "OBSERVATION_MODIFIER", 237, 244]]], ["It has been demonstrated by us and others that human cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12), are fully functional in hamster models, but not in mouse models (5, 6).", [["hamster", "ANATOMY", 184, 191], ["human", "ORGANISM", 47, 52], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 74, 122], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 124, 130], ["interleukin-12", "GENE_OR_GENE_PRODUCT", 136, 150], ["IL-12", "GENE_OR_GENE_PRODUCT", 152, 157], ["hamster", "ORGANISM", 184, 191], ["mouse", "ORGANISM", 211, 216], ["human cytokines", "PROTEIN", 47, 62], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 74, 122], ["GM", "PROTEIN", 124, 126], ["CSF", "PROTEIN", 127, 130], ["interleukin-12", "PROTEIN", 136, 150], ["IL", "PROTEIN", 152, 154], ["human", "SPECIES", 47, 52], ["hamster", "SPECIES", 184, 191], ["mouse", "SPECIES", 211, 216], ["human", "SPECIES", 47, 52], ["hamster", "SPECIES", 184, 191], ["mouse", "SPECIES", 211, 216], ["human cytokines", "TEST", 47, 62], ["granulocyte", "TEST", 74, 85], ["macrophage colony", "TEST", 86, 103], ["stimulating factor", "TEST", 104, 122], ["GM-CSF", "TEST", 124, 130], ["interleukin", "TEST", 136, 147], ["IL", "TEST", 152, 154]]], ["Together with other advantages, such as fast reproductive rate and ease of handling, Syrian hamsters are a superior choice compared with other small animals.IntroductionAlthough Syrian hamsters have historically been used in diseases research, their value as an animal model in the study of infectious diseases has only recently been realized.", [["infectious diseases", "DISEASE", 291, 310], ["Syrian hamsters", "ORGANISM", 85, 100], ["Syrian hamsters", "ORGANISM", 178, 193], ["Syrian hamsters", "SPECIES", 85, 100], ["hamsters", "SPECIES", 185, 193], ["Syrian hamsters", "SPECIES", 85, 100], ["Syrian hamsters", "SPECIES", 178, 193], ["infectious diseases", "PROBLEM", 291, 310], ["infectious", "OBSERVATION", 291, 301]]], ["With advancements in gene editing technologies, their popularity has increased significantly (Figure 1).", [["gene editing technologies", "TREATMENT", 21, 46], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["The use of genetically engineered Syrian hamster (GESH) models is critical for understanding disease progression and for developing prophylactic and therapeutic treatment regimens.", [["hamster", "ANATOMY", 41, 48], ["GESH", "ANATOMY", 50, 54], ["Syrian hamster", "ORGANISM", 34, 48], ["GESH", "CELL", 50, 54], ["Syrian hamster", "SPECIES", 34, 48], ["Syrian hamster", "SPECIES", 34, 48], ["genetically engineered Syrian hamster (GESH) models", "TREATMENT", 11, 62], ["understanding disease progression", "PROBLEM", 79, 112], ["developing prophylactic", "TREATMENT", 121, 144], ["therapeutic treatment regimens", "TREATMENT", 149, 179]]], ["The first STAT2 gene knockout (KO) Syrian hamster was developed in 2014, using the CRISPR/Cas9 system to target the hamster germline (7).", [["hamster", "ANATOMY", 42, 49], ["STAT2", "GENE_OR_GENE_PRODUCT", 10, 15], ["hamster", "ORGANISM", 42, 49], ["hamster", "ORGANISM", 116, 123], ["STAT2 gene", "DNA", 10, 20], ["CRISPR", "DNA", 83, 89], ["hamster germline", "DNA", 116, 132], ["hamster", "SPECIES", 42, 49], ["hamster", "SPECIES", 116, 123], ["Syrian hamster", "SPECIES", 35, 49], ["the CRISPR/Cas9 system", "TREATMENT", 79, 101]]], ["STAT2 is a crucial element of the type I interferon (IFN) signal transduction pathway and the hamster model has emerged as the only small animal model permissive for Adenovirus (AdV) infection, thus, the STAT2 KO model has been critical for the characterization of Adenovirus pathogenesis (8).West Nile Virus ::: Syrian Hamster Used for Research in Viral InfectionsThe most intensively studied virus in Syrian hamsters is West Nile virus (WNV).", [["hamster", "ANATOMY", 94, 101], ["Adenovirus (AdV) infection", "DISEASE", 166, 192], ["Viral Infections", "DISEASE", 349, 365], ["STAT2", "GENE_OR_GENE_PRODUCT", 0, 5], ["type I interferon", "GENE_OR_GENE_PRODUCT", 34, 51], ["IFN", "GENE_OR_GENE_PRODUCT", 53, 56], ["hamster", "ORGANISM", 94, 101], ["Adenovirus", "ORGANISM", 166, 176], ["AdV", "ORGANISM", 178, 181], ["STAT2", "GENE_OR_GENE_PRODUCT", 204, 209], ["Adenovirus", "ORGANISM", 265, 275], ["West Nile Virus", "ORGANISM", 293, 308], ["Syrian hamsters", "ORGANISM", 403, 418], ["West Nile virus", "ORGANISM", 422, 437], ["WNV", "ORGANISM", 439, 442], ["STAT2", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 53, 56], ["STAT2", "PROTEIN", 204, 209], ["Syrian hamsters", "SPECIES", 403, 418], ["West Nile virus", "SPECIES", 422, 437], ["hamster", "SPECIES", 94, 101], ["Adenovirus", "SPECIES", 166, 176], ["AdV", "SPECIES", 178, 181], ["Adenovirus", "SPECIES", 265, 275], ["West Nile Virus", "SPECIES", 293, 308], ["Syrian hamsters", "SPECIES", 403, 418], ["West Nile virus", "SPECIES", 422, 437], ["WNV", "SPECIES", 439, 442], ["the type I interferon (IFN) signal transduction pathway", "TREATMENT", 30, 85], ["the hamster model", "TREATMENT", 90, 107], ["Adenovirus (AdV) infection", "PROBLEM", 166, 192], ["the STAT2 KO model", "TEST", 200, 218], ["Adenovirus pathogenesis", "PROBLEM", 265, 288], ["Syrian Hamster", "TREATMENT", 313, 327], ["Viral Infections", "PROBLEM", 349, 365], ["infection", "OBSERVATION", 183, 192], ["Adenovirus", "OBSERVATION", 265, 275], ["Viral Infections", "OBSERVATION", 349, 365]]], ["WNV is a member of the genus Flavivirus (family Flaviviridae), an emerging zoonotic arbovirus widely distributed throughout the world (38).", [["WNV", "DISEASE", 0, 3], ["zoonotic arbovirus", "DISEASE", 75, 93], ["WNV", "ORGANISM", 0, 3], ["WNV", "SPECIES", 0, 3], ["an emerging zoonotic arbovirus", "PROBLEM", 63, 93], ["zoonotic", "OBSERVATION_MODIFIER", 75, 83], ["arbovirus", "OBSERVATION", 84, 93]]], ["WNV is usually transmitted via bites on infected arthropods (mosquitos).", [["mosquitos", "ANATOMY", 61, 70], ["WNV is usually transmitted via bites on infected arthropods", "DISEASE", 0, 59], ["WNV", "ORGANISM", 0, 3], ["mosquitos", "CANCER", 61, 70], ["WNV", "SPECIES", 0, 3], ["WNV", "PROBLEM", 0, 3]]], ["In humans, the majority of WNV infections are asymptomatic, with only 20% of infected individuals developing symptomatic West Nile fever (WNF) (39).", [["WNV infections", "DISEASE", 27, 41], ["West Nile fever", "DISEASE", 121, 136], ["WNF", "DISEASE", 138, 141], ["humans", "ORGANISM", 3, 9], ["WNV", "ORGANISM", 27, 30], ["West Nile fever", "ORGANISM", 121, 136], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["WNV", "SPECIES", 27, 30], ["West Nile fever (WNF)", "SPECIES", 121, 142], ["WNV infections", "PROBLEM", 27, 41], ["asymptomatic", "PROBLEM", 46, 58], ["infected individuals", "PROBLEM", 77, 97], ["Nile fever", "PROBLEM", 126, 136], ["WNV", "OBSERVATION_MODIFIER", 27, 30], ["infections", "OBSERVATION", 31, 41], ["symptomatic", "OBSERVATION_MODIFIER", 109, 120]]], ["However, WNV is an important emerging neurotropic virus causing severe encephalitis in human posing a significant threat to global health (40).", [["WNV", "DISEASE", 9, 12], ["encephalitis", "DISEASE", 71, 83], ["WNV", "ORGANISM", 9, 12], ["neurotropic virus", "ORGANISM", 38, 55], ["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["WNV", "SPECIES", 9, 12], ["human", "SPECIES", 87, 92], ["WNV", "PROBLEM", 9, 12], ["neurotropic virus", "PROBLEM", 38, 55], ["severe encephalitis in human", "PROBLEM", 64, 92], ["WNV", "OBSERVATION", 9, 12], ["neurotropic virus", "OBSERVATION", 38, 55], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["encephalitis", "OBSERVATION", 71, 83], ["significant", "OBSERVATION_MODIFIER", 102, 113]]], ["Syrian hamsters can be readily infected by mosquito bite, ingestion (oral) or needle inoculation and infected hamsters develop viremia and illness, with symptoms similar to those experienced during human infection (41, 42).", [["oral", "ANATOMY", 69, 73], ["mosquito bite", "DISEASE", 43, 56], ["viremia", "DISEASE", 127, 134], ["illness", "DISEASE", 139, 146], ["infection", "DISEASE", 204, 213], ["Syrian hamsters", "ORGANISM", 0, 15], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["hamsters", "ORGANISM", 110, 118], ["human", "ORGANISM", 198, 203], ["Syrian hamsters", "SPECIES", 0, 15], ["human", "SPECIES", 198, 203], ["Syrian hamsters", "SPECIES", 0, 15], ["hamsters", "SPECIES", 110, 118], ["human", "SPECIES", 198, 203], ["needle inoculation", "TREATMENT", 78, 96], ["viremia", "PROBLEM", 127, 134], ["illness", "PROBLEM", 139, 146], ["symptoms", "PROBLEM", 153, 161], ["human infection", "PROBLEM", 198, 213], ["viremia", "OBSERVATION", 127, 134], ["infection", "OBSERVATION", 204, 213]]], ["Using this hamster model, Xiao et al. observed both histologic abnormalities and appearance of viral antigen in the brain first followed by the spinal cord, with infection eventually leading to acute central nervous system (CNS) injury (13).", [["brain", "ANATOMY", 116, 121], ["spinal cord", "ANATOMY", 144, 155], ["central nervous system", "ANATOMY", 200, 222], ["CNS", "ANATOMY", 224, 227], ["infection", "DISEASE", 162, 171], ["acute central nervous system (CNS) injury", "DISEASE", 194, 235], ["hamster", "ORGANISM", 11, 18], ["brain", "ORGAN", 116, 121], ["spinal cord", "ORGAN", 144, 155], ["central nervous system", "ANATOMICAL_SYSTEM", 200, 222], ["CNS", "ANATOMICAL_SYSTEM", 224, 227], ["viral antigen", "PROTEIN", 95, 108], ["hamster", "SPECIES", 11, 18], ["this hamster model", "TREATMENT", 6, 24], ["both histologic abnormalities", "PROBLEM", 47, 76], ["viral antigen in the brain", "PROBLEM", 95, 121], ["infection", "PROBLEM", 162, 171], ["acute central nervous system (CNS) injury", "PROBLEM", 194, 235], ["both", "OBSERVATION_MODIFIER", 47, 51], ["histologic", "OBSERVATION_MODIFIER", 52, 62], ["abnormalities", "OBSERVATION", 63, 76], ["viral antigen", "OBSERVATION", 95, 108], ["brain", "ANATOMY", 116, 121], ["spinal cord", "ANATOMY", 144, 155], ["infection", "OBSERVATION", 162, 171], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["central", "ANATOMY_MODIFIER", 200, 207], ["nervous system", "ANATOMY", 208, 222], ["CNS", "ANATOMY", 224, 227], ["injury", "OBSERVATION", 229, 235]]], ["Infected hamsters developed neurological disease (43\u201346) and association of suppressed diaphragmatic electromyographs (EMGs) with infection of the medulla oblongata (47).", [["neurological", "ANATOMY", 28, 40], ["diaphragmatic electromyographs", "ANATOMY", 87, 117], ["medulla oblongata", "ANATOMY", 147, 164], ["neurological disease", "DISEASE", 28, 48], ["diaphragmatic electromyographs", "DISEASE", 87, 117], ["infection of the medulla oblongata", "DISEASE", 130, 164], ["hamsters", "ORGANISM", 9, 17], ["diaphragmatic", "ORGAN", 87, 100], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 147, 164], ["hamsters", "SPECIES", 9, 17], ["neurological disease", "PROBLEM", 28, 48], ["suppressed diaphragmatic electromyographs", "PROBLEM", 76, 117], ["infection of the medulla oblongata", "PROBLEM", 130, 164], ["neurological disease", "OBSERVATION", 28, 48], ["diaphragmatic", "ANATOMY", 87, 100], ["infection", "OBSERVATION", 130, 139], ["medulla oblongata", "ANATOMY", 147, 164]]], ["Samuel et al. also found that inoculation of Syrian hamster with WNV resulted in paralysis of the hind limb ipsilateral but not contralateral to the injection site (48).", [["hamster", "ANATOMY", 52, 59], ["hind limb", "ANATOMY", 98, 107], ["WNV", "DISEASE", 65, 68], ["paralysis", "DISEASE", 81, 90], ["Syrian hamster", "ORGANISM", 45, 59], ["WNV", "ORGANISM", 65, 68], ["hind limb", "ORGANISM_SUBDIVISION", 98, 107], ["Syrian hamster", "SPECIES", 45, 59], ["Syrian hamster", "SPECIES", 45, 59], ["WNV", "SPECIES", 65, 68], ["WNV", "PROBLEM", 65, 68], ["paralysis of the hind limb ipsilateral", "PROBLEM", 81, 119], ["inoculation", "OBSERVATION", 30, 41], ["WNV", "OBSERVATION", 65, 68], ["paralysis", "OBSERVATION", 81, 90], ["hind limb", "ANATOMY", 98, 107], ["ipsilateral", "ANATOMY_MODIFIER", 108, 119]]], ["Mateo et al. generated a model of immunosuppressed Syrian hamsters using cyclophosphamide and after infection the hamsters displayed similar clinical signs to those observed in an immunosuppressed cancer patient infected with WNV (49).", [["cancer", "ANATOMY", 197, 203], ["cyclophosphamide", "CHEMICAL", 73, 89], ["infection", "DISEASE", 100, 109], ["cancer", "DISEASE", 197, 203], ["cyclophosphamide", "CHEMICAL", 73, 89], ["Syrian hamsters", "ORGANISM", 51, 66], ["cyclophosphamide", "SIMPLE_CHEMICAL", 73, 89], ["hamsters", "ORGANISM", 114, 122], ["cancer", "CANCER", 197, 203], ["patient", "ORGANISM", 204, 211], ["WNV", "ORGANISM", 226, 229], ["Syrian hamsters", "SPECIES", 51, 66], ["patient", "SPECIES", 204, 211], ["Syrian hamsters", "SPECIES", 51, 66], ["hamsters", "SPECIES", 114, 122], ["WNV", "SPECIES", 226, 229], ["immunosuppressed Syrian hamsters", "TREATMENT", 34, 66], ["cyclophosphamide", "TREATMENT", 73, 89], ["infection", "PROBLEM", 100, 109], ["an immunosuppressed cancer", "PROBLEM", 177, 203], ["immunosuppressed", "OBSERVATION_MODIFIER", 180, 196], ["cancer", "OBSERVATION", 197, 203]]], ["By observing the pathogenesis of disease in WNV-infected immunocompromised hamsters, the animals were shown to develop chronic viremia and sustained renal infection for 8 months (50).", [["renal", "ANATOMY", 149, 154], ["WNV-infected", "DISEASE", 44, 56], ["viremia", "DISEASE", 127, 134], ["renal infection", "DISEASE", 149, 164], ["WNV", "ORGANISM", 44, 47], ["hamsters", "ORGANISM", 75, 83], ["animals", "ORGANISM", 89, 96], ["renal", "ORGAN", 149, 154], ["WNV", "SPECIES", 44, 47], ["hamsters", "SPECIES", 75, 83], ["disease", "PROBLEM", 33, 40], ["WNV", "PROBLEM", 44, 47], ["infected immunocompromised hamsters", "PROBLEM", 48, 83], ["chronic viremia", "PROBLEM", 119, 134], ["sustained renal infection", "PROBLEM", 139, 164], ["disease", "OBSERVATION", 33, 40], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["immunocompromised hamsters", "OBSERVATION", 57, 83], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["viremia", "OBSERVATION", 127, 134], ["renal", "ANATOMY", 149, 154], ["infection", "OBSERVATION", 155, 164]]], ["Syrian hamsters not only display an adaptive immune response but also mount an innate immune response to WNV infection.", [["WNV infection", "DISEASE", 105, 118], ["Syrian hamsters", "ORGANISM", 0, 15], ["WNV", "ORGANISM", 105, 108], ["Syrian hamsters", "SPECIES", 0, 15], ["Syrian hamsters", "SPECIES", 0, 15], ["WNV", "SPECIES", 105, 108], ["WNV infection", "PROBLEM", 105, 118], ["WNV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118]]], ["Since the Syrian hamster has been shown to be a suitable model for WNV infection, it has also been used to test the efficacy of anti-WNV-neutralizing humanized monoclonal antibody, hE16 (44).", [["hamster", "ANATOMY", 17, 24], ["WNV infection", "DISEASE", 67, 80], ["Syrian hamster", "ORGANISM", 10, 24], ["WNV", "ORGANISM", 67, 70], ["anti-WNV", "SIMPLE_CHEMICAL", 128, 136], ["anti-WNV", "PROTEIN", 128, 136], ["neutralizing humanized monoclonal antibody", "PROTEIN", 137, 179], ["hE16 (44)", "PROTEIN", 181, 190], ["Syrian hamster", "SPECIES", 10, 24], ["Syrian hamster", "SPECIES", 10, 24], ["WNV", "SPECIES", 67, 70], ["WNV infection", "PROBLEM", 67, 80], ["anti-WNV", "TEST", 128, 136], ["infection", "OBSERVATION", 71, 80]]], ["Antibody immunoprophylaxis induced by delivery of recombinant antigens (WN-80E or WN-NS1) also protected Syrian hamster from WNV infection (51).", [["hamster", "ANATOMY", 112, 119], ["WNV infection", "DISEASE", 125, 138], ["WN-80E", "ORGANISM", 72, 78], ["WN-NS1", "ORGANISM", 82, 88], ["Syrian hamster", "ORGANISM", 105, 119], ["WNV", "ORGANISM", 125, 128], ["recombinant antigens", "PROTEIN", 50, 70], ["80E", "PROTEIN", 75, 78], ["WN", "PROTEIN", 82, 84], ["NS1", "PROTEIN", 85, 88], ["Syrian hamster", "SPECIES", 105, 119], ["Syrian hamster", "SPECIES", 105, 119], ["WNV", "SPECIES", 125, 128], ["Antibody immunoprophylaxis", "TREATMENT", 0, 26], ["recombinant antigens", "TEST", 50, 70], ["WNV infection", "PROBLEM", 125, 138], ["WNV", "OBSERVATION_MODIFIER", 125, 128], ["infection", "OBSERVATION", 129, 138]]], ["Using a Syrian hamster model, Widman et al. successfully demonstrated that RepliVAX WN, a single cycle flavivirus vaccine platform, was able to induce durable protective immunity against WNV challenge (52).", [["RepliVAX", "CHEMICAL", 75, 83], ["Syrian hamster", "ORGANISM", 8, 22], ["RepliVAX WN", "ORGANISM", 75, 86], ["WNV", "ORGANISM", 187, 190], ["hamster", "SPECIES", 15, 22], ["Syrian hamster", "SPECIES", 8, 22], ["WNV", "SPECIES", 187, 190], ["a Syrian hamster model", "TREATMENT", 6, 28], ["RepliVAX WN", "TREATMENT", 75, 86], ["a single cycle flavivirus vaccine platform", "TREATMENT", 88, 130]]], ["These studies demonstrate Syrian hamster as an ideal model for study of the pathogenesis of WNV infection and assessing new approaches for WNV treatment and prevention.Yellow Fever Virus ::: Syrian Hamster Used for Research in Viral InfectionsYFV is an arthropod-borne virus of the genus Flavivirus (family Flaviviridae) and has high morbidity and mortality rates in regions of sub-Saharan Africa and South America (53).", [["hamster", "ANATOMY", 33, 40], ["WNV infection", "DISEASE", 92, 105], ["WNV", "DISEASE", 139, 142], ["Viral InfectionsYFV", "DISEASE", 227, 246], ["Syrian hamster", "ORGANISM", 26, 40], ["WNV", "ORGANISM", 92, 95], ["WNV", "ORGANISM", 139, 142], ["Yellow Fever Virus", "ORGANISM", 168, 186], ["Viral InfectionsYFV", "ORGANISM", 227, 246], ["Syrian hamster", "SPECIES", 26, 40], ["Syrian hamster", "SPECIES", 26, 40], ["WNV", "SPECIES", 92, 95], ["WNV", "SPECIES", 139, 142], ["Yellow Fever Virus", "SPECIES", 168, 186], ["YFV", "SPECIES", 243, 246], ["These studies", "TEST", 0, 13], ["Syrian hamster", "TREATMENT", 26, 40], ["WNV infection", "PROBLEM", 92, 105], ["WNV treatment", "TREATMENT", 139, 152], ["prevention", "TREATMENT", 157, 167], ["Yellow Fever Virus", "PROBLEM", 168, 186], ["Syrian Hamster", "TREATMENT", 191, 205], ["Research in Viral InfectionsYFV", "PROBLEM", 215, 246], ["an arthropod", "PROBLEM", 250, 262], ["high morbidity", "PROBLEM", 329, 343], ["WNV", "OBSERVATION_MODIFIER", 92, 95], ["infection", "OBSERVATION", 96, 105], ["Fever Virus", "OBSERVATION", 175, 186], ["Viral", "OBSERVATION_MODIFIER", 227, 232], ["Infections", "OBSERVATION", 233, 243], ["high", "OBSERVATION_MODIFIER", 329, 333], ["morbidity", "OBSERVATION", 334, 343], ["sub", "OBSERVATION_MODIFIER", 378, 381]]], ["It was one of the first viruses of humans to be identified, isolated, propagated in vitro and studied by genomic sequencing (54).", [["humans", "ORGANISM", 35, 41], ["humans", "SPECIES", 35, 41], ["humans", "SPECIES", 35, 41]]], ["The study of infection mechanism of YFV has historically been hindered by the lack of appropriate small animal model and non-human primate (NHP) models have typically been used.", [["infection", "DISEASE", 13, 22], ["YFV", "DISEASE", 36, 39], ["YFV", "ORGANISM", 36, 39], ["non-human primate", "ORGANISM", 121, 138], ["NHP", "ORGANISM", 140, 143], ["YFV", "SPECIES", 36, 39], ["The study", "TEST", 0, 9], ["infection mechanism of YFV", "PROBLEM", 13, 39], ["infection", "OBSERVATION", 13, 22]]], ["More recently, several research groups have generated animal models using Syrian hamsters that can be successfully infected with YFV (55\u201358).", [["Syrian hamsters", "ORGANISM", 74, 89], ["YFV", "ORGANISM", 129, 132], ["Syrian hamsters", "SPECIES", 74, 89], ["Syrian hamsters", "SPECIES", 74, 89], ["YFV", "SPECIES", 129, 132], ["Syrian hamsters", "TREATMENT", 74, 89]]], ["McArthur et al. reported adapted viral strains (Asibi/hamster p7) allow the reproduction of yellow fever disease in hamsters with features similar to the human disease (59).", [["yellow fever", "DISEASE", 92, 104], ["disease", "DISEASE", 105, 112], ["Asibi/hamster p7", "ORGANISM", 48, 64], ["yellow fever", "ORGANISM", 92, 104], ["hamsters", "ORGANISM", 116, 124], ["human", "ORGANISM", 154, 159], ["hamster", "SPECIES", 54, 61], ["human", "SPECIES", 154, 159], ["hamster", "SPECIES", 54, 61], ["hamsters", "SPECIES", 116, 124], ["human", "SPECIES", 154, 159], ["adapted viral strains", "PROBLEM", 25, 46], ["Asibi/hamster p7", "TREATMENT", 48, 64], ["yellow fever disease in hamsters", "PROBLEM", 92, 124], ["the human disease", "PROBLEM", 150, 167], ["viral strains", "OBSERVATION", 33, 46]]], ["Further, studies have also shown that infection of Syrian hamster results in immune responses that correspond to those observed in infected humans, with marked increases in IFN-\u03b3, IL-2, TNF-\u03b1 in the spleen, kidney, and heart, but reduced levels of these seen in the liver.", [["hamster", "ANATOMY", 58, 65], ["spleen", "ANATOMY", 199, 205], ["kidney", "ANATOMY", 207, 213], ["heart", "ANATOMY", 219, 224], ["liver", "ANATOMY", 266, 271], ["infection", "DISEASE", 38, 47], ["Syrian hamster", "ORGANISM", 51, 65], ["humans", "ORGANISM", 140, 146], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 173, 178], ["IL-2", "GENE_OR_GENE_PRODUCT", 180, 184], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 186, 191], ["spleen", "ORGAN", 199, 205], ["kidney", "ORGAN", 207, 213], ["heart", "ORGAN", 219, 224], ["liver", "ORGAN", 266, 271], ["IFN", "PROTEIN", 173, 176], ["TNF-\u03b1", "PROTEIN", 186, 191], ["Syrian hamster", "SPECIES", 51, 65], ["humans", "SPECIES", 140, 146], ["Syrian hamster", "SPECIES", 51, 65], ["humans", "SPECIES", 140, 146], ["Further, studies", "TEST", 0, 16], ["infection of Syrian hamster", "PROBLEM", 38, 65], ["immune responses", "PROBLEM", 77, 93], ["infected humans", "PROBLEM", 131, 146], ["IFN", "TEST", 173, 176], ["IL", "TEST", 180, 182], ["TNF", "TEST", 186, 189], ["infection", "OBSERVATION", 38, 47], ["infected", "OBSERVATION", 131, 139], ["marked", "OBSERVATION_MODIFIER", 153, 159], ["increases", "OBSERVATION_MODIFIER", 160, 169], ["spleen", "ANATOMY", 199, 205], ["kidney", "ANATOMY", 207, 213], ["heart", "ANATOMY", 219, 224], ["reduced", "OBSERVATION", 230, 237], ["liver", "ANATOMY", 266, 271]]], ["In addition, these studies found increased levels of IL-10 and reduced levels of TGF-\u03b2 in the liver, spleen, and heart in early and mid-stages of infection (60).", [["liver", "ANATOMY", 94, 99], ["spleen", "ANATOMY", 101, 107], ["heart", "ANATOMY", 113, 118], ["infection", "DISEASE", 146, 155], ["IL-10", "GENE_OR_GENE_PRODUCT", 53, 58], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 81, 86], ["liver", "ORGAN", 94, 99], ["spleen", "ORGAN", 101, 107], ["heart", "ORGAN", 113, 118], ["IL-10", "PROTEIN", 53, 58], ["TGF-\u03b2", "PROTEIN", 81, 86], ["these studies", "TEST", 13, 26], ["increased levels of IL", "PROBLEM", 33, 55], ["TGF", "TEST", 81, 84], ["infection", "PROBLEM", 146, 155], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["TGF", "OBSERVATION", 81, 84], ["liver", "ANATOMY", 94, 99], ["spleen", "ANATOMY", 101, 107], ["heart", "ANATOMY", 113, 118], ["early", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 146, 155]]], ["Syrian hamster can be used both to study the pathogenesis of the YFV infection, and to validate antiviral drugs and antiviral therapies.", [["hamster", "ANATOMY", 7, 14], ["YFV infection", "DISEASE", 65, 78], ["Syrian hamster", "ORGANISM", 0, 14], ["YFV", "ORGANISM", 65, 68], ["Syrian hamster", "SPECIES", 0, 14], ["Syrian hamster", "SPECIES", 0, 14], ["YFV", "SPECIES", 65, 68], ["Syrian hamster", "TREATMENT", 0, 14], ["the YFV infection", "PROBLEM", 61, 78], ["antiviral drugs", "TREATMENT", 96, 111], ["antiviral therapies", "TREATMENT", 116, 135], ["infection", "OBSERVATION", 69, 78]]], ["Recent findings have shown that treatment with the anti-viral compounds 2\u2032-C-methyl cytidine (61), T-1106 (62), IFN alfacon-1 (63), and BCX4430 (64) pre- and post-YFV exposure can significantly improve Syrian hamster survival.", [["hamster", "ANATOMY", 209, 216], ["2\u2032-C-methyl cytidine", "CHEMICAL", 72, 92], ["T-1106", "CHEMICAL", 99, 105], ["IFN alfacon-1", "CHEMICAL", 112, 125], ["BCX4430", "CHEMICAL", 136, 143], ["2\u2032-C-methyl cytidine", "CHEMICAL", 72, 92], ["T-1106", "CHEMICAL", 99, 105], ["BCX4430", "CHEMICAL", 136, 143], ["2\u2032-C-methyl cytidine", "SIMPLE_CHEMICAL", 72, 92], ["T-1106", "SIMPLE_CHEMICAL", 99, 105], ["IFN alfacon-1", "GENE_OR_GENE_PRODUCT", 112, 125], ["BCX4430", "SIMPLE_CHEMICAL", 136, 143], ["YFV", "ORGANISM", 163, 166], ["Syrian hamster", "ORGANISM", 202, 216], ["IFN", "PROTEIN", 112, 115], ["T-1106", "SPECIES", 99, 105], ["YFV", "SPECIES", 163, 166], ["Syrian hamster", "SPECIES", 202, 216], ["treatment", "TREATMENT", 32, 41], ["the anti-viral compounds", "TREATMENT", 47, 71], ["methyl cytidine", "TREATMENT", 77, 92], ["IFN alfacon", "TEST", 112, 123]]], ["In a study by Julander et al. immunization with DEF201, an AdV type-5 vector expressing IFN alpha (IFN-\u03b1), can effectively reduce the viral titer in hamster's liver and serum post-YFV infection (65).", [["hamster", "ANATOMY", 149, 156], ["liver", "ANATOMY", 159, 164], ["serum", "ANATOMY", 169, 174], ["DEF201", "CHEMICAL", 48, 54], ["IFN alpha (IFN-\u03b1", "CHEMICAL", 88, 104], ["infection", "DISEASE", 184, 193], ["DEF201", "SIMPLE_CHEMICAL", 48, 54], ["AdV type-5", "ORGANISM", 59, 69], ["IFN alpha", "GENE_OR_GENE_PRODUCT", 88, 97], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 99, 104], ["hamster", "ORGANISM", 149, 156], ["liver", "ORGAN", 159, 164], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["post-YFV", "ORGANISM", 175, 183], ["IFN alpha", "PROTEIN", 88, 97], ["IFN", "PROTEIN", 99, 102], ["\u03b1", "PROTEIN", 103, 104], ["hamster", "SPECIES", 149, 156], ["hamster", "SPECIES", 149, 156], ["YFV", "SPECIES", 180, 183], ["a study", "TEST", 3, 10], ["immunization", "TREATMENT", 30, 42], ["DEF201", "TREATMENT", 48, 54], ["an AdV type-5 vector", "TREATMENT", 56, 76], ["the viral titer in hamster's liver", "PROBLEM", 130, 164], ["serum post-YFV infection", "PROBLEM", 169, 193], ["viral titer", "OBSERVATION", 134, 145], ["liver", "ANATOMY", 159, 164], ["infection", "OBSERVATION", 184, 193]]], ["Immunoprophylaxis with XRX-001, a vaccine containing inactivated yellow fever antigen with an alum adjuvant, can elicit high titers of neutralizing antibodies in vivo to protect Syrian hamsters from YFV infection (66, 67).", [["XRX-001", "CHEMICAL", 23, 30], ["yellow fever", "DISEASE", 65, 77], ["YFV infection", "DISEASE", 199, 212], ["XRX-001", "CHEMICAL", 23, 30], ["alum", "CHEMICAL", 94, 98], ["XRX-001", "SIMPLE_CHEMICAL", 23, 30], ["yellow fever", "ORGANISM", 65, 77], ["antigen", "GENE_OR_GENE_PRODUCT", 78, 85], ["alum", "SIMPLE_CHEMICAL", 94, 98], ["Syrian hamsters", "ORGANISM", 178, 193], ["YFV", "ORGANISM", 199, 202], ["neutralizing antibodies", "PROTEIN", 135, 158], ["yellow fever", "SPECIES", 65, 77], ["Syrian hamsters", "SPECIES", 178, 193], ["Syrian hamsters", "SPECIES", 178, 193], ["YFV", "SPECIES", 199, 202], ["Immunoprophylaxis", "TREATMENT", 0, 17], ["XRX", "TREATMENT", 23, 26], ["a vaccine", "TREATMENT", 32, 41], ["inactivated yellow fever antigen", "PROBLEM", 53, 85], ["an alum adjuvant", "TREATMENT", 91, 107], ["neutralizing antibodies", "TREATMENT", 135, 158], ["YFV infection", "PROBLEM", 199, 212], ["infection", "OBSERVATION", 203, 212]]], ["Interestingly, Xiao et al. (67) and Tesh et al. (68) demonstrate that prior exposure of Syrian hamsters to heterologous flaviviruses reduces the risk of YFV infection.Nipah Virus ::: Syrian Hamster Used for Research in Viral InfectionsNipah is paramyxovirus of the genus Henipavirus (family Paramyxoviridae) with a high fatality rate (69).", [["flaviviruses", "DISEASE", 120, 132], ["YFV infection", "DISEASE", 153, 166], ["Nipah Virus", "DISEASE", 167, 178], ["Viral InfectionsNipah", "DISEASE", 219, 240], ["Syrian hamsters", "ORGANISM", 88, 103], ["YFV", "ORGANISM", 153, 156], ["Nipah Virus", "ORGANISM", 167, 178], ["Viral", "ORGANISM", 219, 224], ["Nipah", "ORGANISM", 235, 240], ["Syrian hamsters", "SPECIES", 88, 103], ["Nipah", "SPECIES", 167, 172], ["Nipah", "SPECIES", 235, 240], ["Syrian hamsters", "SPECIES", 88, 103], ["YFV", "SPECIES", 153, 156], ["Nipah Virus", "SPECIES", 167, 178], ["Syrian hamsters", "TREATMENT", 88, 103], ["heterologous flaviviruses", "PROBLEM", 107, 132], ["YFV infection", "PROBLEM", 153, 166], ["Syrian Hamster", "TREATMENT", 183, 197], ["Viral InfectionsNipah", "PROBLEM", 219, 240], ["the genus Henipavirus (family Paramyxoviridae", "TREATMENT", 261, 306], ["YFV", "OBSERVATION_MODIFIER", 153, 156], ["infection", "OBSERVATION", 157, 166], ["Viral", "OBSERVATION_MODIFIER", 219, 224], ["Infections", "OBSERVATION", 225, 235]]], ["Infection in humans usually causes severe encephalitic and respiratory disease (70).", [["encephalitic", "ANATOMY", 42, 54], ["respiratory", "ANATOMY", 59, 70], ["Infection", "DISEASE", 0, 9], ["encephalitic and respiratory disease", "DISEASE", 42, 78], ["humans", "ORGANISM", 13, 19], ["humans", "SPECIES", 13, 19], ["humans", "SPECIES", 13, 19], ["Infection in humans", "PROBLEM", 0, 19], ["severe encephalitic", "PROBLEM", 35, 54], ["respiratory disease", "PROBLEM", 59, 78], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["encephalitic", "OBSERVATION", 42, 54], ["respiratory disease", "OBSERVATION", 59, 78]]], ["After inoculation with Nipah virus (NiV), Syrian hamsters also develop characterisitic neurological disease (12).", [["neurological", "ANATOMY", 87, 99], ["Nipah virus", "DISEASE", 23, 34], ["neurological disease", "DISEASE", 87, 107], ["Nipah virus", "ORGANISM", 23, 34], ["NiV", "ORGANISM", 36, 39], ["Syrian hamsters", "ORGANISM", 42, 57], ["Nipah virus", "SPECIES", 23, 34], ["Syrian hamsters", "SPECIES", 42, 57], ["Nipah virus", "SPECIES", 23, 34], ["NiV", "SPECIES", 36, 39], ["Syrian hamsters", "SPECIES", 42, 57], ["Nipah virus (NiV", "TREATMENT", 23, 39], ["Syrian hamsters", "TREATMENT", 42, 57], ["characterisitic neurological disease", "PROBLEM", 71, 107], ["Nipah virus", "OBSERVATION", 23, 34], ["characterisitic", "OBSERVATION_MODIFIER", 71, 86], ["neurological disease", "OBSERVATION", 87, 107]]], ["Similar to symptoms after human infection, pathological lesions are the most severe and extensive in the hamster brain and viral antigen and RNA can be detected in neurons (11), lung (71), kidney, and spleen (11).", [["lesions", "ANATOMY", 56, 63], ["hamster brain", "ANATOMY", 105, 118], ["neurons", "ANATOMY", 164, 171], ["lung", "ANATOMY", 178, 182], ["kidney", "ANATOMY", 189, 195], ["spleen", "ANATOMY", 201, 207], ["human infection", "DISEASE", 26, 41], ["human", "ORGANISM", 26, 31], ["pathological lesions", "PATHOLOGICAL_FORMATION", 43, 63], ["hamster", "ORGANISM", 105, 112], ["brain", "ORGAN", 113, 118], ["viral antigen", "GENE_OR_GENE_PRODUCT", 123, 136], ["neurons", "CELL", 164, 171], ["lung", "ORGAN", 178, 182], ["kidney", "ORGAN", 189, 195], ["spleen", "ORGAN", 201, 207], ["human", "SPECIES", 26, 31], ["hamster", "SPECIES", 105, 112], ["human", "SPECIES", 26, 31], ["hamster", "SPECIES", 105, 112], ["symptoms", "PROBLEM", 11, 19], ["human infection", "PROBLEM", 26, 41], ["pathological lesions", "PROBLEM", 43, 63], ["extensive in the hamster brain", "PROBLEM", 88, 118], ["viral antigen and RNA", "PROBLEM", 123, 144], ["infection", "OBSERVATION", 32, 41], ["lesions", "OBSERVATION", 56, 63], ["most severe", "OBSERVATION_MODIFIER", 72, 83], ["extensive", "OBSERVATION_MODIFIER", 88, 97], ["hamster brain", "ANATOMY", 105, 118], ["viral antigen", "OBSERVATION", 123, 136], ["lung", "ANATOMY", 178, 182], ["kidney", "ANATOMY", 189, 195], ["spleen", "ANATOMY", 201, 207]]], ["The Syrian hamsters in the majority of NiV infection studies are treated by intraperitoneal (IP) injection or intranasal (IN.) delivery and these models have revealed that different inoculation method can cause diverse pathological responses (11).", [["intraperitoneal", "ANATOMY", 76, 91], ["NiV infection", "DISEASE", 39, 52], ["Syrian hamsters", "ORGANISM", 4, 19], ["NiV", "ORGANISM", 39, 42], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 91], ["Syrian hamsters", "SPECIES", 4, 19], ["Syrian hamsters", "SPECIES", 4, 19], ["NiV", "SPECIES", 39, 42], ["The Syrian hamsters", "TREATMENT", 0, 19], ["NiV infection studies", "PROBLEM", 39, 60], ["intraperitoneal (IP) injection", "TREATMENT", 76, 106], ["intranasal", "TREATMENT", 110, 120], ["delivery", "TREATMENT", 127, 135], ["these models", "TEST", 140, 152], ["different inoculation method", "TREATMENT", 172, 200], ["majority", "OBSERVATION_MODIFIER", 27, 35], ["NiV infection", "OBSERVATION", 39, 52]]], ["In Wong's work, IP injection of NiV in Syrian hamsters caused primarily neurological disease, while IN delivery developed neurological symptoms as well as labored breathing due to lung infection in the final stages of disease (11).", [["neurological", "ANATOMY", 72, 84], ["neurological", "ANATOMY", 122, 134], ["lung", "ANATOMY", 180, 184], ["neurological disease", "DISEASE", 72, 92], ["neurological symptoms", "DISEASE", 122, 143], ["labored breathing", "DISEASE", 155, 172], ["lung infection", "DISEASE", 180, 194], ["IP", "SIMPLE_CHEMICAL", 16, 18], ["NiV", "ORGANISM", 32, 35], ["Syrian hamsters", "ORGANISM", 39, 54], ["lung", "ORGAN", 180, 184], ["Syrian hamsters", "SPECIES", 39, 54], ["Syrian hamsters", "SPECIES", 39, 54], ["IP injection", "TREATMENT", 16, 28], ["NiV", "TREATMENT", 32, 35], ["primarily neurological disease", "PROBLEM", 62, 92], ["neurological symptoms", "PROBLEM", 122, 143], ["labored breathing", "PROBLEM", 155, 172], ["lung infection", "PROBLEM", 180, 194], ["disease", "PROBLEM", 218, 225], ["neurological disease", "OBSERVATION", 72, 92], ["lung", "ANATOMY", 180, 184], ["infection", "OBSERVATION", 185, 194], ["disease", "OBSERVATION", 218, 225]]], ["Disease progression is usually much rapid and the time to death post-infection is shorter following intraperitoneal rather than intranasal inoculation (72).", [["intraperitoneal", "ANATOMY", 100, 115], ["death", "DISEASE", 58, 63], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 100, 115], ["Disease progression", "PROBLEM", 0, 19], ["intranasal inoculation", "TREATMENT", 128, 150]]], ["Since the Syrian hamster has shown suitability for studying NiV infection, it was further used to study the viral transmission (73\u201375), demonstrating that Nipah virus is transmitted efficiently via direct contact and inefficiently via fomites, but not via aerosols.", [["hamster", "ANATOMY", 17, 24], ["NiV infection", "DISEASE", 60, 73], ["Nipah virus", "DISEASE", 155, 166], ["Syrian hamster", "ORGANISM", 10, 24], ["NiV", "ORGANISM", 60, 63], ["Nipah virus", "ORGANISM", 155, 166], ["Syrian hamster", "SPECIES", 10, 24], ["Nipah virus", "SPECIES", 155, 166], ["Syrian hamster", "SPECIES", 10, 24], ["NiV", "SPECIES", 60, 63], ["Nipah virus", "SPECIES", 155, 166], ["NiV infection", "PROBLEM", 60, 73], ["the viral transmission", "TEST", 104, 126], ["Nipah virus", "PROBLEM", 155, 166], ["infection", "OBSERVATION", 64, 73], ["Nipah virus", "OBSERVATION", 155, 166]]], ["Regarding the use of these models for development of disease treatment and prophylaxis, recent studies have shown that pretreatment with Poly(I)-poly(C12U) can significantly decrease the mortality caused by NiV infection of Syrian hamster (76).", [["Poly(I)-poly(C12U", "CHEMICAL", 137, 154], ["NiV infection", "DISEASE", 207, 220], ["Poly(I)-poly(C12U)", "CHEMICAL", 137, 155], ["Poly(I)-poly", "SIMPLE_CHEMICAL", 137, 149], ["C12U", "SIMPLE_CHEMICAL", 150, 154], ["NiV", "ORGANISM", 207, 210], ["Syrian hamster", "ORGANISM", 224, 238], ["Syrian hamster", "SPECIES", 224, 238], ["NiV", "SPECIES", 207, 210], ["Syrian hamster", "SPECIES", 224, 238], ["these models", "TREATMENT", 21, 33], ["disease treatment", "TREATMENT", 53, 70], ["prophylaxis", "TREATMENT", 75, 86], ["recent studies", "TEST", 88, 102], ["pretreatment with Poly(I)-poly(C12U)", "TREATMENT", 119, 155], ["disease", "OBSERVATION", 53, 60], ["infection", "OBSERVATION", 211, 220]]], ["In addition, the model was used as a platform for evaluation of vaccines for NiV (77\u201380).", [["NiV", "ORGANISM", 77, 80], ["NiV", "SPECIES", 77, 80], ["evaluation", "TEST", 50, 60], ["vaccines", "TREATMENT", 64, 72], ["NiV", "TREATMENT", 77, 80]]], ["Walpita et al. discovered purified NiV-like particles (VLP) can protect the Syrian hamster using either multiple-dose or single-dose vaccination regimens followed by NiV challenge (81).Ebola Virus ::: Syrian Hamster Used for Research in Viral InfectionsEbola virus (EBOV) is one of five known viruses within the genus Ebolavirus (family Filoviridae) (10).", [["hamster", "ANATOMY", 83, 90], ["Ebola Virus", "DISEASE", 185, 196], ["Viral InfectionsEbola virus", "DISEASE", 237, 264], ["NiV-like particles", "GENE_OR_GENE_PRODUCT", 35, 53], ["VLP", "ORGANISM", 55, 58], ["Syrian hamster", "ORGANISM", 76, 90], ["NiV", "ORGANISM", 166, 169], ["Ebola Virus", "ORGANISM", 185, 196], ["Syrian Hamster", "ORGANISM", 201, 215], ["Viral Infections", "ORGANISM", 237, 253], ["Ebola virus", "ORGANISM", 253, 264], ["EBOV", "ORGANISM", 266, 270], ["Syrian hamster", "SPECIES", 76, 90], ["Ebola Virus", "SPECIES", 185, 196], ["Ebola virus", "SPECIES", 253, 264], ["Syrian hamster", "SPECIES", 76, 90], ["NiV", "SPECIES", 166, 169], ["Ebola Virus", "SPECIES", 185, 196], ["Ebola virus", "SPECIES", 253, 264], ["EBOV", "SPECIES", 266, 270], ["purified NiV", "TREATMENT", 26, 38], ["single-dose vaccination regimens", "TREATMENT", 121, 153], ["Syrian Hamster", "TREATMENT", 201, 215], ["Research in Viral InfectionsEbola virus", "PROBLEM", 225, 264], ["five known viruses", "PROBLEM", 282, 300], ["Viral", "OBSERVATION_MODIFIER", 237, 242], ["Infections", "OBSERVATION", 243, 253], ["viruses", "OBSERVATION", 293, 300], ["genus Ebolavirus", "OBSERVATION", 312, 328]]], ["It's classified as biosafety level 4 (BSL-4) pathogen by the WHO.", [["biosafety level", "TEST", 19, 34], ["BSL", "TEST", 38, 41], ["pathogen", "PROBLEM", 45, 53]]], ["Not only can Syrian hamsters be effectively infected with mouse adapted (MA)-EBOV, they additionally display major hallmarks infection and pathogenesis seen in humans and non-human primates (NHPs).", [["infection", "DISEASE", 125, 134], ["Syrian hamsters", "ORGANISM", 13, 28], ["mouse", "ORGANISM", 58, 63], ["adapted (MA)-EBOV", "ORGANISM", 64, 81], ["humans", "ORGANISM", 160, 166], ["non-human primates", "ORGANISM", 171, 189], ["NHPs", "ORGANISM", 191, 195], ["Syrian hamsters", "SPECIES", 13, 28], ["mouse", "SPECIES", 58, 63], ["humans", "SPECIES", 160, 166], ["Syrian hamsters", "SPECIES", 13, 28], ["mouse", "SPECIES", 58, 63], ["EBOV", "SPECIES", 77, 81], ["humans", "SPECIES", 160, 166], ["EBOV", "PROBLEM", 77, 81], ["major hallmarks infection", "PROBLEM", 109, 134], ["pathogenesis", "PROBLEM", 139, 151], ["infection", "OBSERVATION", 125, 134]]], ["Syrian hamsters could be inoculated via intraperitoneal injection with mouse adapted Zaire Ebola virus (MA-ZEBOV).", [["intraperitoneal", "ANATOMY", 40, 55], ["Syrian hamsters", "ORGANISM", 0, 15], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 55], ["mouse", "ORGANISM", 71, 76], ["Zaire Ebola virus", "ORGANISM", 85, 102], ["MA-ZEBOV", "ORGANISM", 104, 112], ["Syrian hamsters", "SPECIES", 0, 15], ["mouse", "SPECIES", 71, 76], ["Zaire Ebola virus", "SPECIES", 85, 102], ["Syrian hamsters", "SPECIES", 0, 15], ["mouse", "SPECIES", 71, 76], ["Zaire Ebola virus", "SPECIES", 85, 102], ["ZEBOV", "SPECIES", 107, 112], ["Syrian hamsters", "TREATMENT", 0, 15], ["intraperitoneal injection", "TREATMENT", 40, 65], ["intraperitoneal", "ANATOMY", 40, 55]]], ["The pathology caused by this infection is similar to that of humans, which includes significant spleen and liver damage, cytokine dysregulation, severe coagulopathy, lymphocyte apoptosis, and infected organ necrosis or apoptosis (21, 82).", [["spleen", "ANATOMY", 96, 102], ["liver", "ANATOMY", 107, 112], ["lymphocyte", "ANATOMY", 166, 176], ["organ", "ANATOMY", 201, 206], ["infection", "DISEASE", 29, 38], ["spleen and liver damage", "DISEASE", 96, 119], ["coagulopathy", "DISEASE", 152, 164], ["infected organ necrosis", "DISEASE", 192, 215], ["humans", "ORGANISM", 61, 67], ["spleen", "ORGAN", 96, 102], ["liver", "ORGAN", 107, 112], ["lymphocyte", "CELL", 166, 176], ["organ", "ORGAN", 201, 206], ["cytokine", "PROTEIN", 121, 129], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67], ["The pathology", "TEST", 0, 13], ["this infection", "PROBLEM", 24, 38], ["significant spleen", "PROBLEM", 84, 102], ["liver damage", "PROBLEM", 107, 119], ["cytokine dysregulation", "PROBLEM", 121, 143], ["severe coagulopathy", "PROBLEM", 145, 164], ["lymphocyte apoptosis", "PROBLEM", 166, 186], ["infected organ necrosis", "PROBLEM", 192, 215], ["apoptosis", "PROBLEM", 219, 228], ["infection", "OBSERVATION", 29, 38], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["spleen", "ANATOMY", 96, 102], ["liver", "ANATOMY", 107, 112], ["damage", "OBSERVATION", 113, 119], ["cytokine dysregulation", "OBSERVATION", 121, 143], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["coagulopathy", "OBSERVATION", 152, 164], ["lymphocyte apoptosis", "OBSERVATION", 166, 186], ["infected", "OBSERVATION_MODIFIER", 192, 200], ["organ", "ANATOMY", 201, 206], ["necrosis", "OBSERVATION", 207, 215], ["apoptosis", "OBSERVATION_MODIFIER", 219, 228]]], ["The immune responses of infected Syrian hamsters include activation of T cell and antibody production.", [["T cell", "ANATOMY", 71, 77], ["Syrian hamsters", "ORGANISM", 33, 48], ["T cell", "CELL", 71, 77], ["Syrian hamsters", "SPECIES", 33, 48], ["Syrian hamsters", "SPECIES", 33, 48], ["infected Syrian hamsters", "TREATMENT", 24, 48], ["T cell", "PROBLEM", 71, 77], ["antibody production", "PROBLEM", 82, 101], ["infected Syrian hamsters", "OBSERVATION", 24, 48], ["T cell", "OBSERVATION", 71, 77]]], ["In a recent study, the results of Ebola virus infection in hamsters demonstrate that CD4+ T cells are required for natural immunity and CD4-dependent antibody responses are required for immunity against the virus in this model (83).", [["CD4+", "ANATOMY", 85, 89], ["T cells", "ANATOMY", 90, 97], ["Ebola virus infection", "DISEASE", 34, 55], ["Ebola virus", "ORGANISM", 34, 45], ["hamsters", "ORGANISM", 59, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["T cells", "CELL", 90, 97], ["CD4", "GENE_OR_GENE_PRODUCT", 136, 139], ["CD4", "PROTEIN", 85, 88], ["T cells", "CELL_TYPE", 90, 97], ["CD4", "PROTEIN", 136, 139], ["Ebola virus", "SPECIES", 34, 45], ["hamsters", "SPECIES", 59, 67], ["Ebola virus", "SPECIES", 34, 45], ["hamsters", "SPECIES", 59, 67], ["a recent study", "TEST", 3, 17], ["Ebola virus infection", "PROBLEM", 34, 55], ["CD4", "TEST", 85, 88], ["T cells", "PROBLEM", 90, 97], ["natural immunity", "TREATMENT", 115, 131], ["CD4-dependent antibody responses", "TEST", 136, 168], ["the virus", "PROBLEM", 203, 212], ["Ebola virus", "OBSERVATION", 34, 45], ["CD4", "OBSERVATION", 85, 88]]], ["Syrian hamsters can be used to evaluate a bivalent vaccine comprising recombinant Vesicular stomatitis virus (VSV) expressing two different immunogens derived from ZEBOV envelope glycoprotein (84) and Andes Virus (ANDV) (32).", [["Vesicular stomatitis", "DISEASE", 82, 102], ["Syrian hamsters", "ORGANISM", 0, 15], ["recombinant", "ORGANISM", 70, 81], ["Vesicular stomatitis virus", "ORGANISM", 82, 108], ["VSV", "ORGANISM", 110, 113], ["ZEBOV envelope glycoprotein", "ORGANISM", 164, 191], ["Andes Virus", "ORGANISM", 201, 212], ["ZEBOV envelope glycoprotein", "PROTEIN", 164, 191], ["Syrian hamsters", "SPECIES", 0, 15], ["Vesicular stomatitis virus", "SPECIES", 82, 108], ["Syrian hamsters", "SPECIES", 0, 15], ["Vesicular stomatitis virus", "SPECIES", 82, 108], ["VSV", "SPECIES", 110, 113], ["ZEBOV", "SPECIES", 164, 169], ["ANDV", "SPECIES", 214, 218], ["Syrian hamsters", "TREATMENT", 0, 15], ["a bivalent vaccine", "TREATMENT", 40, 58], ["recombinant Vesicular stomatitis virus", "PROBLEM", 70, 108], ["ZEBOV envelope glycoprotein", "TREATMENT", 164, 191], ["Andes Virus", "PROBLEM", 201, 212], ["Vesicular stomatitis", "OBSERVATION", 82, 102]]], ["The results showed that a single immunization with this vaccine provides hamsters complete and sterile protection against lethal challenge with MA-ZEBOV or ANDV (85).Marburg Virus ::: Syrian Hamster Used for Research in Viral InfectionsMarburg virus (MARV) is also a negative sense RNA virus belonging to the family Filoviridae that causes hemorrhagic fever (86).", [["MA", "CHEMICAL", 144, 146], ["Viral InfectionsMarburg virus", "DISEASE", 220, 249], ["hemorrhagic fever", "DISEASE", 340, 357], ["hamsters", "ORGANISM", 73, 81], ["MA-ZEBOV", "ORGANISM", 144, 152], ["Marburg Virus", "ORGANISM", 166, 179], ["Syrian Hamster", "ORGANISM", 184, 198], ["Viral InfectionsMarburg virus", "ORGANISM", 220, 249], ["MARV", "ORGANISM", 251, 255], ["Marburg virus", "SPECIES", 236, 249], ["hamsters", "SPECIES", 73, 81], ["ZEBOV", "SPECIES", 147, 152], ["ANDV", "SPECIES", 156, 160], ["Marburg Virus", "SPECIES", 166, 179], ["Viral InfectionsMarburg virus", "SPECIES", 220, 249], ["MARV", "SPECIES", 251, 255], ["a single immunization", "TREATMENT", 24, 45], ["this vaccine", "TREATMENT", 51, 63], ["sterile protection", "TREATMENT", 95, 113], ["Syrian Hamster", "TREATMENT", 184, 198], ["Viral InfectionsMarburg virus", "PROBLEM", 220, 249], ["a negative sense RNA virus", "PROBLEM", 265, 291], ["Filoviridae", "TREATMENT", 316, 327], ["hemorrhagic fever", "PROBLEM", 340, 357], ["Viral", "OBSERVATION_MODIFIER", 220, 225], ["Infections", "OBSERVATION", 226, 236], ["hemorrhagic", "OBSERVATION_MODIFIER", 340, 351]]], ["Researchers have shown that Syrian hamsters can be used to study MARV infection.", [["MARV infection", "DISEASE", 65, 79], ["Syrian hamsters", "ORGANISM", 28, 43], ["MARV", "ORGANISM", 65, 69], ["hamsters", "SPECIES", 35, 43], ["Syrian hamsters", "SPECIES", 28, 43], ["MARV", "SPECIES", 65, 69], ["Syrian hamsters", "TREATMENT", 28, 43], ["MARV infection", "PROBLEM", 65, 79], ["infection", "OBSERVATION", 70, 79]]], ["The Syrian hamster model was established to study MARV infection using the Angola variant (HA-MARV) (22).", [["MARV infection", "DISEASE", 50, 64], ["Syrian hamster", "ORGANISM", 4, 18], ["MARV", "ORGANISM", 50, 54], ["HA-MARV", "ORGANISM", 91, 98], ["hamster", "SPECIES", 11, 18], ["Syrian hamster", "SPECIES", 4, 18], ["MARV", "SPECIES", 50, 54], ["The Syrian hamster model", "TREATMENT", 0, 24], ["MARV infection", "PROBLEM", 50, 64], ["infection", "OBSERVATION", 55, 64]]], ["In the study, hamsters inoculated with HA-MARV developed hemorrhagic manifestations, coagulation abnormalities, dysregulation of pro-inflammatory chemokines MIP-1\u03b1 and IP-10, and increment of type I interferon responses (22, 87).", [["hemorrhagic", "DISEASE", 57, 68], ["coagulation abnormalities", "DISEASE", 85, 110], ["hamsters", "ORGANISM", 14, 22], ["HA-MARV", "ORGANISM", 39, 46], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 157, 163], ["IP-10", "GENE_OR_GENE_PRODUCT", 168, 173], ["type I interferon", "GENE_OR_GENE_PRODUCT", 192, 209], ["pro-inflammatory chemokines", "PROTEIN", 129, 156], ["MIP-1\u03b1", "PROTEIN", 157, 163], ["IP", "PROTEIN", 168, 170], ["type I interferon", "PROTEIN", 192, 209], ["hamsters", "SPECIES", 14, 22], ["hamsters", "SPECIES", 14, 22], ["MARV", "SPECIES", 42, 46], ["the study", "TEST", 3, 12], ["HA", "PROBLEM", 39, 41], ["MARV", "PROBLEM", 42, 46], ["hemorrhagic manifestations", "PROBLEM", 57, 83], ["coagulation abnormalities", "PROBLEM", 85, 110], ["pro-inflammatory chemokines MIP", "TEST", 129, 160], ["IP", "TEST", 168, 170], ["type I interferon responses", "PROBLEM", 192, 219], ["hemorrhagic", "OBSERVATION_MODIFIER", 57, 68], ["pro-inflammatory", "OBSERVATION_MODIFIER", 129, 145]]], ["In addition, Atkins et al. recently developed a small animal model for wild-type MARV infection using STAT2 KO Syrian hamster, in which viral replication rapidly progresses to multiorgan infection and extensive viremia (23), demonstrating STAT2 as a key host factor affecting wild-type MARV infection.Rift Valley Fever Virus ::: Syrian Hamster Used for Research in Viral InfectionsRVFV is a member of the Bunyaviridae family and the genus Phlebovirus (88, 89).", [["hamster", "ANATOMY", 118, 125], ["multiorgan", "ANATOMY", 176, 186], ["MARV infection", "DISEASE", 81, 95], ["multiorgan infection", "DISEASE", 176, 196], ["viremia", "DISEASE", 211, 218], ["infection", "DISEASE", 291, 300], ["Rift Valley Fever", "DISEASE", 301, 318], ["Viral InfectionsRVFV", "DISEASE", 365, 385], ["wild-type", "ORGANISM", 71, 80], ["MARV", "ORGANISM", 81, 85], ["STAT2", "GENE_OR_GENE_PRODUCT", 102, 107], ["Syrian hamster", "ORGANISM", 111, 125], ["STAT2", "GENE_OR_GENE_PRODUCT", 239, 244], ["wild-type MARV", "ORGANISM", 276, 290], ["Rift Valley Fever Virus", "ORGANISM", 301, 324], ["STAT2", "PROTEIN", 102, 107], ["STAT2", "PROTEIN", 239, 244], ["Syrian hamster", "SPECIES", 111, 125], ["MARV", "SPECIES", 81, 85], ["Syrian hamster", "SPECIES", 111, 125], ["MARV", "SPECIES", 286, 290], ["Rift Valley Fever Virus", "SPECIES", 301, 324], ["a small animal model", "PROBLEM", 46, 66], ["type MARV infection", "PROBLEM", 76, 95], ["STAT2 KO Syrian hamster", "TREATMENT", 102, 125], ["viral replication", "PROBLEM", 136, 153], ["multiorgan infection", "PROBLEM", 176, 196], ["extensive viremia", "PROBLEM", 201, 218], ["type MARV infection", "PROBLEM", 281, 300], ["the genus Phlebovirus", "TEST", 429, 450], ["small", "OBSERVATION_MODIFIER", 48, 53], ["infection", "OBSERVATION", 86, 95], ["viral replication", "OBSERVATION", 136, 153], ["multiorgan", "ANATOMY", 176, 186], ["infection", "OBSERVATION", 187, 196], ["extensive", "OBSERVATION_MODIFIER", 201, 210], ["viremia", "OBSERVATION", 211, 218], ["type MARV", "OBSERVATION_MODIFIER", 281, 290], ["infection", "OBSERVATION", 291, 300], ["Viral InfectionsRVFV", "OBSERVATION", 365, 385], ["genus Phlebovirus", "ANATOMY", 433, 450]]], ["RVFV is usually transmitted via bites of infected mosquitos and can lead to mild febrile illness, retinitis, fulminant hepatitis, encephalitis and viral hemorrhagic fever (90).", [["mosquitos", "ANATOMY", 50, 59], ["RVFV", "DISEASE", 0, 4], ["infected mosquitos", "DISEASE", 41, 59], ["febrile illness", "DISEASE", 81, 96], ["retinitis", "DISEASE", 98, 107], ["fulminant hepatitis", "DISEASE", 109, 128], ["encephalitis", "DISEASE", 130, 142], ["viral hemorrhagic fever", "DISEASE", 147, 170], ["RVFV", "ORGANISM", 0, 4], ["viral hemorrhagic fever", "SPECIES", 147, 170], ["RVFV", "SPECIES", 0, 4], ["RVFV", "PROBLEM", 0, 4], ["infected mosquitos", "PROBLEM", 41, 59], ["mild febrile illness", "PROBLEM", 76, 96], ["retinitis", "PROBLEM", 98, 107], ["fulminant hepatitis", "PROBLEM", 109, 128], ["encephalitis", "PROBLEM", 130, 142], ["viral hemorrhagic fever", "PROBLEM", 147, 170], ["mild", "OBSERVATION_MODIFIER", 76, 80], ["febrile", "OBSERVATION", 81, 88], ["retinitis", "OBSERVATION", 98, 107], ["fulminant", "OBSERVATION_MODIFIER", 109, 118], ["hepatitis", "OBSERVATION", 119, 128], ["encephalitis", "OBSERVATION", 130, 142], ["viral", "OBSERVATION_MODIFIER", 147, 152], ["hemorrhagic", "OBSERVATION_MODIFIER", 153, 164]]], ["The infection of RVFV in Syrian hamsters has been well-described (91).", [["infection", "DISEASE", 4, 13], ["RVFV", "DISEASE", 17, 21], ["RVFV", "ORGANISM", 17, 21], ["Syrian hamsters", "ORGANISM", 25, 40], ["Syrian hamsters", "SPECIES", 25, 40], ["RVFV", "SPECIES", 17, 21], ["Syrian hamsters", "SPECIES", 25, 40], ["The infection of RVFV", "PROBLEM", 0, 21], ["infection", "OBSERVATION", 4, 13], ["RVFV", "OBSERVATION", 17, 21]]], ["The study results have assessed the susceptibility of Syrian hamsters to RVFV infection and shown that viral infection results in viremia, elevation of viral loads in liver, brain, and spleen tissues, observation of severe hepatocellular necrosis in the early stage of infection, and intense immunoreactivity of affected hepatocytes (27, 92, 93).", [["liver", "ANATOMY", 167, 172], ["brain", "ANATOMY", 174, 179], ["spleen tissues", "ANATOMY", 185, 199], ["hepatocellular", "ANATOMY", 223, 237], ["hepatocytes", "ANATOMY", 321, 332], ["RVFV infection", "DISEASE", 73, 87], ["viral infection", "DISEASE", 103, 118], ["viremia", "DISEASE", 130, 137], ["hepatocellular necrosis", "DISEASE", 223, 246], ["infection", "DISEASE", 269, 278], ["Syrian hamsters", "ORGANISM", 54, 69], ["RVFV", "ORGANISM", 73, 77], ["liver", "ORGAN", 167, 172], ["brain", "ORGAN", 174, 179], ["spleen tissues", "TISSUE", 185, 199], ["hepatocellular", "ORGAN", 223, 237], ["hepatocytes", "CELL", 321, 332], ["hepatocytes", "CELL_TYPE", 321, 332], ["Syrian hamsters", "SPECIES", 54, 69], ["Syrian hamsters", "SPECIES", 54, 69], ["RVFV", "SPECIES", 73, 77], ["The study", "TEST", 0, 9], ["RVFV infection", "PROBLEM", 73, 87], ["viral infection", "PROBLEM", 103, 118], ["viremia", "PROBLEM", 130, 137], ["elevation of viral loads in liver, brain, and spleen tissues", "PROBLEM", 139, 199], ["severe hepatocellular necrosis", "PROBLEM", 216, 246], ["infection", "PROBLEM", 269, 278], ["intense immunoreactivity of affected hepatocytes", "PROBLEM", 284, 332], ["RVFV", "OBSERVATION_MODIFIER", 73, 77], ["infection", "OBSERVATION", 78, 87], ["viral", "OBSERVATION_MODIFIER", 103, 108], ["infection", "OBSERVATION", 109, 118], ["viremia", "OBSERVATION", 130, 137], ["elevation", "OBSERVATION_MODIFIER", 139, 148], ["viral loads", "OBSERVATION", 152, 163], ["liver", "ANATOMY", 167, 172], ["brain", "ANATOMY", 174, 179], ["spleen tissues", "ANATOMY", 185, 199], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["hepatocellular", "OBSERVATION_MODIFIER", 223, 237], ["necrosis", "OBSERVATION", 238, 246], ["early stage", "OBSERVATION_MODIFIER", 254, 265], ["infection", "OBSERVATION", 269, 278], ["intense", "OBSERVATION_MODIFIER", 284, 291], ["immunoreactivity", "OBSERVATION_MODIFIER", 292, 308], ["affected", "OBSERVATION_MODIFIER", 312, 320], ["hepatocytes", "ANATOMY", 321, 332]]], ["Furthermore, using Syrian hamsters, Scharton et al. proved that prophylactic Favipiravir (T-705) can effectively protect infected individuals against RVFV infection and reduce delayed-onset neurologic disease observed with ribavirin treatment (94).", [["neurologic", "ANATOMY", 190, 200], ["Favipiravir", "CHEMICAL", 77, 88], ["T-705", "CHEMICAL", 90, 95], ["RVFV infection", "DISEASE", 150, 164], ["neurologic disease", "DISEASE", 190, 208], ["ribavirin", "CHEMICAL", 223, 232], ["Favipiravir", "CHEMICAL", 77, 88], ["T-705", "CHEMICAL", 90, 95], ["ribavirin", "CHEMICAL", 223, 232], ["Syrian hamsters", "ORGANISM", 19, 34], ["Favipiravir", "SIMPLE_CHEMICAL", 77, 88], ["T-705", "SIMPLE_CHEMICAL", 90, 95], ["individuals", "ORGANISM", 130, 141], ["RVFV", "ORGANISM", 150, 154], ["ribavirin", "SIMPLE_CHEMICAL", 223, 232], ["Syrian hamsters", "SPECIES", 19, 34], ["RVFV", "SPECIES", 150, 154], ["prophylactic Favipiravir", "TREATMENT", 64, 88], ["RVFV infection", "PROBLEM", 150, 164], ["delayed-onset neurologic disease", "PROBLEM", 176, 208], ["ribavirin treatment", "TREATMENT", 223, 242], ["-onset", "OBSERVATION_MODIFIER", 183, 189], ["neurologic disease", "OBSERVATION", 190, 208]]], ["In another study, Gowen et al. used hamsters to demonstrate protection from infection with just a single-dose intranasal treatment of the AdV-IFN\u03b1 vector DEF201 (95).", [["infection", "DISEASE", 76, 85], ["hamsters", "ORGANISM", 36, 44], ["AdV", "ORGANISM", 138, 141], ["IFN", "PROTEIN", 142, 145], ["another study", "TEST", 3, 16], ["infection", "PROBLEM", 76, 85], ["a single-dose intranasal treatment", "TREATMENT", 96, 130], ["infection", "OBSERVATION", 76, 85]]], ["In addtion, results presented by Westover et al. demonstrate that the adenosine analog, galidesivir (BCX4430), can effectively reduce the RVFV titer in infected Syrian hamsters (96).Other Viruses ::: Syrian Hamster Used for Research in Viral InfectionsA large number of other studies have also demonstrated that Syrian hamster is a permissive small animal model for other viruses, for example, Syrian hamster model was successfully used to test the efficacy of anti-F MAbs to reduce Hendra virus infection (12).", [["adenosine", "CHEMICAL", 70, 79], ["galidesivir", "CHEMICAL", 88, 99], ["BCX4430", "CHEMICAL", 101, 108], ["Viral Infections", "DISEASE", 236, 252], ["Hendra virus infection", "DISEASE", 483, 505], ["adenosine", "CHEMICAL", 70, 79], ["galidesivir", "CHEMICAL", 88, 99], ["BCX4430", "CHEMICAL", 101, 108], ["adenosine", "SIMPLE_CHEMICAL", 70, 79], ["galidesivir", "SIMPLE_CHEMICAL", 88, 99], ["BCX4430", "SIMPLE_CHEMICAL", 101, 108], ["RVFV", "ORGANISM", 138, 142], ["Syrian hamsters", "ORGANISM", 161, 176], ["Syrian hamster", "ORGANISM", 312, 326], ["Syrian hamster", "ORGANISM", 394, 408], ["anti-F MAbs", "GENE_OR_GENE_PRODUCT", 461, 472], ["Hendra virus", "ORGANISM", 483, 495], ["anti-F MAbs", "PROTEIN", 461, 472], ["Syrian hamsters", "SPECIES", 161, 176], ["Syrian hamster", "SPECIES", 312, 326], ["Syrian hamster", "SPECIES", 394, 408], ["Hendra virus", "SPECIES", 483, 495], ["RVFV", "SPECIES", 138, 142], ["Syrian hamsters", "SPECIES", 161, 176], ["Syrian hamster", "SPECIES", 312, 326], ["Syrian hamster", "SPECIES", 394, 408], ["Hendra virus", "SPECIES", 483, 495], ["the adenosine analog", "TREATMENT", 66, 86], ["the RVFV titer", "PROBLEM", 134, 148], ["Viral Infections", "PROBLEM", 236, 252], ["other studies", "TEST", 270, 283], ["other viruses", "PROBLEM", 366, 379], ["Syrian hamster model", "TREATMENT", 394, 414], ["anti-F MAbs", "TREATMENT", 461, 472], ["Hendra virus infection", "PROBLEM", 483, 505], ["RVFV", "OBSERVATION", 138, 142], ["Viruses", "OBSERVATION", 188, 195], ["Viral", "OBSERVATION_MODIFIER", 236, 241], ["Infections", "OBSERVATION", 242, 252], ["large", "OBSERVATION_MODIFIER", 254, 259], ["viruses", "OBSERVATION", 372, 379], ["Hendra virus", "OBSERVATION", 483, 495]]], ["STAT2 KO Syrian hamster have shown successful infection with Zika virus (ZIKV) and the infected hamsters displayed the similar symptoms as in human (15).", [["hamster", "ANATOMY", 16, 23], ["infection", "DISEASE", 46, 55], ["STAT2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Syrian hamster", "ORGANISM", 9, 23], ["Zika virus", "ORGANISM", 61, 71], ["hamsters", "ORGANISM", 96, 104], ["human", "ORGANISM", 142, 147], ["STAT2", "PROTEIN", 0, 5], ["Syrian hamster", "SPECIES", 9, 23], ["Zika virus", "SPECIES", 61, 71], ["hamsters", "SPECIES", 96, 104], ["human", "SPECIES", 142, 147], ["Syrian hamster", "SPECIES", 9, 23], ["Zika virus", "SPECIES", 61, 71], ["ZIKV", "SPECIES", 73, 77], ["hamsters", "SPECIES", 96, 104], ["human", "SPECIES", 142, 147], ["successful infection", "PROBLEM", 35, 55], ["Zika virus", "PROBLEM", 61, 71], ["the similar symptoms", "PROBLEM", 115, 135], ["successful", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 46, 55]]], ["Also, an immunosuppressed Syrian hamster generated by Schaecher et al. strengthened its valuable application in study of severe acute respiratory syndrome coronavirus (SARS-CoV) infection (34).", [["acute respiratory syndrome coronavirus", "DISEASE", 128, 166], ["SARS-CoV) infection", "DISEASE", 168, 187], ["Syrian hamster", "ORGANISM", 26, 40], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 121, 166], ["SARS-CoV", "ORGANISM", 168, 176], ["Syrian hamster", "SPECIES", 26, 40], ["Syrian hamster", "SPECIES", 26, 40], ["severe acute respiratory syndrome coronavirus", "SPECIES", 121, 166], ["SARS-CoV", "SPECIES", 168, 176], ["an immunosuppressed Syrian hamster", "TREATMENT", 6, 40], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 121, 166], ["SARS-CoV) infection", "PROBLEM", 168, 187], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["respiratory syndrome", "OBSERVATION", 134, 154]]], ["Syrian hamster has successfully been characterized for infection of human influenza, including the recent H1N1, pdm09, and H3N2 viruses (97).", [["hamster", "ANATOMY", 7, 14], ["infection", "DISEASE", 55, 64], ["influenza", "DISEASE", 74, 83], ["Syrian hamster", "ORGANISM", 0, 14], ["human", "ORGANISM", 68, 73], ["pdm09", "GENE_OR_GENE_PRODUCT", 112, 117], ["H3N2 viruses", "ORGANISM", 123, 135], ["Syrian hamster", "SPECIES", 0, 14], ["human", "SPECIES", 68, 73], ["H3N2", "SPECIES", 123, 127], ["Syrian hamster", "SPECIES", 0, 14], ["human", "SPECIES", 68, 73], ["infection", "PROBLEM", 55, 64], ["human influenza", "PROBLEM", 68, 83], ["the recent H1N1", "PROBLEM", 95, 110], ["pdm09", "PROBLEM", 112, 117], ["H3N2 viruses", "PROBLEM", 123, 135], ["infection", "OBSERVATION", 55, 64], ["H1N1", "OBSERVATION", 106, 110]]], ["Moreover, as a permissive immunocompetent animal model for the study of oncolytic adenovirus, its use has been expanding for the study of cancer virotherapies (98\u2013100).Leptospira interrogan ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsPathogenic Leptospira interrogans is spirochete bacteria responsible for leptospirosis, a widespread and emerging neglected zoonotic.", [["cancer", "ANATOMY", 138, 144], ["cancer", "DISEASE", 138, 144], ["Parasitic Infections", "DISEASE", 244, 264], ["Leptospira interrogans", "DISEASE", 275, 297], ["leptospirosis", "DISEASE", 337, 350], ["adenovirus", "ORGANISM", 82, 92], ["cancer", "CANCER", 138, 144], ["Leptospira interrogans", "ORGANISM", 275, 297], ["Leptospira interrogans", "SPECIES", 275, 297], ["adenovirus", "SPECIES", 82, 92], ["Leptospira interrogan", "SPECIES", 168, 189], ["Leptospira interrogans", "SPECIES", 275, 297], ["the study", "TEST", 59, 68], ["oncolytic adenovirus", "TREATMENT", 72, 92], ["the study", "TEST", 125, 134], ["cancer virotherapies", "TEST", 138, 158], ["Syrian Hamster", "TREATMENT", 194, 208], ["Research in Bacterial and Parasitic Infections", "PROBLEM", 218, 264], ["Pathogenic Leptospira interrogans", "PROBLEM", 264, 297], ["spirochete bacteria", "PROBLEM", 301, 320], ["leptospirosis", "PROBLEM", 337, 350], ["Bacterial", "OBSERVATION_MODIFIER", 230, 239], ["Parasitic", "OBSERVATION_MODIFIER", 244, 253], ["Infections", "OBSERVATION", 254, 264]]], ["Syrian hamster is the preferred model to study the infection of serovars of Leptospira interrogans, with bacteria traveling rapidly to the bloodstream via the lymphatics, then invading tissues and infecting all organs prior to the death of the hamsters (108).", [["hamster", "ANATOMY", 7, 14], ["bloodstream", "ANATOMY", 139, 150], ["lymphatics", "ANATOMY", 159, 169], ["tissues", "ANATOMY", 185, 192], ["organs", "ANATOMY", 211, 217], ["infection", "DISEASE", 51, 60], ["death", "DISEASE", 231, 236], ["Syrian hamster", "ORGANISM", 0, 14], ["Leptospira interrogans", "ORGANISM", 76, 98], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 159, 169], ["tissues", "TISSUE", 185, 192], ["organs", "ORGAN", 211, 217], ["hamsters", "ORGANISM", 244, 252], ["Syrian hamster", "SPECIES", 0, 14], ["Leptospira interrogans", "SPECIES", 76, 98], ["Syrian hamster", "SPECIES", 0, 14], ["Leptospira interrogans", "SPECIES", 76, 98], ["Leptospira interrogans", "PROBLEM", 76, 98], ["bacteria", "PROBLEM", 105, 113], ["infection", "OBSERVATION", 51, 60], ["lymphatics", "ANATOMY", 159, 169]]], ["Similar to human, the presence of Leptospira interrogans can be detected in liver and kidney, with the destruction of hepatocyte junctions that leads to jaundice, thrombotic glomerulopathy, and interstitial nephritis (109, 110).", [["liver", "ANATOMY", 76, 81], ["kidney", "ANATOMY", 86, 92], ["hepatocyte junctions", "ANATOMY", 118, 138], ["interstitial", "ANATOMY", 194, 206], ["jaundice", "DISEASE", 153, 161], ["thrombotic glomerulopathy", "DISEASE", 163, 188], ["interstitial nephritis", "DISEASE", 194, 216], ["human", "ORGANISM", 11, 16], ["Leptospira interrogans", "ORGANISM", 34, 56], ["liver", "ORGAN", 76, 81], ["kidney", "ORGAN", 86, 92], ["hepatocyte junctions", "TISSUE", 118, 138], ["human", "SPECIES", 11, 16], ["Leptospira interrogans", "SPECIES", 34, 56], ["human", "SPECIES", 11, 16], ["Leptospira interrogans", "SPECIES", 34, 56], ["Leptospira interrogans", "PROBLEM", 34, 56], ["the destruction of hepatocyte junctions", "PROBLEM", 99, 138], ["jaundice", "PROBLEM", 153, 161], ["thrombotic glomerulopathy", "PROBLEM", 163, 188], ["interstitial nephritis", "PROBLEM", 194, 216], ["Leptospira interrogans", "OBSERVATION", 34, 56], ["liver", "ANATOMY", 76, 81], ["kidney", "ANATOMY", 86, 92], ["destruction", "OBSERVATION", 103, 114], ["hepatocyte junctions", "OBSERVATION", 118, 138], ["jaundice", "OBSERVATION", 153, 161], ["thrombotic", "OBSERVATION_MODIFIER", 163, 173], ["glomerulopathy", "OBSERVATION", 174, 188], ["interstitial", "ANATOMY_MODIFIER", 194, 206], ["nephritis", "OBSERVATION", 207, 216]]], ["Infected animals develop the enhanced expression of pro-inflammatory cytokines by peripheral blood cells, such as IL-1\u03b1, IL-10, TNF-\u03b1 (111).", [["peripheral blood cells", "ANATOMY", 82, 104], ["animals", "ORGANISM", 9, 16], ["peripheral blood cells", "CELL", 82, 104], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 114, 119], ["IL-10", "GENE_OR_GENE_PRODUCT", 121, 126], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 128, 133], ["pro-inflammatory cytokines", "PROTEIN", 52, 78], ["peripheral blood cells", "CELL_TYPE", 82, 104], ["IL", "PROTEIN", 114, 116], ["TNF", "PROTEIN", 128, 131], ["Infected animals", "PROBLEM", 0, 16], ["pro-inflammatory cytokines", "PROBLEM", 52, 78], ["peripheral blood cells", "TEST", 82, 104], ["IL", "TEST", 114, 116], ["IL", "TEST", 121, 123], ["TNF", "TEST", 128, 131], ["pro-inflammatory cytokines", "OBSERVATION", 52, 78]]], ["Dramatic imbalance in the cytokine production upon Leptospira infection might play an important role in the development of severe leptospirosis (112).", [["Leptospira infection", "DISEASE", 51, 71], ["leptospirosis", "DISEASE", 130, 143], ["Leptospira", "ORGANISM", 51, 61], ["cytokine", "PROTEIN", 26, 34], ["Dramatic imbalance", "PROBLEM", 0, 18], ["the cytokine production", "PROBLEM", 22, 45], ["Leptospira infection", "PROBLEM", 51, 71], ["severe leptospirosis", "PROBLEM", 123, 143], ["imbalance", "OBSERVATION", 9, 18], ["cytokine production", "OBSERVATION", 26, 45], ["Leptospira", "OBSERVATION_MODIFIER", 51, 61], ["infection", "OBSERVATION", 62, 71], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["leptospirosis", "OBSERVATION", 130, 143]]], ["Since the Syrian hamster has been shown to be a suitable model, it has been used to test the efficacy of vaccines against this disease.", [["hamster", "ANATOMY", 17, 24], ["Syrian hamster", "ORGANISM", 10, 24], ["Syrian hamster", "SPECIES", 10, 24], ["Syrian hamster", "SPECIES", 10, 24], ["vaccines", "TREATMENT", 105, 113], ["this disease", "PROBLEM", 122, 134]]], ["Palaniappan et al. demonstrate that the immunization of Syrian hamster with recombinant LigA (rLigA) prevents fatalities, with decreased histopathological lesions in kidney and inhibited the growth of the organisms (113).", [["hamster", "ANATOMY", 63, 70], ["histopathological lesions", "ANATOMY", 137, 162], ["kidney", "ANATOMY", 166, 172], ["Syrian hamster", "ORGANISM", 56, 70], ["LigA", "GENE_OR_GENE_PRODUCT", 88, 92], ["rLigA", "GENE_OR_GENE_PRODUCT", 94, 99], ["histopathological lesions", "PATHOLOGICAL_FORMATION", 137, 162], ["kidney", "ORGAN", 166, 172], ["recombinant LigA", "PROTEIN", 76, 92], ["rLigA", "PROTEIN", 94, 99], ["Syrian hamster", "SPECIES", 56, 70], ["Syrian hamster", "SPECIES", 56, 70], ["the immunization of Syrian hamster", "TREATMENT", 36, 70], ["decreased histopathological lesions in kidney", "PROBLEM", 127, 172], ["decreased", "OBSERVATION_MODIFIER", 127, 136], ["histopathological", "OBSERVATION_MODIFIER", 137, 154], ["lesions", "OBSERVATION", 155, 162], ["kidney", "ANATOMY", 166, 172]]], ["In another study, a vaccine using a conserved region of the leptospiral immunoglobulin-like B protein (LigB, 131\u2013645) and aluminum hydroxide (AH) can significantly increase IgG and IgM levels in the hamster, protecting the animal from mortality after challenge (114).Clostridium difficile ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsClostridium difficile disease caused by Clostridium difficile infection (CDI) is one of the most common infectious diseases worldwide (115).", [["hamster", "ANATOMY", 199, 206], ["aluminum hydroxide", "CHEMICAL", 122, 140], ["AH", "CHEMICAL", 142, 144], ["Clostridium difficile", "DISEASE", 267, 288], ["Parasitic Infections", "DISEASE", 343, 363], ["Clostridium difficile disease", "DISEASE", 363, 392], ["Clostridium difficile infection", "DISEASE", 403, 434], ["CDI", "DISEASE", 436, 439], ["aluminum hydroxide", "CHEMICAL", 122, 140], ["immunoglobulin-like B", "GENE_OR_GENE_PRODUCT", 72, 93], ["aluminum hydroxide", "SIMPLE_CHEMICAL", 122, 140], ["AH", "SIMPLE_CHEMICAL", 142, 144], ["IgG", "GENE_OR_GENE_PRODUCT", 173, 176], ["IgM", "GENE_OR_GENE_PRODUCT", 181, 184], ["hamster", "ORGANISM", 199, 206], ["Clostridium difficile", "ORGANISM", 267, 288], ["Parasitic InfectionsClostridium difficile", "ORGANISM", 343, 384], ["Clostridium difficile", "ORGANISM", 403, 424], ["leptospiral immunoglobulin-like B protein", "PROTEIN", 60, 101], ["LigB", "PROTEIN", 103, 107], ["IgG", "PROTEIN", 173, 176], ["IgM", "PROTEIN", 181, 184], ["hamster", "SPECIES", 199, 206], ["Clostridium difficile", "SPECIES", 267, 288], ["Clostridium difficile", "SPECIES", 363, 384], ["Clostridium difficile", "SPECIES", 403, 424], ["hamster", "SPECIES", 199, 206], ["Clostridium difficile", "SPECIES", 267, 288], ["Clostridium difficile", "SPECIES", 363, 384], ["Clostridium difficile", "SPECIES", 403, 424], ["another study", "TEST", 3, 16], ["a vaccine", "TREATMENT", 18, 27], ["the leptospiral immunoglobulin", "TEST", 56, 86], ["LigB", "TEST", 103, 107], ["aluminum hydroxide (AH)", "TREATMENT", 122, 145], ["IgG", "TEST", 173, 176], ["IgM levels", "TEST", 181, 191], ["Clostridium difficile", "PROBLEM", 267, 288], ["Syrian Hamster", "TREATMENT", 293, 307], ["Parasitic InfectionsClostridium difficile disease", "PROBLEM", 343, 392], ["Clostridium difficile infection", "PROBLEM", 403, 434], ["IgM levels", "OBSERVATION", 181, 191], ["difficile", "OBSERVATION", 279, 288], ["Bacterial", "OBSERVATION_MODIFIER", 329, 338], ["Parasitic", "OBSERVATION_MODIFIER", 343, 352], ["Infections", "OBSERVATION", 353, 363], ["Clostridium", "OBSERVATION_MODIFIER", 403, 414], ["difficile", "OBSERVATION_MODIFIER", 415, 424], ["infection", "OBSERVATION", 425, 434], ["most common", "OBSERVATION_MODIFIER", 455, 466], ["infectious", "OBSERVATION", 467, 477]]], ["The increasing threat of morbidity and mortality caused by the infection is mostly due to the emergence of hypervirulent strains, increased use and misuse of antibiotics (116).", [["infection", "DISEASE", 63, 72], ["morbidity", "PROBLEM", 25, 34], ["the infection", "PROBLEM", 59, 72], ["hypervirulent strains", "PROBLEM", 107, 128], ["antibiotics", "TREATMENT", 158, 169], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["threat", "OBSERVATION_MODIFIER", 15, 21], ["morbidity", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 63, 72], ["hypervirulent strains", "OBSERVATION", 107, 128]]], ["The use of mouse animal model has been unable to provide CDI drug discoveries, so it is necessary to find new animal models (117, 118).", [["mouse", "ORGANISM", 11, 16], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["mouse animal model", "TREATMENT", 11, 29]]], ["Several groups have generated Syrian hamster models for CDI, which developed many of clinical symptoms observed in infected humans (119\u2013121).", [["CDI", "DISEASE", 56, 59], ["Syrian hamster", "ORGANISM", 30, 44], ["humans", "ORGANISM", 124, 130], ["humans", "SPECIES", 124, 130], ["Syrian hamster", "SPECIES", 30, 44], ["humans", "SPECIES", 124, 130], ["Syrian hamster models", "TREATMENT", 30, 51], ["CDI", "PROBLEM", 56, 59], ["clinical symptoms", "PROBLEM", 85, 102]]], ["In these studies, Syrian hamsters were conditioned with a single subcutaneous injection of clindamycin to induce Clostridium difficile colitis model.", [["subcutaneous", "ANATOMY", 65, 77], ["clindamycin", "CHEMICAL", 91, 102], ["Clostridium difficile colitis", "DISEASE", 113, 142], ["clindamycin", "CHEMICAL", 91, 102], ["Syrian hamsters", "ORGANISM", 18, 33], ["clindamycin", "SIMPLE_CHEMICAL", 91, 102], ["colitis", "PATHOLOGICAL_FORMATION", 135, 142], ["hamsters", "SPECIES", 25, 33], ["Clostridium difficile", "SPECIES", 113, 134], ["Syrian hamsters", "SPECIES", 18, 33], ["Clostridium difficile", "SPECIES", 113, 134], ["these studies", "TEST", 3, 16], ["a single subcutaneous injection of clindamycin", "TREATMENT", 56, 102], ["Clostridium difficile colitis model", "PROBLEM", 113, 148], ["Clostridium difficile colitis", "OBSERVATION", 113, 142]]], ["Using this infection model, the efficacy of LFF571 antibiotic against Clostridium difficile was assessed (122) and the oral mixture of kefir-isolated bacteria and yeasts to prevent diarrhea and enterocolitis triggered by Clostridium difficile was tested (123).Leishmania donovani ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsVisceral leishmaniasis (VL; also known as kala-azar) is the most severe form of leishmaniasis caused by Leishmania donovani and Leishmania infantum (Leishmania chagasi in the Americas) (124).", [["oral", "ANATOMY", 119, 123], ["infection", "DISEASE", 11, 20], ["LFF571", "CHEMICAL", 44, 50], ["Clostridium difficile", "DISEASE", 70, 91], ["diarrhea", "DISEASE", 181, 189], ["enterocolitis", "DISEASE", 194, 207], ["Clostridium difficile", "DISEASE", 221, 242], ["Parasitic Infections", "DISEASE", 334, 354], ["Visceral leishmaniasis", "DISEASE", 354, 376], ["VL", "DISEASE", 378, 380], ["kala-azar", "DISEASE", 396, 405], ["leishmaniasis", "DISEASE", 434, 447], ["Leishmania donovani", "DISEASE", 458, 477], ["Leishmania infantum", "DISEASE", 482, 501], ["Leishmania chagasi", "DISEASE", 503, 521], ["LFF571", "CHEMICAL", 44, 50], ["LFF571", "SIMPLE_CHEMICAL", 44, 50], ["Clostridium difficile", "ORGANISM", 70, 91], ["oral", "ORGANISM_SUBDIVISION", 119, 123], ["kefir", "SIMPLE_CHEMICAL", 135, 140], ["Clostridium difficile", "ORGANISM", 221, 242], ["Leishmania donovani", "ORGANISM", 260, 279], ["Leishmania donovani", "ORGANISM", 458, 477], ["Leishmania infantum", "ORGANISM", 482, 501], ["Leishmania chagasi", "ORGANISM", 503, 521], ["Clostridium difficile", "SPECIES", 70, 91], ["Clostridium difficile", "SPECIES", 221, 242], ["Leishmania donovani", "SPECIES", 260, 279], ["kala-azar", "SPECIES", 396, 405], ["Leishmania donovani", "SPECIES", 458, 477], ["Leishmania infantum", "SPECIES", 482, 501], ["Leishmania chagasi", "SPECIES", 503, 521], ["Clostridium difficile", "SPECIES", 70, 91], ["Clostridium difficile", "SPECIES", 221, 242], ["Leishmania donovani", "SPECIES", 260, 279], ["Leishmania donovani", "SPECIES", 458, 477], ["Leishmania infantum", "SPECIES", 482, 501], ["Leishmania chagasi", "SPECIES", 503, 521], ["this infection model", "TREATMENT", 6, 26], ["LFF571 antibiotic", "TREATMENT", 44, 61], ["Clostridium difficile", "PROBLEM", 70, 91], ["kefir-isolated bacteria", "PROBLEM", 135, 158], ["yeasts", "PROBLEM", 163, 169], ["diarrhea", "PROBLEM", 181, 189], ["enterocolitis", "PROBLEM", 194, 207], ["Clostridium difficile", "PROBLEM", 221, 242], ["Syrian Hamster", "TREATMENT", 284, 298], ["Research in Bacterial and Parasitic InfectionsVisceral leishmaniasis", "PROBLEM", 308, 376], ["leishmaniasis", "PROBLEM", 434, 447], ["Leishmania donovani", "PROBLEM", 458, 477], ["Leishmania infantum", "PROBLEM", 482, 501], ["infection", "OBSERVATION", 11, 20], ["enterocolitis", "OBSERVATION", 194, 207], ["Bacterial", "OBSERVATION_MODIFIER", 320, 329], ["Parasitic", "OBSERVATION_MODIFIER", 334, 343], ["Infections", "OBSERVATION_MODIFIER", 344, 354], ["Visceral", "ANATOMY", 354, 362], ["leishmaniasis", "OBSERVATION", 363, 376], ["most severe", "OBSERVATION_MODIFIER", 414, 425], ["leishmaniasis", "OBSERVATION", 434, 447], ["Leishmania donovani", "OBSERVATION", 458, 477], ["Leishmania", "OBSERVATION_MODIFIER", 482, 492]]], ["The Syrian hamster is highly susceptible to infection with visceralizing Leishmania species and is considered the best experimental model to study VL as it reproduces the clinicopathological features of human disease and quite distinct from those noted in murine models of infection (125).", [["hamster", "ANATOMY", 11, 18], ["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 273, 282], ["Syrian hamster", "ORGANISM", 4, 18], ["Leishmania species", "ORGANISM", 73, 91], ["human", "ORGANISM", 203, 208], ["murine", "ORGANISM", 256, 262], ["Syrian hamster", "SPECIES", 4, 18], ["human", "SPECIES", 203, 208], ["murine", "SPECIES", 256, 262], ["Syrian hamster", "SPECIES", 4, 18], ["human", "SPECIES", 203, 208], ["infection", "PROBLEM", 44, 53], ["visceralizing Leishmania species", "PROBLEM", 59, 91], ["study VL", "TEST", 141, 149], ["human disease", "PROBLEM", 203, 216], ["infection", "PROBLEM", 273, 282], ["Syrian hamster", "OBSERVATION", 4, 18], ["highly susceptible to", "UNCERTAINTY", 22, 43], ["infection", "OBSERVATION", 44, 53], ["Leishmania species", "OBSERVATION", 73, 91], ["human disease", "OBSERVATION", 203, 216], ["infection", "OBSERVATION", 273, 282]]], ["In the majority of studies, animals were infected by the intracardial route.", [["intracardial", "ANATOMY", 57, 69], ["animals", "ORGANISM", 28, 35], ["infected", "OBSERVATION", 41, 49]]], ["Infected animals demonstrate up-regulated expression of Th1-associated cytokine mRNA, such as IFN-\u03b3, IL-2, and TNF-\u03b1 in the spleen, but limited induction of IL-4 mRNA (126).", [["spleen", "ANATOMY", 124, 130], ["Th1", "GENE_OR_GENE_PRODUCT", 56, 59], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-2", "GENE_OR_GENE_PRODUCT", 101, 105], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 111, 116], ["spleen", "ORGAN", 124, 130], ["IL-4", "GENE_OR_GENE_PRODUCT", 157, 161], ["Th1-associated cytokine mRNA", "RNA", 56, 84], ["IFN", "PROTEIN", 94, 97], ["TNF-\u03b1", "PROTEIN", 111, 116], ["IL-4 mRNA", "RNA", 157, 166], ["Infected animals", "PROBLEM", 0, 16], ["Th1-associated cytokine mRNA", "PROBLEM", 56, 84], ["IFN", "TEST", 94, 97], ["IL", "TEST", 101, 103], ["TNF", "TEST", 111, 114], ["IL", "TEST", 157, 159], ["up-regulated", "OBSERVATION_MODIFIER", 29, 41], ["expression", "OBSERVATION_MODIFIER", 42, 52], ["Th1", "OBSERVATION", 56, 59], ["cytokine mRNA", "OBSERVATION", 71, 84], ["TNF", "ANATOMY", 111, 114], ["spleen", "ANATOMY", 124, 130]]], ["In murine models, Leishmania is controlled through nitric oxide (NO) generation, and however in hamsters, as in humans, NO does not have a role in macrophage function.", [["macrophage", "ANATOMY", 147, 157], ["nitric oxide", "CHEMICAL", 51, 63], ["NO", "CHEMICAL", 65, 67], ["NO", "CHEMICAL", 120, 122], ["nitric oxide", "CHEMICAL", 51, 63], ["NO", "CHEMICAL", 65, 67], ["NO", "CHEMICAL", 120, 122], ["murine", "ORGANISM", 3, 9], ["Leishmania", "ORGANISM", 18, 28], ["nitric oxide", "SIMPLE_CHEMICAL", 51, 63], ["NO", "SIMPLE_CHEMICAL", 65, 67], ["hamsters", "ORGANISM", 96, 104], ["humans", "ORGANISM", 112, 118], ["NO", "GENE_OR_GENE_PRODUCT", 120, 122], ["macrophage", "CELL", 147, 157], ["murine", "SPECIES", 3, 9], ["humans", "SPECIES", 112, 118], ["hamsters", "SPECIES", 96, 104], ["humans", "SPECIES", 112, 118], ["Leishmania", "PROBLEM", 18, 28], ["nitric oxide", "TREATMENT", 51, 63], ["Leishmania", "OBSERVATION", 18, 28]]], ["Inducible NO synthetase (iNOS) mRNA was not detected in livers or spleen of hamsters, which may explain the uncontrolled parasite replication occurring in hamsters and humans, despite the induction of a strong Th1 cytokine response (126).", [["livers", "ANATOMY", 56, 62], ["spleen", "ANATOMY", 66, 72], ["NO", "CHEMICAL", 10, 12], ["NO", "CHEMICAL", 10, 12], ["Inducible NO synthetase", "GENE_OR_GENE_PRODUCT", 0, 23], ["iNOS", "GENE_OR_GENE_PRODUCT", 25, 29], ["livers", "ORGAN", 56, 62], ["spleen", "ORGAN", 66, 72], ["hamsters", "ORGANISM", 76, 84], ["hamsters", "ORGANISM", 155, 163], ["humans", "ORGANISM", 168, 174], ["Inducible NO synthetase (iNOS) mRNA", "RNA", 0, 35], ["Th1 cytokine", "PROTEIN", 210, 222], ["humans", "SPECIES", 168, 174], ["hamsters", "SPECIES", 76, 84], ["hamsters", "SPECIES", 155, 163], ["humans", "SPECIES", 168, 174], ["synthetase (iNOS) mRNA", "PROBLEM", 13, 35], ["the uncontrolled parasite replication", "PROBLEM", 104, 141], ["NO", "UNCERTAINTY", 10, 12], ["livers", "ANATOMY", 56, 62], ["spleen", "ANATOMY", 66, 72], ["may explain", "UNCERTAINTY", 92, 103], ["uncontrolled", "OBSERVATION_MODIFIER", 108, 120], ["parasite replication", "OBSERVATION", 121, 141]]], ["Not only can Syrian hamster model be used to study the pathogenesis of Leishmania donovani infection, but also to test vaccines as recent studies have shown.", [["Leishmania donovani infection", "DISEASE", 71, 100], ["Syrian hamster", "ORGANISM", 13, 27], ["Leishmania donovani", "ORGANISM", 71, 90], ["Syrian hamster", "SPECIES", 13, 27], ["Leishmania donovani", "SPECIES", 71, 90], ["Syrian hamster", "SPECIES", 13, 27], ["Leishmania donovani", "SPECIES", 71, 90], ["Leishmania donovani infection", "PROBLEM", 71, 100], ["test vaccines", "TREATMENT", 114, 127], ["recent studies", "TEST", 131, 145], ["Leishmania donovani infection", "OBSERVATION", 71, 100]]], ["Kushawaha et al. used a Syrian hamster model to show that recombinant Leishmania donovani protein disulfide isomerase (rLdPDI) generated a robust cellular immune response with increased iNOS transcription and TNF-\u03b1, IFN-\u03b3, and IL-12 levels (127).", [["hamster", "ANATOMY", 31, 38], ["cellular", "ANATOMY", 146, 154], ["disulfide", "CHEMICAL", 98, 107], ["Syrian hamster", "ORGANISM", 24, 38], ["Leishmania donovani", "ORGANISM", 70, 89], ["protein disulfide isomerase", "GENE_OR_GENE_PRODUCT", 90, 117], ["rLdPDI", "GENE_OR_GENE_PRODUCT", 119, 125], ["cellular", "CELL", 146, 154], ["iNOS", "GENE_OR_GENE_PRODUCT", 186, 190], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 209, 214], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 216, 221], ["IL-12", "GENE_OR_GENE_PRODUCT", 227, 232], ["recombinant Leishmania donovani protein disulfide isomerase", "PROTEIN", 58, 117], ["rLdPDI", "PROTEIN", 119, 125], ["iNOS", "PROTEIN", 186, 190], ["TNF", "PROTEIN", 209, 212], ["IFN", "PROTEIN", 216, 219], ["Syrian hamster", "SPECIES", 24, 38], ["Leishmania donovani", "SPECIES", 70, 89], ["Syrian hamster", "SPECIES", 24, 38], ["Leishmania donovani", "SPECIES", 70, 89], ["a Syrian hamster model", "TREATMENT", 22, 44], ["recombinant Leishmania donovani protein disulfide isomerase (rLdPDI)", "PROBLEM", 58, 126], ["increased iNOS transcription", "PROBLEM", 176, 204], ["TNF", "TEST", 209, 212], ["IFN", "TEST", 216, 219], ["IL", "TEST", 227, 229]]], ["In another study by Samant et al. vaccination with DNA-encoding N-terminal domain of the PPG gene in golden hamsters yielded 80% protection against Leishmania donovani challenge with generation of Th1 type of immune response (128).Leishmania infantum ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsBesides Leishmania donovani, Leishmania infantum has also been studied using the Syrian hamster model.", [["Leishmania donovani", "DISEASE", 148, 167], ["Leishmania infantum", "DISEASE", 231, 250], ["Parasitic Infections", "DISEASE", 305, 325], ["Leishmania donovani", "DISEASE", 333, 352], ["Leishmania infantum", "DISEASE", 354, 373], ["N", "CHEMICAL", 64, 65], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["PPG", "GENE_OR_GENE_PRODUCT", 89, 92], ["golden hamsters", "ORGANISM", 101, 116], ["Leishmania donovani", "ORGANISM", 148, 167], ["Leishmania infantum", "ORGANISM", 231, 250], ["Leishmania donovani", "ORGANISM", 333, 352], ["Leishmania infantum", "ORGANISM", 354, 373], ["Syrian hamster", "ORGANISM", 406, 420], ["N-terminal domain", "PROTEIN", 64, 81], ["PPG gene", "DNA", 89, 97], ["golden hamsters", "SPECIES", 101, 116], ["Leishmania donovani", "SPECIES", 148, 167], ["Leishmania infantum", "SPECIES", 231, 250], ["Leishmania donovani", "SPECIES", 333, 352], ["Leishmania infantum", "SPECIES", 354, 373], ["Syrian hamster", "SPECIES", 406, 420], ["golden hamsters", "SPECIES", 101, 116], ["Leishmania donovani", "SPECIES", 148, 167], ["Leishmania infantum", "SPECIES", 231, 250], ["Leishmania donovani", "SPECIES", 333, 352], ["Leishmania infantum", "SPECIES", 354, 373], ["Syrian hamster", "SPECIES", 406, 420], ["vaccination", "TREATMENT", 34, 45], ["DNA", "PROBLEM", 51, 54], ["the PPG gene", "TREATMENT", 85, 97], ["Leishmania donovani challenge", "TREATMENT", 148, 177], ["Leishmania infantum", "PROBLEM", 231, 250], ["Syrian Hamster", "TREATMENT", 255, 269], ["Bacterial", "PROBLEM", 291, 300], ["Parasitic Infections", "PROBLEM", 305, 325], ["Leishmania donovani", "PROBLEM", 333, 352], ["Leishmania infantum", "PROBLEM", 354, 373], ["the Syrian hamster model", "TREATMENT", 402, 426], ["Bacterial", "OBSERVATION_MODIFIER", 291, 300], ["Parasitic", "OBSERVATION_MODIFIER", 305, 314], ["Infections", "OBSERVATION", 315, 325], ["Leishmania donovani", "OBSERVATION", 333, 352]]], ["Moreira et al. generated a model using Syrian hamsters featuring a similar human clinical picture on Leishmania infantum infection (129).", [["Leishmania infantum infection", "DISEASE", 101, 130], ["Syrian hamsters", "ORGANISM", 39, 54], ["human", "ORGANISM", 75, 80], ["Leishmania infantum", "ORGANISM", 101, 120], ["human", "SPECIES", 75, 80], ["Leishmania infantum", "SPECIES", 101, 120], ["Syrian hamsters", "SPECIES", 39, 54], ["human", "SPECIES", 75, 80], ["Leishmania infantum", "SPECIES", 101, 120], ["Leishmania infantum infection", "PROBLEM", 101, 130]]], ["The animals developed hepatosplenomegaly, severe weight loss, anemia, and leucopenia.", [["hepatosplenomegaly", "DISEASE", 22, 40], ["weight loss", "DISEASE", 49, 60], ["anemia", "DISEASE", 62, 68], ["leucopenia", "DISEASE", 74, 84], ["animals", "ORGANISM", 4, 11], ["hepatosplenomegaly", "PROBLEM", 22, 40], ["severe weight loss", "PROBLEM", 42, 60], ["anemia", "PROBLEM", 62, 68], ["leucopenia", "PROBLEM", 74, 84], ["hepatosplenomegaly", "OBSERVATION", 22, 40], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["weight loss", "OBSERVATION", 49, 60], ["anemia", "OBSERVATION", 62, 68], ["leucopenia", "OBSERVATION", 74, 84]]], ["A study found increased levels of IgG in hamsters infected with Leishmania infantum (130).", [["Leishmania infantum", "DISEASE", 64, 83], ["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["hamsters", "ORGANISM", 41, 49], ["Leishmania infantum", "ORGANISM", 64, 83], ["IgG", "PROTEIN", 34, 37], ["Leishmania infantum", "SPECIES", 64, 83], ["hamsters", "SPECIES", 41, 49], ["Leishmania infantum", "SPECIES", 64, 83], ["A study", "TEST", 0, 7], ["increased levels of IgG in hamsters", "PROBLEM", 14, 49], ["Leishmania infantum", "PROBLEM", 64, 83], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["Leishmania infantum", "OBSERVATION", 64, 83]]], ["Similar to humans, Syrian hamsters can develop the progressive fatal disease, with major sites of parasites replication being the liver, spleen, and bone marrow, eventually causing death of the host (131).", [["sites", "ANATOMY", 89, 94], ["liver", "ANATOMY", 130, 135], ["spleen", "ANATOMY", 137, 143], ["bone marrow", "ANATOMY", 149, 160], ["death", "DISEASE", 181, 186], ["humans", "ORGANISM", 11, 17], ["Syrian hamsters", "ORGANISM", 19, 34], ["liver", "ORGAN", 130, 135], ["spleen", "ORGAN", 137, 143], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 149, 160], ["humans", "SPECIES", 11, 17], ["Syrian hamsters", "SPECIES", 19, 34], ["humans", "SPECIES", 11, 17], ["Syrian hamsters", "SPECIES", 19, 34], ["the progressive fatal disease", "PROBLEM", 47, 76], ["parasites replication", "PROBLEM", 98, 119], ["progressive", "OBSERVATION_MODIFIER", 51, 62], ["fatal", "OBSERVATION_MODIFIER", 63, 68], ["disease", "OBSERVATION", 69, 76], ["parasites", "OBSERVATION", 98, 107], ["liver", "ANATOMY", 130, 135], ["spleen", "ANATOMY", 137, 143], ["bone marrow", "ANATOMY", 149, 160]]], ["Infection of the hamsters showed a strong humoral response against Leishmania antigens, and high antibody levels (131).", [["hamsters", "ORGANISM", 17, 25], ["Leishmania", "ORGANISM", 67, 77], ["Leishmania antigens", "PROTEIN", 67, 86], ["Infection of the hamsters", "PROBLEM", 0, 25], ["Leishmania antigens", "TEST", 67, 86], ["high antibody levels", "TEST", 92, 112], ["strong", "OBSERVATION_MODIFIER", 35, 41], ["humoral response", "OBSERVATION", 42, 58]]], ["Study have tested the LJM19 (Immunization with 16 DNA plasmids coding for salivary proteins of Lu. longipalpis) protein protected hamsters against the fatal outcome of VL (132).Entamoeba histolytica ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsEntamoeba histolytica is a popular protozoan parasite causing amebiasis in humans that is a major source of morbidity and mortality in the developing countries (133).", [["LJM19", "CHEMICAL", 22, 27], ["VL", "DISEASE", 168, 170], ["InfectionsEntamoeba histolytica", "DISEASE", 263, 294], ["protozoan parasite", "DISEASE", 308, 326], ["amebiasis", "DISEASE", 335, 344], ["LJM19", "GENE_OR_GENE_PRODUCT", 22, 27], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["Lu. longipalpis", "ORGANISM", 95, 110], ["hamsters", "ORGANISM", 130, 138], ["Entamoeba histolytica", "ORGANISM", 273, 294], ["humans", "ORGANISM", 348, 354], ["LJM19", "DNA", 22, 27], ["16 DNA plasmids", "DNA", 47, 62], ["salivary proteins of Lu. longipalpis) protein", "PROTEIN", 74, 119], ["Lu. longipalpis", "SPECIES", 95, 110], ["hamsters", "SPECIES", 130, 138], ["Entamoeba histolytica", "SPECIES", 273, 294], ["humans", "SPECIES", 348, 354], ["Lu. longipalpis", "SPECIES", 95, 110], ["hamsters", "SPECIES", 130, 138], ["Entamoeba histolytica", "SPECIES", 177, 198], ["Entamoeba histolytica", "SPECIES", 273, 294], ["humans", "SPECIES", 348, 354], ["Study", "TEST", 0, 5], ["Immunization", "TREATMENT", 29, 41], ["16 DNA plasmids", "TREATMENT", 47, 62], ["salivary proteins", "TREATMENT", 74, 91], ["protein protected hamsters", "TREATMENT", 112, 138], ["Entamoeba histolytica", "PROBLEM", 177, 198], ["Syrian Hamster", "TREATMENT", 203, 217], ["Research in Bacterial", "TREATMENT", 227, 248], ["Parasitic Infections", "PROBLEM", 253, 273], ["Entamoeba histolytica", "PROBLEM", 273, 294], ["a popular protozoan parasite", "PROBLEM", 298, 326], ["amebiasis in humans", "PROBLEM", 335, 354], ["morbidity", "PROBLEM", 381, 390], ["histolytica", "OBSERVATION", 187, 198], ["Bacterial", "OBSERVATION_MODIFIER", 239, 248], ["Parasitic", "OBSERVATION_MODIFIER", 253, 262], ["Infections", "OBSERVATION", 263, 273], ["amebiasis", "OBSERVATION", 335, 344], ["morbidity", "OBSERVATION", 381, 390]]], ["Parasitic Entamoeba histolytica produces amebic colitis and an amebic liver abscess (ALA).", [["amebic", "ANATOMY", 41, 47], ["amebic liver abscess", "ANATOMY", 63, 83], ["Parasitic Entamoeba histolytica", "DISEASE", 0, 31], ["amebic colitis", "DISEASE", 41, 55], ["amebic liver abscess", "DISEASE", 63, 83], ["ALA", "CHEMICAL", 85, 88], ["Entamoeba histolytica", "ORGANISM", 10, 31], ["amebic colitis", "PATHOLOGICAL_FORMATION", 41, 55], ["liver", "ORGAN", 70, 75], ["abscess", "PATHOLOGICAL_FORMATION", 76, 83], ["ALA", "SIMPLE_CHEMICAL", 85, 88], ["Entamoeba histolytica", "SPECIES", 10, 31], ["Entamoeba histolytica", "SPECIES", 10, 31], ["Parasitic Entamoeba histolytica", "PROBLEM", 0, 31], ["amebic colitis", "PROBLEM", 41, 55], ["an amebic liver abscess", "PROBLEM", 60, 83], ["amebic colitis", "OBSERVATION", 41, 55], ["amebic", "OBSERVATION_MODIFIER", 63, 69], ["liver", "ANATOMY", 70, 75], ["abscess", "OBSERVATION", 76, 83], ["ALA", "OBSERVATION_MODIFIER", 85, 88]]], ["Syrian hamster can be successfully infected with Entamoeba histolytica (104).", [["hamster", "ANATOMY", 7, 14], ["Entamoeba histolytica", "DISEASE", 49, 70], ["Syrian hamster", "ORGANISM", 0, 14], ["Entamoeba histolytica", "ORGANISM", 49, 70], ["Syrian hamster", "SPECIES", 0, 14], ["Entamoeba histolytica", "SPECIES", 49, 70], ["Syrian hamster", "SPECIES", 0, 14], ["Entamoeba histolytica", "SPECIES", 49, 70], ["Entamoeba histolytica", "PROBLEM", 49, 70]]], ["Similar to symptoms after human infection, the main extraintestinal complication, ALA, is also found in the hamster.", [["hamster", "ANATOMY", 108, 115], ["human infection", "DISEASE", 26, 41], ["ALA", "CHEMICAL", 82, 85], ["ALA", "CHEMICAL", 82, 85], ["human", "ORGANISM", 26, 31], ["ALA", "SIMPLE_CHEMICAL", 82, 85], ["hamster", "ORGANISM", 108, 115], ["human", "SPECIES", 26, 31], ["hamster", "SPECIES", 108, 115], ["human", "SPECIES", 26, 31], ["hamster", "SPECIES", 108, 115], ["symptoms", "PROBLEM", 11, 19], ["human infection", "PROBLEM", 26, 41], ["the main extraintestinal complication", "PROBLEM", 43, 80], ["infection", "OBSERVATION", 32, 41], ["main", "OBSERVATION_MODIFIER", 47, 51], ["extraintestinal", "OBSERVATION_MODIFIER", 52, 67], ["complication", "OBSERVATION", 68, 80]]], ["In the hamster, liver recruitment of neutrophils is the initial host response to Entamoeba histolytica infection (134).", [["hamster", "ANATOMY", 7, 14], ["liver", "ANATOMY", 16, 21], ["neutrophils", "ANATOMY", 37, 48], ["Entamoeba histolytica infection", "DISEASE", 81, 112], ["hamster", "ORGANISM", 7, 14], ["liver", "ORGAN", 16, 21], ["neutrophils", "CELL", 37, 48], ["Entamoeba histolytica", "ORGANISM", 81, 102], ["neutrophils", "CELL_TYPE", 37, 48], ["hamster", "SPECIES", 7, 14], ["Entamoeba histolytica", "SPECIES", 81, 102], ["hamster", "SPECIES", 7, 14], ["Entamoeba histolytica", "SPECIES", 81, 102], ["Entamoeba histolytica infection", "PROBLEM", 81, 112], ["hamster", "ANATOMY", 7, 14], ["liver", "ANATOMY", 16, 21], ["recruitment", "OBSERVATION_MODIFIER", 22, 33], ["neutrophils", "OBSERVATION", 37, 48], ["Entamoeba", "OBSERVATION_MODIFIER", 81, 90], ["histolytica", "OBSERVATION_MODIFIER", 91, 102], ["infection", "OBSERVATION", 103, 112]]], ["A study indicated that leukocytes can induce Entamoeba histolytica trophozoites to undergo cell death (135).", [["leukocytes", "ANATOMY", 23, 33], ["trophozoites", "ANATOMY", 67, 79], ["cell", "ANATOMY", 91, 95], ["death", "DISEASE", 96, 101], ["leukocytes", "CELL", 23, 33], ["Entamoeba histolytica trophozoites", "CELL", 45, 79], ["cell", "CELL", 91, 95], ["leukocytes", "CELL_TYPE", 23, 33], ["Entamoeba histolytica", "SPECIES", 45, 66], ["Entamoeba histolytica", "SPECIES", 45, 66], ["A study", "TEST", 0, 7], ["leukocytes", "PROBLEM", 23, 33], ["Entamoeba histolytica trophozoites", "PROBLEM", 45, 79], ["cell death", "TEST", 91, 101]]], ["Although an anti-parasitic drug (Metronidazole) exists, side effects of toxicity exist in patients; thus this model has been used to develop alternative therapeutic agents.", [["Metronidazole", "CHEMICAL", 33, 46], ["toxicity", "DISEASE", 72, 80], ["Metronidazole", "CHEMICAL", 33, 46], ["Metronidazole", "SIMPLE_CHEMICAL", 33, 46], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["an anti-parasitic drug (Metronidazole)", "TREATMENT", 9, 47], ["toxicity", "PROBLEM", 72, 80], ["alternative therapeutic agents", "TREATMENT", 141, 171], ["anti-parasitic", "OBSERVATION_MODIFIER", 12, 26]]], ["One research group showed that bovine lactoferrin protected against hepatic amoebiasis in Syrian hamster model (136).", [["hepatic", "ANATOMY", 68, 75], ["hepatic amoebiasis", "DISEASE", 68, 86], ["bovine", "ORGANISM", 31, 37], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 38, 49], ["hepatic", "ORGAN", 68, 75], ["Syrian hamster", "ORGANISM", 90, 104], ["bovine lactoferrin", "PROTEIN", 31, 49], ["bovine", "SPECIES", 31, 37], ["Syrian hamster", "SPECIES", 90, 104], ["bovine", "SPECIES", 31, 37], ["Syrian hamster", "SPECIES", 90, 104], ["bovine lactoferrin", "TREATMENT", 31, 49], ["hepatic amoebiasis", "PROBLEM", 68, 86], ["hepatic", "ANATOMY", 68, 75], ["amoebiasis", "OBSERVATION", 76, 86]]], ["Hamsters were also used to show that intraperitoneal injection of Entamoeba histolytica surface metalloprotease (EhMSP-1), an antigen vaccine, protected against the amebic liver abscesses (137).", [["intraperitoneal", "ANATOMY", 37, 52], ["surface", "ANATOMY", 88, 95], ["amebic liver abscesses", "ANATOMY", 165, 187], ["amebic liver abscesses", "DISEASE", 165, 187], ["Hamsters", "ORGANISM", 0, 8], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 52], ["Entamoeba histolytica surface metalloprotease", "GENE_OR_GENE_PRODUCT", 66, 111], ["EhMSP-1", "GENE_OR_GENE_PRODUCT", 113, 120], ["liver", "ORGAN", 172, 177], ["Entamoeba histolytica surface metalloprotease", "PROTEIN", 66, 111], ["EhMSP", "PROTEIN", 113, 118], ["Hamsters", "SPECIES", 0, 8], ["Entamoeba histolytica", "SPECIES", 66, 87], ["Hamsters", "SPECIES", 0, 8], ["Entamoeba histolytica", "SPECIES", 66, 87], ["intraperitoneal injection", "TREATMENT", 37, 62], ["Entamoeba histolytica surface metalloprotease (EhMSP", "TREATMENT", 66, 118], ["an antigen vaccine", "TREATMENT", 123, 141], ["the amebic liver abscesses", "PROBLEM", 161, 187], ["amebic", "OBSERVATION_MODIFIER", 165, 171], ["liver", "ANATOMY", 172, 177], ["abscesses", "OBSERVATION", 178, 187]]], ["In this study, EhMSP-1 immunization stimulated a robust IgG antibody response, IgG bound to the surface of Entamoeba histolytica trophozoites and accelerated amebic lysis via activation of the classical complement cascade.", [["surface", "ANATOMY", 96, 103], ["trophozoites", "ANATOMY", 129, 141], ["amebic", "ANATOMY", 158, 164], ["amebic", "DISEASE", 158, 164], ["EhMSP-1", "GENE_OR_GENE_PRODUCT", 15, 22], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 56, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 79, 82], ["surface", "CELLULAR_COMPONENT", 96, 103], ["Entamoeba histolytica trophozoites", "CELL", 107, 141], ["EhMSP", "PROTEIN", 15, 20], ["IgG antibody", "PROTEIN", 56, 68], ["IgG", "PROTEIN", 79, 82], ["Entamoeba histolytica", "SPECIES", 107, 128], ["Entamoeba histolytica", "SPECIES", 107, 128], ["this study", "TEST", 3, 13], ["EhMSP", "TEST", 15, 20], ["immunization", "TREATMENT", 23, 35], ["a robust IgG antibody response", "TEST", 47, 77], ["IgG", "TEST", 79, 82], ["Entamoeba histolytica trophozoites", "TREATMENT", 107, 141], ["accelerated amebic lysis", "TREATMENT", 146, 170], ["the classical complement cascade", "TREATMENT", 189, 221], ["amebic lysis", "OBSERVATION", 158, 170]]], ["The same animal model used for Entamoeba histolytica infection was used to show that baculovirus driving the expression of the Gal-Lectin LC3 fragment, when administeredvia intramuscular injection, increased IFN \u03b3 and IL-4 levels in the liver to protect against ALA (138).Schistosoma haematobium ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsSchistosoma haematobium (urinary blood fluke) is the etiologic agent for urogenital schistosomiasis, a source of morbidity and mortality for over 112 million people worldwide (139).", [["intramuscular", "ANATOMY", 173, 186], ["liver", "ANATOMY", 237, 242], ["urinary blood fluke", "ANATOMY", 395, 414], ["urogenital", "ANATOMY", 443, 453], ["Entamoeba histolytica infection", "DISEASE", 31, 62], ["ALA", "CHEMICAL", 262, 265], ["Schistosoma haematobium", "DISEASE", 272, 295], ["InfectionsSchistosoma haematobium", "DISEASE", 360, 393], ["urinary blood fluke", "DISEASE", 395, 414], ["urogenital schistosomiasis", "DISEASE", 443, 469], ["ALA", "CHEMICAL", 262, 265], ["Entamoeba histolytica", "ORGANISM", 31, 52], ["baculovirus", "ORGANISM", 85, 96], ["Gal-Lectin LC3", "GENE_OR_GENE_PRODUCT", 127, 141], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 173, 186], ["IFN \u03b3", "GENE_OR_GENE_PRODUCT", 208, 213], ["IL-4", "GENE_OR_GENE_PRODUCT", 218, 222], ["liver", "ORGAN", 237, 242], ["ALA", "SIMPLE_CHEMICAL", 262, 265], ["Schistosoma haematobium", "ORGANISM", 272, 295], ["Parasitic Infections", "ORGANISM", 350, 370], ["Schistosoma haematobium", "ORGANISM", 370, 393], ["urinary blood fluke", "ORGANISM_SUBSTANCE", 395, 414], ["people", "ORGANISM", 528, 534], ["Gal-Lectin LC3 fragment", "PROTEIN", 127, 150], ["IFN \u03b3", "PROTEIN", 208, 213], ["Entamoeba histolytica", "SPECIES", 31, 52], ["Schistosoma haematobium", "SPECIES", 272, 295], ["Schistosoma haematobium", "SPECIES", 370, 393], ["people", "SPECIES", 528, 534], ["Entamoeba histolytica", "SPECIES", 31, 52], ["baculovirus", "SPECIES", 85, 96], ["Schistosoma haematobium", "SPECIES", 272, 295], ["Schistosoma haematobium", "SPECIES", 370, 393], ["Entamoeba histolytica infection", "PROBLEM", 31, 62], ["baculovirus", "TREATMENT", 85, 96], ["the Gal-Lectin LC3 fragment", "PROBLEM", 123, 150], ["administeredvia intramuscular injection", "TREATMENT", 157, 196], ["increased IFN \u03b3 and IL", "TREATMENT", 198, 220], ["ALA", "TEST", 262, 265], ["Schistosoma haematobium", "PROBLEM", 272, 295], ["Syrian Hamster", "TREATMENT", 300, 314], ["Research in Bacterial", "PROBLEM", 324, 345], ["Parasitic Infections", "PROBLEM", 350, 370], ["Schistosoma haematobium (urinary blood fluke", "PROBLEM", 370, 414], ["urogenital schistosomiasis", "PROBLEM", 443, 469], ["morbidity", "PROBLEM", 483, 492], ["LC3 fragment", "OBSERVATION", 138, 150], ["liver", "ANATOMY", 237, 242], ["haematobium", "OBSERVATION", 284, 295], ["Bacterial", "OBSERVATION_MODIFIER", 336, 345], ["Parasitic", "OBSERVATION_MODIFIER", 350, 359], ["Infections", "OBSERVATION", 360, 370], ["urinary blood", "ANATOMY", 395, 408], ["schistosomiasis", "OBSERVATION", 454, 469]]], ["Although an improved mouse model of S. haematobium urinary tract infection can recapitulate several aspects of human urogenital schistosomiasis (139), Syrian hamsters still show advantages compared to mouse.", [["urinary tract", "ANATOMY", 51, 64], ["urogenital", "ANATOMY", 117, 127], ["S. haematobium urinary tract infection", "DISEASE", 36, 74], ["urogenital schistosomiasis", "DISEASE", 117, 143], ["mouse", "ORGANISM", 21, 26], ["S. haematobium", "ORGANISM", 36, 50], ["urinary tract", "ORGANISM", 51, 64], ["human", "ORGANISM", 111, 116], ["urogenital", "ORGANISM_SUBDIVISION", 117, 127], ["Syrian hamsters", "ORGANISM", 151, 166], ["mouse", "ORGANISM", 201, 206], ["mouse", "SPECIES", 21, 26], ["S. haematobium", "SPECIES", 36, 50], ["human", "SPECIES", 111, 116], ["Syrian hamsters", "SPECIES", 151, 166], ["mouse", "SPECIES", 201, 206], ["mouse", "SPECIES", 21, 26], ["S. haematobium", "SPECIES", 36, 50], ["human", "SPECIES", 111, 116], ["Syrian hamsters", "SPECIES", 151, 166], ["mouse", "SPECIES", 201, 206], ["S. haematobium urinary tract infection", "PROBLEM", 36, 74], ["human urogenital schistosomiasis", "PROBLEM", 111, 143], ["improved", "OBSERVATION_MODIFIER", 12, 20], ["mouse model", "OBSERVATION", 21, 32], ["urinary tract", "ANATOMY", 51, 64], ["infection", "OBSERVATION", 65, 74], ["urogenital", "ANATOMY", 117, 127], ["schistosomiasis", "OBSERVATION", 128, 143]]], ["Syrian hamsters can be transdermally infected with Schistosoma haematobium cercariae (140, 141).", [["Schistosoma haematobium cercariae", "DISEASE", 51, 84], ["Syrian hamsters", "ORGANISM", 0, 15], ["Schistosoma haematobium", "ORGANISM", 51, 74], ["cercariae", "ORGANISM", 75, 84], ["Syrian hamsters", "SPECIES", 0, 15], ["Schistosoma haematobium", "SPECIES", 51, 74], ["Syrian hamsters", "SPECIES", 0, 15], ["Schistosoma haematobium cercariae", "SPECIES", 51, 84], ["Schistosoma haematobium cercariae", "PROBLEM", 51, 84], ["Schistosoma", "OBSERVATION_MODIFIER", 51, 62], ["haematobium", "OBSERVATION", 63, 74]]], ["A model with Schistosoma haematobium cercariae granulomatous-like immune reaction and hepatic fibrosis infection using Syrian hamsters was generated by Botelho et al. (142).", [["hepatic", "ANATOMY", 86, 93], ["Schistosoma haematobium cercariae", "DISEASE", 13, 46], ["hepatic fibrosis infection", "DISEASE", 86, 112], ["Schistosoma haematobium", "ORGANISM", 13, 36], ["cercariae", "ORGANISM", 37, 46], ["hepatic", "ORGAN", 86, 93], ["Syrian hamsters", "ORGANISM", 119, 134], ["Schistosoma haematobium cercariae", "SPECIES", 13, 46], ["Syrian hamsters", "SPECIES", 119, 134], ["Schistosoma haematobium", "SPECIES", 13, 36], ["Syrian hamsters", "SPECIES", 119, 134], ["Schistosoma haematobium cercariae granulomatous", "PROBLEM", 13, 60], ["immune reaction", "PROBLEM", 66, 81], ["hepatic fibrosis infection", "PROBLEM", 86, 112], ["Syrian hamsters", "TREATMENT", 119, 134], ["Schistosoma", "OBSERVATION_MODIFIER", 13, 24], ["haematobium", "OBSERVATION_MODIFIER", 25, 36], ["cercariae granulomatous", "OBSERVATION", 37, 60], ["immune reaction", "OBSERVATION", 66, 81], ["hepatic", "ANATOMY", 86, 93], ["fibrosis", "OBSERVATION", 94, 102]]], ["Botros et al. used Syrian hamster model to analyze and test praziquantel (PZQ) treatment (143).", [["praziquantel", "CHEMICAL", 60, 72], ["PZQ", "CHEMICAL", 74, 77], ["praziquantel", "CHEMICAL", 60, 72], ["PZQ", "CHEMICAL", 74, 77], ["Syrian hamster", "ORGANISM", 19, 33], ["praziquantel", "SIMPLE_CHEMICAL", 60, 72], ["PZQ", "SIMPLE_CHEMICAL", 74, 77], ["Syrian hamster", "SPECIES", 19, 33], ["Syrian hamster model", "TREATMENT", 19, 39], ["test praziquantel (PZQ) treatment", "TREATMENT", 55, 88]]], ["This animal model revealed predominant CD4+ T cells in the acute phase of granuloma formation in the liver [75 days post-infection (PI)], Confluent granulomata with multiple eggs in the center were observed in the liver and urinary bladder with the preponderance of CD8+ positive T cells in the liver (95 and 115 days PI).", [["CD4+ T cells", "ANATOMY", 39, 51], ["granuloma", "ANATOMY", 74, 83], ["liver", "ANATOMY", 101, 106], ["granulomata", "ANATOMY", 148, 159], ["eggs", "ANATOMY", 174, 178], ["liver", "ANATOMY", 214, 219], ["urinary bladder", "ANATOMY", 224, 239], ["CD8+ positive T cells", "ANATOMY", 266, 287], ["liver", "ANATOMY", 295, 300], ["granuloma", "DISEASE", 74, 83], ["granulomata", "DISEASE", 148, 159], ["CD4", "GENE_OR_GENE_PRODUCT", 39, 42], ["granuloma", "PATHOLOGICAL_FORMATION", 74, 83], ["liver", "ORGAN", 101, 106], ["liver", "ORGAN", 214, 219], ["urinary bladder", "ORGAN", 224, 239], ["CD8", "GENE_OR_GENE_PRODUCT", 266, 269], ["liver", "ORGAN", 295, 300], ["CD4", "PROTEIN", 39, 42], ["T cells", "CELL_TYPE", 44, 51], ["CD8+ positive T cells", "CELL_TYPE", 266, 287], ["This animal model", "TEST", 0, 17], ["T cells", "PROBLEM", 44, 51], ["granuloma formation in the liver", "PROBLEM", 74, 106], ["Confluent granulomata", "PROBLEM", 138, 159], ["multiple eggs in the center", "PROBLEM", 165, 192], ["positive T cells in the liver", "PROBLEM", 271, 300], ["predominant", "OBSERVATION_MODIFIER", 27, 38], ["CD4+ T cells", "OBSERVATION", 39, 51], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["phase", "OBSERVATION_MODIFIER", 65, 70], ["granuloma", "OBSERVATION", 74, 83], ["liver", "ANATOMY", 101, 106], ["75 days", "OBSERVATION_MODIFIER", 108, 115], ["Confluent", "OBSERVATION_MODIFIER", 138, 147], ["granulomata", "OBSERVATION", 148, 159], ["multiple", "OBSERVATION_MODIFIER", 165, 173], ["eggs", "OBSERVATION", 174, 178], ["liver", "ANATOMY", 214, 219], ["urinary bladder", "ANATOMY", 224, 239], ["positive T cells", "OBSERVATION", 271, 287], ["liver", "ANATOMY", 295, 300]]], ["In this model, high dose PZQ was clearly curative from 75 days PI.Others ::: Syrian Hamster Used for Research in Bacterial and Parasitic InfectionsThere are many studies detailing the pathogenesis of other bacteria and parasitic infections using the Syrian hamster animal model that cannot be discussed here in detail.", [["PZQ", "CHEMICAL", 25, 28], ["Parasitic Infections", "DISEASE", 127, 147], ["parasitic infections", "DISEASE", 219, 239], ["PZQ", "CHEMICAL", 25, 28], ["PZQ", "SIMPLE_CHEMICAL", 25, 28], ["Syrian hamster", "ORGANISM", 250, 264], ["Syrian hamster", "SPECIES", 250, 264], ["Syrian hamster", "SPECIES", 250, 264], ["high dose PZQ", "TREATMENT", 15, 28], ["Research in Bacterial and Parasitic Infections", "PROBLEM", 101, 147], ["many studies", "TEST", 157, 169], ["other bacteria", "PROBLEM", 200, 214], ["parasitic infections", "PROBLEM", 219, 239], ["the Syrian hamster animal model", "TREATMENT", 246, 277], ["Bacterial", "OBSERVATION_MODIFIER", 113, 122], ["Parasitic", "OBSERVATION_MODIFIER", 127, 136], ["Infections", "OBSERVATION", 137, 147], ["parasitic", "OBSERVATION_MODIFIER", 219, 228], ["infections", "OBSERVATION", 229, 239]]], ["A Syrian hamster model to study Borrelia burgdorferi infection was established by Johnson et al. (144).", [["hamster", "ANATOMY", 9, 16], ["Borrelia burgdorferi infection", "DISEASE", 32, 62], ["Syrian hamster", "ORGANISM", 2, 16], ["Borrelia burgdorferi", "ORGANISM", 32, 52], ["hamster", "SPECIES", 9, 16], ["Borrelia burgdorferi", "SPECIES", 32, 52], ["Syrian hamster", "SPECIES", 2, 16], ["Borrelia burgdorferi", "SPECIES", 32, 52], ["A Syrian hamster model", "TREATMENT", 0, 22], ["Borrelia burgdorferi infection", "PROBLEM", 32, 62]]], ["After Borrelia burgodrferi infection, hamsters were utilized to study articular manifestations of Lyme borreliosis, which is similar to human (145).", [["articular", "ANATOMY", 70, 79], ["Borrelia burgodrferi infection", "DISEASE", 6, 36], ["Lyme borreliosis", "DISEASE", 98, 114], ["Borrelia burgodrferi", "ORGANISM", 6, 26], ["hamsters", "ORGANISM", 38, 46], ["articular", "TISSUE", 70, 79], ["human", "ORGANISM", 136, 141], ["Borrelia burgodrferi", "SPECIES", 6, 26], ["hamsters", "SPECIES", 38, 46], ["human", "SPECIES", 136, 141], ["Borrelia burgodrferi", "SPECIES", 6, 26], ["hamsters", "SPECIES", 38, 46], ["human", "SPECIES", 136, 141], ["Borrelia burgodrferi infection", "PROBLEM", 6, 36], ["Lyme borreliosis", "PROBLEM", 98, 114], ["articular", "ANATOMY", 70, 79], ["Lyme borreliosis", "OBSERVATION", 98, 114]]], ["Syrian hamster can be successfully infected with Leishmania panamensis (146).", [["hamster", "ANATOMY", 7, 14], ["Syrian hamster", "ORGANISM", 0, 14], ["Leishmania panamensis", "ORGANISM", 49, 70], ["Syrian hamster", "SPECIES", 0, 14], ["Leishmania panamensis", "SPECIES", 49, 70], ["Syrian hamster", "SPECIES", 0, 14], ["Leishmania panamensis", "SPECIES", 49, 70], ["Leishmania panamensis", "OBSERVATION", 49, 70]]], ["Infected animals have up-regulated expression of type II cytokines (IL-4 and IL-13), down-regulation of IL-12, and up-regulation of the type II chemokine CCL17 and its receptor CCR4 in lymph node.", [["lymph node", "ANATOMY", 185, 195], ["type II cytokines", "GENE_OR_GENE_PRODUCT", 49, 66], ["IL-4", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-13", "GENE_OR_GENE_PRODUCT", 77, 82], ["IL-12", "GENE_OR_GENE_PRODUCT", 104, 109], ["type II chemokine", "GENE_OR_GENE_PRODUCT", 136, 153], ["CCL17", "GENE_OR_GENE_PRODUCT", 154, 159], ["CCR4", "GENE_OR_GENE_PRODUCT", 177, 181], ["lymph node", "MULTI-TISSUE_STRUCTURE", 185, 195], ["type II cytokines", "PROTEIN", 49, 66], ["IL-4", "PROTEIN", 68, 72], ["IL-13", "PROTEIN", 77, 82], ["IL-12", "PROTEIN", 104, 109], ["type II chemokine", "PROTEIN", 136, 153], ["CCL17", "PROTEIN", 154, 159], ["CCR4", "PROTEIN", 177, 181], ["Infected animals", "PROBLEM", 0, 16], ["type II cytokines", "PROBLEM", 49, 66], ["IL", "TEST", 68, 70], ["IL", "TEST", 77, 79], ["IL", "TEST", 104, 106], ["the type II chemokine CCL17", "TEST", 132, 159], ["type II", "OBSERVATION_MODIFIER", 49, 56], ["lymph node", "OBSERVATION", 185, 195]]], ["Grogl et al. generated a model using Syrian hamsters for drug discovery for Leishmania panamesis infection (147).", [["Leishmania panamesis infection", "DISEASE", 76, 106], ["Syrian hamsters", "ORGANISM", 37, 52], ["Leishmania panamesis", "ORGANISM", 76, 96], ["Syrian hamsters", "SPECIES", 37, 52], ["Leishmania panamesis", "SPECIES", 76, 96], ["Syrian hamsters", "TREATMENT", 37, 52], ["Leishmania panamesis infection", "PROBLEM", 76, 106]]], ["After Leishmania braziliensis infection, Ribeiro-Romao et al. observed large and ulcerated lesions with elevated levels of interferon-\u03b3 and tumor necrosis factor (TNF) during the infection endpoint, which suggests that these cytokines contribute to tissue injury (148).", [["ulcerated lesions", "ANATOMY", 81, 98], ["tissue", "ANATOMY", 249, 255], ["Leishmania braziliensis infection", "DISEASE", 6, 39], ["tumor", "DISEASE", 140, 145], ["necrosis", "DISEASE", 146, 154], ["infection", "DISEASE", 179, 188], ["tissue injury", "DISEASE", 249, 262], ["Leishmania braziliensis", "ORGANISM", 6, 29], ["ulcerated lesions", "PATHOLOGICAL_FORMATION", 81, 98], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 123, 135], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 140, 161], ["TNF", "GENE_OR_GENE_PRODUCT", 163, 166], ["tissue", "TISSUE", 249, 255], ["interferon-\u03b3", "PROTEIN", 123, 135], ["tumor necrosis factor", "PROTEIN", 140, 161], ["TNF", "PROTEIN", 163, 166], ["cytokines", "PROTEIN", 225, 234], ["Leishmania braziliensis", "SPECIES", 6, 29], ["Leishmania braziliensis", "SPECIES", 6, 29], ["Leishmania braziliensis infection", "PROBLEM", 6, 39], ["Ribeiro", "TREATMENT", 41, 48], ["large and ulcerated lesions", "PROBLEM", 71, 98], ["elevated levels of interferon", "PROBLEM", 104, 133], ["tumor necrosis factor", "PROBLEM", 140, 161], ["TNF", "PROBLEM", 163, 166], ["the infection endpoint", "PROBLEM", 175, 197], ["these cytokines", "PROBLEM", 219, 234], ["tissue injury", "PROBLEM", 249, 262], ["Leishmania", "OBSERVATION", 6, 16], ["braziliensis infection", "OBSERVATION", 17, 39], ["large", "OBSERVATION_MODIFIER", 71, 76], ["ulcerated", "OBSERVATION_MODIFIER", 81, 90], ["lesions", "OBSERVATION", 91, 98], ["elevated", "OBSERVATION_MODIFIER", 104, 112], ["levels", "OBSERVATION_MODIFIER", 113, 119], ["interferon", "OBSERVATION_MODIFIER", 123, 133], ["tumor", "OBSERVATION_MODIFIER", 140, 145], ["necrosis", "OBSERVATION_MODIFIER", 146, 154]]], ["Treatment of Leishmania amazonensis infection by intralesional administration of dimethyl carbaporphyrin ketal (CKOMe) reduced the parasite load without noticeable toxic effects in liver (149).", [["liver", "ANATOMY", 181, 186], ["Leishmania amazonensis infection", "DISEASE", 13, 45], ["dimethyl carbaporphyrin ketal", "CHEMICAL", 81, 110], ["CKOMe", "CHEMICAL", 112, 117], ["dimethyl carbaporphyrin ketal", "CHEMICAL", 81, 110], ["CKOMe", "CHEMICAL", 112, 117], ["Leishmania amazonensis", "ORGANISM", 13, 35], ["dimethyl carbaporphyrin ketal", "SIMPLE_CHEMICAL", 81, 110], ["CKOMe", "SIMPLE_CHEMICAL", 112, 117], ["liver", "ORGAN", 181, 186], ["Leishmania amazonensis", "SPECIES", 13, 35], ["Leishmania amazonensis", "SPECIES", 13, 35], ["Leishmania amazonensis infection", "PROBLEM", 13, 45], ["intralesional administration of dimethyl carbaporphyrin ketal (CKOMe", "TREATMENT", 49, 117], ["the parasite load", "PROBLEM", 127, 144], ["noticeable toxic effects in liver", "PROBLEM", 153, 186], ["Leishmania amazonensis infection", "OBSERVATION", 13, 45], ["toxic", "OBSERVATION_MODIFIER", 164, 169], ["liver", "ANATOMY", 181, 186]]], ["A Syrian hamster model to study Plasmodium berghei infection (150) demonstrated induction of severe malaria in the Syrian hamster window chamber model and was used to investigate microcirculatory changes and tissue oxygenation (151).", [["hamster", "ANATOMY", 9, 16], ["microcirculatory", "ANATOMY", 179, 195], ["tissue", "ANATOMY", 208, 214], ["Plasmodium berghei infection", "DISEASE", 32, 60], ["malaria", "DISEASE", 100, 107], ["Syrian hamster", "ORGANISM", 2, 16], ["Plasmodium berghei", "ORGANISM", 32, 50], ["hamster", "ORGANISM", 122, 129], ["tissue", "TISSUE", 208, 214], ["Syrian hamster", "SPECIES", 2, 16], ["Plasmodium berghei", "SPECIES", 32, 50], ["Syrian hamster", "SPECIES", 115, 129], ["Syrian hamster", "SPECIES", 2, 16], ["Plasmodium berghei", "SPECIES", 32, 50], ["Syrian hamster", "SPECIES", 115, 129], ["A Syrian hamster model", "TREATMENT", 0, 22], ["Plasmodium berghei infection", "PROBLEM", 32, 60], ["severe malaria", "PROBLEM", 93, 107], ["microcirculatory changes", "PROBLEM", 179, 203], ["tissue oxygenation", "TEST", 208, 226], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["malaria", "OBSERVATION", 100, 107], ["oxygenation", "OBSERVATION_MODIFIER", 215, 226]]], ["The reader is referred to the relevant publications for further information regarding the use of Syrian hamster models to investigate these infections.Concluding RemarksIn this review, we described the use of the Syrian hamster model as an extraordinarily effective and relevant platform for evaluation of the molecular mechanisms of immune responses to infectious diseases.", [["infections", "DISEASE", 140, 150], ["infectious diseases", "DISEASE", 354, 373], ["Syrian hamster", "ORGANISM", 97, 111], ["Syrian hamster", "ORGANISM", 213, 227], ["Syrian hamster", "SPECIES", 213, 227], ["Syrian hamster", "SPECIES", 97, 111], ["Syrian hamster", "SPECIES", 213, 227], ["Syrian hamster models", "TREATMENT", 97, 118], ["these infections", "PROBLEM", 134, 150], ["the Syrian hamster model", "TREATMENT", 209, 233], ["evaluation", "TEST", 292, 302], ["infectious diseases", "PROBLEM", 354, 373], ["infections", "OBSERVATION", 140, 150]]], ["These studies focus on several infectious pathogens including those of viral, parasitic, and bacterial origins.", [["These studies", "TEST", 0, 13], ["several infectious pathogens", "PROBLEM", 23, 51], ["viral, parasitic, and bacterial origins", "PROBLEM", 71, 110], ["several", "OBSERVATION_MODIFIER", 23, 30], ["infectious", "OBSERVATION_MODIFIER", 31, 41], ["viral", "OBSERVATION", 71, 76], ["parasitic", "OBSERVATION_MODIFIER", 78, 87], ["bacterial origins", "OBSERVATION", 93, 110]]], ["The results indicate that the Syrian hamster immune response is more physiological similar to the human immune response when compared to other animals, thus offering unique advantages when studying the disease pathogenesis and for novel drug and treatment discovery.", [["Syrian hamster", "ORGANISM", 30, 44], ["human", "ORGANISM", 98, 103], ["hamster", "SPECIES", 37, 44], ["human", "SPECIES", 98, 103], ["Syrian hamster", "SPECIES", 30, 44], ["human", "SPECIES", 98, 103], ["the disease pathogenesis", "PROBLEM", 198, 222], ["novel drug", "TREATMENT", 231, 241], ["treatment discovery", "TREATMENT", 246, 265]]], ["Future studies should consider determining additional similarities between the Syrian hamster and human immune response activation through pathogen manipulation of host metabolism.", [["hamster", "ANATOMY", 86, 93], ["Syrian hamster", "ORGANISM", 79, 93], ["human", "ORGANISM", 98, 103], ["hamster", "SPECIES", 86, 93], ["human", "SPECIES", 98, 103], ["Syrian hamster", "SPECIES", 79, 93], ["human", "SPECIES", 98, 103], ["Future studies", "TEST", 0, 14], ["the Syrian hamster", "TREATMENT", 75, 93], ["human immune response activation", "TREATMENT", 98, 130], ["host metabolism", "OBSERVATION", 164, 179]]], ["Increased research efforts will ultimately allow for the development of new technologies and tools to study the Syrian hamster, such as more accurate sequencing technology along with specific antibodies against hamster proteins that are currently limited in comparison to similar tools for studying murine responses to infection.", [["hamster", "ANATOMY", 119, 126], ["infection", "DISEASE", 319, 328], ["Syrian hamster", "ORGANISM", 112, 126], ["hamster", "ORGANISM", 211, 218], ["murine", "ORGANISM", 299, 305], ["antibodies", "PROTEIN", 192, 202], ["hamster proteins", "PROTEIN", 211, 227], ["Syrian hamster", "SPECIES", 112, 126], ["hamster", "SPECIES", 211, 218], ["murine", "SPECIES", 299, 305], ["Syrian hamster", "SPECIES", 112, 126], ["hamster", "SPECIES", 211, 218], ["specific antibodies", "TEST", 183, 202], ["hamster proteins", "PROBLEM", 211, 227], ["infection", "PROBLEM", 319, 328], ["infection", "OBSERVATION", 319, 328]]], ["We believe that the recent advances that the Syrian hamster model has contributed enormously to our understanding of infectious diseases and disease management and demonstrates the strong potential for future research and development of anti-viral drug discovery.Concluding RemarksHowever, as discussed, the lack of research tools represents a major barrier to effective use of Syrian hamster models.", [["infectious diseases", "DISEASE", 117, 136], ["Syrian hamster", "ORGANISM", 45, 59], ["Syrian hamster", "ORGANISM", 378, 392], ["hamster", "SPECIES", 52, 59], ["Syrian hamster", "SPECIES", 45, 59], ["Syrian hamster", "SPECIES", 378, 392], ["infectious diseases", "PROBLEM", 117, 136], ["disease management", "TREATMENT", 141, 159], ["anti-viral drug discovery", "TREATMENT", 237, 262], ["Syrian hamster models", "TREATMENT", 378, 399], ["infectious", "OBSERVATION", 117, 127], ["anti-viral drug", "OBSERVATION", 237, 252]]], ["Immunologic reagents for examing host immune response and particular gene expression, and transgenic disease models will all be required for a more complete evaluation of the value of this model.", [["Immunologic reagents", "TREATMENT", 0, 20], ["transgenic disease models", "PROBLEM", 90, 115], ["a more complete evaluation", "TEST", 141, 167]]], ["To overcome this, research groups are developing or identifying a considerable number of antibodies against Syrian hamster (Table 3) and hamster specific quantitative real-time PCR (RT-qPCR), transcriptome analysis and microarrays have also been developed (169).", [["Syrian hamster", "ORGANISM", 108, 122], ["hamster", "ORGANISM", 137, 144], ["antibodies", "PROTEIN", 89, 99], ["Syrian hamster", "SPECIES", 108, 122], ["hamster", "SPECIES", 137, 144], ["Syrian hamster", "SPECIES", 108, 122], ["hamster", "SPECIES", 137, 144], ["PCR", "TEST", 177, 180], ["RT-qPCR", "TEST", 182, 189], ["transcriptome analysis", "TEST", 192, 214], ["microarrays", "TEST", 219, 230]]], ["Most strikingly, CRISPR/Cas9 technology has rapidly sped up the creation of transgenic Syrian hamster disease models (170).", [["hamster disease", "DISEASE", 94, 109], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 17, 28], ["Syrian hamster", "ORGANISM", 87, 101], ["CRISPR", "DNA", 17, 23], ["Cas9", "DNA", 24, 28], ["Syrian hamster", "SPECIES", 87, 101], ["Syrian hamster", "SPECIES", 87, 101]]], ["These tools will overcome the limitations to research using Syrian hamsters, opening up a powerful platform for recapitulation of human disease pathogensis.Conflict of Interest ::: Author ContributionsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["human disease pathogensis", "DISEASE", 130, 155], ["Syrian hamsters", "ORGANISM", 60, 75], ["human", "ORGANISM", 130, 135], ["Syrian hamsters", "SPECIES", 60, 75], ["human", "SPECIES", 130, 135], ["Syrian hamsters", "SPECIES", 60, 75], ["human disease pathogensis", "SPECIES", 130, 155], ["Syrian hamsters", "TREATMENT", 60, 75], ["human disease pathogensis", "PROBLEM", 130, 155], ["human disease", "OBSERVATION", 130, 143]]]], "f000c7059e15cb6b3b6942cb598c5d4cae53561a": [["IntroductionPeripheral and central regulatory peptides play important roles in mechanisms of appetite and body weight control.", [["body", "ANATOMY", 106, 110], ["body", "ORGANISM_SUBDIVISION", 106, 110], ["IntroductionPeripheral and central regulatory peptides", "TREATMENT", 0, 54], ["body weight control", "TREATMENT", 106, 125], ["central", "ANATOMY_MODIFIER", 27, 34]]], ["For instance, gastrointestinal or adipose tissue-derived peptide hormones such as ghrelin, insulin, peptide tyrosinetyrosine (PYY), and leptin signal to the brain the state of hunger or satiety or energy storage [1] [2] [3] [4] [5] [6] .", [["gastrointestinal", "ANATOMY", 14, 30], ["adipose tissue", "ANATOMY", 34, 48], ["brain", "ANATOMY", 157, 162], ["tyrosinetyrosine", "CHEMICAL", 108, 124], ["tyrosinetyrosine", "CHEMICAL", 108, 124], ["gastrointestinal", "ORGAN", 14, 30], ["adipose tissue", "TISSUE", 34, 48], ["ghrelin", "GENE_OR_GENE_PRODUCT", 82, 89], ["insulin", "GENE_OR_GENE_PRODUCT", 91, 98], ["tyrosinetyrosine", "GENE_OR_GENE_PRODUCT", 108, 124], ["PYY", "GENE_OR_GENE_PRODUCT", 126, 129], ["leptin", "GENE_OR_GENE_PRODUCT", 136, 142], ["brain", "ORGAN", 157, 162], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 212, 235], ["insulin", "PROTEIN", 91, 98], ["gastrointestinal or adipose tissue", "PROBLEM", 14, 48], ["derived peptide hormones", "TREATMENT", 49, 73], ["ghrelin, insulin", "TREATMENT", 82, 98], ["leptin signal", "PROBLEM", 136, 149], ["hunger", "PROBLEM", 176, 182], ["energy storage", "TEST", 197, 211], ["gastrointestinal", "ANATOMY", 14, 30], ["adipose tissue", "ANATOMY", 34, 48]]], ["In the brain, these peptides interact with neuronal circuitries expressing orexi-genic neuropeptides such as neuropeptide Y (NPY), agoutirelated protein (AgRP), galanin, melanin-concentrating hormone (MCH), and orexin or anorexigenic neuropeptides such as \u2423-melanocyte-stimulating hormone (\u2423-MSH), corticotropin-releasing hormone (CRH), oxytocin, and vasopressin [7] [8] [9] [10] [11] [12] .", [["brain", "ANATOMY", 7, 12], ["neuronal", "ANATOMY", 43, 51], ["\u2423-MSH", "CHEMICAL", 290, 295], ["oxytocin", "CHEMICAL", 337, 345], ["vasopressin [7] [8] [9] [10] [11] [12]", "CHEMICAL", 351, 389], ["oxytocin", "CHEMICAL", 337, 345], ["vasopressin", "CHEMICAL", 351, 362], ["brain", "ORGAN", 7, 12], ["neuronal", "CELL", 43, 51], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 109, 123], ["NPY", "GENE_OR_GENE_PRODUCT", 125, 128], ["agoutirelated protein", "GENE_OR_GENE_PRODUCT", 131, 152], ["AgRP", "GENE_OR_GENE_PRODUCT", 154, 158], ["galanin", "GENE_OR_GENE_PRODUCT", 161, 168], ["melanin-concentrating hormone", "GENE_OR_GENE_PRODUCT", 170, 199], ["MCH", "GENE_OR_GENE_PRODUCT", 201, 204], ["orexin", "GENE_OR_GENE_PRODUCT", 211, 217], ["\u2423-melanocyte-stimulating hormone", "GENE_OR_GENE_PRODUCT", 256, 288], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 290, 295], ["corticotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 298, 329], ["CRH", "GENE_OR_GENE_PRODUCT", 331, 334], ["oxytocin", "SIMPLE_CHEMICAL", 337, 345], ["vasopressin [7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 351, 389], ["orexi-genic neuropeptides", "PROTEIN", 75, 100], ["agoutirelated protein", "PROTEIN", 131, 152], ["AgRP", "PROTEIN", 154, 158], ["orexi-genic neuropeptides", "PROBLEM", 75, 100], ["galanin", "TEST", 161, 168], ["melanin", "TEST", 170, 177], ["orexin", "PROBLEM", 211, 217], ["anorexigenic neuropeptides", "PROBLEM", 221, 247], ["\u2423-melanocyte-stimulating hormone", "TREATMENT", 256, 288], ["corticotropin-releasing hormone", "TREATMENT", 298, 329], ["oxytocin", "TREATMENT", 337, 345], ["vasopressin", "TREATMENT", 351, 362], ["brain", "ANATOMY", 7, 12]]], ["In addition to appetite regulation, orexigenic and anorexigenic neuropeptides are involved in mechanisms related to stress, sleep/wakefulness, and reproductive, defensive/aggressive, and social behaviors, thereby integrating appetite, emotions, and other homeostatic functions [13] [14] [15] .", [["[13] [14] [15]", "SIMPLE_CHEMICAL", 277, 291], ["orexigenic and anorexigenic neuropeptides", "PROBLEM", 36, 77], ["stress", "PROBLEM", 116, 122], ["sleep/wakefulness", "PROBLEM", 124, 141]]], ["Moreover, there is evidence that neuropeptides known for their central sites of action, such as NPY, also contribute to the mechanisms of energy homeostasis via peripheral effects [16] .IntroductionRecently, autoantibodies (autoAbs) directed against two melanocortin (MC) peptides, \u2423-MSH and adrenocorticotropic hormone (ACTH), have been detected in subjects with eating disorders, suggesting that the immune system may interfere with peptidergic systems involved in appetite and emotional control [17] .", [["immune system", "ANATOMY", 402, 415], ["eating disorders", "DISEASE", 364, 380], ["NPY", "GENE_OR_GENE_PRODUCT", 96, 99], ["autoAbs", "GENE_OR_GENE_PRODUCT", 224, 231], ["melanocortin", "GENE_OR_GENE_PRODUCT", 254, 266], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 282, 287], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 292, 319], ["ACTH", "GENE_OR_GENE_PRODUCT", 321, 325], ["autoantibodies", "PROTEIN", 208, 222], ["autoAbs", "PROTEIN", 224, 231], ["energy homeostasis", "PROBLEM", 138, 156], ["autoantibodies (autoAbs)", "TREATMENT", 208, 232], ["two melanocortin (MC) peptides", "TREATMENT", 250, 280], ["\u2423-MSH and adrenocorticotropic hormone (ACTH)", "PROBLEM", 282, 326], ["eating disorders", "PROBLEM", 364, 380], ["the immune system", "PROBLEM", 398, 415], ["peptidergic systems", "TREATMENT", 435, 454], ["emotional control", "TREATMENT", 480, 497]]], ["In fact, levels of \u2423-MSH auto-Abs correlated with the core psychopathologic traits in patients with eating disorders [18] .", [["eating disorders", "DISEASE", 100, 116], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 19, 24], ["auto-Abs", "GENE_OR_GENE_PRODUCT", 25, 33], ["patients", "ORGANISM", 86, 94], ["\u2423-MSH auto-Abs", "PROTEIN", 19, 33], ["patients", "SPECIES", 86, 94], ["levels", "TEST", 9, 15], ["the core psychopathologic traits", "PROBLEM", 50, 82], ["eating disorders", "PROBLEM", 100, 116]]], ["Moreover, a recent study implicated T cells in the cholecystokinin-mediated control of food intake [19] .", [["T cells", "ANATOMY", 36, 43], ["cholecystokinin", "CHEMICAL", 51, 66], ["T cells", "CELL", 36, 43], ["cholecystokinin", "GENE_OR_GENE_PRODUCT", 51, 66], ["food", "ORGANISM_SUBDIVISION", 87, 91], ["T cells", "CELL_TYPE", 36, 43], ["a recent study", "TEST", 10, 24], ["T cells", "PROBLEM", 36, 43]]], ["Other studies have revealed the existence of autoAbs directed against several other regulatory peptides including vasoactive intestinal peptide, bradykinin, and hypocretin [20 -22] .", [["bradykinin", "CHEMICAL", 145, 155], ["bradykinin", "CHEMICAL", 145, 155], ["autoAbs", "GENE_OR_GENE_PRODUCT", 45, 52], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 114, 143], ["bradykinin", "SIMPLE_CHEMICAL", 145, 155], ["hypocretin", "GENE_OR_GENE_PRODUCT", 161, 171], ["autoAbs", "PROTEIN", 45, 52], ["Other studies", "TEST", 0, 13], ["autoAbs", "TREATMENT", 45, 52], ["several other regulatory peptides", "PROBLEM", 70, 103], ["vasoactive intestinal peptide", "TREATMENT", 114, 143], ["bradykinin", "PROBLEM", 145, 155], ["hypocretin", "TEST", 161, 171]]], ["In addition, since the initial reports of insulin autoAbs before insulin treatment [23, 24] , abundant data on autoAbs directed against insulin in diabetes have been accumulated [25] .", [["diabetes", "DISEASE", 147, 155], ["insulin", "GENE_OR_GENE_PRODUCT", 42, 49], ["insulin", "GENE_OR_GENE_PRODUCT", 65, 72], ["autoAbs", "SIMPLE_CHEMICAL", 111, 118], ["insulin", "GENE_OR_GENE_PRODUCT", 136, 143], ["insulin", "PROTEIN", 42, 49], ["insulin", "PROTEIN", 136, 143], ["insulin", "TREATMENT", 42, 49], ["insulin treatment", "TREATMENT", 65, 82], ["autoAbs", "TREATMENT", 111, 118], ["insulin", "TREATMENT", 136, 143], ["diabetes", "PROBLEM", 147, 155]]], ["These studies have reported that autoAbs directed against regulatory peptides can be also present in apparently healthy subjects, a finding that might signify physiologic roles of these autoAbs, such as modulation of the binding of regulatory peptides to their receptors [18] or post-transcriptional modification [20] .", [["Abs directed against regulatory peptides", "GENE_OR_GENE_PRODUCT", 37, 77], ["autoAbs", "GENE_OR_GENE_PRODUCT", 186, 193], ["Abs", "PROTEIN", 37, 40], ["autoAbs", "PROTEIN", 186, 193], ["These studies", "TEST", 0, 13], ["post-transcriptional modification", "TREATMENT", 279, 312]]], ["However, because self-reacting Abs are normally associated with autoimmune diseases [26] , the presence of autoAbs directed against regulatory peptides in healthy subjects remains largely unexplored.IntroductionIt is also unknown if autoAbs exist against appetiteregulating peptide hormones including ghrelin, PYY, or leptin or neuropeptides including NPY, AgRP, galanin, and CRH.", [["autoimmune diseases", "DISEASE", 64, 83], ["Abs", "GENE_OR_GENE_PRODUCT", 31, 34], ["autoAbs directed against regulatory peptides", "GENE_OR_GENE_PRODUCT", 107, 151], ["autoAbs", "SIMPLE_CHEMICAL", 233, 240], ["ghrelin", "GENE_OR_GENE_PRODUCT", 301, 308], ["PYY", "GENE_OR_GENE_PRODUCT", 310, 313], ["leptin", "GENE_OR_GENE_PRODUCT", 318, 324], ["NPY", "GENE_OR_GENE_PRODUCT", 352, 355], ["AgRP", "GENE_OR_GENE_PRODUCT", 357, 361], ["galanin", "GENE_OR_GENE_PRODUCT", 363, 370], ["CRH", "GENE_OR_GENE_PRODUCT", 376, 379], ["Abs", "PROTEIN", 31, 34], ["autoAbs", "PROTEIN", 107, 114], ["autoAbs", "PROTEIN", 233, 240], ["self-reacting Abs", "PROBLEM", 17, 34], ["autoimmune diseases", "PROBLEM", 64, 83], ["autoAbs", "TREATMENT", 107, 114], ["galanin", "TREATMENT", 363, 370], ["CRH", "PROBLEM", 376, 379]]], ["Thus, in the present work, we investigated the presence in physiologic conditions of autoAbs directed against these peptides and studied gut-related factors that might influence production of these autoAbs.", [["gut", "ANATOMY", 137, 140], ["gut", "ORGANISM_SUBDIVISION", 137, 140], ["Abs", "PROTEIN", 202, 205], ["these peptides", "PROBLEM", 110, 124]]], ["First, we examined healthy subjects for the presence of immunoglobulin (Ig) G and IgA autoAbs able to bind any of 14 regulatory peptides chosen for their key roles in mechanisms of appetite and body weight.", [["body", "ANATOMY", 194, 198], ["immunoglobulin (Ig) G", "GENE_OR_GENE_PRODUCT", 56, 77], ["IgA", "GENE_OR_GENE_PRODUCT", 82, 85], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["immunoglobulin (Ig) G", "PROTEIN", 56, 77], ["IgA autoAbs", "PROTEIN", 82, 93], ["immunoglobulin (Ig)", "TREATMENT", 56, 75], ["IgA autoAbs", "PROBLEM", 82, 93], ["14 regulatory peptides", "TREATMENT", 114, 136], ["body weight", "TEST", 194, 205]]], ["The presence of the IgA class of autoAbs may point to a luminal, most commonly intestinal origin of the antigenic stimulation, including food-derived antigens and gut microflora [27] .IntroductionIn fact, the gut-associated lymphoid tissue is one of the main sources of IgA, produced by the class switch from IgM stimulated by cytokines such as transforming growth factor-\u2424 [28] .", [["luminal", "ANATOMY", 56, 63], ["intestinal", "ANATOMY", 79, 89], ["gut microflora", "ANATOMY", 163, 177], ["gut", "ANATOMY", 209, 212], ["lymphoid tissue", "ANATOMY", 224, 239], ["luminal", "CHEMICAL", 56, 63], ["IgA", "GENE_OR_GENE_PRODUCT", 20, 23], ["autoAbs", "GENE_OR_GENE_PRODUCT", 33, 40], ["intestinal", "ORGAN", 79, 89], ["gut", "ORGANISM_SUBDIVISION", 209, 212], ["lymphoid tissue", "TISSUE", 224, 239], ["IgA", "GENE_OR_GENE_PRODUCT", 270, 273], ["IgM", "GENE_OR_GENE_PRODUCT", 309, 312], ["transforming growth factor-\u2424", "GENE_OR_GENE_PRODUCT", 345, 373], ["IgA class", "PROTEIN", 20, 29], ["autoAbs", "PROTEIN", 33, 40], ["food-derived antigens", "PROTEIN", 137, 158], ["IgA", "PROTEIN", 270, 273], ["IgM", "PROTEIN", 309, 312], ["cytokines", "PROTEIN", 327, 336], ["transforming growth factor", "PROTEIN", 345, 371], ["the antigenic stimulation", "TREATMENT", 100, 125], ["lymphoid tissue", "PROBLEM", 224, 239], ["IgM", "TREATMENT", 309, 312], ["transforming growth factor", "TEST", 345, 371], ["IgA", "OBSERVATION", 20, 23], ["luminal", "ANATOMY_MODIFIER", 56, 63], ["antigenic stimulation", "OBSERVATION", 104, 125], ["gut", "ANATOMY", 209, 212], ["lymphoid tissue", "OBSERVATION", 224, 239], ["main", "OBSERVATION_MODIFIER", 254, 258], ["IgA", "OBSERVATION", 270, 273]]], ["The IgA is the predominant immunoglobulin class in mucosal secretions and plays an important role by binding bacterial and viral antigens.", [["mucosal secretions", "ANATOMY", 51, 69], ["IgA", "GENE_OR_GENE_PRODUCT", 4, 7], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 27, 41], ["mucosal secretions", "ORGANISM_SUBSTANCE", 51, 69], ["IgA", "PROTEIN", 4, 7], ["immunoglobulin class", "PROTEIN", 27, 47], ["bacterial and viral antigens", "PROTEIN", 109, 137], ["the predominant immunoglobulin class in mucosal secretions", "PROBLEM", 11, 69], ["binding bacterial and viral antigens", "PROBLEM", 101, 137], ["IgA", "OBSERVATION", 4, 7], ["predominant", "OBSERVATION_MODIFIER", 15, 26], ["immunoglobulin class", "OBSERVATION", 27, 47], ["mucosal", "ANATOMY", 51, 58], ["secretions", "OBSERVATION", 59, 69]]], ["In serum IgA accounts for 6 -15% of total immunoglobulins.", [["serum", "ANATOMY", 3, 8], ["serum", "ORGANISM_SUBSTANCE", 3, 8], ["IgA", "GENE_OR_GENE_PRODUCT", 9, 12], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 42, 57], ["serum IgA", "PROTEIN", 3, 12], ["immunoglobulins", "PROTEIN", 42, 57], ["serum IgA", "TEST", 3, 12], ["total immunoglobulins", "TREATMENT", 36, 57]]], ["Although the systemic role of IgA has not been fully clarified, human peripheral blood neutrophils express Fc\u2423 immunoglobulin receptors that may trigger IgA-mediated functional responses including phagocytosis or release of interleukin-6 and tumor necrosis factor-\u2423 cytokines [29, 30] .", [["peripheral blood neutrophils", "ANATOMY", 70, 98], ["necrosis", "DISEASE", 248, 256], ["IgA", "GENE_OR_GENE_PRODUCT", 30, 33], ["human", "ORGANISM", 64, 69], ["peripheral blood neutrophils", "CELL", 70, 98], ["Fc\u2423 immunoglobulin receptors", "GENE_OR_GENE_PRODUCT", 107, 135], ["IgA", "GENE_OR_GENE_PRODUCT", 153, 156], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 224, 237], ["tumor necrosis factor-\u2423", "GENE_OR_GENE_PRODUCT", 242, 265], ["IgA", "PROTEIN", 30, 33], ["human peripheral blood neutrophils", "CELL_TYPE", 64, 98], ["Fc\u2423 immunoglobulin receptors", "PROTEIN", 107, 135], ["IgA", "PROTEIN", 153, 156], ["interleukin-6", "PROTEIN", 224, 237], ["tumor necrosis factor-\u2423 cytokines", "PROTEIN", 242, 275], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["human peripheral blood neutrophils", "TEST", 64, 98], ["immunoglobulin receptors", "TEST", 111, 135], ["IgA", "TEST", 153, 156], ["phagocytosis", "PROBLEM", 197, 209], ["interleukin", "TEST", 224, 235], ["tumor necrosis factor", "PROBLEM", 242, 263], ["cytokines", "TEST", 266, 275], ["tumor", "OBSERVATION_MODIFIER", 242, 247], ["necrosis", "OBSERVATION", 248, 256]]], ["In this study, we focused on the possible role of intestinal microflora in relation to neuropeptide autoAb response.", [["intestinal microflora", "ANATOMY", 50, 71], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 50, 71], ["autoAb", "GENE_OR_GENE_PRODUCT", 100, 106], ["this study", "TEST", 3, 13], ["intestinal microflora", "TREATMENT", 50, 71], ["intestinal", "ANATOMY", 50, 60]]], ["However, the role of nutrients, as direct sources of antigens or as prebiotics, may also be important in this process.", [["antigens", "PROTEIN", 53, 61], ["prebiotics", "TREATMENT", 68, 78]]], ["For instance, serum IgA antigliadin antibodies induced by a wheat protein comprise a well-established marker of celiac disease, but this antibody can also bind to neurons [31] .", [["serum", "ANATOMY", 14, 19], ["celiac", "ANATOMY", 112, 118], ["neurons", "ANATOMY", 163, 170], ["celiac disease", "DISEASE", 112, 126], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["IgA", "GENE_OR_GENE_PRODUCT", 20, 23], ["celiac", "ORGAN", 112, 118], ["neurons", "CELL", 163, 170], ["serum IgA antigliadin antibodies", "PROTEIN", 14, 46], ["wheat protein", "PROTEIN", 60, 73], ["wheat", "SPECIES", 60, 65], ["wheat", "SPECIES", 60, 65], ["serum IgA antigliadin antibodies", "TEST", 14, 46], ["a wheat protein", "PROBLEM", 58, 73], ["celiac disease", "PROBLEM", 112, 126], ["this antibody", "PROBLEM", 132, 145], ["celiac", "ANATOMY", 112, 118], ["disease", "OBSERVATION", 119, 126]]], ["In contrast, IgG is the predominant class of immunoglobulins found in serum and it is the main molecule of adaptive immunity by activating complement and phagocytosis pathways.", [["serum", "ANATOMY", 70, 75], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 45, 60], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["IgG", "PROTEIN", 13, 16], ["immunoglobulins", "PROTEIN", 45, 60], ["immunoglobulins", "PROBLEM", 45, 60], ["serum", "TEST", 70, 75], ["phagocytosis pathways", "TEST", 154, 175], ["immunoglobulins", "OBSERVATION", 45, 60]]], ["The presence of IgG reflects previous exposure to antigens.IntroductionThe microflora of the gastrointestinal system is a major antigenic source with approximately 10 14 micro-organisms [32] .", [["gastrointestinal system", "ANATOMY", 93, 116], ["IgG", "GENE_OR_GENE_PRODUCT", 16, 19], ["gastrointestinal", "ORGAN", 93, 109], ["IgG", "PROTEIN", 16, 19], ["antigens", "PROTEIN", 50, 58], ["IgG", "PROBLEM", 16, 19], ["previous exposure to antigens", "PROBLEM", 29, 58], ["IgG", "OBSERVATION", 16, 19], ["gastrointestinal system", "ANATOMY", 93, 116]]], ["Based on the concept of molecular mimicry [33] , such intestinal antigens could potentially trigger the production of autoAbs cross-reacting with regulatory peptides.", [["intestinal", "ANATOMY", 54, 64], ["intestinal", "ORGAN", 54, 64], ["Abs", "PROTEIN", 122, 125], ["such intestinal antigens", "PROBLEM", 49, 73], ["regulatory peptides", "TREATMENT", 146, 165], ["intestinal", "ANATOMY", 54, 64]]], ["Hence, the second goal of this study was to determine the presence of amino acid (aa) sequence homologies between appetiteregulating peptides and microbial proteins of bacterial, viral, or fungal origin.", [["amino acid", "CHEMICAL", 70, 80], ["amino acid", "CHEMICAL", 70, 80], ["amino acid", "AMINO_ACID", 70, 80], ["microbial proteins", "PROTEIN", 146, 164], ["this study", "TEST", 26, 36], ["amino acid (aa) sequence homologies between appetiteregulating peptides", "PROBLEM", 70, 141], ["microbial proteins of bacterial, viral, or fungal origin", "PROBLEM", 146, 202], ["bacterial", "OBSERVATION_MODIFIER", 168, 177], ["viral", "OBSERVATION", 179, 184], ["fungal origin", "OBSERVATION", 189, 202]]], ["To verify the relevance of intestinal microflora to the presence of these autoAbs, their serum levels were measured in germ-free and specific pathogen-free rats.Study subjectsHealthy female volunteers (n \u03ed 15, mean \u03ee SD 30 \u03ee 5 y of age, body mass index 21.5 \u03ee 1 kg/m 2 ) served as study subjects.", [["intestinal microflora", "ANATOMY", 27, 48], ["serum", "ANATOMY", 89, 94], ["germ", "ANATOMY", 119, 123], ["body", "ANATOMY", 237, 241], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 27, 48], ["autoAbs", "GENE_OR_GENE_PRODUCT", 74, 81], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["rats", "ORGANISM", 156, 160], ["volunteers", "ORGANISM", 190, 200], ["body", "ORGANISM_SUBDIVISION", 237, 241], ["autoAbs", "PROTEIN", 74, 81], ["rats", "SPECIES", 156, 160], ["intestinal microflora", "TREATMENT", 27, 48], ["these autoAbs", "TEST", 68, 81], ["their serum levels", "TEST", 83, 101], ["Study subjects", "TEST", 161, 175], ["body mass index", "PROBLEM", 237, 252], ["intestinal", "ANATOMY", 27, 37]]], ["They were recruited by the Department of Nutrition at Rouen University Hospital, France, and gave informed consent for involvement in the study approved by the Rouen University Hospital ethical committee.", [["the study", "TEST", 134, 143]]], ["Routine venous blood samples were taken; serum was immediately separated by centrifugation and frozen at \u03ea20\u00b0C.Detection of autoantibodies against appetite-regulating peptidesSerum levels of IgG or IgA autoAbs reacting with 14 regulatory peptides, including human leptin (amino acids , insulin (Sigma, St. Louis, MO, USA), PYY (amino acids 29 -64), ghrelin (amino acids 24 -51), NPY, AgRP (amino acids 83-132; Phoenix Pharmaceutical Inc., Belmont, CA, USA), galanin (amino acids , orexin A, MCH, \u2423-MSH, ACTH, CRH, oxytocin, and vasopressin, were measured using an enzyme-linked immunosorbent as-say (ELISA) technique.", [["venous blood samples", "ANATOMY", 8, 28], ["serum", "ANATOMY", 41, 46], ["amino acids", "CHEMICAL", 272, 283], ["amino acids 29 -64", "CHEMICAL", 328, 346], ["amino acids 24 -51)", "CHEMICAL", 358, 377], ["amino acids 83-132", "CHEMICAL", 390, 408], ["galanin", "CHEMICAL", 458, 465], ["amino acids", "CHEMICAL", 467, 478], ["oxytocin", "CHEMICAL", 514, 522], ["vasopressin", "CHEMICAL", 528, 539], ["amino acids", "CHEMICAL", 272, 283], ["amino acids", "CHEMICAL", 328, 339], ["amino acids", "CHEMICAL", 358, 369], ["amino acids 83-132", "CHEMICAL", 390, 408], ["amino acids", "CHEMICAL", 467, 478], ["oxytocin", "CHEMICAL", 514, 522], ["venous blood samples", "ORGANISM_SUBSTANCE", 8, 28], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["peptidesSerum", "SIMPLE_CHEMICAL", 167, 180], ["IgG", "GENE_OR_GENE_PRODUCT", 191, 194], ["IgA", "GENE_OR_GENE_PRODUCT", 198, 201], ["human", "ORGANISM", 258, 263], ["leptin", "GENE_OR_GENE_PRODUCT", 264, 270], ["amino acids", "AMINO_ACID", 272, 283], ["insulin", "GENE_OR_GENE_PRODUCT", 286, 293], ["St. Louis", "ORGANISM", 302, 311], ["MO", "GENE_OR_GENE_PRODUCT", 313, 315], ["USA", "GENE_OR_GENE_PRODUCT", 317, 320], ["PYY", "GENE_OR_GENE_PRODUCT", 323, 326], ["amino acids", "AMINO_ACID", 328, 339], ["ghrelin", "GENE_OR_GENE_PRODUCT", 349, 356], ["amino acids", "AMINO_ACID", 358, 369], ["NPY", "GENE_OR_GENE_PRODUCT", 379, 382], ["AgRP", "GENE_OR_GENE_PRODUCT", 384, 388], ["amino acids", "AMINO_ACID", 390, 401], ["galanin", "GENE_OR_GENE_PRODUCT", 458, 465], ["amino acids", "AMINO_ACID", 467, 478], ["orexin A", "GENE_OR_GENE_PRODUCT", 481, 489], ["MCH", "GENE_OR_GENE_PRODUCT", 491, 494], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 496, 501], ["ACTH", "GENE_OR_GENE_PRODUCT", 503, 507], ["CRH", "GENE_OR_GENE_PRODUCT", 509, 512], ["oxytocin", "SIMPLE_CHEMICAL", 514, 522], ["vasopressin", "GENE_OR_GENE_PRODUCT", 528, 539], ["autoantibodies", "PROTEIN", 124, 138], ["IgG", "PROTEIN", 191, 194], ["IgA autoAbs", "PROTEIN", 198, 209], ["human leptin", "PROTEIN", 258, 270], ["insulin", "PROTEIN", 286, 293], ["human", "SPECIES", 258, 263], ["human", "SPECIES", 258, 263], ["Routine venous blood samples", "TEST", 0, 28], ["autoantibodies", "TEST", 124, 138], ["appetite", "TEST", 147, 155], ["peptidesSerum levels", "TEST", 167, 187], ["IgG", "TEST", 191, 194], ["IgA autoAbs", "PROBLEM", 198, 209], ["14 regulatory peptides", "TREATMENT", 224, 246], ["human leptin (amino acids", "TREATMENT", 258, 283], ["insulin", "TREATMENT", 286, 293], ["PYY (amino acids", "TEST", 323, 339], ["ghrelin (amino acids", "TEST", 349, 369], ["amino acids", "TEST", 390, 401], ["Belmont", "TREATMENT", 439, 446], ["CA, USA", "TREATMENT", 448, 455], ["galanin (amino acids", "TREATMENT", 458, 478], ["MCH", "TEST", 491, 494], ["ACTH", "TEST", 503, 507], ["CRH", "TEST", 509, 512], ["oxytocin", "TREATMENT", 514, 522], ["vasopressin", "TREATMENT", 528, 539], ["an enzyme", "TEST", 561, 570], ["venous", "ANATOMY", 8, 14]]], ["The peptides (all purchased from Bachem AG, Bubendorf, Switzerland, unless specified) were coated on Maxisorp plates (Nunc, Rochester, NY, USA) using 100 L and a concentration of 2 g/mL in 100 mM NaHCO 3 buffer, pH 9.6, for 24 h at 4\u00b0C. Plates were washed (5 min \u03eb 3) in phosphate buffered saline (PBS) with 0.05% Tween 200, pH 7.4, and then incubated overnight at 4\u00b0C with 100 L of serum from subjects diluted 1:100 in PBS.", [["serum", "ANATOMY", 383, 388], ["phosphate", "CHEMICAL", 271, 280], ["NaHCO 3", "CHEMICAL", 196, 203], ["phosphate", "CHEMICAL", 271, 280], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 271, 296], ["serum", "ORGANISM_SUBSTANCE", 383, 388], ["100 mM NaHCO", "TREATMENT", 189, 201], ["pH", "TEST", 212, 214], ["Plates", "TEST", 237, 243], ["phosphate buffered saline (PBS", "TREATMENT", 271, 301], ["pH", "TEST", 325, 327]]], ["The plates were washed (\u03eb3) and incubated with 100 L of alkaline phosphatase-conjugated rabbit antihuman IgG or IgA (1:2000; Sigma) for 3 h at room temperature.", [["rabbit", "ORGANISM", 88, 94], ["IgA", "GENE_OR_GENE_PRODUCT", 112, 115], ["alkaline phosphatase", "PROTEIN", 56, 76], ["conjugated rabbit antihuman IgG", "PROTEIN", 77, 108], ["IgA", "PROTEIN", 112, 115], ["rabbit", "SPECIES", 88, 94], ["rabbit", "SPECIES", 88, 94], ["The plates", "TEST", 0, 10], ["alkaline phosphatase", "TEST", 56, 76], ["conjugated rabbit antihuman IgG", "TREATMENT", 77, 108], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["After washing (\u03eb3), 100 L of p-nitrophenyl phosphate solution (Sigma) was added as an alkaline phosphatase substrate.", [["p-nitrophenyl phosphate", "CHEMICAL", 29, 52], ["p-nitrophenyl phosphate", "CHEMICAL", 29, 52], ["p-nitrophenyl phosphate solution", "SIMPLE_CHEMICAL", 29, 61], ["Sigma", "SIMPLE_CHEMICAL", 63, 68], ["alkaline phosphatase substrate", "PROTEIN", 86, 116], ["p-nitrophenyl phosphate solution", "TREATMENT", 29, 61], ["an alkaline phosphatase substrate", "TEST", 83, 116]]], ["After 40 min of incubation at room temperature, the reaction was stopped by adding 3 N NaOH.", [["N NaOH", "CHEMICAL", 85, 91], ["3 N NaOH", "CHEMICAL", 83, 91], ["the reaction", "PROBLEM", 48, 60]]], ["The optical density (OD) was determined at 405 nm using a microplate reader.", [["a microplate reader", "TREATMENT", 56, 75], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19]]], ["Blank OD values resulting from the reading of plates without addition of human sera were subtracted from the sample OD values.", [["sera", "ANATOMY", 79, 83], ["human", "ORGANISM", 73, 78], ["sera", "ORGANISM_SUBSTANCE", 79, 83], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["Blank OD values", "TEST", 0, 15], ["human sera", "TREATMENT", 73, 83], ["the sample OD values", "TEST", 105, 125]]], ["The optimal dilutions of human sera (1:100) were determined by dilution curves (1:50, 1:100, 1:200).", [["sera", "ANATOMY", 31, 35], ["human", "ORGANISM", 25, 30], ["sera", "ORGANISM_SUBSTANCE", 31, 35], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["optimal", "OBSERVATION_MODIFIER", 4, 11], ["dilutions", "OBSERVATION_MODIFIER", 12, 21]]], ["Each determination was done in duplicate.", [["Each determination", "TEST", 0, 18]]], ["The coefficient of variation between duplicate values was \u03fd5%.", [["duplicate values", "TEST", 37, 53], ["coefficient", "OBSERVATION_MODIFIER", 4, 15]]], ["To estimate the concentrations of measured autoAbs, standard linear curves (R 2 \u03ed 0.99) were obtained by sandwich ELISA on serial dilutions of total human IgG and IgA (Sigma) with known concentrations.Detection of autoantibodies against appetite-regulating peptidesBriefly, ELISA plates were coated overnight with 100 L of anti-human immunoglobulin polyvalent (Caltag Laboratories, Burlingame, CA, USA; 1:1000 in coating buffer).", [["human", "ORGANISM", 149, 154], ["IgG", "GENE_OR_GENE_PRODUCT", 155, 158], ["IgA", "GENE_OR_GENE_PRODUCT", 163, 166], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 334, 348], ["total human IgG", "PROTEIN", 143, 158], ["IgA", "PROTEIN", 163, 166], ["Sigma", "PROTEIN", 168, 173], ["autoantibodies", "PROTEIN", 214, 228], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["standard linear curves", "TEST", 52, 74], ["sandwich ELISA", "TEST", 105, 119], ["serial dilutions", "TEST", 123, 139], ["total human IgG", "TREATMENT", 143, 158], ["known concentrations", "PROBLEM", 180, 200], ["autoantibodies against appetite", "PROBLEM", 214, 245], ["regulating peptides", "TREATMENT", 246, 265], ["ELISA plates", "TREATMENT", 274, 286], ["anti-human immunoglobulin polyvalent", "TREATMENT", 323, 359], ["Caltag Laboratories", "TEST", 361, 380]]], ["Plates were washed in PBS, incubated with 100 L of 3% bovine serum albumin, washed again, and incubated overnight at 4\u00b0C with 24 serial dilutions (each 1:2) of IgG or IgA standards starting from 1 g/mL.", [["serum", "ANATOMY", 61, 66], ["bovine", "ORGANISM", 54, 60], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["albumin", "GENE_OR_GENE_PRODUCT", 67, 74], ["IgG", "GENE_OR_GENE_PRODUCT", 160, 163], ["IgA", "GENE_OR_GENE_PRODUCT", 167, 170], ["IgG", "PROTEIN", 160, 163], ["IgA", "PROTEIN", 167, 170], ["bovine", "SPECIES", 54, 60], ["bovine", "SPECIES", 54, 60], ["PBS", "TREATMENT", 22, 25], ["3% bovine serum albumin", "TREATMENT", 51, 74], ["IgG or IgA standards", "TREATMENT", 160, 180]]], ["Plates were washed (\u03eb3) and incubated with 100 L of alkaline phosphataseconjugated rabbit anti-human IgG or IgA (1:2000; Sigma) for 3 h at room temperature.", [["rabbit", "ORGANISM", 83, 89], ["IgG", "GENE_OR_GENE_PRODUCT", 101, 104], ["IgA", "GENE_OR_GENE_PRODUCT", 108, 111], ["alkaline phosphataseconjugated rabbit anti-human IgG", "PROTEIN", 52, 104], ["IgA", "PROTEIN", 108, 111], ["rabbit", "SPECIES", 83, 89], ["rabbit", "SPECIES", 83, 89], ["Plates", "TEST", 0, 6], ["alkaline phosphataseconjugated rabbit anti-human IgG", "TREATMENT", 52, 104]]], ["After washing (\u03eb3), the chromogenic reaction and OD reading was performed as described above.", [["the chromogenic reaction", "PROBLEM", 20, 44], ["OD reading", "TEST", 49, 59]]], ["This ELISA test showed detection limits of 0.2 ng/mL for IgG and 1.0 ng/mL for IgA.", [["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["IgA", "GENE_OR_GENE_PRODUCT", 79, 82], ["IgG", "PROTEIN", 57, 60], ["IgA", "PROTEIN", 79, 82], ["This ELISA test", "TEST", 0, 15], ["IgG", "TEST", 57, 60], ["IgA", "PROBLEM", 79, 82]]], ["The specificity of IgA and IgG binding to each regulatory peptide was determined by ELISA after preadsorption of sera with decreasing concentrations of the corresponding synthetic peptide.", [["sera", "ANATOMY", 113, 117], ["IgA", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 27, 30], ["sera", "ORGANISM_SUBSTANCE", 113, 117], ["IgA", "PROTEIN", 19, 22], ["IgG", "PROTEIN", 27, 30], ["IgA and IgG binding", "PROBLEM", 19, 38], ["sera", "TREATMENT", 113, 117]]], ["In addition to whole serum (1:100 in PBS), sera from several subjects were purified from IgG using protein G agarose (Sigma, P7700) and from IgM using dialysis against distilled water via a membrane (MWCO 6-8000, Spectrum Laboratory, Inc. Interchim, France).", [["serum", "ANATOMY", 21, 26], ["sera", "ANATOMY", 43, 47], ["membrane", "ANATOMY", 190, 198], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["sera", "ORGANISM_SUBSTANCE", 43, 47], ["IgG", "ORGANISM_SUBSTANCE", 89, 92], ["protein G agarose", "GENE_OR_GENE_PRODUCT", 99, 116], ["Sigma", "SIMPLE_CHEMICAL", 118, 123], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["IgG", "PROTEIN", 89, 92], ["IgM", "PROTEIN", 141, 144], ["whole serum", "TEST", 15, 26], ["sera", "TEST", 43, 47], ["IgG", "TEST", 89, 92], ["protein G agarose", "TEST", 99, 116], ["IgM", "TEST", 141, 144], ["dialysis", "TREATMENT", 151, 159]]], ["The remaining serum (diluted 1:20 in PBS) containing IgA, but not IgG or IgM, was incubated overnight in decreasing concentrations of each peptide (0.2, 0.04, and 0.02 g/L) in a volume of 300 L. Controls consisted of overnight incubation of the IgA-containing sera in PBS only.", [["serum", "ANATOMY", 14, 19], ["sera", "ANATOMY", 260, 264], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["IgA", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["IgM", "GENE_OR_GENE_PRODUCT", 73, 76], ["IgA", "GENE_OR_GENE_PRODUCT", 245, 248], ["sera", "ORGANISM_SUBSTANCE", 260, 264], ["IgA", "PROTEIN", 53, 56], ["IgG", "PROTEIN", 66, 69], ["IgM", "PROTEIN", 73, 76], ["IgA", "PROTEIN", 245, 248], ["The remaining serum", "TEST", 0, 19], ["IgA", "TEST", 53, 56], ["IgG", "TEST", 66, 69], ["IgM", "TEST", 73, 76], ["a volume", "TEST", 176, 184], ["overnight incubation", "TREATMENT", 217, 237], ["the IgA", "TREATMENT", 241, 248], ["sera in PBS", "TREATMENT", 260, 271]]], ["The ELISA was performed as described above with peptide coating (0.2 g/mL).", [["The ELISA", "TEST", 0, 9], ["peptide coating", "TREATMENT", 48, 63]]], ["As an additional specificity control, the purified IgG fraction was tested on ELISA for the presence of IgA autoAbs.Molecular mimicry with appetite-regulating peptidesTo test the concept of molecular mimicry (for details, see DISCUSSION) in relation to the origin of autoAbs reacting with all 14 regulatory peptides, the aa sequence of these peptides was \"blasted\" in the protein databases of bacteria, viruses, fungi, or archaea at the National Center for Biotechnology Information (NCBI; Bethesda, MD, USA; www.ncbi. nlm.nih.gov).", [["IgG", "GENE_OR_GENE_PRODUCT", 51, 54], ["IgA", "GENE_OR_GENE_PRODUCT", 104, 107], ["IgA autoAbs", "PROTEIN", 104, 115], ["Abs", "PROTEIN", 271, 274], ["the purified IgG fraction", "TEST", 38, 63], ["ELISA", "TEST", 78, 83], ["IgA autoAbs", "PROBLEM", 104, 115], ["all 14 regulatory peptides", "TREATMENT", 289, 315], ["the aa sequence", "TEST", 317, 332], ["these peptides", "TEST", 336, 350], ["the protein databases", "TEST", 368, 389], ["bacteria", "PROBLEM", 393, 401], ["viruses", "PROBLEM", 403, 410], ["fungi", "PROBLEM", 412, 417], ["bacteria", "OBSERVATION", 393, 401]]], ["The identical (at least five aa consecutive sequences) were recorded and aligned with the sequence of the corresponding regulatory peptide (displaying the name of the source micro-organism).", [["aa consecutive sequences", "TEST", 29, 53]]], ["In some cases longer sequences of six or more identical amino acids were also included, even if the alignment was interrupted by one or two non-matching amino acids.Autoantibodies against appetite-regulating peptides in ratsGerm-free and specific pathogen-free (SPF) 12-wk-old male Sprague-Dawley rats (n \u03ed 6/group) were purchased from Charles River Laboratories (L'Arbresle, France).", [["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 153, 164], ["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 153, 164], ["amino acids", "AMINO_ACID", 56, 67], ["amino acids", "AMINO_ACID", 153, 164], ["appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 188, 216], ["rats", "ORGANISM", 220, 224], ["Sprague-Dawley rats", "ORGANISM", 282, 301], ["n \u03ed 6", "ORGANISM", 303, 308], ["rats", "SPECIES", 220, 224], ["Sprague-Dawley rats", "SPECIES", 282, 301], ["identical amino acids", "TEST", 46, 67], ["two non-matching amino acids", "TREATMENT", 136, 164], ["Autoantibodies", "TEST", 165, 179], ["appetite", "TEST", 188, 196], ["specific pathogen", "TEST", 238, 255]]], ["The germfree status of the rats was routinely verified before delivery by analyzing feces for aerobic and anaerobic bacteria and yeast growth.", [["germfree", "ORGAN", 4, 12], ["rats", "ORGANISM", 27, 31], ["feces", "ORGANISM_SUBSTANCE", 84, 89], ["rats", "SPECIES", 27, 31], ["yeast", "SPECIES", 129, 134], ["yeast", "SPECIES", 129, 134], ["delivery", "TREATMENT", 62, 70], ["analyzing feces", "TEST", 74, 89], ["aerobic and anaerobic bacteria", "PROBLEM", 94, 124], ["yeast growth", "PROBLEM", 129, 141], ["yeast growth", "OBSERVATION", 129, 141]]], ["Upon arrival (germ-free rats in sterile boxes), all rats were immediately anesthetized by sodium thiopental (1 mL/ kg, intraperitoneally) and 4-mL blood samples were taken from the right atrium.", [["germ", "ANATOMY", 14, 18], ["blood samples", "ANATOMY", 147, 160], ["right atrium", "ANATOMY", 181, 193], ["sodium thiopental", "CHEMICAL", 90, 107], ["sodium thiopental", "CHEMICAL", 90, 107], ["rats", "ORGANISM", 24, 28], ["rats", "ORGANISM", 52, 56], ["sodium thiopental", "SIMPLE_CHEMICAL", 90, 107], ["blood samples", "ORGANISM_SUBSTANCE", 147, 160], ["right atrium", "MULTI-TISSUE_STRUCTURE", 181, 193], ["rats", "SPECIES", 24, 28], ["rats", "SPECIES", 52, 56], ["germ-free rats in sterile boxes", "TREATMENT", 14, 45], ["sodium thiopental", "TREATMENT", 90, 107], ["blood samples", "TEST", 147, 160], ["right atrium", "ANATOMY", 181, 193]]], ["Body weight (mean \u03ee SD) did not differ significantly between groups of germ-free and SPF rats (402.8 \u03ee 43.3 versus 401.2 \u03ee 3.5 g, respectively), and all animals were of good physical appearance.", [["Body", "ANATOMY", 0, 4], ["germ", "ANATOMY", 71, 75], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["SPF rats", "ORGANISM", 85, 93], ["rats", "SPECIES", 89, 93], ["SPF", "SPECIES", 85, 88], ["Body weight", "TEST", 0, 11], ["SPF rats", "TEST", 85, 93]]], ["Serum was separated by centrifugation and the detection of autoAbs directed against appetite-regulating peptides was performed by ELISA as described above, with the exception of serum dilution (1:25) and the use of anti-rat IgG or anti-rat IgA goat antibodies conjugated with alkaline phosphatase at 1:500 (Rockland, Gilbertsville, PA, USA).", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 178, 183], ["appetite", "CHEMICAL", 84, 92], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 178, 183], ["IgG", "GENE_OR_GENE_PRODUCT", 224, 227], ["IgA", "GENE_OR_GENE_PRODUCT", 240, 243], ["Abs", "PROTEIN", 63, 66], ["anti-rat IgG", "PROTEIN", 215, 227], ["anti-rat IgA goat antibodies", "PROTEIN", 231, 259], ["alkaline phosphatase", "PROTEIN", 276, 296], ["anti-rat", "SPECIES", 231, 239], ["goat", "SPECIES", 244, 248], ["goat", "SPECIES", 244, 248], ["Serum", "TEST", 0, 5], ["regulating peptides", "TREATMENT", 93, 112], ["serum dilution", "TEST", 178, 192], ["anti-rat IgG", "TREATMENT", 215, 227], ["anti-rat IgA goat antibodies", "TEST", 231, 259], ["alkaline phosphatase", "TEST", 276, 296]]], ["Data were analyzed in the GraphPad inStat program (GraphPad Software Inc., San Diego, CA, USA) using Student's t test or Mann-Whitney test according to the normality test.Detection of autoantibodies against appetite-regulating peptides in human subjectsClearly detectable IgG and IgA autoAbs serum levels with signal intensity exceeding \u05464\u03eb background of the detection system (range 4 -20\u03eb) reacting with leptin, insulin, PYY, ghrelin, NPY, AgRP, galanin, orexin A, MCH, \u2423-MSH, ACTH, CRH, oxytocin, or vasopressin were found in all subjects.", [["serum", "ANATOMY", 292, 297], ["oxytocin", "CHEMICAL", 489, 497], ["vasopressin", "CHEMICAL", 502, 513], ["oxytocin", "CHEMICAL", 489, 497], ["autoantibodies against appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 184, 235], ["human", "ORGANISM", 239, 244], ["IgG", "GENE_OR_GENE_PRODUCT", 272, 275], ["IgA", "GENE_OR_GENE_PRODUCT", 280, 283], ["serum", "ORGANISM_SUBSTANCE", 292, 297], ["leptin", "GENE_OR_GENE_PRODUCT", 405, 411], ["insulin", "GENE_OR_GENE_PRODUCT", 413, 420], ["PYY", "GENE_OR_GENE_PRODUCT", 422, 425], ["ghrelin", "GENE_OR_GENE_PRODUCT", 427, 434], ["NPY", "GENE_OR_GENE_PRODUCT", 436, 439], ["AgRP", "GENE_OR_GENE_PRODUCT", 441, 445], ["galanin", "GENE_OR_GENE_PRODUCT", 447, 454], ["orexin A", "GENE_OR_GENE_PRODUCT", 456, 464], ["MCH", "GENE_OR_GENE_PRODUCT", 466, 469], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 471, 476], ["ACTH", "GENE_OR_GENE_PRODUCT", 478, 482], ["CRH", "GENE_OR_GENE_PRODUCT", 484, 487], ["oxytocin", "SIMPLE_CHEMICAL", 489, 497], ["vasopressin", "GENE_OR_GENE_PRODUCT", 502, 513], ["autoantibodies", "PROTEIN", 184, 198], ["IgG", "PROTEIN", 272, 275], ["IgA", "PROTEIN", 280, 283], ["leptin", "PROTEIN", 405, 411], ["insulin", "PROTEIN", 413, 420], ["human", "SPECIES", 239, 244], ["human", "SPECIES", 239, 244], ["Student's t test", "TEST", 101, 117], ["Whitney test", "TEST", 126, 138], ["the normality test", "TEST", 152, 170], ["autoantibodies against appetite", "PROBLEM", 184, 215], ["IgG", "TEST", 272, 275], ["IgA autoAbs serum levels", "TEST", 280, 304], ["signal intensity", "TEST", 310, 326], ["the detection system", "TEST", 355, 375], ["leptin", "TREATMENT", 405, 411], ["insulin", "TREATMENT", 413, 420], ["ghrelin", "TREATMENT", 427, 434], ["AgRP", "TEST", 441, 445], ["galanin", "TREATMENT", 447, 454], ["MCH", "TEST", 466, 469], ["ACTH", "TEST", 478, 482], ["CRH", "PROBLEM", 484, 487], ["oxytocin", "TREATMENT", 489, 497], ["vasopressin", "TREATMENT", 502, 513], ["IgG", "OBSERVATION", 272, 275]]], ["Signal intensity (OD 0.4 -2.0) was in the linear range and was transformed into concentrations according the standard curve formula.", [["Signal intensity", "TEST", 0, 16], ["OD", "TEST", 18, 20], ["the standard curve formula", "TREATMENT", 105, 131], ["intensity", "OBSERVATION_MODIFIER", 7, 16]]], ["Considering sample dilutions (1:100), plasma concentrations of these autoAbs were found to be in the range of 100 -900 ng/mL (Fig. 1) .Detection of autoantibodies against appetite-regulating peptides in human subjectsThe specificity tests showed that preadsorption of the IgA-containing sera after extraction of IgG and IgM or of whole serum with increasing concentrations of each appetiteregulating synthetic peptide was able to dose-dependently modify the IgA levels ( Fig. 2) .", [["sample", "ANATOMY", 12, 18], ["plasma", "ANATOMY", 38, 44], ["sera", "ANATOMY", 287, 291], ["serum", "ANATOMY", 336, 341], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["autoantibodies against appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 148, 199], ["human", "ORGANISM", 203, 208], ["IgA", "GENE_OR_GENE_PRODUCT", 272, 275], ["sera", "ORGANISM_SUBSTANCE", 287, 291], ["IgG", "GENE_OR_GENE_PRODUCT", 312, 315], ["IgM", "GENE_OR_GENE_PRODUCT", 320, 323], ["serum", "ORGANISM_SUBSTANCE", 336, 341], ["IgA", "GENE_OR_GENE_PRODUCT", 458, 461], ["autoantibodies", "PROTEIN", 148, 162], ["IgA", "PROTEIN", 272, 275], ["IgG", "PROTEIN", 312, 315], ["IgM", "PROTEIN", 320, 323], ["IgA", "PROTEIN", 458, 461], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["sample dilutions", "TEST", 12, 28], ["Abs", "TEST", 73, 76], ["autoantibodies against appetite", "PROBLEM", 148, 179], ["The specificity tests", "TEST", 217, 238], ["the IgA", "TEST", 268, 275], ["sera", "TREATMENT", 287, 291], ["extraction", "TREATMENT", 298, 308], ["IgG", "TEST", 312, 315], ["IgM", "TEST", 320, 323], ["whole serum", "TEST", 330, 341], ["increasing concentrations", "PROBLEM", 347, 372], ["each appetiteregulating synthetic peptide", "TREATMENT", 376, 417], ["the IgA levels", "TEST", 454, 468]]], ["Similar results were obtained in IgG preadsorption tests.", [["IgG", "GENE_OR_GENE_PRODUCT", 33, 36], ["IgG", "PROTEIN", 33, 36], ["IgG preadsorption tests", "TEST", 33, 56]]], ["In a majority of cases, increasing concentrations of preadsorbing peptide were associated with reduced IgA and IgG autoAb binding, but several reverse responses such as with insulin were also observed.", [["IgA", "GENE_OR_GENE_PRODUCT", 103, 106], ["IgG", "GENE_OR_GENE_PRODUCT", 111, 114], ["autoAb", "GENE_OR_GENE_PRODUCT", 115, 121], ["insulin", "GENE_OR_GENE_PRODUCT", 174, 181], ["IgA", "PROTEIN", 103, 106], ["IgG autoAb", "PROTEIN", 111, 121], ["insulin", "PROTEIN", 174, 181], ["increasing concentrations of preadsorbing peptide", "PROBLEM", 24, 73], ["reduced IgA and IgG autoAb binding", "PROBLEM", 95, 129], ["insulin", "TREATMENT", 174, 181]]], ["Such a reverse response was seen previously in immunohistochemical studies [17] and is most likely related to the kinetics of interactions of preadsorbing peptide with the same peptidecontaining immune complexes.", [["peptidecontaining immune complexes", "PROTEIN", 177, 211], ["immunohistochemical studies", "TEST", 47, 74], ["preadsorbing peptide", "TREATMENT", 142, 162], ["most likely related to", "UNCERTAINTY", 87, 109], ["immune complexes", "OBSERVATION", 195, 211]]], ["In fact, insulin-containing immune complexes have been found in human subjects [34] .", [["insulin", "GENE_OR_GENE_PRODUCT", 9, 16], ["human", "ORGANISM", 64, 69], ["insulin", "PROTEIN", 9, 16], ["immune complexes", "PROTEIN", 28, 44], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["insulin", "TREATMENT", 9, 16], ["immune complexes", "TREATMENT", 28, 44]]], ["ELISA for IgA detection using the IgG fraction purified from the same serum did not result in any detectable signal.Molecular mimicry with regulatory peptidesThe NCBI database search for exact matches between aa sequences of appetite-regulating peptides and proteins from various micro-organisms showed that matches of at least five aa fragments within each of the 14 peptides exist among proteins from bacteria, viruses, fungi, and archaea ( Fig. 3 and supplementary Fig. 1 ).", [["serum", "ANATOMY", 70, 75], ["appetite", "CHEMICAL", 225, 233], ["IgA", "GENE_OR_GENE_PRODUCT", 10, 13], ["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["IgA", "PROTEIN", 10, 13], ["ELISA", "TEST", 0, 5], ["IgA detection", "TEST", 10, 23], ["the IgG fraction", "TEST", 30, 46], ["regulatory peptides", "TREATMENT", 139, 158], ["The NCBI database search", "TEST", 158, 182], ["aa sequences", "TEST", 209, 221], ["appetite", "TEST", 225, 233], ["proteins from various micro-organisms", "PROBLEM", 258, 295], ["five aa fragments", "PROBLEM", 328, 345], ["bacteria", "PROBLEM", 403, 411], ["viruses", "PROBLEM", 413, 420], ["fungi", "PROBLEM", 422, 427], ["aa fragments", "OBSERVATION", 333, 345], ["bacteria", "OBSERVATION", 403, 411]]], ["For instance, within the \u2423-MSH sequence (Fig. 3 ) six five-aa fragments and three six-aa fragments were identical to protein fragments of bacterial origin, four five-aa fragments to protein fragments from viruses, four five-aa fragments and two six-aa fragments to protein fragments from fungi, and six five-aa fragments and one six-aa fragment to protein fragments from archaea.", [["\u2423-MSH sequence", "DNA", 25, 39], ["protein fragments", "PROTEIN", 117, 134], ["protein fragments", "PROTEIN", 182, 199], ["protein fragments", "PROTEIN", 265, 282], ["protein fragments", "PROTEIN", 348, 365], ["the \u2423-MSH sequence", "TEST", 21, 39], ["five-aa fragments", "TREATMENT", 54, 71], ["three six-aa fragments", "TREATMENT", 76, 98], ["bacterial origin", "PROBLEM", 138, 154], ["protein fragments from viruses", "PROBLEM", 182, 212], ["five-aa fragments", "TREATMENT", 219, 236], ["two six-aa fragments", "TREATMENT", 241, 261], ["protein fragments from fungi", "PROBLEM", 265, 293], ["six five-aa fragments", "TREATMENT", 299, 320], ["protein fragments", "PROBLEM", 348, 365], ["archaea", "PROBLEM", 371, 378], ["bacterial origin", "OBSERVATION", 138, 154], ["fragments", "OBSERVATION_MODIFIER", 190, 199], ["viruses", "OBSERVATION", 205, 212], ["five-aa fragments", "OBSERVATION_MODIFIER", 219, 236], ["six-aa fragments", "OBSERVATION_MODIFIER", 245, 261], ["protein fragments", "OBSERVATION_MODIFIER", 265, 282], ["fungi", "OBSERVATION", 288, 293], ["six", "OBSERVATION_MODIFIER", 299, 302], ["five", "OBSERVATION_MODIFIER", 303, 307], ["-aa fragments", "OBSERVATION_MODIFIER", 307, 320], ["aa fragment", "OBSERVATION_MODIFIER", 333, 344], ["protein fragments", "OBSERVATION", 348, 365], ["archaea", "OBSERVATION_MODIFIER", 371, 378]]], ["In addition, many regulatory peptides exhibited alignments of more than six consecutive amino acids, such as leptin, insulin, PYY, ghrelin, NPY, AgRP, galanin, orexin, ACTH, and CRH.Molecular mimicry with regulatory peptidesTo facilitate the analysis of these data (summarized in Tables 1-4), the micro-organisms displaying sequence homology with regulatory peptides were grouped into commensal, intestinal pathogens, other pathogens, or pathogenic and environmental.", [["intestinal", "ANATOMY", 396, 406], ["amino acids", "CHEMICAL", 88, 99], ["amino acids", "CHEMICAL", 88, 99], ["amino acids", "AMINO_ACID", 88, 99], ["leptin", "GENE_OR_GENE_PRODUCT", 109, 115], ["insulin", "GENE_OR_GENE_PRODUCT", 117, 124], ["PYY", "GENE_OR_GENE_PRODUCT", 126, 129], ["ghrelin", "GENE_OR_GENE_PRODUCT", 131, 138], ["NPY", "GENE_OR_GENE_PRODUCT", 140, 143], ["AgRP", "GENE_OR_GENE_PRODUCT", 145, 149], ["galanin", "GENE_OR_GENE_PRODUCT", 151, 158], ["orexin", "GENE_OR_GENE_PRODUCT", 160, 166], ["ACTH", "GENE_OR_GENE_PRODUCT", 168, 172], ["CRH", "GENE_OR_GENE_PRODUCT", 178, 181], ["intestinal", "ORGAN", 396, 406], ["leptin", "PROTEIN", 109, 115], ["insulin", "PROTEIN", 117, 124], ["six consecutive amino acids", "TREATMENT", 72, 99], ["leptin", "TREATMENT", 109, 115], ["insulin", "TREATMENT", 117, 124], ["galanin", "TREATMENT", 151, 158], ["ACTH", "TREATMENT", 168, 172], ["CRH", "PROBLEM", 178, 181], ["regulatory peptides", "TREATMENT", 205, 224], ["the analysis", "TEST", 238, 250], ["these data", "TEST", 254, 264], ["the micro-organisms displaying sequence homology with regulatory peptides", "PROBLEM", 293, 366], ["intestinal pathogens", "PROBLEM", 396, 416], ["other pathogens", "PROBLEM", 418, 433], ["pathogenic", "PROBLEM", 438, 448], ["intestinal", "ANATOMY", 396, 406], ["pathogens", "OBSERVATION", 407, 416]]], ["Although some micro-organisms could play commensal and pathogenic roles, for simplicity they are presented only in one of these groups.Autoantibodies against appetite-regulating peptides in ratsFor many of the regulatory peptides studied, the levels of corresponding IgG autoAbs in germ-free and SPF rats displayed comparatively low OD values (2-3\u03eb of background OD; Fig. 4 ).", [["germ", "ANATOMY", 282, 286], ["appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 158, 186], ["rats", "ORGANISM", 190, 194], ["IgG", "GENE_OR_GENE_PRODUCT", 267, 270], ["autoAbs", "GENE_OR_GENE_PRODUCT", 271, 278], ["SPF rats", "ORGANISM", 296, 304], ["IgG autoAbs", "PROTEIN", 267, 278], ["rats", "SPECIES", 190, 194], ["rats", "SPECIES", 300, 304], ["SPF", "SPECIES", 296, 299], ["some micro-organisms", "PROBLEM", 9, 29], ["Autoantibodies against appetite", "PROBLEM", 135, 166], ["peptides in rats", "TREATMENT", 178, 194], ["the regulatory peptides", "TEST", 206, 229], ["the levels", "TEST", 239, 249], ["corresponding IgG autoAbs", "TEST", 253, 278], ["SPF rats", "TEST", 296, 304]]], ["However, the levels of IgG autoAbs directed against ghrelin in germ-free rats and against ACTH in germ-free and SPF rats were found in a range of around 10\u03eb background OD (Fig. 4) .", [["germ", "ANATOMY", 63, 67], ["germ", "ANATOMY", 98, 102], ["ghrelin", "CHEMICAL", 52, 59], ["IgG autoAbs", "GENE_OR_GENE_PRODUCT", 23, 34], ["ghrelin", "GENE_OR_GENE_PRODUCT", 52, 59], ["germ-free rats", "ORGANISM", 63, 77], ["ACTH", "GENE_OR_GENE_PRODUCT", 90, 94], ["germ-free", "TISSUE", 98, 107], ["SPF rats", "ORGANISM", 112, 120], ["IgG autoAbs", "PROTEIN", 23, 34], ["rats", "SPECIES", 73, 77], ["rats", "SPECIES", 116, 120], ["SPF", "SPECIES", 112, 115], ["the levels", "TEST", 9, 19], ["IgG autoAbs", "TREATMENT", 23, 34], ["ACTH", "TEST", 90, 94], ["SPF rats", "TEST", 112, 120]]], ["The levels of ghrelin IgG autoAbs in germ-free rats were significantly higher than in SPF rats (t test, P \u03fd 0.05).Autoantibodies against appetite-regulating peptides in ratsThe levels of IgA autoAbs directed against all studied regulatory peptides in germ-free and SPF rats were at the limit of detection (OD values 1-2\u03eb background OD; Fig. 5 ).", [["germ", "ANATOMY", 37, 41], ["germ", "ANATOMY", 251, 255], ["ghrelin", "GENE_OR_GENE_PRODUCT", 14, 21], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["germ", "ORGANISM_SUBSTANCE", 37, 41], ["rats", "ORGANISM", 47, 51], ["SPF rats", "ORGANISM", 86, 94], ["appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 137, 165], ["rats", "ORGANISM", 169, 173], ["IgA", "GENE_OR_GENE_PRODUCT", 187, 190], ["germ", "MULTI-TISSUE_STRUCTURE", 251, 255], ["SPF rats", "ORGANISM", 265, 273], ["ghrelin IgG autoAbs", "PROTEIN", 14, 33], ["IgA autoAbs", "PROTEIN", 187, 198], ["rats", "SPECIES", 47, 51], ["rats", "SPECIES", 90, 94], ["rats", "SPECIES", 169, 173], ["rats", "SPECIES", 269, 273], ["SPF", "SPECIES", 86, 89], ["SPF", "SPECIES", 265, 268], ["The levels", "TEST", 0, 10], ["ghrelin IgG", "TEST", 14, 25], ["germ-free rats", "TEST", 37, 51], ["t test", "TEST", 96, 102], ["Autoantibodies against appetite", "PROBLEM", 114, 145], ["IgA autoAbs", "TREATMENT", 187, 198], ["OD values", "TEST", 306, 315]]], ["Germ-free rats displayed significantly lower levels of autoAbs directed against three neuropeptides including AgRP and MCH (both t test, P \u03fd 0.05) and CRH (Mann-Whitney test, P \u03fd 0.05) compared with SPF rats.Finding of autoantibodies directed against appetite-regulating peptidesThis study revealed, for the first time, in healthy human subjects, the presence of autoAbs of IgG and IgA classes reacting specifically with several appetite-regulating peptides, including leptin, ghrelin, PYY, NPY, AgRP, galanin, or CRH.", [["rats", "ORGANISM", 10, 14], ["AgRP", "GENE_OR_GENE_PRODUCT", 110, 114], ["MCH", "GENE_OR_GENE_PRODUCT", 119, 122], ["CRH", "GENE_OR_GENE_PRODUCT", 151, 154], ["rats", "ORGANISM", 203, 207], ["autoantibodies directed against appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 219, 279], ["human", "ORGANISM", 331, 336], ["IgG", "GENE_OR_GENE_PRODUCT", 374, 377], ["IgA", "GENE_OR_GENE_PRODUCT", 382, 385], ["leptin", "GENE_OR_GENE_PRODUCT", 469, 475], ["ghrelin", "GENE_OR_GENE_PRODUCT", 477, 484], ["PYY", "GENE_OR_GENE_PRODUCT", 486, 489], ["NPY", "GENE_OR_GENE_PRODUCT", 491, 494], ["AgRP", "GENE_OR_GENE_PRODUCT", 496, 500], ["galanin", "GENE_OR_GENE_PRODUCT", 502, 509], ["CRH", "GENE_OR_GENE_PRODUCT", 514, 517], ["autoantibodies", "PROTEIN", 219, 233], ["IgG", "PROTEIN", 374, 377], ["IgA classes", "PROTEIN", 382, 393], ["rats", "SPECIES", 10, 14], ["rats", "SPECIES", 203, 207], ["human", "SPECIES", 331, 336], ["SPF", "SPECIES", 199, 202], ["human", "SPECIES", 331, 336], ["Germ-free rats", "TEST", 0, 14], ["AgRP", "TEST", 110, 114], ["MCH", "TEST", 119, 122], ["both t test", "TEST", 124, 135], ["P", "TEST", 137, 138], ["CRH", "TEST", 151, 154], ["Whitney test", "TEST", 161, 173], ["P", "TEST", 175, 176], ["autoantibodies", "PROBLEM", 219, 233], ["regulating peptides", "TREATMENT", 260, 279], ["This study", "TEST", 279, 289], ["IgG", "TEST", 374, 377], ["IgA classes", "TEST", 382, 393], ["leptin, ghrelin", "TREATMENT", 469, 484], ["galanin", "TREATMENT", 502, 509], ["CRH", "PROBLEM", 514, 517], ["free", "OBSERVATION_MODIFIER", 5, 9], ["auto", "OBSERVATION", 55, 59], ["auto", "OBSERVATION", 363, 367], ["IgG", "OBSERVATION", 374, 377]]], ["The levels of these autoAbs were in the range of 100 -900 ng/mL, probably sufficient to influence functions of corresponding regulatory peptides normally present in plasma in the range of picograms to nanograms per milliliter [35] .Finding of autoantibodies directed against appetite-regulating peptidesAutoantibodies directed against all studied appetiteregulating peptides were found at similar levels with levels of insulin autoAbs, which have been extensively studied as a marker of type 1 diabetes, but their levels alone show low predictive value [25] .", [["plasma", "ANATOMY", 165, 171], ["type 1 diabetes", "DISEASE", 487, 502], ["plasma", "ORGANISM_SUBSTANCE", 165, 171], ["insulin", "GENE_OR_GENE_PRODUCT", 419, 426], ["autoAbs", "GENE_OR_GENE_PRODUCT", 427, 434], ["autoantibodies", "PROTEIN", 243, 257], ["insulin autoAbs", "PROTEIN", 419, 434], ["Abs", "TEST", 24, 27], ["autoantibodies", "PROBLEM", 243, 257], ["regulating peptidesAutoantibodies", "TREATMENT", 284, 317], ["all studied appetiteregulating peptides", "PROBLEM", 335, 374], ["insulin autoAbs", "TREATMENT", 419, 434], ["type 1 diabetes", "PROBLEM", 487, 502], ["their levels", "TEST", 508, 520], ["low predictive value", "PROBLEM", 532, 552], ["auto", "OBSERVATION", 20, 24]]], ["Although insulin autoAbs were repeatedly reported in healthy subjects, their physiologic levels (mean \u03ee3 SDs) were used merely to define the detection limit for autoAbs in diabetic patients, with around 49% displaying elevated values compared with 3% of the general population [36] .", [["diabetic", "DISEASE", 172, 180], ["insulin", "GENE_OR_GENE_PRODUCT", 9, 16], ["patients", "ORGANISM", 181, 189], ["insulin", "PROTEIN", 9, 16], ["Abs", "PROTEIN", 21, 24], ["Abs", "PROTEIN", 165, 168], ["patients", "SPECIES", 181, 189], ["insulin", "TREATMENT", 9, 16], ["their physiologic levels", "TEST", 71, 95], ["elevated values", "PROBLEM", 218, 233], ["diabetic", "OBSERVATION", 172, 180], ["elevated", "OBSERVATION", 218, 226]]], ["The limited interest in insulin autoAbs in healthy subjects is probably related to the view that produc-tion of insulin autoAbs must be triggered by \"immunogenic\" insulin derived from pancreatic \u2424-cells destroyed by an autoimmune process, and the assumption that these autoAbs should reflect the disease [37] .", [["pancreatic \u2424-cells", "ANATOMY", 184, 202], ["insulin", "GENE_OR_GENE_PRODUCT", 24, 31], ["insulin", "GENE_OR_GENE_PRODUCT", 112, 119], ["insulin", "GENE_OR_GENE_PRODUCT", 163, 170], ["pancreatic \u2424-cells", "CELL", 184, 202], ["insulin autoAbs", "PROTEIN", 24, 39], ["insulin", "PROTEIN", 112, 119], ["Abs", "PROTEIN", 124, 127], ["insulin", "PROTEIN", 163, 170], ["pancreatic \u2424-cells", "CELL_TYPE", 184, 202], ["Abs", "PROTEIN", 273, 276], ["insulin", "TREATMENT", 112, 119], ["immunogenic\" insulin", "TREATMENT", 150, 170], ["pancreatic \u2424-cells", "PROBLEM", 184, 202], ["an autoimmune process", "PROBLEM", 216, 237], ["the disease", "PROBLEM", 292, 303], ["probably related to", "UNCERTAINTY", 63, 82], ["pancreatic", "ANATOMY", 184, 194], ["autoimmune", "OBSERVATION", 219, 229], ["disease", "OBSERVATION", 296, 303]]], ["Thus, a potential physiologic origin and function of insulin autoAbs has thus far not been considered.", [["insulin", "GENE_OR_GENE_PRODUCT", 53, 60], ["insulin", "PROTEIN", 53, 60], ["Abs", "PROTEIN", 65, 68]]], ["The present data showing that autoAbs directed against insulin and against other regulatory peptides are constantly present in healthy subjects suggest that these autoAbs represent a general phenomenon of possible physiologic significance.Origin of autoantibodies directed against appetite-regulating peptidesThe presence of the IgA class of autoAbs directed against regulatory peptides found in human subjects sug-Origin of autoantibodies directed against appetite-regulating peptides\u2423-MSH, \u2423-melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; AgRP, agouti-related protein; CRH, corticotropin-releasing hormone; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OT, oxytocin; PYY, peptide tyrosine-tyrosine; VP, vasopressin gests that at least some of these autoAbs might be triggered by luminal antigens that can include food-related antigens and gut microflora.", [["luminal", "ANATOMY", 812, 819], ["gut microflora", "ANATOMY", 872, 886], ["oxytocin", "CHEMICAL", 690, 698], ["tyrosine", "CHEMICAL", 713, 721], ["tyrosine", "CHEMICAL", 722, 730], ["vasopressin", "CHEMICAL", 736, 747], ["luminal", "CHEMICAL", 812, 819], ["oxytocin", "CHEMICAL", 690, 698], ["tyrosine", "CHEMICAL", 713, 721], ["tyrosine", "CHEMICAL", 722, 730], ["vasopressin", "CHEMICAL", 736, 747], ["insulin", "GENE_OR_GENE_PRODUCT", 55, 62], ["autoantibodies directed against appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 249, 309], ["IgA", "GENE_OR_GENE_PRODUCT", 329, 332], ["autoAbs", "GENE_OR_GENE_PRODUCT", 342, 349], ["human", "ORGANISM", 396, 401], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 485, 490], ["\u2423-melanocyte-stimulating hormone", "GENE_OR_GENE_PRODUCT", 492, 524], ["ACTH", "GENE_OR_GENE_PRODUCT", 526, 530], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 532, 559], ["AgRP", "GENE_OR_GENE_PRODUCT", 561, 565], ["agouti-related protein", "GENE_OR_GENE_PRODUCT", 567, 589], ["CRH", "GENE_OR_GENE_PRODUCT", 591, 594], ["corticotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 596, 627], ["MCH", "GENE_OR_GENE_PRODUCT", 629, 632], ["melanin-concentrating hormone", "GENE_OR_GENE_PRODUCT", 634, 663], ["NPY", "GENE_OR_GENE_PRODUCT", 665, 668], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 670, 684], ["OT", "GENE_OR_GENE_PRODUCT", 686, 688], ["oxytocin", "SIMPLE_CHEMICAL", 690, 698], ["PYY", "GENE_OR_GENE_PRODUCT", 700, 703], ["peptide tyrosine-tyrosine", "GENE_OR_GENE_PRODUCT", 705, 730], ["vasopressin", "GENE_OR_GENE_PRODUCT", 736, 747], ["luminal antigens", "GENE_OR_GENE_PRODUCT", 812, 828], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 872, 886], ["Abs", "PROTEIN", 34, 37], ["insulin", "PROTEIN", 55, 62], ["Abs", "PROTEIN", 167, 170], ["autoantibodies", "PROTEIN", 249, 263], ["IgA class", "PROTEIN", 329, 338], ["autoAbs", "PROTEIN", 342, 349], ["autoantibodies", "PROTEIN", 425, 439], ["agouti-related protein", "PROTEIN", 567, 589], ["CRH", "PROTEIN", 591, 594], ["Abs", "PROTEIN", 786, 789], ["luminal antigens", "PROTEIN", 812, 828], ["human", "SPECIES", 396, 401], ["human", "SPECIES", 396, 401], ["insulin", "TREATMENT", 55, 62], ["a general phenomenon", "PROBLEM", 181, 201], ["autoantibodies", "PROBLEM", 249, 263], ["regulating peptides", "TREATMENT", 290, 309], ["autoAbs", "TREATMENT", 342, 349], ["regulatory peptides", "PROBLEM", 367, 386], ["autoantibodies", "TEST", 425, 439], ["appetite", "TEST", 457, 465], ["peptides", "TEST", 477, 485], ["MSH", "TEST", 487, 490], ["\u2423-melanocyte", "TEST", 492, 504], ["ACTH", "TEST", 526, 530], ["adrenocorticotropic hormone", "TEST", 532, 559], ["AgRP", "TEST", 561, 565], ["agouti", "TEST", 567, 573], ["protein", "TEST", 582, 589], ["CRH", "TEST", 591, 594], ["corticotropin", "TEST", 596, 609], ["releasing hormone", "TREATMENT", 610, 627], ["MCH", "TEST", 629, 632], ["melanin", "TREATMENT", 634, 641], ["concentrating hormone", "TREATMENT", 642, 663], ["neuropeptide Y", "TREATMENT", 670, 684], ["OT, oxytocin", "TREATMENT", 686, 698], ["PYY", "TREATMENT", 700, 703], ["peptide tyrosine", "TREATMENT", 705, 721], ["tyrosine", "TREATMENT", 722, 730], ["VP", "TREATMENT", 732, 734], ["vasopressin gests", "TREATMENT", 736, 753], ["luminal antigens", "PROBLEM", 812, 828], ["related antigens and gut microflora", "PROBLEM", 851, 886], ["general phenomenon", "OBSERVATION", 183, 201], ["possible", "UNCERTAINTY", 205, 213], ["autoantibodies", "OBSERVATION", 249, 263], ["luminal", "ANATOMY_MODIFIER", 812, 819]]], ["In fact, the major role of commensal and pathogenic microflora in inducing IgA responses has been previously shown [38 -40] .", [["IgA", "GENE_OR_GENE_PRODUCT", 75, 78], ["IgA", "PROTEIN", 75, 78], ["commensal and pathogenic microflora", "PROBLEM", 27, 62]]], ["However, our results obtained from the germ-free rats show that commensal microflora are not required for the presence of IgA or IgG autoAbs directed against regulatory peptides but can selectively influence the levels of at least some of these autoAbs.", [["germ", "ANATOMY", 39, 43], ["rats", "ORGANISM", 49, 53], ["IgA", "GENE_OR_GENE_PRODUCT", 122, 125], ["IgA", "PROTEIN", 122, 125], ["IgG", "PROTEIN", 129, 132], ["Abs", "PROTEIN", 137, 140], ["Abs", "PROTEIN", 249, 252], ["rats", "SPECIES", 49, 53], ["the germ-free rats", "TEST", 35, 53], ["commensal microflora", "PROBLEM", 64, 84], ["IgA", "PROBLEM", 122, 125]]], ["For instance, the relatively lower levels of IgA autoAbs directed against AgRP, MCH, and CRH found in germ-free rats might be related to the absence of intestinal antigens.", [["germ", "ANATOMY", 102, 106], ["intestinal", "ANATOMY", 152, 162], ["IgA", "GENE_OR_GENE_PRODUCT", 45, 48], ["AgRP", "GENE_OR_GENE_PRODUCT", 74, 78], ["MCH", "GENE_OR_GENE_PRODUCT", 80, 83], ["CRH", "GENE_OR_GENE_PRODUCT", 89, 92], ["germ", "ORGANISM_SUBSTANCE", 102, 106], ["rats", "ORGANISM", 112, 116], ["intestinal antigens", "GENE_OR_GENE_PRODUCT", 152, 171], ["IgA autoAbs", "PROTEIN", 45, 56], ["AgRP", "PROTEIN", 74, 78], ["MCH", "PROTEIN", 80, 83], ["CRH", "PROTEIN", 89, 92], ["intestinal antigens", "PROTEIN", 152, 171], ["rats", "SPECIES", 112, 116], ["IgA autoAbs", "TREATMENT", 45, 56], ["MCH", "TEST", 80, 83], ["CRH", "PROBLEM", 89, 92], ["intestinal antigens", "PROBLEM", 152, 171], ["intestinal", "ANATOMY", 152, 162]]], ["However, it appears that the presence of SPF rat microflora would inhibit the production of IgG autoAbs directed against ghrelin, suggesting a complex mechanism of interaction between microbial antigens and levels of IgG autoAbs.", [["ghrelin", "CHEMICAL", 121, 128], ["rat", "ORGANISM", 45, 48], ["IgG", "GENE_OR_GENE_PRODUCT", 92, 95], ["ghrelin", "GENE_OR_GENE_PRODUCT", 121, 128], ["IgG autoAbs", "GENE_OR_GENE_PRODUCT", 217, 228], ["IgG", "PROTEIN", 92, 95], ["microbial antigens", "PROTEIN", 184, 202], ["IgG autoAbs", "PROTEIN", 217, 228], ["rat", "SPECIES", 45, 48], ["rat", "SPECIES", 45, 48], ["SPF rat microflora", "TREATMENT", 41, 59], ["microbial antigens", "TEST", 184, 202], ["IgG autoAbs", "TREATMENT", 217, 228]]], ["The potential ability of the microflora to selectively modulate the levels of some regulatory peptide auto-Abs could also be related to the concept of molecular mimicry.Concept of molecular mimicryThe presence of fragments with identical sequences between microbial proteins and regulatory peptides suggests that such microbial proteins presenting these sequences in the Payer's patches or other lymphoid organs may stimulate the production of immunoglobulins capable of binding to the identical region present in endogenous regulatory peptides.", [["lymphoid organs", "ANATOMY", 396, 411], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 396, 411], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 444, 459], ["Abs", "PROTEIN", 107, 110], ["microbial proteins", "PROTEIN", 256, 274], ["microbial proteins", "PROTEIN", 318, 336], ["immunoglobulins", "PROTEIN", 444, 459], ["the microflora", "TREATMENT", 25, 39], ["some regulatory peptide auto-Abs", "PROBLEM", 78, 110], ["fragments", "PROBLEM", 213, 222], ["microbial proteins and regulatory peptides", "PROBLEM", 256, 298], ["such microbial proteins", "PROBLEM", 313, 336], ["the Payer's patches", "TREATMENT", 367, 386], ["other lymphoid organs", "PROBLEM", 390, 411], ["immunoglobulins capable of binding", "PROBLEM", 444, 478], ["molecular mimicry", "OBSERVATION", 151, 168], ["molecular mimicry", "OBSERVATION", 180, 197], ["fragments", "OBSERVATION", 213, 222], ["lymphoid organs", "OBSERVATION", 396, 411], ["endogenous regulatory peptides", "OBSERVATION", 514, 544]]], ["According to the concept of molecular mimicry, the functional implications of such sequence similarities are possible only if the protein fragment targeted by self-reacting antibodies possesses biological activity [33] .", [["protein fragment", "PROTEIN", 130, 146], ["antibodies", "PROTEIN", 173, 183], ["the protein fragment", "PROBLEM", 126, 146]]], ["For example, it has been shown that six consecutive amino acids shared between hepatitis B virus and myelin basic protein is sufficient to induce experimental autoimmune encephalomyelitis [41] .", [["amino acids", "CHEMICAL", 52, 63], ["hepatitis B", "DISEASE", 79, 90], ["autoimmune encephalomyelitis", "DISEASE", 159, 187], ["amino acids", "CHEMICAL", 52, 63], ["amino acids", "AMINO_ACID", 52, 63], ["hepatitis B virus", "ORGANISM", 79, 96], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 101, 121], ["myelin basic protein", "PROTEIN", 101, 121], ["hepatitis B virus", "SPECIES", 79, 96], ["hepatitis B virus", "SPECIES", 79, 96], ["six consecutive amino acids", "TREATMENT", 36, 63], ["hepatitis B virus", "TREATMENT", 79, 96], ["myelin basic protein", "TEST", 101, 121], ["experimental autoimmune encephalomyelitis", "PROBLEM", 146, 187], ["autoimmune encephalomyelitis", "OBSERVATION", 159, 187]]], ["In the case of regulatory peptides, which are released and function as messenger molecules, any part of their entire sequence targeted by autoAbs could result in modification of their biological activity.", [["messenger molecules", "PROTEIN", 71, 90], ["Abs", "PROTEIN", 142, 145], ["peptides", "OBSERVATION", 26, 34], ["biological activity", "OBSERVATION", 184, 203]]], ["Radioimmunoassay and immunohistochemical studies have shown that antibodies generated by immunization are able to selectively recognize regulatory peptides as small as the three-aa peptide thyrotropin-releasing hormone [42, 43] .", [["thyrotropin", "CHEMICAL", 189, 200], ["thyrotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 189, 218], ["antibodies", "PROTEIN", 65, 75], ["Radioimmunoassay", "TEST", 0, 16], ["immunohistochemical studies", "TEST", 21, 48], ["immunization", "TREATMENT", 89, 101]]], ["In the present study, we recorded the presence of at least five identical consecutive aa fragments in regulatory peptides and microbial proteins qualifying as candidates for molecular mimicry [44] .", [["microbial proteins", "PROTEIN", 126, 144], ["the present study", "TEST", 3, 20], ["identical consecutive aa fragments in regulatory peptides", "PROBLEM", 64, 121], ["microbial proteins", "TREATMENT", 126, 144], ["consecutive", "OBSERVATION_MODIFIER", 74, 85], ["aa fragments", "OBSERVATION", 86, 98]]], ["However, as indicated above, it is important to note that sequences shorter than five amino acids could be implicated, in addition to discontinuous fragment homology.", [["amino acids", "CHEMICAL", 86, 97], ["amino acids", "CHEMICAL", 86, 97], ["amino acids", "AMINO_ACID", 86, 97], ["five amino acids", "TEST", 81, 97], ["discontinuous fragment homology", "PROBLEM", 134, 165]]], ["Of note, only a limited number of microbial Table 3 Examples of commensal or food-associated fungi which may become pathogenic in susceptible individuals as well as some environmental fungi which display identical (at least 5 a. a.) proteins sequences with appetite-regulating peptidesFungi PeptidesLeptin Insulin PYY Ghrelin NPY AgRP Galanin Orexin MCH \u2423-MSH ACTH CRH OT VPFungi PeptidesBlumeria graminis (plants) \u03e9 \u03e9 \u2423-MSH, \u2423-melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; AgRP, agouti-related protein; CRH, corticotropin-releasing hormone; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OT, oxytocin; PYY, peptide tyrosine-tyrosine; VP, vasopressin Table 4 Examples of environmental archea which display identical (at least 5 a. a.) proteins sequences with appetite-regulating peptides Thermococcus (hot sources) \u03e9 \u03e9 \u03e9 \u03e9 \u2423-MSH, \u2423-melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; AgRP, agouti-related protein; CRH, corticotropin-releasing hormone; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OT, oxytocin; PYY, peptide tyrosine-tyrosine; VP, vasopressin protein sequences are currently available in the NCBI database, and molecular mimicry between regulatory peptides and microbial proteins may thus be more extensive.Molecular mimicry with commensal micro-organismsOur screening revealed that molecular mimicry for each studied regulatory peptide is present at least in one microorganism and usually in several representatives of commensal or relatively pathogenic micro-organisms.", [["oxytocin", "CHEMICAL", 624, 632], ["tyrosine", "CHEMICAL", 647, 655], ["tyrosine", "CHEMICAL", 656, 664], ["VP", "CHEMICAL", 666, 668], ["vasopressin", "CHEMICAL", 670, 681], ["oxytocin", "CHEMICAL", 1059, 1067], ["tyrosine", "CHEMICAL", 1082, 1090], ["tyrosine", "CHEMICAL", 1091, 1099], ["vasopressin", "CHEMICAL", 1105, 1116], ["oxytocin", "CHEMICAL", 624, 632], ["tyrosine", "CHEMICAL", 647, 655], ["tyrosine", "CHEMICAL", 656, 664], ["vasopressin", "CHEMICAL", 670, 681], ["oxytocin", "CHEMICAL", 1059, 1067], ["tyrosine", "CHEMICAL", 1082, 1090], ["tyrosine", "CHEMICAL", 1091, 1099], ["Insulin PYY", "GENE_OR_GENE_PRODUCT", 306, 317], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 419, 424], ["\u2423-melanocyte-stimulating hormone", "GENE_OR_GENE_PRODUCT", 426, 458], ["ACTH", "GENE_OR_GENE_PRODUCT", 460, 464], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 466, 493], ["AgRP", "GENE_OR_GENE_PRODUCT", 495, 499], ["agouti-related protein", "GENE_OR_GENE_PRODUCT", 501, 523], ["CRH", "GENE_OR_GENE_PRODUCT", 525, 528], ["corticotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 530, 561], ["MCH", "GENE_OR_GENE_PRODUCT", 563, 566], ["melanin-concentrating hormone", "GENE_OR_GENE_PRODUCT", 568, 597], ["NPY", "GENE_OR_GENE_PRODUCT", 599, 602], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 604, 618], ["OT", "GENE_OR_GENE_PRODUCT", 620, 622], ["oxytocin", "GENE_OR_GENE_PRODUCT", 624, 632], ["PYY", "GENE_OR_GENE_PRODUCT", 634, 637], ["peptide tyrosine-tyrosine", "GENE_OR_GENE_PRODUCT", 639, 664], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 854, 859], ["\u2423-melanocyte-stimulating hormone", "GENE_OR_GENE_PRODUCT", 861, 893], ["ACTH", "GENE_OR_GENE_PRODUCT", 895, 899], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 901, 928], ["AgRP", "GENE_OR_GENE_PRODUCT", 930, 934], ["agouti-related protein", "GENE_OR_GENE_PRODUCT", 936, 958], ["CRH", "GENE_OR_GENE_PRODUCT", 960, 963], ["corticotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 965, 996], ["MCH", "GENE_OR_GENE_PRODUCT", 998, 1001], ["melanin-concentrating hormone", "GENE_OR_GENE_PRODUCT", 1003, 1032], ["NPY", "GENE_OR_GENE_PRODUCT", 1034, 1037], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 1039, 1053], ["OT", "GENE_OR_GENE_PRODUCT", 1055, 1057], ["oxytocin", "GENE_OR_GENE_PRODUCT", 1059, 1067], ["PYY", "GENE_OR_GENE_PRODUCT", 1069, 1072], ["peptide tyrosine-tyrosine", "GENE_OR_GENE_PRODUCT", 1074, 1099], ["VP", "GENE_OR_GENE_PRODUCT", 1101, 1103], ["vasopressin", "GENE_OR_GENE_PRODUCT", 1105, 1116], ["agouti-related protein", "PROTEIN", 501, 523], ["CRH", "PROTEIN", 525, 528], ["MSH", "PROTEIN", 856, 859], ["agouti-related protein", "PROTEIN", 936, 958], ["CRH", "PROTEIN", 960, 963], ["microbial proteins", "PROTEIN", 1235, 1253], ["Blumeria graminis", "SPECIES", 388, 405], ["Blumeria graminis", "SPECIES", 388, 405], ["commensal or food-associated fungi", "PROBLEM", 64, 98], ["pathogenic in susceptible individuals", "PROBLEM", 116, 153], ["some environmental fungi", "PROBLEM", 165, 189], ["proteins sequences", "TEST", 233, 251], ["appetite", "TEST", 257, 265], ["regulating peptides", "TREATMENT", 266, 285], ["Fungi", "TEST", 285, 290], ["Insulin PYY", "TREATMENT", 306, 317], ["Ghrelin", "TEST", 318, 325], ["NPY", "TEST", 326, 329], ["AgRP", "TEST", 330, 334], ["Galanin", "TEST", 335, 342], ["Orexin", "TEST", 343, 349], ["MCH", "TEST", 350, 353], ["\u2423-", "TEST", 354, 356], ["MSH", "TEST", 356, 359], ["ACTH", "TEST", 360, 364], ["CRH", "TEST", 365, 368], ["OT", "TEST", 369, 371], ["VPFungi", "TEST", 372, 379], ["Peptides", "TEST", 380, 388], ["Blumeria", "TEST", 388, 396], ["graminis", "TEST", 397, 405], ["plants", "TEST", 407, 413], ["\u03e9", "TEST", 417, 418], ["MSH", "TEST", 421, 424], ["\u2423-melanocyte", "TEST", 426, 438], ["stimulating hormone", "TEST", 439, 458], ["ACTH", "TEST", 460, 464], ["adrenocorticotropic hormone", "TEST", 466, 493], ["AgRP", "TEST", 495, 499], ["agouti", "TEST", 501, 507], ["related protein", "PROBLEM", 508, 523], ["CRH", "TEST", 525, 528], ["corticotropin", "TEST", 530, 543], ["releasing hormone", "TREATMENT", 544, 561], ["MCH", "TEST", 563, 566], ["melanin", "TREATMENT", 568, 575], ["concentrating hormone", "TREATMENT", 576, 597], ["NPY, neuropeptide Y", "TREATMENT", 599, 618], ["OT, oxytocin", "TREATMENT", 620, 632], ["PYY", "TREATMENT", 634, 637], ["peptide tyrosine", "TREATMENT", 639, 655], ["tyrosine", "TREATMENT", 656, 664], ["VP, vasopressin Table", "TREATMENT", 666, 687], ["proteins sequences", "TEST", 766, 784], ["appetite", "TEST", 790, 798], ["Thermococcus (hot sources", "TEST", 819, 844], ["MSH", "TEST", 856, 859], ["\u2423-melanocyte", "TEST", 861, 873], ["ACTH", "TEST", 895, 899], ["adrenocorticotropic hormone", "TEST", 901, 928], ["AgRP", "TEST", 930, 934], ["agouti", "TEST", 936, 942], ["related protein", "PROBLEM", 943, 958], ["CRH", "TEST", 960, 963], ["corticotropin", "TEST", 965, 978], ["releasing hormone", "TREATMENT", 979, 996], ["MCH", "TEST", 998, 1001], ["melanin", "TREATMENT", 1003, 1010], ["concentrating hormone", "TREATMENT", 1011, 1032], ["NPY, neuropeptide Y", "TREATMENT", 1034, 1053], ["OT, oxytocin", "TREATMENT", 1055, 1067], ["PYY", "TREATMENT", 1069, 1072], ["tyrosine-tyrosine", "TREATMENT", 1082, 1099], ["VP", "TREATMENT", 1101, 1103], ["vasopressin protein sequences", "TREATMENT", 1105, 1134], ["the NCBI database", "TEST", 1162, 1179], ["microbial proteins", "PROBLEM", 1235, 1253], ["commensal micro-organisms", "PROBLEM", 1304, 1329], ["Our screening", "TEST", 1329, 1342], ["molecular mimicry", "PROBLEM", 1357, 1374], ["each studied regulatory peptide", "PROBLEM", 1379, 1410], ["commensal or relatively pathogenic micro-organisms", "PROBLEM", 1494, 1544], ["commensal micro-organisms", "OBSERVATION", 1304, 1329], ["relatively", "OBSERVATION_MODIFIER", 1507, 1517], ["pathogenic", "OBSERVATION_MODIFIER", 1518, 1528], ["micro-organisms", "OBSERVATION", 1529, 1544]]], ["For instance, peptide fragments identical to leptin were found in proteins belonging to Lactococcus lactis, Escherichia coli, Lactobacilli bacteriophage, Yarrowia lipolytica, Candida, and Aspergillus species.", [["leptin", "GENE_OR_GENE_PRODUCT", 45, 51], ["Lactococcus lactis", "ORGANISM", 88, 106], ["Escherichia coli", "ORGANISM", 108, 124], ["Lactobacilli bacteriophage", "ORGANISM", 126, 152], ["Yarrowia lipolytica", "ORGANISM", 154, 173], ["Candida,", "ORGANISM", 175, 183], ["Aspergillus species", "ORGANISM", 188, 207], ["leptin", "PROTEIN", 45, 51], ["Lactococcus lactis", "SPECIES", 88, 106], ["Escherichia coli", "SPECIES", 108, 124], ["Lactobacilli bacteriophage", "SPECIES", 126, 152], ["Yarrowia lipolytica", "SPECIES", 154, 173], ["Lactococcus lactis", "SPECIES", 88, 106], ["Escherichia coli", "SPECIES", 108, 124], ["Yarrowia lipolytica", "SPECIES", 154, 173], ["peptide fragments", "PROBLEM", 14, 31], ["Lactococcus lactis", "TREATMENT", 88, 106], ["Escherichia coli", "PROBLEM", 108, 124], ["Lactobacilli bacteriophage", "TREATMENT", 126, 152], ["Yarrowia lipolytica", "PROBLEM", 154, 173], ["Candida", "PROBLEM", 175, 182], ["Aspergillus species", "PROBLEM", 188, 207], ["peptide fragments", "OBSERVATION", 14, 31], ["Escherichia coli", "OBSERVATION", 108, 124], ["Lactobacilli bacteriophage", "OBSERVATION", 126, 152], ["Aspergillus species", "OBSERVATION", 188, 207]]], ["Notably, the most frequent molecular mimicry (7-12 of the examined regulatory peptides) occurs with the class of fungi (Table 3) .", [["most", "OBSERVATION_MODIFIER", 13, 17], ["frequent", "OBSERVATION_MODIFIER", 18, 26], ["molecular", "OBSERVATION_MODIFIER", 27, 36], ["mimicry", "OBSERVATION", 37, 44], ["fungi", "OBSERVATION", 113, 118]]], ["They include the commensal or relatively pathogenic yeasts Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans, the food-associated yeasts Y. lipolytica and Saccharomyces, and several plant fungi such as Neurospora crassa.", [["Candida albicans", "DISEASE", 59, 75], ["Aspergillus fumigatus", "DISEASE", 77, 98], ["Cryptococcus neoformans", "DISEASE", 104, 127], ["yeasts", "ORGANISM", 52, 58], ["Candida albicans", "ORGANISM", 59, 75], ["Aspergillus fumigatus", "ORGANISM", 77, 98], ["Cryptococcus neoformans", "ORGANISM", 104, 127], ["Y. lipolytica", "ORGANISM", 156, 169], ["Saccharomyces", "ORGANISM", 174, 187], ["Neurospora crassa", "ORGANISM", 221, 238], ["Candida albicans", "SPECIES", 59, 75], ["Aspergillus fumigatus", "SPECIES", 77, 98], ["Cryptococcus neoformans", "SPECIES", 104, 127], ["Y. lipolytica", "SPECIES", 156, 169], ["Neurospora crassa", "SPECIES", 221, 238], ["Candida albicans", "SPECIES", 59, 75], ["Aspergillus fumigatus", "SPECIES", 77, 98], ["Cryptococcus neoformans", "SPECIES", 104, 127], ["Y. lipolytica", "SPECIES", 156, 169], ["Neurospora crassa", "SPECIES", 221, 238], ["relatively pathogenic yeasts Candida albicans", "PROBLEM", 30, 75], ["Aspergillus fumigatus", "PROBLEM", 77, 98], ["Cryptococcus neoformans", "PROBLEM", 104, 127], ["several plant fungi", "PROBLEM", 193, 212], ["Neurospora crassa", "PROBLEM", 221, 238], ["Candida albicans", "OBSERVATION", 59, 75], ["Aspergillus fumigatus", "OBSERVATION", 77, 98], ["Cryptococcus neoformans", "OBSERVATION", 104, 127], ["plant fungi", "OBSERVATION", 201, 212]]], ["Anorexigenic and orexigenic peptides displayed molecular mimicry with the same fungus, thus not allowing an association of a single fungus species with a potential specific effect on food intake.", [["food", "ORGANISM_SUBDIVISION", 183, 187], ["Anorexigenic and orexigenic peptides", "PROBLEM", 0, 36], ["molecular mimicry", "PROBLEM", 47, 64], ["the same fungus", "PROBLEM", 70, 85], ["a single fungus species", "PROBLEM", 123, 146], ["molecular mimicry", "OBSERVATION", 47, 64], ["fungus", "OBSERVATION", 79, 85]]], ["Among the commensal bacteria and viruses, sequence homology was often seen in Lactobacilli and their phages, bacteroides, and commensal strains of E. coli, which displayed molecular mimicry with leptin, insulin, ghrelin, PYY, NPY, AgRP, orexin, \u2423-MSH, ACTH, oxytocin, or vasopressin.", [["oxytocin", "CHEMICAL", 258, 266], ["vasopressin", "CHEMICAL", 271, 282], ["oxytocin", "CHEMICAL", 258, 266], ["Lactobacilli", "SIMPLE_CHEMICAL", 78, 90], ["commensal strains", "ORGANISM", 126, 143], ["E. coli", "ORGANISM", 147, 154], ["leptin", "GENE_OR_GENE_PRODUCT", 195, 201], ["insulin", "GENE_OR_GENE_PRODUCT", 203, 210], ["ghrelin", "GENE_OR_GENE_PRODUCT", 212, 219], ["PYY", "GENE_OR_GENE_PRODUCT", 221, 224], ["NPY", "GENE_OR_GENE_PRODUCT", 226, 229], ["AgRP", "GENE_OR_GENE_PRODUCT", 231, 235], ["orexin", "GENE_OR_GENE_PRODUCT", 237, 243], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 245, 250], ["ACTH", "GENE_OR_GENE_PRODUCT", 252, 256], ["oxytocin", "SIMPLE_CHEMICAL", 258, 266], ["vasopressin", "GENE_OR_GENE_PRODUCT", 271, 282], ["leptin", "PROTEIN", 195, 201], ["insulin", "PROTEIN", 203, 210], ["E. coli", "SPECIES", 147, 154], ["E. coli", "SPECIES", 147, 154], ["the commensal bacteria", "PROBLEM", 6, 28], ["viruses", "PROBLEM", 33, 40], ["sequence homology", "TEST", 42, 59], ["Lactobacilli", "TREATMENT", 78, 90], ["bacteroides", "PROBLEM", 109, 120], ["E. coli", "PROBLEM", 147, 154], ["leptin", "TREATMENT", 195, 201], ["insulin", "TREATMENT", 203, 210], ["ACTH", "TREATMENT", 252, 256], ["oxytocin", "TREATMENT", 258, 266], ["vasopressin", "TREATMENT", 271, 282], ["commensal", "OBSERVATION_MODIFIER", 10, 19], ["bacteria", "OBSERVATION", 20, 28], ["viruses", "OBSERVATION", 33, 40], ["E. coli", "OBSERVATION", 147, 154]]], ["These results suggest that commensal microflora could trigger production of many autoAbs reactive with these regulatory peptides, and that eventually, under normal conditions, not a single regulatory peptide may escape this microbial-derived immune-mediated control.Molecular mimicry with commensal micro-organismsWe found that commensal or relatively pathogenic Enterococcus faecalis displayed molecular mimicry only with ghrelin.", [["ghrelin", "CHEMICAL", 423, 430], ["Enterococcus faecalis", "ORGANISM", 363, 384], ["ghrelin", "GENE_OR_GENE_PRODUCT", 423, 430], ["Enterococcus faecalis", "SPECIES", 363, 384], ["Enterococcus faecalis", "SPECIES", 363, 384], ["commensal microflora", "PROBLEM", 27, 47], ["a single regulatory peptide", "PROBLEM", 180, 207], ["this microbial", "TEST", 219, 233], ["immune-mediated control", "TREATMENT", 242, 265], ["commensal micro-organisms", "PROBLEM", 289, 314], ["relatively pathogenic Enterococcus faecalis", "PROBLEM", 341, 384], ["reactive", "OBSERVATION_MODIFIER", 89, 97], ["commensal micro-organisms", "OBSERVATION", 289, 314], ["Enterococcus faecalis", "OBSERVATION", 363, 384], ["molecular mimicry", "OBSERVATION", 395, 412]]], ["The fact that E. faecalis is present in the original microflora of SPF rats bred in Charles River Laboratories is relevant to our finding that the levels of ghrelin-reactive IgG was higher in germ-free than in SPF rats.", [["germ", "ANATOMY", 192, 196], ["E. faecalis", "ORGANISM", 14, 25], ["SPF rats", "ORGANISM", 67, 75], ["Charles River Laboratories", "ORGANISM", 84, 110], ["ghrelin", "GENE_OR_GENE_PRODUCT", 157, 164], ["IgG", "GENE_OR_GENE_PRODUCT", 174, 177], ["SPF rats", "ORGANISM", 210, 218], ["ghrelin-reactive IgG", "PROTEIN", 157, 177], ["E. faecalis", "SPECIES", 14, 25], ["rats", "SPECIES", 71, 75], ["rats", "SPECIES", 214, 218], ["E. faecalis", "SPECIES", 14, 25], ["SPF", "SPECIES", 210, 213], ["E. faecalis", "PROBLEM", 14, 25], ["the levels", "TEST", 143, 153], ["ghrelin", "TEST", 157, 164], ["reactive IgG", "TEST", 165, 177], ["faecalis", "OBSERVATION", 17, 25], ["reactive", "OBSERVATION_MODIFIER", 165, 173], ["IgG", "OBSERVATION", 174, 177]]], ["These data support the idea that a negative link could exist between production of some IgG autoAbs and selective micro-organisms [45] .", [["IgG", "GENE_OR_GENE_PRODUCT", 88, 91], ["IgG", "PROTEIN", 88, 91], ["selective micro-organisms", "TEST", 104, 129], ["selective", "OBSERVATION_MODIFIER", 104, 113]]], ["Moreover, a recent finding that active immunization with ghrelin fragments reduces adiposity in mice [46] supports our conclusions that ghrelin autoAbs may participate in physiologic regulation of appetite and body weight.Molecular mimicry with pathogenic micro-organismsWe previously reported that levels of \u2423-MSH-reactive IgG autoAbs are associated with core psychopathologic traits in anorexia and bulimia nervosa [18] .", [["body", "ANATOMY", 210, 214], ["anorexia", "DISEASE", 388, 396], ["bulimia nervosa", "DISEASE", 401, 416], ["ghrelin", "GENE_OR_GENE_PRODUCT", 57, 64], ["mice", "ORGANISM", 96, 100], ["ghrelin", "GENE_OR_GENE_PRODUCT", 136, 143], ["body", "ORGANISM_SUBDIVISION", 210, 214], ["MSH", "GENE_OR_GENE_PRODUCT", 311, 314], ["IgG", "GENE_OR_GENE_PRODUCT", 324, 327], ["Abs", "PROTEIN", 148, 151], ["MSH", "PROTEIN", 311, 314], ["IgG autoAbs", "PROTEIN", 324, 335], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["active immunization", "TREATMENT", 32, 51], ["ghrelin fragments", "PROBLEM", 57, 74], ["body weight", "TEST", 210, 221], ["pathogenic micro-organisms", "PROBLEM", 245, 271], ["levels", "TEST", 299, 305], ["MSH", "TEST", 311, 314], ["reactive IgG autoAbs", "PROBLEM", 315, 335], ["core psychopathologic traits", "PROBLEM", 356, 384], ["anorexia", "PROBLEM", 388, 396], ["bulimia nervosa", "PROBLEM", 401, 416], ["active", "OBSERVATION_MODIFIER", 32, 38], ["pathogenic micro-organisms", "OBSERVATION", 245, 271], ["reactive", "OBSERVATION_MODIFIER", 315, 323], ["IgG autoAbs", "OBSERVATION", 324, 335]]], ["In the present study, we demonstrated that various fragments of the \u2423-MSH sequence exists in several pathogenic microorganisms including enteropathogenic E. coli strains, Helicobacter pylori, Clostridium tetani, human immunodeficiency virus type 1, C. albicans, A. fumigatus, and C. neoformans.", [["Helicobacter pylori", "DISEASE", 171, 190], ["human immunodeficiency virus", "DISEASE", 212, 240], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 68, 73], ["enteropathogenic E. coli", "ORGANISM", 137, 161], ["strains", "ORGANISM", 162, 169], ["Helicobacter pylori", "ORGANISM", 171, 190], ["Clostridium tetani", "ORGANISM", 192, 210], ["human immunodeficiency virus type 1", "ORGANISM", 212, 247], ["C. albicans", "ORGANISM", 249, 260], ["A. fumigatus", "ORGANISM", 262, 274], ["C. neoformans", "ORGANISM", 280, 293], ["\u2423-MSH sequence", "DNA", 68, 82], ["E. coli", "SPECIES", 154, 161], ["Helicobacter pylori", "SPECIES", 171, 190], ["Clostridium tetani", "SPECIES", 192, 210], ["human immunodeficiency virus", "SPECIES", 212, 240], ["type 1", "SPECIES", 241, 247], ["C. albicans", "SPECIES", 249, 260], ["A. fumigatus", "SPECIES", 262, 274], ["C. neoformans", "SPECIES", 280, 293], ["E. coli", "SPECIES", 154, 161], ["Helicobacter pylori", "SPECIES", 171, 190], ["Clostridium tetani", "SPECIES", 192, 210], ["human immunodeficiency virus type 1", "SPECIES", 212, 247], ["C. albicans", "SPECIES", 249, 260], ["A. fumigatus", "SPECIES", 262, 274], ["C. neoformans", "SPECIES", 280, 293], ["the present study", "TEST", 3, 20], ["various fragments", "PROBLEM", 43, 60], ["the \u2423-MSH sequence", "TEST", 64, 82], ["several pathogenic microorganisms", "PROBLEM", 93, 126], ["enteropathogenic E. coli strains", "PROBLEM", 137, 169], ["Helicobacter pylori", "PROBLEM", 171, 190], ["Clostridium tetani", "PROBLEM", 192, 210], ["human immunodeficiency virus type", "PROBLEM", 212, 245], ["C. albicans", "PROBLEM", 249, 260], ["A. fumigatus", "PROBLEM", 262, 274], ["C. neoformans", "PROBLEM", 280, 293], ["several", "OBSERVATION_MODIFIER", 93, 100], ["pathogenic", "OBSERVATION_MODIFIER", 101, 111], ["enteropathogenic", "OBSERVATION_MODIFIER", 137, 153], ["E. coli strains", "OBSERVATION", 154, 169], ["Helicobacter pylori", "OBSERVATION", 171, 190], ["neoformans", "OBSERVATION", 283, 293]]], ["Some of these micro-organisms may therefore trigger the production of \u2423-MSH-reactive autoAbs relevant to the pathophysiology of eating disorders.Molecular mimicry with pathogenic micro-organismsInterestingly, molecular mimicry related to proteins belonging to H. pylori was found only among the anorexigenic peptides (Table 1 ), e.g., leptin, insulin, \u2423-MSH, and ACTH, suggesting that H. pylori-triggered autoAbs reactive with these regulatory peptides could selectively alter satiety pathways resulting in appetite change.", [["eating disorders", "DISEASE", 128, 144], ["MSH", "GENE_OR_GENE_PRODUCT", 72, 75], ["H. pylori", "ORGANISM", 260, 269], ["leptin", "GENE_OR_GENE_PRODUCT", 335, 341], ["insulin", "GENE_OR_GENE_PRODUCT", 343, 350], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 352, 357], ["ACTH", "GENE_OR_GENE_PRODUCT", 363, 367], ["H. pylori", "ORGANISM", 385, 394], ["Abs", "PROTEIN", 89, 92], ["leptin", "PROTEIN", 335, 341], ["insulin", "PROTEIN", 343, 350], ["H. pylori", "SPECIES", 260, 269], ["H. pylori", "SPECIES", 385, 394], ["H. pylori", "SPECIES", 260, 269], ["H. pylori", "SPECIES", 385, 394], ["these micro-organisms", "PROBLEM", 8, 29], ["eating disorders", "PROBLEM", 128, 144], ["pathogenic micro-organisms", "PROBLEM", 168, 194], ["H. pylori", "PROBLEM", 260, 269], ["leptin", "TREATMENT", 335, 341], ["insulin", "TREATMENT", 343, 350], ["ACTH", "TEST", 363, 367], ["H. pylori", "PROBLEM", 385, 394], ["these regulatory peptides", "PROBLEM", 427, 452], ["appetite change", "PROBLEM", 507, 522], ["reactive auto", "OBSERVATION", 76, 89], ["pathogenic micro-organisms", "OBSERVATION", 168, 194], ["reactive", "OBSERVATION_MODIFIER", 413, 421]]], ["In fact, the presence of H. pylori has been associated with decreased adiposity [47] , high levels of stomach leptin [48] , and insulin resistance [49] .", [["stomach", "ANATOMY", 102, 109], ["H. pylori", "DISEASE", 25, 34], ["H. pylori", "ORGANISM", 25, 34], ["stomach", "ORGAN", 102, 109], ["leptin", "GENE_OR_GENE_PRODUCT", 110, 116], ["insulin", "GENE_OR_GENE_PRODUCT", 128, 135], ["H. pylori", "SPECIES", 25, 34], ["H. pylori", "SPECIES", 25, 34], ["H. pylori", "PROBLEM", 25, 34], ["decreased adiposity", "PROBLEM", 60, 79], ["high levels of stomach leptin", "PROBLEM", 87, 116], ["insulin resistance", "TEST", 128, 146], ["H. pylori", "OBSERVATION", 25, 34], ["stomach", "ANATOMY", 102, 109]]], ["Serum levels of IgA autoAbs directed against appetite-regulating peptides in germ-free and SPF male Sprague-Dawley rats (mean \u03ee SE). * T test, P \u03fd 0.05; * Mann-Whitney test, P \u03fd 0.05, for CRH. \u2423-MSH, \u2423melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; AgRP, agouti-related protein; autoAbs, autoantibodies; CRH, corticotropinreleasing hormone; IgA, immunoglobulin A; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OD, optical density in enzyme-linked immunosorbent assay; PYY, peptide tyrosine-tyrosine; SPF, specific pathogen-free.", [["Serum", "ANATOMY", 0, 5], ["germ", "ANATOMY", 77, 81], ["tyrosine", "CHEMICAL", 511, 519], ["tyrosine", "CHEMICAL", 520, 528], ["tyrosine", "CHEMICAL", 511, 519], ["tyrosine", "CHEMICAL", 520, 528], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgA", "GENE_OR_GENE_PRODUCT", 16, 19], ["appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 45, 73], ["germ", "MULTI-TISSUE_STRUCTURE", 77, 81], ["SPF male Sprague-Dawley rats", "ORGANISM", 91, 119], ["CRH", "GENE_OR_GENE_PRODUCT", 188, 191], ["MSH", "GENE_OR_GENE_PRODUCT", 195, 198], ["\u2423melanocyte-stimulating hormone", "GENE_OR_GENE_PRODUCT", 200, 231], ["ACTH", "GENE_OR_GENE_PRODUCT", 233, 237], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 239, 266], ["AgRP", "GENE_OR_GENE_PRODUCT", 268, 272], ["agouti-related protein", "GENE_OR_GENE_PRODUCT", 274, 296], ["autoAbs", "GENE_OR_GENE_PRODUCT", 298, 305], ["CRH", "GENE_OR_GENE_PRODUCT", 323, 326], ["corticotropinreleasing hormone", "GENE_OR_GENE_PRODUCT", 328, 358], ["IgA", "GENE_OR_GENE_PRODUCT", 360, 363], ["immunoglobulin A", "GENE_OR_GENE_PRODUCT", 365, 381], ["MCH", "GENE_OR_GENE_PRODUCT", 383, 386], ["melanin-concentrating hormone", "GENE_OR_GENE_PRODUCT", 388, 417], ["NPY", "GENE_OR_GENE_PRODUCT", 419, 422], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 424, 438], ["PYY", "GENE_OR_GENE_PRODUCT", 498, 501], ["peptide tyrosine-tyrosine", "SIMPLE_CHEMICAL", 503, 528], ["IgA autoAbs", "PROTEIN", 16, 27], ["AgRP", "PROTEIN", 268, 272], ["agouti-related protein", "PROTEIN", 274, 296], ["autoAbs", "PROTEIN", 298, 305], ["autoantibodies", "PROTEIN", 307, 321], ["CRH", "PROTEIN", 323, 326], ["IgA", "PROTEIN", 360, 363], ["immunoglobulin A", "PROTEIN", 365, 381], ["MCH", "PROTEIN", 383, 386], ["Sprague-Dawley rats", "SPECIES", 100, 119], ["Sprague-Dawley rats", "SPECIES", 100, 119], ["Serum levels", "TEST", 0, 12], ["IgA autoAbs", "TEST", 16, 27], ["appetite", "TEST", 45, 53], ["T test", "TEST", 135, 141], ["P", "TEST", 143, 144], ["Whitney test", "TEST", 160, 172], ["P", "TEST", 174, 175], ["CRH", "TEST", 188, 191], ["MSH", "TEST", 195, 198], ["\u2423melanocyte", "TEST", 200, 211], ["ACTH", "TEST", 233, 237], ["adrenocorticotropic hormone", "TEST", 239, 266], ["AgRP", "TEST", 268, 272], ["agouti", "TEST", 274, 280], ["protein", "TEST", 289, 296], ["autoAbs", "TEST", 298, 305], ["autoantibodies", "PROBLEM", 307, 321], ["CRH", "TEST", 323, 326], ["corticotropinreleasing hormone", "TEST", 328, 358], ["IgA", "TEST", 360, 363], ["MCH", "TEST", 383, 386], ["optical density in enzyme", "TEST", 444, 469], ["immunosorbent assay", "TEST", 477, 496], ["PYY", "TEST", 498, 501], ["peptide tyrosine", "TREATMENT", 503, 519], ["tyrosine", "TREATMENT", 520, 528], ["SPF", "PROBLEM", 530, 533]]], ["Serum levels of IgG autoAbs directed against appetite-regulating peptides in germ-free and SPF male Sprague-Dawley rats (mean \u03ee SE). * T test, P \u03fd 0.05. \u2423-MSH, \u2423-melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; AgRP, agouti-related protein; autoAbs, autoantibodies; CRH, corticotropin-releasing hormone; IgA, immunoglobulin A; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OD, optical density in enzyme-linked immunosorbent assay; PYY, peptide tyrosine-tyrosine; SPF, specific pathogen-free.Molecular mimicry with pathogenic micro-organismsThe sequence homology of insulin with pathogenic microorganisms such as H. pylori, Burkholderia cepacia, Yersinia pseudotuberculosis, hepatitis C virus, and gastroenteritis virus may be responsible for the production of some insulinreactive autoAbs.", [["Serum", "ANATOMY", 0, 5], ["germ", "ANATOMY", 77, 81], ["tyrosine", "CHEMICAL", 473, 481], ["tyrosine", "CHEMICAL", 482, 490], ["Burkholderia cepacia", "DISEASE", 652, 672], ["Yersinia pseudotuberculosis", "DISEASE", 674, 701], ["hepatitis C", "DISEASE", 703, 714], ["gastroenteritis", "DISEASE", 726, 741], ["tyrosine", "CHEMICAL", 473, 481], ["tyrosine", "CHEMICAL", 482, 490], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgG autoAbs directed against appetite-regulating peptides", "GENE_OR_GENE_PRODUCT", 16, 73], ["germ", "MULTI-TISSUE_STRUCTURE", 77, 81], ["SPF male Sprague-Dawley rats", "ORGANISM", 91, 119], ["MSH", "GENE_OR_GENE_PRODUCT", 155, 158], ["\u2423-melanocyte-stimulating hormone", "GENE_OR_GENE_PRODUCT", 160, 192], ["ACTH", "GENE_OR_GENE_PRODUCT", 194, 198], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 200, 227], ["AgRP", "GENE_OR_GENE_PRODUCT", 229, 233], ["agouti-related protein", "GENE_OR_GENE_PRODUCT", 235, 257], ["autoAbs", "GENE_OR_GENE_PRODUCT", 259, 266], ["CRH", "GENE_OR_GENE_PRODUCT", 284, 287], ["corticotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 289, 320], ["IgA", "GENE_OR_GENE_PRODUCT", 322, 325], ["immunoglobulin A", "GENE_OR_GENE_PRODUCT", 327, 343], ["MCH", "GENE_OR_GENE_PRODUCT", 345, 348], ["melanin-concentrating hormone", "GENE_OR_GENE_PRODUCT", 350, 379], ["NPY", "GENE_OR_GENE_PRODUCT", 381, 384], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 386, 400], ["PYY", "GENE_OR_GENE_PRODUCT", 460, 463], ["peptide tyrosine-tyrosine", "SIMPLE_CHEMICAL", 465, 490], ["insulin", "GENE_OR_GENE_PRODUCT", 594, 601], ["H. pylori", "ORGANISM", 641, 650], ["Burkholderia cepacia", "ORGANISM", 652, 672], ["Yersinia pseudotuberculosis", "ORGANISM", 674, 701], ["hepatitis C virus", "ORGANISM", 703, 720], ["gastroenteritis virus", "ORGANISM", 726, 747], ["autoAbs", "GENE_OR_GENE_PRODUCT", 810, 817], ["IgG autoAbs", "PROTEIN", 16, 27], ["AgRP", "PROTEIN", 229, 233], ["agouti-related protein", "PROTEIN", 235, 257], ["autoAbs", "PROTEIN", 259, 266], ["autoantibodies", "PROTEIN", 268, 282], ["CRH", "PROTEIN", 284, 287], ["IgA", "PROTEIN", 322, 325], ["immunoglobulin A", "PROTEIN", 327, 343], ["MCH", "PROTEIN", 345, 348], ["insulin", "PROTEIN", 594, 601], ["insulinreactive autoAbs", "PROTEIN", 794, 817], ["Sprague-Dawley rats", "SPECIES", 100, 119], ["H. pylori", "SPECIES", 641, 650], ["Burkholderia cepacia", "SPECIES", 652, 672], ["Yersinia pseudotuberculosis", "SPECIES", 674, 701], ["hepatitis C virus", "SPECIES", 703, 720], ["gastroenteritis virus", "SPECIES", 726, 747], ["Sprague-Dawley rats", "SPECIES", 100, 119], ["H. pylori", "SPECIES", 641, 650], ["Burkholderia cepacia", "SPECIES", 652, 672], ["Yersinia pseudotuberculosis", "SPECIES", 674, 701], ["hepatitis C virus", "SPECIES", 703, 720], ["gastroenteritis virus", "SPECIES", 726, 747], ["Serum levels", "TEST", 0, 12], ["IgG autoAbs", "TEST", 16, 27], ["appetite", "TEST", 45, 53], ["T test", "TEST", 135, 141], ["P", "TEST", 143, 144], ["MSH", "TEST", 155, 158], ["\u2423-melanocyte", "TEST", 160, 172], ["ACTH", "TEST", 194, 198], ["adrenocorticotropic hormone", "TEST", 200, 227], ["AgRP", "TEST", 229, 233], ["agouti", "TEST", 235, 241], ["protein", "TEST", 250, 257], ["autoAbs", "TEST", 259, 266], ["autoantibodies", "PROBLEM", 268, 282], ["CRH", "TEST", 284, 287], ["corticotropin", "TEST", 289, 302], ["IgA", "TEST", 322, 325], ["MCH", "TEST", 345, 348], ["optical density in enzyme", "TEST", 406, 431], ["immunosorbent assay", "TEST", 439, 458], ["PYY", "TEST", 460, 463], ["peptide tyrosine", "TREATMENT", 465, 481], ["tyrosine", "TREATMENT", 482, 490], ["SPF", "PROBLEM", 492, 495], ["pathogenic micro-organisms", "PROBLEM", 543, 569], ["insulin", "TREATMENT", 594, 601], ["pathogenic microorganisms", "PROBLEM", 607, 632], ["H. pylori", "PROBLEM", 641, 650], ["Burkholderia cepacia", "PROBLEM", 652, 672], ["Yersinia pseudotuberculosis", "PROBLEM", 674, 701], ["hepatitis C virus", "PROBLEM", 703, 720], ["gastroenteritis virus", "PROBLEM", 726, 747], ["some insulinreactive autoAbs", "PROBLEM", 789, 817], ["pathogenic micro-organisms", "OBSERVATION", 543, 569], ["Yersinia pseudotuberculosis", "OBSERVATION", 674, 701]]], ["These autoAbs, in our view, would not be markers of pancreatic \u2424-cell lysis, but could be mechanistically relevant to altered insulin signaling in diabetes.", [["pancreatic \u2424-cell", "ANATOMY", 52, 69], ["diabetes", "DISEASE", 147, 155], ["autoAbs", "GENE_OR_GENE_PRODUCT", 6, 13], ["pancreatic \u2424-cell", "CELL", 52, 69], ["insulin", "GENE_OR_GENE_PRODUCT", 126, 133], ["autoAbs", "PROTEIN", 6, 13], ["pancreatic \u2424-cell lysis", "TREATMENT", 52, 75], ["altered insulin signaling", "PROBLEM", 118, 143], ["diabetes", "PROBLEM", 147, 155], ["pancreatic", "ANATOMY", 52, 62], ["\u2424-cell lysis", "OBSERVATION", 63, 75], ["insulin signaling", "OBSERVATION", 126, 143], ["diabetes", "OBSERVATION", 147, 155]]], ["In fact, it has been shown that sera of some diabetic patients can inhibit insulin binding to its receptor [50] .", [["sera", "ANATOMY", 32, 36], ["diabetic", "DISEASE", 45, 53], ["sera", "ORGANISM_SUBSTANCE", 32, 36], ["patients", "ORGANISM", 54, 62], ["insulin", "GENE_OR_GENE_PRODUCT", 75, 82], ["patients", "SPECIES", 54, 62], ["some diabetic patients", "PROBLEM", 40, 62], ["insulin binding", "TREATMENT", 75, 90]]], ["Recent data corroborate our conclusions showing that some pathologic properties of insulin autoAbs [51] may be related to their epitopes [52] , whereas changes in intestinal microflora were associated with the development of diabetes and obesity [53, 54] .Physiologic versus pathologic role of autoantibodiesThe presence of various sequence homologies for the same regulatory peptide found in commensal and pathogenic micro-organisms suggests that they could be responsible for the appearance of cross-reacting autoAbs.", [["intestinal microflora", "ANATOMY", 163, 184], ["diabetes", "DISEASE", 225, 233], ["obesity", "DISEASE", 238, 245], ["insulin", "GENE_OR_GENE_PRODUCT", 83, 90], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 163, 184], ["autoantibodies", "GENE_OR_GENE_PRODUCT", 294, 308], ["insulin", "PROTEIN", 83, 90], ["epitopes", "PROTEIN", 128, 136], ["autoantibodies", "PROTEIN", 294, 308], ["Abs", "PROTEIN", 515, 518], ["Recent data", "TEST", 0, 11], ["intestinal microflora", "PROBLEM", 163, 184], ["diabetes", "PROBLEM", 225, 233], ["obesity", "PROBLEM", 238, 245], ["Physiologic versus pathologic role of autoantibodies", "PROBLEM", 256, 308], ["various sequence homologies", "TEST", 324, 351], ["the same regulatory peptide", "PROBLEM", 356, 383], ["commensal and pathogenic micro-organisms", "PROBLEM", 393, 433], ["intestinal", "ANATOMY", 163, 173], ["microflora", "OBSERVATION", 174, 184], ["diabetes", "OBSERVATION", 225, 233], ["obesity", "OBSERVATION", 238, 245], ["autoantibodies", "OBSERVATION", 294, 308]]], ["However, the functional implication of binding of such autoAbs to the regulatory peptide could be different depending on what part of the molecule was targeted.", [["Abs", "PROTEIN", 59, 62]]], ["We found that sequence homologies were often different between commensal and pathogenic micro-organisms.", [["sequence homologies", "TEST", 14, 33], ["commensal and pathogenic micro-organisms", "PROBLEM", 63, 103]]], ["For instance, commensal bacteroides have mimicry close to the carboxylterminal side of \u2423-MSH, whereas pathogenic H. pylori displays homology with the larger part of its carboxylterminal and pathogenic E. coli strains with various regions of the peptide (Fig. 3A) .", [["\u2423-MSH", "CHEMICAL", 87, 92], ["commensal bacteroides", "ORGANISM", 14, 35], ["MSH", "GENE_OR_GENE_PRODUCT", 89, 92], ["H. pylori", "ORGANISM", 113, 122], ["carboxylterminal", "GENE_OR_GENE_PRODUCT", 169, 185], ["E. coli", "ORGANISM", 201, 208], ["H. pylori", "SPECIES", 113, 122], ["E. coli", "SPECIES", 201, 208], ["H. pylori", "SPECIES", 113, 122], ["E. coli", "SPECIES", 201, 208], ["commensal bacteroides", "PROBLEM", 14, 35], ["pathogenic H. pylori", "PROBLEM", 102, 122], ["pathogenic E. coli strains", "PROBLEM", 190, 216], ["bacteroides", "OBSERVATION", 24, 35], ["larger", "OBSERVATION_MODIFIER", 150, 156], ["E. coli strains", "OBSERVATION", 201, 216]]], ["It is well known that different parts of the \u2423-MSH peptide have specific functions [55] .", [["MSH", "GENE_OR_GENE_PRODUCT", 47, 50]]], ["For example, the central core sequence HFRW is responsible for the binding of \u2423-MSH to the appetite-related melanocortin receptor MC4; the amino terminal SYS is important for binding at MC3 and MC5 receptors, thus influencing autonomic functions; and the amino terminal KPV sequence may trigger the anti-inflammatory effects at MC1 receptors [56, 57] .", [["amino terminal", "CHEMICAL", 139, 153], ["amino", "CHEMICAL", 139, 144], ["amino", "CHEMICAL", 255, 260], ["HFRW", "GENE_OR_GENE_PRODUCT", 39, 43], ["\u2423-MSH", "GENE_OR_GENE_PRODUCT", 78, 83], ["MC4", "GENE_OR_GENE_PRODUCT", 130, 133], ["amino terminal", "AMINO_ACID", 139, 153], ["SYS", "GENE_OR_GENE_PRODUCT", 154, 157], ["MC3", "GENE_OR_GENE_PRODUCT", 186, 189], ["MC5 receptors", "GENE_OR_GENE_PRODUCT", 194, 207], ["central core sequence", "DNA", 17, 38], ["melanocortin receptor", "PROTEIN", 108, 129], ["MC4", "PROTEIN", 130, 133], ["amino terminal SYS", "PROTEIN", 139, 157], ["MC3", "PROTEIN", 186, 189], ["MC5 receptors", "PROTEIN", 194, 207], ["amino terminal KPV sequence", "PROTEIN", 255, 282], ["MC1 receptors", "PROTEIN", 328, 341], ["the central core sequence HFRW", "TEST", 13, 43], ["melanocortin receptor MC4", "TREATMENT", 108, 133], ["the amino terminal SYS", "TREATMENT", 135, 157], ["binding at MC3 and MC5 receptors", "PROBLEM", 175, 207], ["influencing autonomic functions", "PROBLEM", 214, 245], ["the amino terminal KPV sequence", "TREATMENT", 251, 282]]], ["Thus, autoAbs binding to different regions of \u2423-MSH peptide could differentially influence its biological activities.Physiologic versus pathologic role of autoantibodiesIt is likely that infections or changes in the composition of intestinal microflora could result in an appearance of pathologic autoAbs able to alter peptidergic transmission with corresponding metabolic and behavioral consequences.", [["intestinal microflora", "ANATOMY", 231, 252], ["infections", "DISEASE", 187, 197], ["autoAbs", "GENE_OR_GENE_PRODUCT", 6, 13], ["MSH peptide", "GENE_OR_GENE_PRODUCT", 48, 59], ["autoantibodies", "GENE_OR_GENE_PRODUCT", 155, 169], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 231, 252], ["autoAbs", "PROTEIN", 6, 13], ["autoantibodies", "PROTEIN", 155, 169], ["autoAbs binding", "PROBLEM", 6, 21], ["\u2423-MSH peptide", "PROBLEM", 46, 59], ["Physiologic versus pathologic role of autoantibodies", "PROBLEM", 117, 169], ["infections", "PROBLEM", 187, 197], ["intestinal microflora", "PROBLEM", 231, 252], ["corresponding metabolic and behavioral consequences", "PROBLEM", 349, 400], ["autoantibodies", "OBSERVATION", 155, 169], ["is likely", "UNCERTAINTY", 172, 181], ["infections", "OBSERVATION", 187, 197], ["intestinal", "ANATOMY", 231, 241], ["pathologic", "OBSERVATION", 286, 296]]], ["The factors triggering such a switch may be related directly to alterations of intestinal microflora, such as special diets, starvation, antibiotic or antifungal treatment, and gastrointestinal infections, or to changes in the mechanisms of antigen presentation to the immune system, including alterations of the intestinal barrier by inflammation or stress [58] , and genetic vulnerability in downstream pathways of the immune system leading to autoAb production.", [["intestinal", "ANATOMY", 79, 89], ["gastrointestinal", "ANATOMY", 177, 193], ["immune system", "ANATOMY", 269, 282], ["intestinal barrier", "ANATOMY", 313, 331], ["immune system", "ANATOMY", 421, 434], ["gastrointestinal infections", "DISEASE", 177, 204], ["inflammation", "DISEASE", 335, 347], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 79, 100], ["gastrointestinal", "ORGANISM_SUBDIVISION", 177, 193], ["intestinal barrier", "TISSUE", 313, 331], ["autoAb", "GENE_OR_GENE_PRODUCT", 446, 452], ["intestinal microflora", "TREATMENT", 79, 100], ["starvation", "TREATMENT", 125, 135], ["antibiotic", "TREATMENT", 137, 147], ["antifungal treatment", "TREATMENT", 151, 171], ["gastrointestinal infections", "PROBLEM", 177, 204], ["the intestinal barrier", "TREATMENT", 309, 331], ["inflammation", "PROBLEM", 335, 347], ["stress", "PROBLEM", 351, 357], ["genetic vulnerability", "PROBLEM", 369, 390], ["autoAb production", "PROBLEM", 446, 463], ["intestinal", "ANATOMY", 79, 89], ["gastrointestinal", "ANATOMY", 177, 193], ["infections", "OBSERVATION", 194, 204], ["intestinal", "ANATOMY", 313, 323]]], ["In fact, many of these factors have previously been proposed to contribute to the etiology of eating disorders, one example being the association of anorexia nervosa with streptococcal infection [59] .", [["eating disorders", "DISEASE", 94, 110], ["anorexia nervosa", "DISEASE", 149, 165], ["streptococcal infection", "DISEASE", 171, 194], ["eating disorders", "PROBLEM", 94, 110], ["anorexia nervosa", "PROBLEM", 149, 165], ["streptococcal infection", "PROBLEM", 171, 194], ["streptococcal", "OBSERVATION_MODIFIER", 171, 184], ["infection", "OBSERVATION", 185, 194]]], ["Following this example, we have in this study revealed the existence of sequence homology between Streptococcus and leptin and in a previous study with gonadotropin-releasing hormone [60] , presenting a potential link between micro-organisms and immune-mediated regulation of appetite-related peptides.", [["leptin", "GENE_OR_GENE_PRODUCT", 116, 122], ["gonadotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 152, 182], ["this study", "TEST", 35, 45], ["Streptococcus", "PROBLEM", 98, 111], ["leptin", "TREATMENT", 116, 122], ["a previous study", "TEST", 130, 146], ["gonadotropin-releasing hormone", "TREATMENT", 152, 182], ["micro-organisms", "PROBLEM", 226, 241], ["related peptides", "PROBLEM", 285, 301]]], ["Interestingly, increased levels of autoAbs against gonadotropin-releasing hormone were associated with intestinal pseudo-obstruction [61] , suggesting that this link might also be relevant to the regulation of the gut propulsive activity considering important role of several neuropeptides including CRH in gut motor function [62] .Concluding remarksSome gastrointestinal and neuropsychiatric disorders may have pathophysiologic mechanisms in common, involving the bidirectional brain-gut axis signaling through humoral and neural routes [63] [64] [65] [66] .", [["intestinal", "ANATOMY", 103, 113], ["gut", "ANATOMY", 214, 217], ["gut", "ANATOMY", 307, 310], ["gastrointestinal", "ANATOMY", 355, 371], ["brain", "ANATOMY", 479, 484], ["neural", "ANATOMY", 524, 530], ["gastrointestinal and neuropsychiatric disorders", "DISEASE", 355, 402], ["gonadotropin-releasing hormone", "GENE_OR_GENE_PRODUCT", 51, 81], ["intestinal", "ORGAN", 103, 113], ["gut", "ORGANISM_SUBDIVISION", 214, 217], ["CRH", "GENE_OR_GENE_PRODUCT", 300, 303], ["gut", "ORGANISM_SUBDIVISION", 307, 310], ["gastrointestinal", "ORGAN", 355, 371], ["brain", "ORGAN", 479, 484], ["gut", "ORGANISM_SUBDIVISION", 485, 488], ["gonadotropin", "TREATMENT", 51, 63], ["releasing hormone", "TREATMENT", 64, 81], ["intestinal pseudo-obstruction", "PROBLEM", 103, 132], ["several neuropeptides", "TREATMENT", 268, 289], ["Some gastrointestinal and neuropsychiatric disorders", "PROBLEM", 350, 402], ["pathophysiologic mechanisms", "PROBLEM", 412, 439], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["auto", "OBSERVATION", 35, 39], ["intestinal", "ANATOMY", 103, 113], ["pseudo-obstruction", "OBSERVATION", 114, 132], ["gastrointestinal", "ANATOMY", 355, 371], ["neuropsychiatric", "OBSERVATION", 376, 392], ["bidirectional", "ANATOMY_MODIFIER", 465, 478], ["brain", "ANATOMY", 479, 484], ["gut axis", "ANATOMY", 485, 493]]], ["The present work suggests an additional link between the gut and the brain, which could contribute to the elaborate interactions existing between the immune and nervous systems [67] [68] [69] .", [["gut", "ANATOMY", 57, 60], ["brain", "ANATOMY", 69, 74], ["nervous", "ANATOMY", 161, 168], ["gut", "ORGANISM_SUBDIVISION", 57, 60], ["brain", "ORGAN", 69, 74], ["nervous", "ANATOMICAL_SYSTEM", 161, 168], ["an additional link between the gut and the brain", "PROBLEM", 26, 74], ["gut", "ANATOMY", 57, 60], ["brain", "ANATOMY", 69, 74]]], ["In fact, the results of this study show that the phenomenon of autoAbs directed against regulatory peptides is not restricted to pathologic conditions but may be involved in the regulation of energy and emotional homeostases in healthy subjects.", [["Abs directed against regulatory peptides", "GENE_OR_GENE_PRODUCT", 67, 107], ["Abs", "PROTEIN", 67, 70], ["this study", "TEST", 24, 34]]], ["Furthermore, our data provide evidence that production of these autoAbs can be influenced by intestinal microflora, suggesting that autoAbs directed against regulatory peptides may constitute a functional link between intestinal microflora and mechanisms of appetite and emotion.Concluding remarksSuch a link may represent a fundamental evolutionary mechanism of adaptation, whereby intrinsic neuroendocrine mechanisms of homeostasis are tuned according to the prevailing microbial environment.", [["intestinal microflora", "ANATOMY", 93, 114], ["intestinal microflora", "ANATOMY", 218, 239], ["neuroendocrine", "ANATOMY", 393, 407], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 93, 114], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 218, 239], ["Abs", "PROTEIN", 68, 71], ["Abs", "PROTEIN", 136, 139], ["intestinal microflora", "PROBLEM", 93, 114], ["regulatory peptides", "TREATMENT", 157, 176], ["intestinal", "ANATOMY", 93, 103], ["microflora", "OBSERVATION", 104, 114], ["auto", "OBSERVATION", 132, 136], ["intestinal microflora", "ANATOMY", 218, 239], ["may represent", "UNCERTAINTY", 309, 322]]], ["Moreover, our data demonstrate multiple cases of molecular mimicry of regulatory peptides with microbial proteins, identifying micro-organisms as putative biological targets to be tested for their relevance to the normal or pathophysiologic mechanisms of appetite and emotion.", [["microbial proteins", "PROTEIN", 95, 113], ["our data", "TEST", 10, 18], ["microbial proteins", "PROBLEM", 95, 113], ["micro-organisms", "PROBLEM", 127, 142], ["multiple", "OBSERVATION_MODIFIER", 31, 39]]]], "08e8cd9cddb6f5f55f2f08a36fb5458c3d643344": [["IntroductionThe primary aim of genome-wide association studies (GWAS) and other genetic association studies is arguably to serve as the first step in elucidation of the biological mechanisms responsible for the onset of disease, which will eventually lead to their translation into clinical practice.IntroductionWhile GWAS and other genetic association studies have made great steps towards understanding many diseases, progress has so far fallen short of initial expectations for most neuropsychiatric disorders.", [["neuropsychiatric disorders", "DISEASE", 486, 512], ["other genetic association studies", "TEST", 74, 107], ["disease", "PROBLEM", 220, 227], ["most neuropsychiatric disorders", "PROBLEM", 481, 512], ["disease", "OBSERVATION", 220, 227]]], ["This is primarily due to the difficulty of identifying the biological effect of variants identified as significantly associated with the disorder.", [["the disorder", "PROBLEM", 133, 145]]], ["More philosophically, it is becoming increasingly recognised that considering interactions across the whole system is required to understand mechanisms in biology [1] , and this may be particularly the case for brain disorders [2] .", [["brain", "ANATOMY", 211, 216], ["brain disorders", "DISEASE", 211, 226], ["brain", "ORGAN", 211, 216], ["brain disorders", "PROBLEM", 211, 226]]], ["In the rest of the article we will refer to GWAS because they are the focus of much genetic research in neuropsychiatric disorders at the moment, but the same issues apply to other genetic association studies.IntroductionThe GWAS approach attempts to identify the statistically significant overrepresentation of specific single-nucleotide polymorphism (SNP) alleles in a group of affected individuals vs. a healthy control group.", [["neuropsychiatric disorders", "DISEASE", 104, 130], ["SNP", "CHEMICAL", 353, 356], ["neuropsychiatric disorders", "PROBLEM", 104, 130], ["specific single-nucleotide polymorphism (SNP) alleles", "TREATMENT", 312, 365]]], ["This is performed for a panel of hundreds of thousands of SNPs, selected such that they \"tag\" each linkage disequilibrium (LD) block across the genome at least once.", [["a panel", "TEST", 22, 29], ["SNPs", "TREATMENT", 58, 62], ["each linkage disequilibrium (LD) block", "PROBLEM", 94, 132]]], ["Due to the LD structure of the genome, each identified variant will have hundreds to thousands of other variants in its proximity that are also significantly associated with the trait.", [["genome", "CELLULAR_COMPONENT", 31, 37], ["genome", "OBSERVATION", 31, 37]]], ["The first stumbling block when interpreting GWAS results is thus the identification of the causal variant responsible for the statistical association of the tagged SNP and the trait being studied.", [["SNP", "CHEMICAL", 164, 167], ["The first stumbling block", "PROBLEM", 0, 25], ["the tagged SNP", "TREATMENT", 153, 167]]], ["The identification of the variant that underlies the biological effect responsible for the statistical association with the disease is known as fine mapping (reviewed in [3] ).", [["the disease", "PROBLEM", 120, 131], ["disease", "OBSERVATION", 124, 131]]], ["This procedure is highly dependent on the quality of genotyped data used for the reference (relatively large LD blocks present in the European population were historically especially problematic [4] ), the size of the GWAS sample and the concordance of variant quality control across studies used [5] , with notable recent success by Mahajan et al. [6] and others [7, 8] .IntroductionEven with knowledge of the exact causal variant responsible for a GWAS hit, there is often significant difficulty in identifying its biological effect, particularly in the case of non-coding SNPs.", [["non-coding SNPs", "DNA", 564, 579], ["This procedure", "TREATMENT", 0, 14], ["relatively large LD blocks", "TREATMENT", 92, 118], ["the GWAS sample", "TEST", 214, 229], ["a GWAS hit", "PROBLEM", 448, 458], ["non-coding SNPs", "PROBLEM", 564, 579], ["highly", "OBSERVATION_MODIFIER", 18, 24], ["dependent", "OBSERVATION_MODIFIER", 25, 34], ["large", "OBSERVATION_MODIFIER", 103, 108], ["size", "OBSERVATION_MODIFIER", 206, 210], ["significant", "OBSERVATION_MODIFIER", 475, 486], ["difficulty", "OBSERVATION", 487, 497]]], ["In the catalogue of published GWAS,~95% of the~47,000 identified SNPs (as of April 2018) fall in non-coding regions of the genome, and are enriched in regulatory elements [9, 10] .", [["genome", "CELLULAR_COMPONENT", 123, 129], ["non-coding regions", "DNA", 97, 115], ["regulatory elements", "DNA", 151, 170], ["SNPs", "PROBLEM", 65, 69], ["genome", "ANATOMY", 123, 129]]], ["Historically, the most prevalent practice in the literature is to assign a non-coding variant's effect to the closest gene in terms of genomic distance.", [["a non-coding variant's effect", "PROBLEM", 73, 102]]], ["However, this approach neglects the three-dimensional structure of the genome, and fails to consider that many genes are subject to long-range regulation by enhancers up to a megabase away from their transcription start site, discussed in more detail in Box 1.", [["Box 1", "GENE_OR_GENE_PRODUCT", 254, 259], ["enhancers", "DNA", 157, 166], ["transcription start site", "DNA", 200, 224], ["Box 1", "DNA", 254, 259]]], ["This is often the case for developmental genes such as SHH [11] , MYC [12] and SOX9 [13] , many of which are relevant to neuropsychiatric disorders.", [["neuropsychiatric disorders", "DISEASE", 121, 147], ["SHH [11]", "GENE_OR_GENE_PRODUCT", 55, 63], ["MYC [12]", "GENE_OR_GENE_PRODUCT", 66, 74], ["SOX9", "GENE_OR_GENE_PRODUCT", 79, 83], ["developmental genes", "DNA", 27, 46], ["SHH [11]", "DNA", 55, 63], ["MYC [12]", "DNA", 66, 74], ["SOX9", "DNA", 79, 83], ["neuropsychiatric disorders", "PROBLEM", 121, 147]]], ["In each of these cases enhancers loop over large genomic distances to contact the promoter of their target gene, even in the presence of intervening genes (Fig. 1a) .", [["enhancers", "DNA", 23, 32], ["promoter", "DNA", 82, 90], ["target gene", "DNA", 100, 111], ["intervening genes", "DNA", 137, 154], ["loop", "OBSERVATION_MODIFIER", 33, 37], ["large", "OBSERVATION_MODIFIER", 43, 48], ["genomic distances", "OBSERVATION", 49, 66]]], ["Thus, assigning SNPs that are part of regulatory elements to the genes nearest to their loci means their more distant targets may be missed and the wrong genes can end up being investigated for disease mechanism.", [["SNPs", "DNA", 16, 20], ["regulatory elements", "DNA", 38, 57], ["SNPs", "TREATMENT", 16, 20], ["disease mechanism", "PROBLEM", 194, 211]]], ["These long-range regulatory elements are often grouped together on chromosomes in arrays known as genomic regulatory blocks (GRBs) [14] [15] [16] .", [["chromosomes", "ANATOMY", 67, 78], ["chromosomes", "CELLULAR_COMPONENT", 67, 78], ["long-range regulatory elements", "DNA", 6, 36], ["chromosomes", "DNA", 67, 78], ["These long-range regulatory elements", "PROBLEM", 0, 36], ["genomic regulatory blocks", "PROBLEM", 98, 123]]], ["GRBs have particular characteristics that can be used to identify them and their targets (see Box 1 for more details).IntroductionRagvin et al. have applied the GRB model to successfully determine the regulatory targets of non-coding SNPs associated with type 2 diabetes and obesity [17] .", [["type 2 diabetes", "DISEASE", 255, 270], ["obesity", "DISEASE", 275, 282], ["non-coding SNPs", "DNA", 223, 238], ["the GRB model", "TREATMENT", 157, 170], ["non-coding SNPs", "PROBLEM", 223, 238], ["type 2 diabetes", "PROBLEM", 255, 270], ["obesity", "PROBLEM", 275, 282]]], ["For example, they re-examined an SNP initially linked to the FTO gene.", [["SNP", "CHEMICAL", 33, 36], ["FTO", "GENE_OR_GENE_PRODUCT", 61, 64], ["FTO gene", "DNA", 61, 69], ["an SNP", "TREATMENT", 30, 36]]], ["Using the extent of non-coding conservation and the GRB boundaries between humans and zebrafish, the authors were able to predict the correct regulatory targets of conserved non-coding elements (CNEs) spanning the GWAS implicated LD blocks for three loci, leading to predictions that the SNP in the FTO region disrupted a conserved motif regulating IRX3 (Fig. 1) .", [["SNP", "CHEMICAL", 288, 291], ["humans", "ORGANISM", 75, 81], ["zebrafish", "ORGANISM", 86, 95], ["FTO", "GENE_OR_GENE_PRODUCT", 299, 302], ["IRX3", "GENE_OR_GENE_PRODUCT", 349, 353], ["GRB boundaries", "DNA", 52, 66], ["regulatory targets", "DNA", 142, 160], ["conserved non-coding elements", "DNA", 164, 193], ["CNEs", "DNA", 195, 199], ["GWAS", "DNA", 214, 218], ["LD", "DNA", 230, 232], ["FTO region", "DNA", 299, 309], ["IRX3", "DNA", 349, 353], ["humans", "SPECIES", 75, 81], ["zebrafish", "SPECIES", 86, 95], ["humans", "SPECIES", 75, 81], ["non-coding conservation", "TREATMENT", 20, 43], ["LD blocks", "TREATMENT", 230, 239], ["the SNP in the FTO region", "TREATMENT", 284, 309], ["a conserved motif regulating IRX3", "TREATMENT", 320, 353], ["non-coding conservation", "OBSERVATION", 20, 43]]], ["These predictions were validated by transgenic reporter assays and implicated Box 1 Some of the best known examples of regulatory elements acting on genes across extreme distances include key developmental genes such as SHH [11] , MYC [12] and SOX9 [13] (Fig. 1a) .", [["Box 1", "GENE_OR_GENE_PRODUCT", 78, 83], ["SHH [11]", "GENE_OR_GENE_PRODUCT", 220, 228], ["MYC [12]", "GENE_OR_GENE_PRODUCT", 231, 239], ["SOX9", "GENE_OR_GENE_PRODUCT", 244, 248], ["Fig. 1a", "GENE_OR_GENE_PRODUCT", 255, 262], ["Box 1", "DNA", 78, 83], ["regulatory elements", "DNA", 119, 138], ["developmental genes", "DNA", 192, 211], ["SHH", "DNA", 220, 223], ["MYC [12]", "DNA", 231, 239], ["SOX9", "DNA", 244, 248]]], ["Each of these cases serves to illustrate that enhancers can loop over large genomic distances to contact the promoter of their target gene, even in the presence of intervening genes.", [["enhancers", "DNA", 46, 55], ["promoter", "DNA", 109, 117], ["target gene", "DNA", 127, 138], ["intervening genes", "DNA", 164, 181]]], ["In many cases the regulatory regions of genes under the control of long-range regulation coincide with clusters of extreme non-coding conservation [17] .", [["regulatory regions", "DNA", 18, 36], ["extreme non-coding conservation", "TREATMENT", 115, 146]]], ["These conserved non-coding elements (CNEs) are long stretches of non-coding DNA, which are deeply conserved in vertebrates [68] [69] [70] and function as enhancer elements, driving complex spatiotemporal gene expression patterns [70] [71] [72] .", [["DNA", "CELLULAR_COMPONENT", 76, 79], ["conserved non-coding elements", "DNA", 6, 35], ["CNEs", "DNA", 37, 41], ["non-coding DNA", "DNA", 65, 79], ["enhancer elements", "DNA", 154, 171], ["long stretches of non-coding DNA", "PROBLEM", 47, 79], ["non-coding elements", "OBSERVATION", 16, 35], ["non-coding DNA", "OBSERVATION", 65, 79]]], ["The requirement for regulatory elements to remain in cis with the gene that they regulate [73] has constrained the organization of the genome, resulting in long syntenic arrays of CNEs clustered around genes involved in the regulation of development [14, 15, 69] .", [["genome", "CELLULAR_COMPONENT", 135, 141], ["regulatory elements", "DNA", 20, 39], ["long syntenic arrays", "DNA", 156, 176], ["CNEs", "DNA", 180, 184], ["long syntenic arrays of CNEs", "TREATMENT", 156, 184]]], ["These syntenic arrays, known as genomic regulatory blocks (GRBs), can be used to delimit the boundaries beyond which it is unlikely a non-coding SNP may have an effect on gene expression (Fig. 1b) .", [["SNP", "CHEMICAL", 145, 148], ["syntenic arrays", "DNA", 6, 21], ["genomic regulatory blocks", "DNA", 32, 57], ["GRBs", "DNA", 59, 63], ["non-coding SNP", "DNA", 134, 148], ["These syntenic arrays", "TREATMENT", 0, 21], ["a non-coding SNP", "TREATMENT", 132, 148]]], ["Furthermore, each GRB tends to target a single gene or a few related genes, distinguishable from bystander genes in promoter structure, specific patterns of epigenetic modifications, tissue specificity and range of biological functions [16] (Fig. 1c) .", [["tissue", "ANATOMY", 183, 189], ["GRB", "GENE_OR_GENE_PRODUCT", 18, 21], ["tissue", "TISSUE", 183, 189], ["GRB", "DNA", 18, 21], ["bystander genes", "DNA", 97, 112], ["epigenetic modifications", "PROBLEM", 157, 181], ["tissue specificity", "TEST", 183, 201]]], ["Since the original detection of GRBs and the specific features of their target genes [16] , a more robust, fully automated method for GRB and target gene prediction has been developed (Tan and Lenhard, in preparation, and Supplementary Methods).", [["GRBs", "GENE_OR_GENE_PRODUCT", 32, 36], ["GRBs", "DNA", 32, 36], ["target genes", "DNA", 72, 84], ["GRB", "DNA", 134, 137], ["GRBs", "PROBLEM", 32, 36], ["GRB", "PROBLEM", 134, 137], ["target gene prediction", "PROBLEM", 142, 164]]], ["Briefly, GRBs are detected as clusters of conserved synteny occurring at a higher rate than expected for the two genomes compared (here: human vs. mouse), excluding those GRBs that do not overlap a protein-coding gene.", [["GRBs", "GENE_OR_GENE_PRODUCT", 9, 13], ["human", "ORGANISM", 137, 142], ["mouse", "ORGANISM", 147, 152], ["GRBs", "GENE_OR_GENE_PRODUCT", 171, 175], ["GRBs", "DNA", 9, 13], ["protein-coding gene", "DNA", 198, 217], ["human", "SPECIES", 137, 142], ["mouse", "SPECIES", 147, 152], ["human", "SPECIES", 137, 142], ["mouse", "SPECIES", 147, 152], ["GRBs", "PROBLEM", 9, 13]]], ["A total of 1072 genomic regulatory blocks have been detected in this manner, spanning between 28 kb and 5.35 Mb in length (mean 882 kb).", [["1072 genomic regulatory blocks", "DNA", 11, 41], ["genomic regulatory blocks", "TREATMENT", 16, 41], ["Mb in length", "TEST", 109, 121]]], ["Next, all genes in GRBs are given a target prediction value, based on a random forest model trained on a set of target genes from Akalin et al., using a range of features that are the strongest indicators of genes amenable to long-range regulation, i.e. length of CpG islands, gene entropy and CNE density (for more details, check Supplementary Methods).", [["CpG", "CHEMICAL", 264, 267], ["GRBs", "GENE_OR_GENE_PRODUCT", 19, 23], ["GRBs", "DNA", 19, 23], ["target genes", "DNA", 112, 124], ["CpG islands", "DNA", 264, 275], ["CNE", "DNA", 294, 297], ["long-range regulation", "TREATMENT", 226, 247], ["CpG islands", "PROBLEM", 264, 275]]], ["Using a simple cut-off on the score that has been normalised within each GRB, all genes spanning a GRB are then classified either as bystanders or targets.", [["GRB", "GENE_OR_GENE_PRODUCT", 99, 102], ["GRB", "DNA", 73, 76], ["GRB", "DNA", 99, 102], ["normalised", "OBSERVATION", 50, 60]]], ["Several GWAS detected disease-associated variants within introns of bystanders in GRBs, where the disease phenotype fitted well with loss of function of the target gene, were reviewed by Becker and Rinkwitz [74] , and references therein), arguing for these non-coding variants being involved in regulation of the GRB target genes.", [["GRB", "GENE_OR_GENE_PRODUCT", 313, 316], ["introns", "DNA", 57, 64], ["GRBs", "DNA", 82, 86], ["target gene", "DNA", 157, 168], ["GRB target genes", "DNA", 313, 329], ["Several GWAS detected disease", "PROBLEM", 0, 29], ["associated variants", "PROBLEM", 30, 49], ["bystanders in GRBs", "PROBLEM", 68, 86], ["the disease phenotype", "PROBLEM", 94, 115], ["these non-coding variants", "PROBLEM", 251, 276], ["disease", "OBSERVATION", 22, 29], ["disease", "OBSERVATION", 98, 105]]], ["In particular, they provide the GRB context for the intronic SNPs in ELP4 (a bystander gene, a target is PAX6) linked to aniridia; SNPs in the bystander LMBR (with target SHH a megabase away) causing preaxial polydactyly; again SOX4 being targeted by intronic SNPs in CDKAL1 and IRX3 being targeted by SNPs in introns of the FTO, both associated with type 2 diabetes; and implicate intergenic SNPs between two bystanders to be misregulating MEIS2, ultimately leading to myopia.", [["aniridia", "DISEASE", 121, 129], ["preaxial polydactyly", "DISEASE", 200, 220], ["type 2 diabetes", "DISEASE", 351, 366], ["myopia", "DISEASE", 470, 476], ["ELP4", "GENE_OR_GENE_PRODUCT", 69, 73], ["PAX6", "GENE_OR_GENE_PRODUCT", 105, 109], ["LMBR", "GENE_OR_GENE_PRODUCT", 153, 157], ["SHH", "GENE_OR_GENE_PRODUCT", 171, 174], ["SOX4", "GENE_OR_GENE_PRODUCT", 228, 232], ["CDKAL1", "GENE_OR_GENE_PRODUCT", 268, 274], ["IRX3", "GENE_OR_GENE_PRODUCT", 279, 283], ["FTO", "GENE_OR_GENE_PRODUCT", 325, 328], ["MEIS2", "GENE_OR_GENE_PRODUCT", 441, 446], ["intronic SNPs", "DNA", 52, 65], ["ELP4", "DNA", 69, 73], ["bystander gene", "DNA", 77, 91], ["PAX6", "DNA", 105, 109], ["bystander LMBR", "DNA", 143, 157], ["SHH", "DNA", 171, 174], ["SOX4", "DNA", 228, 232], ["intronic SNPs", "DNA", 251, 264], ["CDKAL1", "DNA", 268, 274], ["IRX3", "DNA", 279, 283], ["SNPs", "DNA", 302, 306], ["introns", "DNA", 310, 317], ["FTO", "DNA", 325, 328], ["intergenic SNPs", "DNA", 382, 397], ["MEIS2", "PROTEIN", 441, 446], ["the intronic SNPs", "PROBLEM", 48, 65], ["aniridia", "PROBLEM", 121, 129], ["SNPs", "TREATMENT", 131, 135], ["preaxial polydactyly", "PROBLEM", 200, 220], ["again SOX4", "PROBLEM", 222, 232], ["intronic SNPs in CDKAL1", "TREATMENT", 251, 274], ["IRX3", "TREATMENT", 279, 283], ["type 2 diabetes", "PROBLEM", 351, 366], ["intergenic SNPs", "PROBLEM", 382, 397], ["MEIS2", "TREATMENT", 441, 446], ["myopia", "PROBLEM", 470, 476], ["preaxial polydactyly", "OBSERVATION", 200, 220], ["diabetes", "OBSERVATION", 358, 366], ["myopia", "OBSERVATION", 470, 476]]], ["1 Long-range gene regulation. a An enhancer can target a gene over large genomic distances. b A genomic regulatory block (GRB) spanning a 1.9 Mb region of the human genome.", [["human", "ORGANISM", 159, 164], ["genomic regulatory block", "DNA", 96, 120], ["GRB", "DNA", 122, 125], ["1.9 Mb region", "DNA", 138, 151], ["human genome", "DNA", 159, 171], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["A genomic regulatory block (GRB)", "PROBLEM", 94, 126], ["large", "OBSERVATION_MODIFIER", 67, 72], ["genomic distances", "OBSERVATION", 73, 90], ["regulatory block", "OBSERVATION", 104, 120], ["1.9 Mb", "OBSERVATION_MODIFIER", 138, 144], ["human genome", "OBSERVATION", 159, 171]]], ["This region displays high levels of non-coding conservation between the human and four vertebrate genomes, reflecting evolution over~435 million years.", [["human", "ORGANISM", 72, 77], ["human and four vertebrate genomes", "DNA", 72, 105], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["high", "OBSERVATION_MODIFIER", 21, 25], ["levels", "OBSERVATION_MODIFIER", 26, 32], ["non-coding conservation", "OBSERVATION", 36, 59], ["human", "ANATOMY", 72, 77], ["four", "OBSERVATION_MODIFIER", 82, 86], ["vertebrate genomes", "OBSERVATION", 87, 105], ["evolution", "OBSERVATION_MODIFIER", 118, 127]]], ["The non-coding conservation peaks around IRX3, the predicted target gene in this GRB.", [["IRX3", "GENE_OR_GENE_PRODUCT", 41, 45], ["GRB", "CANCER", 81, 84], ["IRX3", "DNA", 41, 45], ["predicted target gene", "DNA", 51, 72], ["GRB", "DNA", 81, 84], ["The non-coding conservation peaks", "PROBLEM", 0, 33], ["conservation", "OBSERVATION_MODIFIER", 15, 27], ["peaks", "OBSERVATION_MODIFIER", 28, 33]]], ["The black vertical line and blue rectangle mark the genomic position of the obesity-associated SNPs (rs1421085 and rs9939609) from the Ragvin et al. study, and the linkage disequilibrium block around it, respectively.", [["obesity", "DISEASE", 76, 83], ["obesity-associated SNPs", "DNA", 76, 99], ["The black vertical line and blue rectangle", "TREATMENT", 0, 42], ["the obesity", "PROBLEM", 72, 83], ["study", "TEST", 149, 154], ["the linkage disequilibrium block", "PROBLEM", 160, 192], ["black", "OBSERVATION_MODIFIER", 4, 9], ["vertical line", "OBSERVATION", 10, 23], ["blue rectangle", "OBSERVATION", 28, 42], ["genomic", "OBSERVATION_MODIFIER", 52, 59], ["position", "OBSERVATION_MODIFIER", 60, 68], ["obesity", "OBSERVATION", 76, 83], ["disequilibrium", "OBSERVATION_MODIFIER", 172, 186], ["block", "OBSERVATION_MODIFIER", 187, 192]]], ["Each SNP falls within an enhancer that is capable of activating the expression of the IRX3 gene, shown in red. c The GRB model: conserved non-coding elements (shown in green) within a GRB contact the target gene's promoter (shown in red) through looping and regulate its transcriptional activity in multiple contexts.", [["SNP", "CHEMICAL", 5, 8], ["IRX3", "GENE_OR_GENE_PRODUCT", 86, 90], ["GRB", "GENE_OR_GENE_PRODUCT", 184, 187], ["IRX3 gene", "DNA", 86, 95], ["GRB model", "DNA", 117, 126], ["conserved non-coding elements", "DNA", 128, 157], ["GRB", "DNA", 184, 187], ["target gene's promoter", "DNA", 200, 222], ["Each SNP falls", "PROBLEM", 0, 14], ["The GRB model", "TEST", 113, 126], ["falls", "OBSERVATION", 9, 14], ["red", "OBSERVATION", 106, 109], ["GRB model", "OBSERVATION", 117, 126], ["non-coding elements", "OBSERVATION", 138, 157], ["transcriptional activity", "OBSERVATION", 271, 295]]], ["SNPs in the linkage disequilibrium with regulatory elements involved in long-range gene regulation are often erroneously assigned to the nearest bystander gene, associating the wrong gene to the disease phenotype IRX3 in the development of type 2 diabetes and obesity for the first time.", [["type 2 diabetes", "DISEASE", 240, 255], ["obesity", "DISEASE", 260, 267], ["IRX3", "GENE_OR_GENE_PRODUCT", 213, 217], ["regulatory elements", "DNA", 40, 59], ["long-range gene", "DNA", 72, 87], ["nearest bystander gene", "DNA", 137, 159], ["IRX3", "PROTEIN", 213, 217], ["SNPs in the linkage disequilibrium", "PROBLEM", 0, 34], ["long-range gene regulation", "TREATMENT", 72, 98], ["type 2 diabetes", "PROBLEM", 240, 255], ["obesity", "PROBLEM", 260, 267], ["diabetes", "OBSERVATION", 247, 255], ["obesity", "OBSERVATION", 260, 267]]], ["The mechanism underlying the link between IRX3 and these conditions was since established using both 4-C and CRISPR-Cas9 based methods, which showed that the SNP in the FTO region de-repressed IRX3 expression, leading to altered energy metabolism and increased lipid storage [18, 19] .", [["SNP", "CHEMICAL", 158, 161], ["SNP", "CHEMICAL", 158, 161], ["IRX3", "GENE_OR_GENE_PRODUCT", 42, 46], ["4-C", "SIMPLE_CHEMICAL", 101, 104], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 109, 120], ["FTO", "GENE_OR_GENE_PRODUCT", 169, 172], ["IRX3", "GENE_OR_GENE_PRODUCT", 193, 197], ["lipid", "SIMPLE_CHEMICAL", 261, 266], ["IRX3", "PROTEIN", 42, 46], ["CRISPR", "DNA", 109, 115], ["Cas9", "DNA", 116, 120], ["FTO region", "DNA", 169, 179], ["IRX3", "PROTEIN", 193, 197], ["the SNP in the FTO region", "TREATMENT", 154, 179], ["altered energy metabolism", "PROBLEM", 221, 246], ["increased lipid storage", "PROBLEM", 251, 274], ["altered", "OBSERVATION_MODIFIER", 221, 228], ["energy metabolism", "OBSERVATION", 229, 246], ["increased", "OBSERVATION_MODIFIER", 251, 260], ["lipid storage", "OBSERVATION", 261, 274]]], ["This illustrates the potential value of the GRB model in identifying the targets of non-coding SNPs found to be associated with a disorder in a GWAS.IntroductionRecently, the complexity of the gene regulation has become more broadly appreciated [20, 21] , and there have been efforts to look beyond the closest gene and at the broader genomic context of the locus to identify the target gene affected by the variant [8, [22] [23] [24] .", [["locus", "CELLULAR_COMPONENT", 358, 363], ["non-coding SNPs", "DNA", 84, 99], ["non-coding SNPs", "PROBLEM", 84, 99], ["a disorder", "PROBLEM", 128, 138]]], ["They potentially affected genomic region around the SNP encompassing all genes to be tested for the effect is generally defined in two main ways: (i) by setting a fixed distance around every SNP [24] [25] [26] , typically 0.5-1 Mb (in extreme case 2 Mb) region upstream and downstream of the disease-associated variant, or (ii) using topologically associated domains (TADs), which are based on prior chromatin interaction experiments [27] .", [["chromatin", "ANATOMY", 400, 409], ["SNP", "CHEMICAL", 52, 55], ["SNP", "CHEMICAL", 191, 194], ["SNP", "CHEMICAL", 191, 194], ["chromatin", "CELLULAR_COMPONENT", 400, 409], ["genomic region", "DNA", 26, 40], ["TADs", "DNA", 368, 372], ["chromatin", "DNA", 400, 409], ["a fixed distance around every SNP", "TREATMENT", 161, 194], ["the disease-associated variant", "PROBLEM", 288, 318], ["topologically associated domains (TADs)", "PROBLEM", 334, 373], ["disease", "OBSERVATION", 292, 299]]], ["The former approach uses no additional information, therefore making no assumption on which locus is likely to be involved in long-range genomic interactions and thus considers all genes within a set distance around every locus.", [["locus", "CELLULAR_COMPONENT", 222, 227], ["likely to be", "UNCERTAINTY", 101, 113]]], ["The search space for the target gene(s) is consequently large, which increases the information load and the potential for false positives or negatives.", [["target gene", "DNA", 25, 36], ["false positives", "PROBLEM", 122, 137], ["large", "OBSERVATION_MODIFIER", 56, 61]]], ["In contrast, the second approach uses experimentally determined topologically associated domains to define the search space, based on the functional assumption that interactions between an enhancer and a promoter do not cross TAD boundaries.", [["enhancer", "DNA", 189, 197], ["promoter", "DNA", 204, 212], ["TAD", "PROTEIN", 226, 229]]], ["However, this approach will still evaluate every enhancer-promoter pair as equally plausible, while the GRB model approach identifies the most likely target gene of the long-range regulation in every block.IntroductionTADs are units of 3D genome structure that are megabase-sized in mammalian genomes, and mostly invariant across cell types and to a large extent across species [28] .", [["cell", "ANATOMY", 330, 334], ["cell", "CELL", 330, 334], ["mammalian genomes", "DNA", 283, 300], ["the GRB model approach", "TREATMENT", 100, 122], ["3D genome structure", "TREATMENT", 236, 255], ["megabase-sized in mammalian genomes", "PROBLEM", 265, 300], ["a large extent across species", "PROBLEM", 348, 377], ["megabase", "OBSERVATION_MODIFIER", 265, 273], ["sized", "OBSERVATION_MODIFIER", 274, 279], ["mammalian genomes", "OBSERVATION", 283, 300], ["mostly", "OBSERVATION_MODIFIER", 306, 312], ["invariant", "OBSERVATION_MODIFIER", 313, 322], ["across cell types", "OBSERVATION", 323, 340], ["large", "OBSERVATION_MODIFIER", 350, 355], ["extent", "OBSERVATION_MODIFIER", 356, 362]]], ["TADs delineate regions that preferentially interact with themselves over other regions of the genome; in other words, the vast majority of genomic interactions start and end within the same TAD.", [["TADs", "SIMPLE_CHEMICAL", 0, 4], ["TAD", "GENE_OR_GENE_PRODUCT", 190, 193], ["TADs", "PROTEIN", 0, 4], ["TAD", "PROTEIN", 190, 193], ["TADs delineate regions", "PROBLEM", 0, 22]]], ["Recently, several cases where the disruption of TADs results in the emergence of disease phenotypes have been identified.", [["TADs", "DISEASE", 48, 52], ["TADs", "GENE_OR_GENE_PRODUCT", 48, 52], ["the disruption of TADs", "PROBLEM", 30, 52], ["disease phenotypes", "PROBLEM", 81, 99]]], ["For example, disruption of TADs has been shown to be responsible for introducing de novo enhancer-promoter interactions, resulting in the mis-regulation of gene expression during limb development [29] , for erroneous activation of protooncogenes causing acute lymphoblastic leukaemia [30] and finally TAD data in the developing brain shed new light on the neurodevelopmental disorders [27] .IntroductionIn addition, a large effort has been made to map the interactions between active promoters and the rest of the genome in many tissues and cell types, for example revealing tissue-specific aspects of genome architecture in hematopoiesis [31] .", [["limb", "ANATOMY", 179, 183], ["acute lymphoblastic leukaemia", "ANATOMY", 254, 283], ["brain", "ANATOMY", 328, 333], ["tissues", "ANATOMY", 529, 536], ["cell", "ANATOMY", 541, 545], ["tissue", "ANATOMY", 575, 581], ["TADs", "CHEMICAL", 27, 31], ["acute lymphoblastic leukaemia", "DISEASE", 254, 283], ["neurodevelopmental disorders", "DISEASE", 356, 384], ["TADs", "GENE_OR_GENE_PRODUCT", 27, 31], ["limb", "ORGANISM_SUBDIVISION", 179, 183], ["acute lymphoblastic leukaemia", "CANCER", 254, 283], ["brain", "ORGAN", 328, 333], ["tissues", "TISSUE", 529, 536], ["cell", "CELL", 541, 545], ["tissue", "TISSUE", 575, 581], ["TADs", "PROTEIN", 27, 31], ["protooncogenes", "DNA", 231, 245], ["TAD", "PROTEIN", 301, 304], ["promoters", "DNA", 484, 493], ["disruption of TADs", "PROBLEM", 13, 31], ["erroneous activation of protooncogenes", "PROBLEM", 207, 245], ["acute lymphoblastic leukaemia", "PROBLEM", 254, 283], ["finally TAD data", "PROBLEM", 293, 309], ["the neurodevelopmental disorders", "PROBLEM", 352, 384], ["active promoters", "TREATMENT", 477, 493], ["genome architecture in hematopoiesis", "PROBLEM", 602, 638], ["acute", "OBSERVATION_MODIFIER", 254, 259], ["lymphoblastic leukaemia", "OBSERVATION", 260, 283], ["brain", "ANATOMY", 328, 333], ["new", "OBSERVATION_MODIFIER", 339, 342], ["large", "OBSERVATION_MODIFIER", 418, 423], ["cell types", "OBSERVATION", 541, 551], ["genome architecture", "OBSERVATION", 602, 621], ["hematopoiesis", "OBSERVATION", 625, 638]]], ["However, TAD identification from Hi-C data both necessitates a significant amount of starting material, which is often not available for neuropsychiatric disorders due to limited availability of biological material from human brains, and incurs large sequencing costs due to the depth required to sufficiently cover the spatiotemporal complexity of gene regulation, especially in human genome.IntroductionIt has been recently shown that most TADs correlate well with the span of GRBs: the boundaries of TADs are well predicted by the boundaries of high density of conserved non-coding elements in GRBs, arguing that these are two manifestations of the same underlying regulatory phenomenon [32] .", [["brains", "ANATOMY", 226, 232], ["neuropsychiatric disorders", "DISEASE", 137, 163], ["human", "ORGANISM", 220, 225], ["brains", "DEVELOPING_ANATOMICAL_STRUCTURE", 226, 232], ["human", "ORGANISM", 380, 385], ["TADs", "GENE_OR_GENE_PRODUCT", 442, 446], ["GRBs", "GENE_OR_GENE_PRODUCT", 479, 483], ["TADs", "GENE_OR_GENE_PRODUCT", 503, 507], ["GRBs", "PATHOLOGICAL_FORMATION", 597, 601], ["TAD", "PROTEIN", 9, 12], ["human genome", "DNA", 380, 392], ["TADs", "PROTEIN", 442, 446], ["GRBs", "PROTEIN", 479, 483], ["TADs", "PROTEIN", 503, 507], ["conserved non-coding elements", "DNA", 564, 593], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 380, 385], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 380, 385], ["TAD identification", "TEST", 9, 27], ["Hi-C data", "TEST", 33, 42], ["neuropsychiatric disorders", "PROBLEM", 137, 163], ["large sequencing costs", "PROBLEM", 245, 267], ["the depth", "PROBLEM", 275, 284], ["conserved non-coding elements in GRBs", "PROBLEM", 564, 601], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["amount", "OBSERVATION_MODIFIER", 75, 81], ["human genome", "OBSERVATION", 380, 392], ["high density", "OBSERVATION_MODIFIER", 548, 560], ["non-coding elements", "OBSERVATION", 574, 593]]], ["Thus, the GRB approach discussed above could also help identify gene targets linked to the structural organisation of the genome without the material requirements or costs of Hi-C.", [["GRB", "DNA", 10, 13], ["the GRB approach", "TREATMENT", 6, 22]]], ["An additional advantage of the GRB model is the ability to provide a tissue-invariant classification value of how likely the gene is to be subjected to longrange regulation for all the genes found within the GRB, thus significantly narrowing the search space for targets of SNPs involved in long-range regulation.IntroductionIn the next section, we illustrate the potential use of the GRB approach combined with functional enhancer activity and gene expression data to inform the interpretation of genetic association studies using the example of schizophrenia.Application of the GRB model sheds new light on schizophrenia-associated lociSchizophrenia is a severe mental disorder that is among the leading causes of global disease burden, with a lifetime prevalence of 0.7% [33] [34] [35] .", [["tissue", "ANATOMY", 69, 75], ["schizophrenia", "DISEASE", 547, 560], ["schizophrenia", "DISEASE", 609, 622], ["lociSchizophrenia", "DISEASE", 634, 651], ["mental disorder", "DISEASE", 664, 679], ["tissue", "TISSUE", 69, 75], ["GRB", "GENE_OR_GENE_PRODUCT", 208, 211], ["GRB", "DNA", 208, 211], ["SNPs", "DNA", 274, 278], ["the GRB model", "TEST", 27, 40], ["significantly narrowing the search space", "PROBLEM", 218, 258], ["SNPs", "TREATMENT", 274, 278], ["the GRB approach", "TREATMENT", 381, 397], ["genetic association studies", "TEST", 498, 525], ["schizophrenia", "PROBLEM", 547, 560], ["schizophrenia", "PROBLEM", 609, 622], ["lociSchizophrenia", "PROBLEM", 634, 651], ["a severe mental disorder", "PROBLEM", 655, 679], ["global disease burden", "PROBLEM", 716, 737], ["GRB", "ANATOMY", 208, 211], ["narrowing", "OBSERVATION", 232, 241], ["schizophrenia", "OBSERVATION", 547, 560], ["severe", "OBSERVATION_MODIFIER", 657, 663], ["mental disorder", "OBSERVATION", 664, 679], ["global", "OBSERVATION_MODIFIER", 716, 722], ["disease", "OBSERVATION", 723, 730]]], ["It is a highly heritable neurodevelopmental disorder, but its genetic basis remains elusive [36] [37] [38] [39] .", [["neurodevelopmental disorder", "DISEASE", 25, 52], ["[36] [37] [38] [39]", "SIMPLE_CHEMICAL", 92, 111], ["a highly heritable neurodevelopmental disorder", "PROBLEM", 6, 52], ["highly heritable", "OBSERVATION_MODIFIER", 8, 24], ["neurodevelopmental disorder", "OBSERVATION", 25, 52]]], ["It is thought to be caused by the complex interaction between inherited genetic predisposition and environmental risk factors [39] [40] [41] ; see Box 2 for a discussion on heritability estimates and detectable proportion.", [["inherited genetic predisposition", "DISEASE", 62, 94], ["inherited genetic predisposition", "PROBLEM", 62, 94], ["environmental risk factors", "PROBLEM", 99, 125], ["thought to be", "UNCERTAINTY", 6, 19]]], ["In 2014, Schizophrenia Working Group of the Psychiatric Genomics Consortium performed a large multi-stage schizophrenia GWAS of 36,989 cases and 113,075 controls [42] , further referred to as the PGC GWAS dataset.", [["Schizophrenia", "DISEASE", 9, 22], ["schizophrenia", "DISEASE", 106, 119], ["PGC GWAS dataset", "DNA", 196, 212], ["Schizophrenia", "PROBLEM", 9, 22], ["a large multi-stage schizophrenia GWAS", "PROBLEM", 86, 124], ["large", "OBSERVATION_MODIFIER", 88, 93]]], ["One hundred twenty-eight SNPs statistically associated with schizophrenia were identified.", [["schizophrenia", "DISEASE", 60, 73], ["schizophrenia", "PROBLEM", 60, 73], ["schizophrenia", "OBSERVATION", 60, 73]]], ["These 128 SNPs were then merged based on LD resulting in 108 loci, 83 of which had never been implicated in schizophrenia before.", [["schizophrenia", "DISEASE", 108, 121], ["These 128 SNPs", "TEST", 0, 14], ["schizophrenia", "PROBLEM", 108, 121], ["schizophrenia", "OBSERVATION", 108, 121]]], ["Possible targets for the non-coding SNPs were then assigned to the closest gene, or all genes that fell within a locus.", [["non-coding SNPs", "DNA", 25, 40], ["the non-coding SNPs", "PROBLEM", 21, 40]]], ["This set of loci provides the ideal dataset to illustrate the potential of the GRB model to provide further insights into variants in non-coding regions.Application of the GRB model sheds new light on schizophrenia-associated lociWe identified GRBs based on conserved synteny between human and mouse and overlapped these GRBs with the 108 schizophrenia-associated loci identified by the PGC.", [["schizophrenia", "DISEASE", 201, 214], ["schizophrenia", "DISEASE", 339, 352], ["human", "ORGANISM", 284, 289], ["mouse", "ORGANISM", 294, 299], ["GRBs", "GENE_OR_GENE_PRODUCT", 321, 325], ["non-coding regions", "DNA", 134, 152], ["lociWe", "DNA", 226, 232], ["GRBs", "DNA", 244, 248], ["GRBs", "DNA", 321, 325], ["108 schizophrenia-associated loci", "DNA", 335, 368], ["human", "SPECIES", 284, 289], ["mouse", "SPECIES", 294, 299], ["human", "SPECIES", 284, 289], ["mouse", "SPECIES", 294, 299], ["the GRB model", "TREATMENT", 75, 88], ["schizophrenia", "PROBLEM", 201, 214], ["GRBs", "PROBLEM", 244, 248], ["the 108 schizophrenia", "PROBLEM", 331, 352]]], ["In total 52 of the 108 loci overlapped a GRB, with four GRBs each overlapping two schizophrenia-associated loci.", [["schizophrenia", "DISEASE", 82, 95], ["GRB", "DNA", 41, 44], ["GRBs", "DNA", 56, 60], ["schizophrenia-associated loci", "DNA", 82, 111], ["a GRB", "PROBLEM", 39, 44], ["GRB", "OBSERVATION", 41, 44], ["overlapping", "OBSERVATION_MODIFIER", 66, 77], ["two", "OBSERVATION_MODIFIER", 78, 81], ["schizophrenia", "OBSERVATION", 82, 95], ["loci", "OBSERVATION_MODIFIER", 107, 111]]], ["For each locus, we compared the target genes proposed by the original GWAS with the target gene for that GRB.", [["target genes", "DNA", 32, 44], ["target gene", "DNA", 84, 95], ["GRB", "DNA", 105, 108]]], ["The aim was not to invalidate the gene list proposed in the PGC study, but rather to identify additional, potentially more plausible target genes for loci that are not trivial to interpret.", [["target genes", "DNA", 133, 145], ["the PGC study", "TEST", 56, 69]]], ["All 108 schizophrenia loci are summarised with regard to GRB overlap and GWAS-associated and GRBassociated target genes in Supplementary Table S1.", [["schizophrenia", "DISEASE", 8, 21], ["GRB", "GENE_OR_GENE_PRODUCT", 57, 60], ["GRB", "DNA", 57, 60], ["GWAS", "DNA", 73, 77], ["GRBassociated target genes", "DNA", 93, 119], ["All 108 schizophrenia loci", "PROBLEM", 0, 26], ["GRB overlap", "PROBLEM", 57, 68], ["GWAS", "TEST", 73, 77], ["GRBassociated target genes", "PROBLEM", 93, 119], ["schizophrenia loci", "OBSERVATION", 8, 26]]], ["In short, we found that our GRB-based approach pointed to at least one target gene originally mentioned in the PGC dataset for 25 schizophrenia-associated loci, while for the remaining 27 loci that overlapped GRBs an altogether different target was predicted (Table 1 ).", [["schizophrenia", "DISEASE", 130, 143], ["GRBs", "CANCER", 209, 213], ["GRB", "DNA", 28, 31], ["PGC dataset", "DNA", 111, 122], ["schizophrenia-associated loci", "DNA", 130, 159], ["GRBs", "DNA", 209, 213], ["our GRB", "TEST", 24, 31], ["25 schizophrenia", "PROBLEM", 127, 143]]], ["In total, our method predicts 120 genes to be under long-range regulation in GRBs overlapping schizophrenia-associated loci.Application of the GRB model sheds new light on schizophrenia-associated lociWe applied the same approach to the recent GWAS for autism and bipolar disorder, two other neuropsychiatric disorders with high heritability (Box 2).", [["schizophrenia", "DISEASE", 94, 107], ["schizophrenia", "DISEASE", 172, 185], ["autism", "DISEASE", 253, 259], ["bipolar disorder", "DISEASE", 264, 280], ["neuropsychiatric disorders", "DISEASE", 292, 318], ["GRBs", "GENE_OR_GENE_PRODUCT", 77, 81], ["120 genes", "DNA", 30, 39], ["GRBs overlapping schizophrenia-associated loci", "DNA", 77, 123], ["GRBs overlapping schizophrenia", "PROBLEM", 77, 107], ["schizophrenia", "PROBLEM", 172, 185], ["lociWe", "TREATMENT", 197, 203], ["autism and bipolar disorder", "PROBLEM", 253, 280], ["two other neuropsychiatric disorders", "PROBLEM", 282, 318], ["high heritability (Box", "PROBLEM", 324, 346], ["schizophrenia", "OBSERVATION", 94, 107], ["loci", "OBSERVATION_MODIFIER", 119, 123], ["bipolar disorder", "OBSERVATION", 264, 280]]], ["This analysis shows significant enrichment for the GWAS loci to overlap with GRBs in autism (p < 0.05) but not bipolar disorder (p > 0.9; Fig. 2b ).", [["autism", "DISEASE", 85, 91], ["bipolar disorder", "DISEASE", 111, 127], ["GWAS loci", "DNA", 51, 60], ["This analysis", "TEST", 0, 13], ["significant enrichment", "PROBLEM", 20, 42], ["the GWAS loci", "PROBLEM", 47, 60], ["GRBs in autism", "PROBLEM", 77, 91], ["bipolar disorder", "PROBLEM", 111, 127], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["enrichment", "OBSERVATION", 32, 42]]], ["In autism 82 of the 180 loci overlap a GRB, and the GRB-based analysis indicates different gene targets than those originally assigned for 61 of these loci (Fig. 2a) .", [["autism", "DISEASE", 3, 9], ["GRB", "DNA", 39, 42], ["GRB", "DNA", 52, 55], ["a GRB", "TEST", 37, 42], ["the GRB", "TEST", 48, 55]]], ["Thus, the GRB method could help identify novel gene targets from the GWAS studies of a number of neuropsychiatric disorders, although potentially not for bipolar disorder.Application of the GRB model sheds new light on schizophrenia-associated lociWhile both the vicinity of the non-coding SNP to a gene, and the GRB target gene prediction approach provide one or more putative genes through which a non-coding SNP may contribute to disease emergence, neither should be used as a definitive argument for the gene to be considered the SNP target.", [["neuropsychiatric disorders", "DISEASE", 97, 123], ["bipolar disorder", "DISEASE", 154, 170], ["schizophrenia", "DISEASE", 219, 232], ["SNP", "CHEMICAL", 290, 293], ["SNP", "CHEMICAL", 411, 414], ["SNP", "CHEMICAL", 534, 537], ["GRB", "GENE_OR_GENE_PRODUCT", 313, 316], ["GRB", "DNA", 10, 13], ["non-coding SNP", "DNA", 279, 293], ["GRB target gene", "DNA", 313, 328], ["non-coding SNP", "DNA", 400, 414], ["SNP target", "DNA", 534, 544], ["the GRB method", "TREATMENT", 6, 20], ["the GWAS studies", "TEST", 65, 81], ["neuropsychiatric disorders", "PROBLEM", 97, 123], ["bipolar disorder", "PROBLEM", 154, 170], ["the GRB model", "TREATMENT", 186, 199], ["schizophrenia", "PROBLEM", 219, 232], ["the non-coding SNP", "TREATMENT", 275, 293], ["a non-coding SNP", "TREATMENT", 398, 414], ["disease emergence", "PROBLEM", 433, 450], ["the SNP target", "TREATMENT", 530, 544]]], ["We appreciate that it would be informative to consider the effect of SNPs on all the genes within a GRB/ TAD, but since the experimental validation of each enhancer-promoter pair is prohibitively expensive in terms of experimental time and resources, it is useful to focus on the most likely targets first.", [["GRB", "GENE_OR_GENE_PRODUCT", 100, 103], ["GRB", "DNA", 100, 103], ["TAD", "DNA", 105, 108], ["enhancer-promoter pair", "DNA", 156, 178], ["SNPs", "TREATMENT", 69, 73], ["a GRB/ TAD", "TREATMENT", 98, 108]]], ["Thus, we include an additional metric of how responsive each of the candidate genes (GWAS-proposed genes and GRB target genes) is to the regulatory element(s) within disease-associated locus.", [["GRB", "GENE_OR_GENE_PRODUCT", 109, 112], ["locus", "CELLULAR_COMPONENT", 185, 190], ["candidate genes", "DNA", 68, 83], ["GWAS", "DNA", 85, 89], ["GRB target genes", "DNA", 109, 125], ["regulatory element", "DNA", 137, 155], ["disease-associated locus", "DNA", 166, 190], ["GWAS", "TEST", 85, 89]]], ["The FANTOM5 consortium produced cap analysis of gene expression data (CAGE) for over a thousand human tissues and cell lines, assaying the exact position and quantity of transcription across the genome.", [["tissues", "ANATOMY", 102, 109], ["cell lines", "ANATOMY", 114, 124], ["human", "ORGANISM", 96, 101], ["tissues", "TISSUE", 102, 109], ["cell lines", "CELL", 114, 124], ["genome", "CELLULAR_COMPONENT", 195, 201], ["FANTOM5 consortium", "DNA", 4, 22], ["cell lines", "CELL_LINE", 114, 124], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["cap analysis", "TEST", 32, 44], ["cell lines", "TREATMENT", 114, 124], ["cell lines", "OBSERVATION", 114, 124]]], ["The first advantage of this dataset that make it particularly amenable to investigating developmental aspects of schizophrenia is that unlike some of the recent schizophrenia-associated RNA-seq datasets (used in [23, 24] ) and the GTEx project [43] , FANTOM5 has transcriptional profiles of tissue, including neural tissue, from 75 foetal and newborn subjects.", [["tissue", "ANATOMY", 291, 297], ["neural tissue", "ANATOMY", 309, 322], ["foetal", "ANATOMY", 332, 338], ["schizophrenia", "DISEASE", 113, 126], ["schizophrenia", "DISEASE", 161, 174], ["FANTOM5", "GENE_OR_GENE_PRODUCT", 251, 258], ["tissue", "TISSUE", 291, 297], ["neural tissue", "TISSUE", 309, 322], ["foetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 332, 338], ["FANTOM5", "PROTEIN", 251, 258], ["schizophrenia", "PROBLEM", 113, 126], ["the recent schizophrenia", "PROBLEM", 150, 174], ["transcriptional profiles of tissue", "PROBLEM", 263, 297], ["neural tissue", "PROBLEM", 309, 322], ["neural tissue", "ANATOMY", 309, 322]]], ["Secondly, it was found that enhancers undergo non-productive transcription initiation in contexts in which they are active [44] , making it possible to capture the expression of a gene with the activity of all of the enhancers in its vicinity using a single CAGE experiment.", [["enhancers", "DNA", 28, 37], ["enhancers", "DNA", 217, 226], ["non-productive transcription initiation", "TREATMENT", 46, 85], ["a single CAGE experiment", "TREATMENT", 249, 273], ["active", "OBSERVATION_MODIFIER", 116, 122]]], ["For each GRB, we identify those genes whose Box 2 Neurodevelopmental disorders like schizophrenia, autism and bipolar disorder display high heritability estimates, while at the same time only a small fraction of this heritability can be recapitulated through genome-wide association studies [75] .", [["Neurodevelopmental disorders", "DISEASE", 50, 78], ["schizophrenia", "DISEASE", 84, 97], ["autism", "DISEASE", 99, 105], ["bipolar disorder", "DISEASE", 110, 126], ["GRB", "DNA", 9, 12], ["each GRB", "PROBLEM", 4, 12], ["Neurodevelopmental disorders", "PROBLEM", 50, 78], ["schizophrenia", "PROBLEM", 84, 97], ["autism and bipolar disorder", "PROBLEM", 99, 126], ["high heritability estimates", "PROBLEM", 135, 162], ["high heritability", "OBSERVATION", 135, 152], ["small", "OBSERVATION_MODIFIER", 194, 199], ["fraction", "OBSERVATION", 200, 208]]], ["More specifically, heritability of schizophrenia has been estimated to be between 60% and 80% by large population-based studies and meta-analysis of twin studies [76, 77] ; between 64% and 91% for autism by the most recent meta-analysis on twin studies [78] and between 60% and 80% for bipolar disorders [79] .", [["schizophrenia", "DISEASE", 35, 48], ["autism", "DISEASE", 197, 203], ["bipolar disorders", "DISEASE", 286, 303], ["schizophrenia", "PROBLEM", 35, 48], ["large population", "TEST", 97, 113], ["meta-analysis of twin studies", "TEST", 132, 161], ["twin studies", "TEST", 240, 252], ["bipolar disorders", "PROBLEM", 286, 303], ["schizophrenia", "OBSERVATION", 35, 48]]], ["On the other hand, the SNP-based heritability estimated on liability scale has been estimated between 23% and 32% for schizophrenia [52, 80, 81] , 17% for autism and 25% for bipolar disorder [81] .", [["SNP", "CHEMICAL", 23, 26], ["schizophrenia", "DISEASE", 118, 131], ["autism", "DISEASE", 155, 161], ["bipolar disorder", "DISEASE", 174, 190], ["the SNP", "TEST", 19, 26], ["liability scale", "TEST", 59, 74], ["schizophrenia", "PROBLEM", 118, 131], ["autism", "TEST", 155, 161], ["bipolar disorder", "PROBLEM", 174, 190]]], ["This missing heritability may come from variants with smaller effect sizes thus far missed due to the sheer population size needed to achieve statistical significance when testing for small effects [36] , or other types of genetic variation, such as copy number variants [38, 82, 83] .", [["This missing heritability", "PROBLEM", 0, 25], ["smaller effect sizes", "PROBLEM", 54, 74], ["testing", "TEST", 172, 179], ["small effects", "PROBLEM", 184, 197]]], ["The GRB model is disease-agnostic and broadens the search space for target genes based on conserved synteny.", [["target genes", "DNA", 68, 80], ["disease", "PROBLEM", 17, 24], ["agnostic", "PROBLEM", 25, 33], ["GRB model", "OBSERVATION", 4, 13], ["disease", "OBSERVATION", 17, 24]]], ["This enables the detection of previously unidentified target genes, thereby implicating novel gene families or mechanistic pathways.", [["target genes", "DNA", 54, 66]]], ["While the rest of our analysis focuses exclusively on schizophrenia-associated variants, two additional recent datasets of SNPs associated with other neurodevelopmental phenotypes, i.e. autism spectrum disorder (ASD) [84] and bipolar disorder (BD) [85] , were checked for overrepresentation in genomic regulatory blocks (Fig. 2) .", [["schizophrenia", "DISEASE", 54, 67], ["neurodevelopmental phenotypes", "DISEASE", 150, 179], ["autism spectrum disorder", "DISEASE", 186, 210], ["ASD", "DISEASE", 212, 215], ["bipolar disorder", "DISEASE", 226, 242], ["our analysis", "TEST", 18, 30], ["schizophrenia", "PROBLEM", 54, 67], ["SNPs", "PROBLEM", 123, 127], ["other neurodevelopmental phenotypes", "PROBLEM", 144, 179], ["autism spectrum disorder (ASD)", "PROBLEM", 186, 216], ["bipolar disorder", "PROBLEM", 226, 242]]], ["BD-associated loci showed no significant difference from propensity of a random locus to fall in a genomic regulatory block, however, there was a marked increase in ASD-GWAS and SCZ-GWAS detected loci overlapping a genomic regulatory block, indicating a role of genes involved in developmental transcription factors and/or cell adhesion, cell-cell signalling, axon guidance genes (all are enriched among GRB target genes) in molecular mechanisms leading to autism and schizophrenia.", [["cell", "ANATOMY", 323, 327], ["cell", "ANATOMY", 338, 342], ["cell", "ANATOMY", 343, 347], ["axon", "ANATOMY", 360, 364], ["autism", "DISEASE", 457, 463], ["schizophrenia", "DISEASE", 468, 481], ["BD", "GENE_OR_GENE_PRODUCT", 0, 2], ["cell", "CELL", 323, 327], ["cell", "CELL", 338, 342], ["cell", "CELL", 343, 347], ["GRB", "GENE_OR_GENE_PRODUCT", 404, 407], ["BD-associated loci", "DNA", 0, 18], ["genomic regulatory block", "DNA", 99, 123], ["SCZ", "DNA", 178, 181], ["GWAS", "DNA", 182, 186], ["genomic regulatory block", "DNA", 215, 239], ["transcription factors", "PROTEIN", 294, 315], ["axon guidance genes", "DNA", 360, 379], ["GRB target genes", "DNA", 404, 420], ["a random locus", "PROBLEM", 71, 85], ["a genomic regulatory block", "PROBLEM", 97, 123], ["a marked increase in ASD", "PROBLEM", 144, 168], ["GWAS", "PROBLEM", 169, 173], ["SCZ", "PROBLEM", 178, 181], ["GWAS", "PROBLEM", 182, 186], ["a genomic regulatory block", "PROBLEM", 213, 239], ["developmental transcription factors", "PROBLEM", 280, 315], ["cell adhesion", "PROBLEM", 323, 336], ["autism and schizophrenia", "PROBLEM", 457, 481], ["no", "UNCERTAINTY", 26, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["difference", "OBSERVATION", 41, 51], ["marked", "OBSERVATION_MODIFIER", 146, 152], ["increase", "OBSERVATION_MODIFIER", 153, 161], ["genomic regulatory block", "OBSERVATION", 215, 239], ["schizophrenia", "OBSERVATION", 468, 481]]], ["It is worth noting here that, since the BD-GWAS study is still in preprint form, no data on the LD blocks were available at the time of writing this analysis and thus the LD block around each SNP was inferred (see Supplementary Methods); updating with actual LD blocks might potentially result in under-/over-representation of BD loci in the GRBs.", [["SNP", "CHEMICAL", 192, 195], ["BD", "GENE_OR_GENE_PRODUCT", 40, 42], ["BD", "GENE_OR_GENE_PRODUCT", 327, 329], ["GRBs", "PATHOLOGICAL_FORMATION", 342, 346], ["LD block", "DNA", 171, 179], ["BD loci", "DNA", 327, 334], ["GRBs", "DNA", 342, 346], ["the BD-GWAS study", "TEST", 36, 53], ["the LD blocks", "TEST", 92, 105], ["this analysis", "TEST", 144, 157], ["the LD block", "TREATMENT", 167, 179], ["actual LD blocks", "TREATMENT", 252, 268], ["BD loci in the GRBs", "PROBLEM", 327, 346], ["BD loci", "OBSERVATION", 327, 334]]], ["Only a subset with completely novel target genes by the GRB method proposed is presented here; for the full set of loci from the PGC dataset, see Supplementary Table S1 p < 0.05, *p < 0.001 (permutation test, see Supplementary methods).", [["target genes", "DNA", 36, 48], ["GRB", "DNA", 56, 59], ["permutation test", "TEST", 191, 207]]], ["Note, the schematics are not to scale and merely represent gene order (for to-scale plots, visit http://scz.genereg.net/) putative target of the rs75059851 SNP identified in the original study due to the location of the SNP in the promoter/first intron of two transcript isoforms of the IGSF9B.", [["SNP", "CHEMICAL", 156, 159], ["SNP", "CHEMICAL", 220, 223], ["rs75059851", "GENE_OR_GENE_PRODUCT", 145, 155], ["IGSF9B", "GENE_OR_GENE_PRODUCT", 287, 293], ["rs75059851 SNP", "DNA", 145, 159], ["promoter", "DNA", 231, 239], ["IGSF9B", "PROTEIN", 287, 293], ["the original study", "TEST", 174, 192], ["the SNP", "TREATMENT", 216, 223], ["the promoter/first intron", "TREATMENT", 227, 252]]], ["The expression of all three of the predicted GRB target genes is significantly greater in tissues in which the enhancers are active, Fig. 2c .", [["tissues", "ANATOMY", 90, 97], ["GRB", "GENE_OR_GENE_PRODUCT", 45, 48], ["tissues", "TISSUE", 90, 97], ["GRB target genes", "DNA", 45, 61], ["enhancers", "DNA", 111, 120], ["significantly", "OBSERVATION_MODIFIER", 65, 78], ["greater", "OBSERVATION_MODIFIER", 79, 86], ["active", "OBSERVATION_MODIFIER", 125, 131]]], ["In this case all three predicted target genes are neuronal specific cell adhesion molecules involved in neuronal development and thus likely candidate genes.", [["neuronal", "ANATOMY", 50, 58], ["cell", "ANATOMY", 68, 72], ["neuronal", "ANATOMY", 104, 112], ["neuronal", "CELL", 50, 58], ["cell", "CELL", 68, 72], ["neuronal", "CELL", 104, 112], ["target genes", "DNA", 33, 45], ["neuronal specific cell adhesion molecules", "PROTEIN", 50, 91], ["candidate genes", "DNA", 141, 156], ["neuronal specific cell adhesion molecules", "TREATMENT", 50, 91], ["specific cell", "OBSERVATION", 59, 72], ["adhesion molecules", "OBSERVATION", 73, 91]]], ["Indeed, OPCML has been previously implicated in the development of schizophrenia by multiple studies in European [56] and Thai [57] populations.", [["OPCML", "CHEMICAL", 8, 13], ["schizophrenia", "DISEASE", 67, 80], ["OPCML", "GENE_OR_GENE_PRODUCT", 8, 13], ["OPCML", "PROTEIN", 8, 13], ["schizophrenia", "PROBLEM", 67, 80], ["schizophrenia", "OBSERVATION", 67, 80]]], ["In addition, increased levels of an NTM isoform have recently been detected in the dorsolateral prefrontal cortex of schizophrenia patients [58] .", [["dorsolateral prefrontal cortex", "ANATOMY", 83, 113], ["schizophrenia", "DISEASE", 117, 130], ["dorsolateral prefrontal cortex", "CANCER", 83, 113], ["patients", "ORGANISM", 131, 139], ["NTM isoform", "PROTEIN", 36, 47], ["patients", "SPECIES", 131, 139], ["an NTM isoform", "PROBLEM", 33, 47], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["levels", "OBSERVATION_MODIFIER", 23, 29], ["NTM", "OBSERVATION", 36, 39], ["dorsolateral", "ANATOMY_MODIFIER", 83, 95], ["prefrontal cortex", "ANATOMY", 96, 113], ["schizophrenia", "OBSERVATION", 117, 130]]], ["More importantly, the concordance of putative enhancers in both schizophrenia-associated loci with genes across the entire GRB (Fig. 3c) , including SNX19, supports the idea that variants rs10791097 (found just downstream of, and originally thought to be a bystander locus to SNX19 [42] ) and rs75059851 share some mechanistic aspects in the aetiology of the disease, and calls for testing for effects of their interaction despite the large genomic distance between them.", [["schizophrenia", "DISEASE", 64, 77], ["GRB", "GENE_OR_GENE_PRODUCT", 123, 126], ["SNX19", "GENE_OR_GENE_PRODUCT", 149, 154], ["rs10791097", "GENE_OR_GENE_PRODUCT", 188, 198], ["SNX19 [42]", "GENE_OR_GENE_PRODUCT", 276, 286], ["rs75059851", "GENE_OR_GENE_PRODUCT", 293, 303], ["putative enhancers", "DNA", 37, 55], ["schizophrenia-associated loci", "DNA", 64, 93], ["GRB", "DNA", 123, 126], ["SNX19", "DNA", 149, 154], ["SNX19", "DNA", 276, 281], ["rs75059851", "DNA", 293, 303], ["putative enhancers", "PROBLEM", 37, 55], ["both schizophrenia-associated loci", "PROBLEM", 59, 93], ["the disease", "PROBLEM", 355, 366], ["testing", "TEST", 382, 389], ["putative enhancers", "OBSERVATION", 37, 55], ["both", "OBSERVATION_MODIFIER", 59, 63], ["schizophrenia", "OBSERVATION", 64, 77], ["disease", "OBSERVATION", 359, 366], ["large", "OBSERVATION_MODIFIER", 435, 440]]], ["This example highlights how the GRBs can serve as functional units in which the effects of multiple SNPs can be considered as potentially interacting.The GRB model identifies mechanistically related SNPsThe unbiased prediction of GRB target genes identifies potentially overlooked candidate genes at well-studied lociThe GRB model identifies mechanistically related SNPsThe final example is a locus that overlaps the gene for the dopamine D2 receptor (DRD2)-the target of all licensed antipsychotic therapy drugs [59] .", [["dopamine", "CHEMICAL", 430, 438], ["dopamine", "CHEMICAL", 430, 438], ["GRBs", "GENE_OR_GENE_PRODUCT", 32, 36], ["GRB", "GENE_OR_GENE_PRODUCT", 230, 233], ["dopamine D2 receptor", "GENE_OR_GENE_PRODUCT", 430, 450], ["DRD2", "GENE_OR_GENE_PRODUCT", 452, 456], ["GRBs", "DNA", 32, 36], ["GRB", "DNA", 154, 157], ["SNPs", "DNA", 199, 203], ["GRB target genes", "DNA", 230, 246], ["candidate genes", "DNA", 281, 296], ["SNPs", "DNA", 366, 370], ["dopamine D2 receptor", "PROTEIN", 430, 450], ["DRD2", "PROTEIN", 452, 456], ["functional units", "TREATMENT", 50, 66], ["multiple SNPs", "TREATMENT", 91, 104], ["the dopamine D2 receptor", "TREATMENT", 426, 450], ["all licensed antipsychotic therapy drugs", "TREATMENT", 472, 512], ["GRB model", "OBSERVATION", 154, 163], ["GRB model", "OBSERVATION", 321, 330]]], ["The unpredictability of a patient's response to antipsychotic therapy, and alternative roles of this locus have been under recent scrutiny [60] .", [["patient", "ORGANISM", 26, 33], ["locus", "CELLULAR_COMPONENT", 101, 106], ["patient", "SPECIES", 26, 33], ["antipsychotic therapy", "TREATMENT", 48, 69]]], ["This locus overlaps a GRB containing both DRD2 and a neural cell adhesion molecule gene, NCAM1, shown in Fig. 3d .", [["neural cell", "ANATOMY", 53, 64], ["locus", "CELLULAR_COMPONENT", 5, 10], ["GRB", "GENE_OR_GENE_PRODUCT", 22, 25], ["DRD2", "GENE_OR_GENE_PRODUCT", 42, 46], ["neural cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 53, 82], ["NCAM1", "GENE_OR_GENE_PRODUCT", 89, 94], ["GRB", "DNA", 22, 25], ["DRD2", "DNA", 42, 46], ["neural cell adhesion molecule gene", "DNA", 53, 87], ["NCAM1", "DNA", 89, 94], ["a GRB containing both DRD2", "PROBLEM", 20, 46], ["a neural cell adhesion molecule gene", "TREATMENT", 51, 87], ["GRB", "OBSERVATION", 22, 25], ["both", "OBSERVATION_MODIFIER", 37, 41], ["DRD2", "OBSERVATION_MODIFIER", 42, 46], ["neural cell", "OBSERVATION", 53, 64], ["adhesion molecule", "OBSERVATION", 65, 82]]], ["NCAM1 has previously been implicated in a number of neuropsychiatric disorders, including schizophrenia [61] , and our analysis identifies NCAM1 as another plausible target, despite not being categorized as a GRB target (it's predictive value is just below the threshold, see Supplementary information).", [["NCAM1", "CHEMICAL", 0, 5], ["neuropsychiatric disorders", "DISEASE", 52, 78], ["schizophrenia", "DISEASE", 90, 103], ["NCAM1", "GENE_OR_GENE_PRODUCT", 0, 5], ["NCAM1", "GENE_OR_GENE_PRODUCT", 139, 144], ["NCAM1", "PROTEIN", 0, 5], ["NCAM1", "PROTEIN", 139, 144], ["GRB target", "DNA", 209, 219], ["neuropsychiatric disorders", "PROBLEM", 52, 78], ["schizophrenia", "PROBLEM", 90, 103], ["our analysis", "TEST", 115, 127]]], ["When active, the predicted enhancer element in the schizophrenia-associated locus affects transcription of both DRD2 and NCAM1, with a more prominent effect on the transcription of the NCAM1 gene ( Supplementary Fig. 1 ).", [["schizophrenia", "DISEASE", 51, 64], ["locus", "CELLULAR_COMPONENT", 76, 81], ["DRD2", "GENE_OR_GENE_PRODUCT", 112, 116], ["NCAM1", "GENE_OR_GENE_PRODUCT", 121, 126], ["NCAM1", "GENE_OR_GENE_PRODUCT", 185, 190], ["enhancer element", "DNA", 27, 43], ["schizophrenia-associated locus", "DNA", 51, 81], ["DRD2", "DNA", 112, 116], ["NCAM1", "DNA", 121, 126], ["NCAM1 gene", "DNA", 185, 195], ["the predicted enhancer element", "PROBLEM", 13, 43], ["NCAM1", "TREATMENT", 121, 126], ["active", "OBSERVATION_MODIFIER", 5, 11], ["schizophrenia", "OBSERVATION", 51, 64], ["more prominent", "OBSERVATION_MODIFIER", 135, 149]]], ["This locus illustrates the risk of hypothesis-driven target gene search: once a gene, e.g. DRD2, expected to play a role in disease aetiology is identified, other putative targets in its vicinity may be overlooked.The GRB model identifies mechanistically related SNPsLessons learned from application of the GRB model to disease-associated genomic loci Recent approaches to identifying pathways through which non-coding variants lead to neuropsychiatric disorders such as schizophrenia suffer from three major conceptual oversimplifications.", [["neuropsychiatric disorders", "DISEASE", 436, 462], ["schizophrenia", "DISEASE", 471, 484], ["DRD2", "GENE_OR_GENE_PRODUCT", 91, 95], ["DRD2", "DNA", 91, 95], ["SNPsLessons", "DNA", 263, 274], ["genomic loci", "DNA", 339, 351], ["hypothesis", "PROBLEM", 35, 45], ["disease aetiology", "PROBLEM", 124, 141], ["the GRB model to disease", "PROBLEM", 303, 327], ["genomic loci", "PROBLEM", 339, 351], ["neuropsychiatric disorders", "PROBLEM", 436, 462], ["schizophrenia", "PROBLEM", 471, 484], ["GRB model", "OBSERVATION", 218, 227]]], ["First and foremost, despite the wealth of the literature published on complex modes of regulation [17, 62] , the practice of assigning non-coding variants to nearby genes is still prevalent.", [["nearby genes", "DNA", 158, 170]]], ["The GRB model allows for the expansion of the search for a target beyond adjacent genes and provides boundaries as to which genes should be included and which should not, but only in the cases where GWAS loci occur in the region of the genome implicated in the long-range regulation.", [["GRB", "DNA", 4, 7], ["GWAS loci", "DNA", 199, 208], ["GWAS loci", "PROBLEM", 199, 208], ["GRB model", "OBSERVATION", 4, 13], ["genome", "OBSERVATION", 236, 242]]], ["Further, automated GRB target gene prediction provides a shortlist of genes most likely to be under the control of long-range regulation.The GRB model identifies mechanistically related SNPsNext, epistatic effects between variants have been reported for a range of human complex traits, however systematic approaches to identify pairs of variants displaying epistatic effects suffers from multidimensionality problems and low reproducibility due to high false positive rates (for a review see [63] ).", [["GRB", "GENE_OR_GENE_PRODUCT", 19, 22], ["SNPsNext", "GENE_OR_GENE_PRODUCT", 186, 194], ["human", "ORGANISM", 265, 270], ["GRB target gene", "DNA", 19, 34], ["SNPsNext", "DNA", 186, 194], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 265, 270], ["long-range regulation", "TREATMENT", 115, 136], ["epistatic effects between variants", "PROBLEM", 196, 230], ["systematic approaches", "TREATMENT", 295, 316], ["epistatic effects", "PROBLEM", 358, 375], ["multidimensionality problems", "PROBLEM", 389, 417], ["low reproducibility", "PROBLEM", 422, 441], ["high false positive rates", "PROBLEM", 449, 474], ["GRB model", "OBSERVATION", 141, 150]]], ["GRBs as functional regulatory units may allow us to identify epistatic effects of noncoding variants that fall within the same GRBs (as in the NTM/OPCML/IGSF9B example in the Fig. 3c ), as this effectively reduces the number of statistical tests required potentially allowing for the detection of modest epistatic effects.The GRB model identifies mechanistically related SNPsFinally, identification of target genes linked to a given locus is often biased towards genes with functions and pathways previously associated with the trait or disease under investigation, potentially overlooking plausible alternative hypotheses.", [["GRBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GRBs", "GENE_OR_GENE_PRODUCT", 127, 131], ["Fig. 3c", "GENE_OR_GENE_PRODUCT", 175, 182], ["SNPsFinally", "GENE_OR_GENE_PRODUCT", 371, 382], ["locus", "CELLULAR_COMPONENT", 433, 438], ["GRBs", "PROTEIN", 0, 4], ["GRBs", "DNA", 127, 131], ["OPCML", "DNA", 147, 152], ["SNPsFinally", "DNA", 371, 382], ["target genes", "DNA", 402, 414], ["epistatic effects of noncoding variants", "PROBLEM", 61, 100], ["statistical tests", "TEST", 228, 245], ["the detection", "TEST", 280, 293], ["modest epistatic effects", "PROBLEM", 297, 321], ["the trait", "PROBLEM", 524, 533], ["disease", "PROBLEM", 537, 544], ["GRB model", "OBSERVATION", 326, 335]]], ["The evolutionary nature of the GRB model allows for an unbiased approach to identification of potential target genes, potentially identifying novel target genes and new disease mechanisms.", [["target genes", "DNA", 104, 116], ["target genes", "DNA", 148, 160], ["new disease mechanisms", "PROBLEM", 165, 187], ["GRB model", "OBSERVATION", 31, 40], ["new", "OBSERVATION_MODIFIER", 165, 168], ["disease", "OBSERVATION", 169, 176]]], ["Of particular interest is a network of mutually interacting transcription factors involved in neuronal development of cortical layers, predicted as targets in SCZ-GRBs: BCL11B, BCL11A, TBR1, SATB2 and FEZF2 (Supplementary Fig. S2 ).", [["neuronal", "ANATOMY", 94, 102], ["cortical layers", "ANATOMY", 118, 133], ["neuronal", "CELL", 94, 102], ["cortical layers", "MULTI-TISSUE_STRUCTURE", 118, 133], ["SCZ-GRBs", "GENE_OR_GENE_PRODUCT", 159, 167], ["BCL11B", "GENE_OR_GENE_PRODUCT", 169, 175], ["BCL11A", "GENE_OR_GENE_PRODUCT", 177, 183], ["TBR1", "GENE_OR_GENE_PRODUCT", 185, 189], ["SATB2", "GENE_OR_GENE_PRODUCT", 191, 196], ["FEZF2", "GENE_OR_GENE_PRODUCT", 201, 206], ["transcription factors", "PROTEIN", 60, 81], ["GRBs", "PROTEIN", 163, 167], ["BCL11B", "PROTEIN", 169, 175], ["BCL11A", "PROTEIN", 177, 183], ["TBR1", "DNA", 185, 189], ["SATB2", "DNA", 191, 196], ["FEZF2", "DNA", 201, 206], ["S2", "PROTEIN", 227, 229], ["cortical layers", "PROBLEM", 118, 133], ["SCZ", "TEST", 159, 162], ["BCL11B", "TEST", 169, 175], ["BCL11A", "TEST", 177, 183], ["TBR1", "TEST", 185, 189], ["SATB2", "TEST", 191, 196], ["FEZF2", "TEST", 201, 206], ["cortical layers", "OBSERVATION", 118, 133], ["BCL11B", "ANATOMY", 169, 175], ["BCL11A", "ANATOMY", 177, 183]]], ["Of these, only BCL11B is listed among targets in the PGC study with remainder not detected based on the assignment of noncoding SNPs to the closest gene.", [["BCL11B", "GENE_OR_GENE_PRODUCT", 15, 21], ["BCL11B", "DNA", 15, 21], ["noncoding SNPs", "DNA", 118, 132], ["the PGC study", "TEST", 49, 62], ["noncoding SNPs", "TREATMENT", 118, 132], ["BCL11B", "OBSERVATION", 15, 21]]], ["GRBs often target genes involved in development, which require complex regulation [16] .", [["GRBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GRBs", "PROTEIN", 0, 4]]], ["Our finding that the non-coding genetic loci associated with schizophrenia and autism, but not bipolar disorder, are significantly more likely to occur in GRBs is thus consistent with other evidence that there is a stronger neurodevelopmental component to these disorders than bipolar [64, 65] , and indicates novel potential developmental genes linked to these disorders.Other schizophrenia GWAS datasetsSince the conception of this study, several smaller schizophrenia GWAS datasets have emerged [8, 23, 24, 26, 27] , with many signals from the 2014 PGC study replicated, and some new loci discovered.", [["schizophrenia", "DISEASE", 61, 74], ["autism", "DISEASE", 79, 85], ["bipolar disorder", "DISEASE", 95, 111], ["bipolar", "DISEASE", 277, 284], ["schizophrenia", "DISEASE", 378, 391], ["schizophrenia", "DISEASE", 457, 470], ["GRBs", "CANCER", 155, 159], ["non-coding genetic loci", "DNA", 21, 44], ["developmental genes", "DNA", 326, 345], ["the non-coding genetic loci", "PROBLEM", 17, 44], ["schizophrenia", "PROBLEM", 61, 74], ["autism", "PROBLEM", 79, 85], ["bipolar disorder", "PROBLEM", 95, 111], ["a stronger neurodevelopmental component", "PROBLEM", 213, 252], ["these disorders", "PROBLEM", 256, 271], ["these disorders", "PROBLEM", 356, 371], ["Other schizophrenia GWAS datasets", "PROBLEM", 372, 405], ["this study", "TEST", 429, 439], ["several smaller schizophrenia GWAS datasets", "PROBLEM", 441, 484], ["PGC study", "TEST", 552, 561], ["some new loci", "PROBLEM", 578, 591], ["genetic loci", "OBSERVATION", 32, 44], ["schizophrenia", "OBSERVATION", 61, 74], ["consistent with", "UNCERTAINTY", 168, 183], ["schizophrenia", "OBSERVATION", 378, 391], ["smaller", "OBSERVATION_MODIFIER", 449, 456], ["schizophrenia", "OBSERVATION", 457, 470], ["new", "OBSERVATION_MODIFIER", 583, 586]]], ["The most significant change in these is a notable trend towards functional characterisation of SNPs in view of finding regulatory variants using eQTL information [8, 24, 26, 66] , chromatin contacts [8, 27] and transcription factor binding profiles [26] .", [["chromatin", "ANATOMY", 180, 189], ["chromatin", "CELLULAR_COMPONENT", 180, 189], ["SNPs", "DNA", 95, 99], ["transcription factor", "PROTEIN", 211, 231], ["eQTL information", "TEST", 145, 161], ["transcription factor binding profiles", "TEST", 211, 248], ["most significant", "OBSERVATION_MODIFIER", 4, 20], ["change", "OBSERVATION", 21, 27]]], ["We have analysed the three largest datasets [8, 26, 67] in the same way as the PGC GWAS represented here ( Supplementary Fig. S3) , and showed that the GRB target gene prediction still implicates many novel long-range contacts not documented in even the most recent published data (Supplementary information and Supplementary Tables S2 andS3) .", [["GRB", "GENE_OR_GENE_PRODUCT", 152, 155], ["PGC GWAS", "DNA", 79, 87], ["GRB target gene", "DNA", 152, 167], ["the PGC GWAS", "TEST", 75, 87], ["the GRB target gene prediction", "PROBLEM", 148, 178], ["largest", "OBSERVATION_MODIFIER", 27, 34]]], ["While a greater coverage of high-resolution tissue-specific chromatin contacts, allelespecific gene expression, transcriptome maps and genomewide binding profiles for a wider range of transcription factors will partially close this gap in the future, the GRB approach will stand as an elegant method of shortlisting (or adding additional evidence for) genes through which regulatory non-coding variants exert their effects on disease emergence.ConclusionsThe last few years have seen a step change in the power of GWAS in neuropsychiatric disorders.", [["tissue", "ANATOMY", 44, 50], ["chromatin", "ANATOMY", 60, 69], ["neuropsychiatric disorders", "DISEASE", 522, 548], ["tissue", "TISSUE", 44, 50], ["chromatin", "CELLULAR_COMPONENT", 60, 69], ["transcription factors", "PROTEIN", 184, 205], ["regulatory non-coding variants", "DNA", 372, 402], ["allelespecific gene expression", "TREATMENT", 80, 110], ["transcriptome maps", "TEST", 112, 130], ["genomewide binding profiles", "TEST", 135, 162], ["transcription factors", "PROBLEM", 184, 205], ["the GRB approach", "TREATMENT", 251, 267], ["genes through which regulatory non-coding variants", "PROBLEM", 352, 402], ["disease emergence", "PROBLEM", 426, 443], ["a step change", "PROBLEM", 484, 497], ["neuropsychiatric disorders", "PROBLEM", 522, 548], ["neuropsychiatric disorders", "OBSERVATION", 522, 548]]], ["This has led to large numbers of novel loci being identified, but raises a new challenge: determining the correct gene(s) linked to these loci.", [["large", "OBSERVATION_MODIFIER", 16, 21], ["numbers", "OBSERVATION_MODIFIER", 22, 29], ["novel loci", "OBSERVATION", 33, 43]]], ["The common practice of assigning noncoding loci identified in GWAS to the nearest is likely to be an oversimplification in a substantial proportion of cases.", [["noncoding loci", "DNA", 33, 47], ["assigning noncoding loci", "PROBLEM", 23, 47], ["common", "OBSERVATION_MODIFIER", 4, 10], ["noncoding loci", "OBSERVATION", 33, 47], ["likely to be", "UNCERTAINTY", 85, 97], ["oversimplification", "OBSERVATION", 101, 119]]], ["In particular, it neglects the topological organisation of the genome, and the possibility that a locus may be in, or linked to, a non-coding element that regulates a distant gene.", [["genome", "CELLULAR_COMPONENT", 63, 69], ["locus", "CELLULAR_COMPONENT", 98, 103], ["non-coding element", "DNA", 131, 149], ["distant gene", "DNA", 167, 179], ["a non-coding element", "PROBLEM", 129, 149]]], ["New understanding on the characteristics of non-coding elements in highly conserved GRBs, and their link to TADs can be used to identify the potential target genes for loci in GRBs.", [["GRBs", "GENE_OR_GENE_PRODUCT", 84, 88], ["TADs", "GENE_OR_GENE_PRODUCT", 108, 112], ["GRBs", "PATHOLOGICAL_FORMATION", 176, 180], ["non-coding elements", "DNA", 44, 63], ["GRBs", "DNA", 84, 88], ["TADs", "DNA", 108, 112], ["target genes", "DNA", 151, 163], ["GRBs", "DNA", 176, 180], ["non-coding elements", "PROBLEM", 44, 63], ["loci in GRBs", "PROBLEM", 168, 180]]], ["We applied this knowledge to the loci from recent GWAS in three neuropsychiatric disorders, to show that for two of them, schizophrenia and autism, there was an excess of loci located in GRBs than would be expected by chance.", [["neuropsychiatric disorders", "DISEASE", 64, 90], ["schizophrenia", "DISEASE", 122, 135], ["autism", "DISEASE", 140, 146], ["GRBs", "GENE_OR_GENE_PRODUCT", 187, 191], ["GRBs", "DNA", 187, 191], ["recent GWAS in three neuropsychiatric disorders", "PROBLEM", 43, 90], ["schizophrenia", "PROBLEM", 122, 135], ["autism", "PROBLEM", 140, 146], ["an excess of loci", "PROBLEM", 158, 175], ["schizophrenia", "OBSERVATION", 122, 135]]], ["Further analysis showed the potential of this approach to identify novel plausible genes for the schizophrenia, such as NTM, ARHGAP15 and ZEB2.", [["schizophrenia", "DISEASE", 97, 110], ["NTM", "DISEASE", 120, 123], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 125, 133], ["ZEB2", "GENE_OR_GENE_PRODUCT", 138, 142], ["ARHGAP15", "DNA", 125, 133], ["ZEB2", "PROTEIN", 138, 142], ["Further analysis", "TEST", 0, 16], ["this approach", "TREATMENT", 41, 54], ["the schizophrenia", "PROBLEM", 93, 110], ["ARHGAP15", "TREATMENT", 125, 133], ["ZEB2", "TREATMENT", 138, 142], ["schizophrenia", "OBSERVATION", 97, 110]]], ["This illustrates the potential value of the GRB approach and the need to consider the role of non-coding elements to guide the biological analysis of loci identified by GWAS.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Compliance with ethical standardsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Compliance with ethical standardsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.", [["non-coding elements", "DNA", 94, 113], ["the GRB approach", "TREATMENT", 40, 56], ["the biological analysis", "TEST", 123, 146], ["ethical standards", "TREATMENT", 190, 207], ["ethical standards", "TREATMENT", 303, 320], ["ethical standards", "TREATMENT", 471, 488], ["Open Access", "TREATMENT", 488, 499]]], ["The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "a931971f82306b2f1fead76587315934ff2a49de": [["IntroductionHepatitis E is an acute human liver disease caused by the hepatitis E virus (HEV) and can have a zoonotic origin.", [["liver", "ANATOMY", 42, 47], ["Hepatitis E", "DISEASE", 12, 23], ["liver disease", "DISEASE", 42, 55], ["hepatitis E", "DISEASE", 70, 81], ["Hepatitis E", "ORGANISM", 12, 23], ["human", "ORGANISM", 36, 41], ["liver", "ORGAN", 42, 47], ["hepatitis E virus", "ORGANISM", 70, 87], ["HEV", "ORGANISM", 89, 92], ["human", "SPECIES", 36, 41], ["hepatitis E virus", "SPECIES", 70, 87], ["Hepatitis E", "SPECIES", 12, 23], ["human", "SPECIES", 36, 41], ["hepatitis E virus", "SPECIES", 70, 87], ["HEV", "SPECIES", 89, 92], ["Hepatitis E", "PROBLEM", 12, 23], ["an acute human liver disease", "PROBLEM", 27, 55], ["the hepatitis E virus", "PROBLEM", 66, 87], ["Hepatitis", "OBSERVATION", 12, 21], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["liver", "ANATOMY", 42, 47], ["disease", "OBSERVATION", 48, 55], ["hepatitis", "OBSERVATION", 70, 79], ["zoonotic", "OBSERVATION_MODIFIER", 109, 117]]], ["Hepatitis E is usually a mild self-limiting disease; however, it may be fatal, especially among pregnant women in developing countries, or become chronic in immunocompromised individuals.", [["Hepatitis E", "DISEASE", 0, 11], ["Hepatitis E", "ORGANISM", 0, 11], ["women", "ORGANISM", 105, 110], ["women", "SPECIES", 105, 110], ["Hepatitis E", "SPECIES", 0, 11], ["Hepatitis E", "PROBLEM", 0, 11], ["a mild self-limiting disease", "PROBLEM", 23, 51], ["chronic in immunocompromised individuals", "PROBLEM", 146, 186], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["self-limiting", "OBSERVATION_MODIFIER", 30, 43], ["disease", "OBSERVATION", 44, 51], ["may be", "UNCERTAINTY", 65, 71], ["fatal", "OBSERVATION_MODIFIER", 72, 77], ["chronic", "OBSERVATION_MODIFIER", 146, 153], ["immunocompromised individuals", "OBSERVATION", 157, 186]]], ["Besides the infection of humans, HEV or HEV-related viruses have been identified in an increasing number of domestic and wild animal species (Smith et al., 2013) .", [["infection", "DISEASE", 12, 21], ["humans", "ORGANISM", 25, 31], ["HEV", "ORGANISM", 33, 36], ["HEV-related viruses", "ORGANISM", 40, 59], ["humans", "SPECIES", 25, 31], ["humans", "SPECIES", 25, 31], ["HEV", "SPECIES", 33, 36], ["HEV", "SPECIES", 40, 43], ["the infection of humans", "PROBLEM", 8, 31], ["HEV", "PROBLEM", 33, 36], ["HEV-related viruses", "PROBLEM", 40, 59], ["infection", "OBSERVATION", 12, 21], ["viruses", "OBSERVATION", 52, 59], ["increasing", "OBSERVATION_MODIFIER", 87, 97], ["number", "OBSERVATION_MODIFIER", 98, 104]]], ["Nearly 57,000 people die yearly from hepatitis E-related causes (WHO, 2013) .", [["hepatitis E", "DISEASE", 37, 48], ["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20], ["hepatitis E", "PROBLEM", 37, 48], ["hepatitis", "OBSERVATION", 37, 46]]], ["According to the World Health Organization (WHO), 20 million people get infected with HEV and three million develop acute hepatitis every year (WHO, 2013) .", [["HEV", "DISEASE", 86, 89], ["hepatitis", "DISEASE", 122, 131], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["HEV", "SPECIES", 86, 89], ["HEV", "PROBLEM", 86, 89], ["acute hepatitis", "PROBLEM", 116, 131], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["hepatitis", "OBSERVATION", 122, 131]]], ["The disease is endemic in both developing and developed countries although the epidemiological profile varies between countries according to the level of development.", [["The disease", "PROBLEM", 0, 11], ["endemic", "PROBLEM", 15, 22], ["disease", "OBSERVATION", 4, 11], ["endemic", "OBSERVATION_MODIFIER", 15, 22]]], ["In developed countries, hepatitis E is more associated with animal contact and the ingestion of raw or uncooked meat, especially liver (swine, wild boar and deer) (Wichmann et al., 2008; Lewis et al., 2010) .", [["meat", "ANATOMY", 112, 116], ["liver", "ANATOMY", 129, 134], ["hepatitis E", "DISEASE", 24, 35], ["hepatitis E", "ORGANISM", 24, 35], ["meat", "ORGANISM_SUBDIVISION", 112, 116], ["liver", "ORGAN", 129, 134], ["boar", "ORGANISM", 148, 152], ["deer", "ORGANISM_SUBDIVISION", 157, 161], ["swine", "SPECIES", 136, 141], ["uncooked", "SPECIES", 103, 111], ["swine", "SPECIES", 136, 141], ["hepatitis E", "PROBLEM", 24, 35], ["hepatitis", "OBSERVATION", 24, 33], ["liver", "ANATOMY", 129, 134]]], ["In developing countries, hepatitis E is still linked to poor sanitary conditions ( (CDC) , C. f.", [["hepatitis E", "DISEASE", 25, 36], ["C. f.", "SPECIES", 91, 96], ["hepatitis E", "PROBLEM", 25, 36], ["poor sanitary conditions", "PROBLEM", 56, 80], ["hepatitis", "OBSERVATION", 25, 34]]], ["D. C. a.", [["D. C. a.", "SPECIES", 0, 8]]], ["P., 2013).IntroductionThe first epidemiological study of hepatitis E came from India in the early fifties (Viswanathan, 1957) and described a waterborne infection due to sewage contamination of the Yamuna River (Viswanathan, 1957; Khuroo, 2011) .", [["hepatitis E", "DISEASE", 57, 68], ["waterborne infection", "DISEASE", 142, 162], ["hepatitis E", "PROBLEM", 57, 68], ["a waterborne infection", "PROBLEM", 140, 162], ["hepatitis", "OBSERVATION", 57, 66], ["infection", "OBSERVATION", 153, 162]]], ["The unknown viral agent was only identified in the eighties and named 'enterically transmitted non-A and non-B hepatitis' (ET-NANBH; Francis and Maynard, 1979; Sreenivasan et al., 1984) .", [["hepatitis", "DISEASE", 111, 120], ["viral agent", "OBSERVATION", 12, 23], ["hepatitis", "OBSERVATION", 111, 120]]], ["Later in the nineties, the ET-NANBH virus was inoculated into cynomolgus monkeys, HEV cDNA was isolated for the first time, and the name 'HEV' was proposed (Reyes et al., 1990) .", [["ET-NANBH virus", "ORGANISM", 27, 41], ["cynomolgus", "ORGANISM", 62, 72], ["monkeys", "ORGANISM", 73, 80], ["HEV", "ORGANISM", 82, 85], ["HEV", "ORGANISM", 138, 141], ["HEV cDNA", "DNA", 82, 90], ["cynomolgus monkeys", "SPECIES", 62, 80], ["NANBH virus", "SPECIES", 30, 41], ["cynomolgus monkeys", "SPECIES", 62, 80], ["HEV", "SPECIES", 82, 85], ["the ET-NANBH virus", "TREATMENT", 23, 41], ["HEV cDNA", "TEST", 82, 90]]], ["Since then the number of reports on HEV infections in the human population has increased considerably, showing that HEV was present in many different countries (Aye et al., 1992; Huang et al., 1992; Tsarev et al., 1992; Yin et al., 1994) .IntroductionNatural infection of HEV was detected in pigs for the first time in 1995 in Nepal (Clayson et al., 1995) .", [["HEV infections", "DISEASE", 36, 50], ["Natural infection", "DISEASE", 251, 268], ["HEV", "ORGANISM", 36, 39], ["human", "ORGANISM", 58, 63], ["HEV", "ORGANISM", 116, 119], ["HEV", "ORGANISM", 272, 275], ["pigs", "ORGANISM", 292, 296], ["human", "SPECIES", 58, 63], ["pigs", "SPECIES", 292, 296], ["HEV", "SPECIES", 36, 39], ["human", "SPECIES", 58, 63], ["HEV", "SPECIES", 116, 119], ["HEV", "SPECIES", 272, 275], ["pigs", "SPECIES", 292, 296], ["HEV infections in the human population", "PROBLEM", 36, 74], ["Natural infection of HEV", "PROBLEM", 251, 275], ["infections", "OBSERVATION", 40, 50], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["considerably", "OBSERVATION_MODIFIER", 89, 101], ["infection", "OBSERVATION", 259, 268]]], ["Further studies showed that the porcine HEV strain is closely related to but distinct from the human HEV strains observed so far and represents the HEV genotype 3 (HEV-3) (Meng et al., 1997) .", [["porcine HEV strain", "ORGANISM", 32, 50], ["human", "ORGANISM", 95, 100], ["HEV strains", "ORGANISM", 101, 112], ["HEV genotype 3", "ORGANISM", 148, 162], ["HEV-3", "ORGANISM", 164, 169], ["porcine", "SPECIES", 32, 39], ["human", "SPECIES", 95, 100], ["HEV", "SPECIES", 40, 43], ["human HEV", "SPECIES", 95, 104], ["HEV", "SPECIES", 148, 151], ["Further studies", "TEST", 0, 15], ["the porcine HEV strain", "PROBLEM", 28, 50], ["the human HEV strains", "PROBLEM", 91, 112], ["the HEV genotype", "TEST", 144, 160], ["HEV strains", "OBSERVATION", 101, 112]]], ["Later, genotype 4 (HEV-4) was also found in humans and swine (Wang et al., 1999 (Wang et al., , 2002 .Current Nomenclature of HEVHepatitis E virus was initially classified in the Picornaviridae family with hepatitis A virus, based on clinical and epidemiological characteristics (Sreenivasan et al., 1984) .", [["hepatitis A virus", "DISEASE", 206, 223], ["HEV-4", "ORGANISM", 19, 24], ["humans", "ORGANISM", 44, 50], ["HEVHepatitis E virus", "ORGANISM", 126, 146], ["hepatitis A virus", "ORGANISM", 206, 223], ["humans", "SPECIES", 44, 50], ["swine", "SPECIES", 55, 60], ["hepatitis A virus", "SPECIES", 206, 223], ["HEV-4", "SPECIES", 19, 24], ["humans", "SPECIES", 44, 50], ["swine", "SPECIES", 55, 60], ["HEVHepatitis E virus", "SPECIES", 126, 146], ["hepatitis A virus", "SPECIES", 206, 223], ["genotype", "TEST", 7, 15], ["HEV", "TEST", 19, 22], ["HEVHepatitis E virus", "PROBLEM", 126, 146], ["hepatitis A virus", "PROBLEM", 206, 223]]], ["However, due to morphological features and similarities to noroviruses in genome organization, HEV was thereafter repositioned as a member of the Caliciviridae, in the genus Hepevirus (Bradley et al., 1988) .", [["noroviruses", "DISEASE", 59, 70], ["HEV", "ORGANISM", 95, 98], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 146, 159], ["HEV", "SPECIES", 95, 98], ["morphological features", "PROBLEM", 16, 38], ["noroviruses", "PROBLEM", 59, 70], ["the Caliciviridae", "TREATMENT", 142, 159], ["noroviruses", "OBSERVATION", 59, 70]]], ["Later on, based on molecular analyses, HEV was placed as the sole species of the family Hepeviridae, genus Hepevirus and viruses were grouped into four major genotypes (1-4) Meng et al., 2011) .", [["HEV", "ORGANISM", 39, 42], ["Hepeviridae", "GENE_OR_GENE_PRODUCT", 88, 99], ["HEV", "SPECIES", 39, 42], ["molecular analyses", "TEST", 19, 37], ["HEV", "PROBLEM", 39, 42], ["the family Hepeviridae", "TREATMENT", 77, 99], ["genus Hepevirus", "TREATMENT", 101, 116], ["viruses", "TREATMENT", 121, 128]]], ["In the meantime, other HEVrelated viruses were detected (e.g. in rats), but not assigned until the most recent proposed classification (Table 1 ; Meng et al., 2011; Smith et al., 2014) .HEV genotypesRecently, the ICTV Hepeviridae Study Group proposed a new consensual classification, placing all the HEV and HEV-related viruses into two genera: Orthohepevirus with four species (A-D) and Piscihepevirus with a single species (A) (Smith et al., 2014) .", [["HEVrelated viruses", "ORGANISM", 23, 41], ["rats", "ORGANISM", 65, 69], ["HEV", "ORGANISM", 186, 189], ["HEV", "ORGANISM", 300, 303], ["HEV", "ORGANISM", 308, 311], ["A-D", "CELL", 379, 382], ["rats", "SPECIES", 65, 69], ["HEV", "SPECIES", 186, 189], ["ICTV", "SPECIES", 213, 217], ["HEV", "SPECIES", 300, 303], ["other HEVrelated viruses", "PROBLEM", 17, 41], ["four species", "PROBLEM", 365, 377], ["Piscihepevirus", "PROBLEM", 388, 402], ["viruses", "OBSERVATION", 34, 41]]], ["Accordingly, Orthohepevirus A comprises sequences found in humans, pigs, wild boar, rabbit, deer, mongoose and camel; Orthohepevirus B contains viruses found in chickens; Orthohepevirus C encompasses sequences found in rats (HEV-C1) and ferrets (HEV-C2); and Orthohepevirus D, the bat virus (Table 1) .", [["Orthohepevirus A", "GENE_OR_GENE_PRODUCT", 13, 29], ["humans", "ORGANISM", 59, 65], ["pigs", "ORGANISM", 67, 71], ["wild boar", "ORGANISM", 73, 82], ["rabbit", "ORGANISM", 84, 90], ["deer", "ORGANISM", 92, 96], ["mongoose", "ORGANISM", 98, 106], ["camel", "ORGANISM", 111, 116], ["Orthohepevirus B", "ORGANISM", 118, 134], ["chickens", "ORGANISM", 161, 169], ["Orthohepevirus C", "ORGANISM", 171, 187], ["rats", "ORGANISM", 219, 223], ["HEV-C1", "ORGANISM", 225, 231], ["ferrets", "ORGANISM", 237, 244], ["HEV-C2", "ORGANISM", 246, 252], ["Orthohepevirus D", "ORGANISM", 259, 275], ["bat virus", "ORGANISM", 281, 290], ["humans", "SPECIES", 59, 65], ["pigs", "SPECIES", 67, 71], ["boar", "SPECIES", 78, 82], ["rabbit", "SPECIES", 84, 90], ["deer", "SPECIES", 92, 96], ["camel", "SPECIES", 111, 116], ["chickens", "SPECIES", 161, 169], ["rats", "SPECIES", 219, 223], ["ferrets", "SPECIES", 237, 244], ["bat virus", "SPECIES", 281, 290], ["Orthohepevirus A", "SPECIES", 13, 29], ["humans", "SPECIES", 59, 65], ["pigs", "SPECIES", 67, 71], ["rabbit", "SPECIES", 84, 90], ["camel", "SPECIES", 111, 116], ["chickens", "SPECIES", 161, 169], ["ferrets", "SPECIES", 237, 244], ["Orthohepevirus A comprises sequences", "TEST", 13, 49], ["viruses", "PROBLEM", 144, 151], ["Orthohepevirus C encompasses sequences", "TEST", 171, 209], ["HEV", "TEST", 225, 228], ["viruses", "OBSERVATION", 144, 151], ["bat", "ANATOMY", 281, 284]]], ["Genotypes were also proposed for Orthohepevirus A: genotypes HEV-1 and HEV-2 have only been identified in humans, genotypes HEV-3 and HEV-4 have been reported in both humans and different animal species and are associated with the zoonotic cases.", [["Orthohepevirus A", "ORGANISM", 33, 49], ["HEV-1", "ORGANISM", 61, 66], ["HEV-2", "ORGANISM", 71, 76], ["humans", "ORGANISM", 106, 112], ["HEV-3", "ORGANISM", 124, 129], ["HEV-4", "ORGANISM", 134, 139], ["humans", "ORGANISM", 167, 173], ["HEV-1", "SPECIES", 61, 66], ["HEV-2", "SPECIES", 71, 76], ["humans", "SPECIES", 106, 112], ["HEV-3", "SPECIES", 124, 129], ["HEV-", "SPECIES", 134, 138], ["humans", "SPECIES", 167, 173], ["Orthohepevirus A", "SPECIES", 33, 49], ["HEV-1", "SPECIES", 61, 66], ["HEV-2", "SPECIES", 71, 76], ["humans", "SPECIES", 106, 112], ["HEV-3", "SPECIES", 124, 129], ["HEV-4", "SPECIES", 134, 139], ["humans", "SPECIES", 167, 173], ["genotypes HEV", "TEST", 51, 64], ["HEV", "TEST", 71, 74], ["genotypes HEV", "TEST", 114, 127], ["HEV", "TEST", 134, 137], ["animal species", "OBSERVATION", 188, 202]]], ["Genotypes HEV-5 and HEV-6 have been found in wild boar in Japan and genotype HEV-7 in dromedary camels in Dubai (Table 1; Smith et al., 2014; Pavio et al., 2010) .", [["HEV-5", "ORGANISM", 10, 15], ["HEV-6", "ORGANISM", 20, 25], ["boar", "ORGANISM", 50, 54], ["HEV-7", "ORGANISM", 77, 82], ["HEV-", "SPECIES", 10, 14], ["HEV-", "SPECIES", 20, 24], ["boar", "SPECIES", 50, 54], ["HEV-5", "SPECIES", 10, 15], ["HEV-6", "SPECIES", 20, 25], ["HEV-7", "SPECIES", 77, 82], ["Genotypes", "TEST", 0, 9], ["HEV", "TEST", 10, 13], ["HEV", "TEST", 20, 23], ["genotype HEV", "TEST", 68, 80]]], ["Partial sequences from other potential members of the family were recently identified in moose, fox and mink.", [["fox", "ORGANISM", 96, 99], ["mink", "ORGANISM", 104, 108], ["mink", "SPECIES", 104, 108], ["moose", "SPECIES", 89, 94], ["mink", "SPECIES", 104, 108]]], ["They show similarities to HEV in genome organization, size and phylogenetic analyses, suggesting they could represent new members of the Hepeviridae family.", [["HEV", "ORGANISM", 26, 29], ["Hepeviridae", "GENE_OR_GENE_PRODUCT", 137, 148], ["Hepeviridae family", "PROTEIN", 137, 155], ["HEV", "SPECIES", 26, 29], ["phylogenetic analyses", "TEST", 63, 84], ["genome organization", "OBSERVATION", 33, 52], ["size", "OBSERVATION_MODIFIER", 54, 58], ["new", "OBSERVATION_MODIFIER", 118, 121]]], ["The moose virus appears to cluster closely to genotypes 1-7, while HEV isolated from mink is closely related to the ferret virus (HEV-C2), and the virus found in foxes is related to that in rats (HEV-C1) virus ( Fig. 1 ; Lin et al., 2013; Woo et al., 2014; Batts et al., 2011; Raj et al., 2012; Drexler et al., 2012) .", [["moose virus", "ORGANISM", 4, 15], ["1-7", "ORGANISM", 56, 59], ["HEV", "ORGANISM", 67, 70], ["mink", "ORGANISM", 85, 89], ["ferret virus", "ORGANISM", 116, 128], ["HEV-C2", "ORGANISM", 130, 136], ["foxes", "ORGANISM", 162, 167], ["rats (", "ORGANISM", 190, 196], ["HEV-C1) virus", "ORGANISM", 196, 209], ["mink", "SPECIES", 85, 89], ["ferret virus", "SPECIES", 116, 128], ["rats", "SPECIES", 190, 194], ["moose virus", "SPECIES", 4, 15], ["HEV", "SPECIES", 67, 70], ["mink", "SPECIES", 85, 89], ["ferret virus", "SPECIES", 116, 128], ["HEV", "SPECIES", 130, 133], ["HEV-C1) virus", "SPECIES", 196, 209], ["The moose virus", "PROBLEM", 0, 15], ["genotypes", "TEST", 46, 55], ["HEV", "PROBLEM", 67, 70], ["the ferret virus", "PROBLEM", 112, 128], ["the virus", "PROBLEM", 143, 152], ["moose virus", "OBSERVATION", 4, 15]]], ["These viruses have not been placed in any specific genotype because complete genomic sequences are required to place these viruses definitively.HEV subgenotypesClassification under the genotype level is very useful and important for both clinical and epidemiological studies.", [["HEV", "ORGANISM", 144, 147], ["genomic sequences", "DNA", 77, 94], ["HEV", "SPECIES", 144, 147], ["These viruses", "PROBLEM", 0, 13], ["these viruses", "PROBLEM", 117, 130], ["HEV subgenotypesClassification under the genotype level", "TEST", 144, 199], ["epidemiological studies", "TEST", 251, 274], ["viruses", "OBSERVATION", 6, 13], ["viruses", "OBSERVATION", 123, 130]]], ["The most frequently used classification was proposed by Lu et al. (2006) and encompasses 24 subtypes.", [["24 subtypes", "OBSERVATION_MODIFIER", 89, 100]]], ["Genotypes 1-4 are split into five (a-e), two (a-b), 10 (a-j) and seven (a-g) subtypes, respectively (Lu et al., 2006) .", [["a-e)", "GENE_OR_GENE_PRODUCT", 35, 39], ["Genotypes", "TEST", 0, 9]]], ["For instance, there are a number of publications including partial and complete genomic sequences of HEV with no differentiation under the genotype level Tei et al., 2003; Sonoda et al., 2004; Wibawa et al., 2004) .", [["HEV", "ORGANISM", 101, 104]]], ["The main concern is related to the reliability of the subtype separation and, consequently, the usefulness of subtyping (Oliveira-Filho et al., 2013; Smith et al., 2013) .", [["main", "OBSERVATION_MODIFIER", 4, 8], ["subtype separation", "OBSERVATION", 54, 72]]], ["The ICTV study group has not defined a permanent system for classification under genotype level (subgenotype or subtypes); however, it has recommended the use of approaches based on labelling clades according to tree topology (Smith et al., 2014) .", [["The ICTV study", "TEST", 0, 14], ["approaches", "TREATMENT", 162, 172]]], ["Thus, genotype HEV-3 has been divided into three subgenotypes 3.1 (or G3 group 1), 3.2 (or G3 group 2) and 3.3 (Oliveira-Filho et al., 2013; Ijaz et al., 2014) , and genotype HEV-4 has been divided into seven subgenotypes 4 a-g (Dai et al., 2013) .HEV subgenotypesSo far all the different viruses infecting humans from genotypes HEV-1 to HEV-4 are grouped in a single serotype.", [["HEV-3", "ORGANISM", 15, 20], ["HEV-4", "ORGANISM", 175, 180], ["HEV", "ORGANISM", 248, 251], ["humans", "ORGANISM", 307, 313], ["genotypes HEV-1", "ORGANISM", 319, 334], ["HEV-4", "ORGANISM", 338, 343], ["humans", "SPECIES", 307, 313], ["HEV-1", "SPECIES", 329, 334], ["HEV-3", "SPECIES", 15, 20], ["HEV-4", "SPECIES", 175, 180], ["HEV", "SPECIES", 248, 251], ["humans", "SPECIES", 307, 313], ["HEV-1", "SPECIES", 329, 334], ["HEV-4", "SPECIES", 338, 343], ["genotype HEV", "TEST", 6, 18], ["Oliveira", "TEST", 112, 120], ["genotype HEV", "TEST", 166, 178], ["genotypes HEV", "TEST", 319, 332], ["HEV", "TEST", 338, 341], ["subgenotypes", "OBSERVATION", 252, 264], ["different", "OBSERVATION_MODIFIER", 279, 288], ["viruses", "OBSERVATION", 289, 296]]], ["The serological diversity of the other hepeviruses remains uncertain, although it is known that specific assays can distinguish between viruses from Orthohepevirus B and HEV-C1 and the HEV-1-HEV-4 (Dremsek et al., 2012; Liu et al., 2014) .StructureHepatitis E virus is a small non-enveloped virus with a diameter of approximately 27-34 nm and an icosahedral capsid.", [["Orthohepevirus B", "ORGANISM", 149, 165], ["HEV-C1", "ORGANISM", 170, 176], ["HEV-1-HEV-4", "ORGANISM", 185, 196], ["StructureHepatitis E virus", "ORGANISM", 239, 265], ["icosahedral capsid", "PROTEIN", 346, 364], ["HEV-1-HEV", "SPECIES", 185, 194], ["E virus", "SPECIES", 258, 265], ["Orthohepevirus B", "SPECIES", 149, 165], ["HEV-C1", "SPECIES", 170, 176], ["HEV-1", "SPECIES", 185, 190], ["StructureHepatitis E virus", "SPECIES", 239, 265], ["specific assays", "TEST", 96, 111], ["viruses", "PROBLEM", 136, 143], ["Orthohepevirus", "TEST", 149, 163], ["HEV", "TEST", 170, 173], ["the HEV", "TEST", 181, 188], ["StructureHepatitis E virus", "PROBLEM", 239, 265], ["a small non-enveloped virus", "PROBLEM", 269, 296], ["an icosahedral capsid", "PROBLEM", 343, 364], ["C1", "ANATOMY", 174, 176], ["HEV", "ANATOMY", 185, 188], ["virus", "OBSERVATION", 260, 265], ["small", "OBSERVATION_MODIFIER", 271, 276], ["non-enveloped", "OBSERVATION_MODIFIER", 277, 290], ["virus", "OBSERVATION", 291, 296], ["diameter", "OBSERVATION_MODIFIER", 304, 312], ["27-34 nm", "OBSERVATION_MODIFIER", 330, 338], ["icosahedral capsid", "OBSERVATION", 346, 364]]], ["The genome consists of a single-stranded positive RNA of 6.6-7.3 kb in length, polyadenylated at its 3 0 -end and 5 0 -capped with a 7-methylguanine.", [["7-methylguanine", "CHEMICAL", 133, 148], ["7-methylguanine", "CHEMICAL", 133, 148], ["7-methylguanine", "SIMPLE_CHEMICAL", 133, 148], ["single-stranded positive RNA", "RNA", 25, 53], ["3 0 -end", "DNA", 101, 109], ["a single-stranded positive RNA", "PROBLEM", 23, 53], ["length", "TEST", 71, 77], ["polyadenylated", "TEST", 79, 93], ["a 7-methylguanine", "TREATMENT", 131, 148]]], ["It contains three partly overlapping open reading frames (ORFs; Fig. 2 ) (Mushahwar, 2008) .", [["open reading frames", "DNA", 37, 56], ["ORFs", "DNA", 58, 62], ["overlapping", "OBSERVATION_MODIFIER", 25, 36], ["open", "OBSERVATION_MODIFIER", 37, 41], ["reading frames", "OBSERVATION", 42, 56]]], ["In addition, subgenomic viral RNA is also synthesized (Graff et al., 2006) .StructureThe 5 0 end of the genome contains a short non-coding region (NCR), 26-28 nucleotides in length.", [["subgenomic viral RNA", "RNA", 13, 33], ["5 0 end", "DNA", 89, 96], ["short non-coding region", "DNA", 122, 145], ["NCR", "DNA", 147, 150], ["subgenomic viral RNA", "PROBLEM", 13, 33], ["a short non-coding region", "PROBLEM", 120, 145], ["subgenomic", "OBSERVATION", 13, 23], ["viral RNA", "OBSERVATION", 24, 33], ["5 0 end", "OBSERVATION_MODIFIER", 89, 96], ["genome", "OBSERVATION", 104, 110], ["short", "OBSERVATION_MODIFIER", 122, 127], ["length", "OBSERVATION_MODIFIER", 174, 180]]], ["ORF1 has a size of approximately 1693 amino acids (aa).", [["amino acids", "CHEMICAL", 38, 49], ["amino acids", "CHEMICAL", 38, 49], ["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["amino acids", "AMINO_ACID", 38, 49], ["ORF1", "DNA", 0, 4], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["This region encodes a polyprotein which is probably cleaved into the viral non-structural proteins including methyltransferase, papain-like cysteine protease, macro domain, helicase and RNA-dependent RNA polymerase (RdRp); these enzymes are involved in viral replication, transcription and polyprotein cleavage (Reyes et al., 1990; Kaur et al., 1992; Koonin et al., 1992; Holla et al., 2013) .", [["cysteine", "CHEMICAL", 140, 148], ["methyltransferase", "GENE_OR_GENE_PRODUCT", 109, 126], ["papain-like cysteine protease", "GENE_OR_GENE_PRODUCT", 128, 157], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 186, 214], ["RdRp", "GENE_OR_GENE_PRODUCT", 216, 220], ["viral non-structural proteins", "PROTEIN", 69, 98], ["methyltransferase", "PROTEIN", 109, 126], ["papain", "PROTEIN", 128, 134], ["cysteine protease", "PROTEIN", 140, 157], ["macro domain", "PROTEIN", 159, 171], ["helicase", "PROTEIN", 173, 181], ["RNA-dependent RNA polymerase", "PROTEIN", 186, 214], ["RdRp", "PROTEIN", 216, 220], ["enzymes", "PROTEIN", 229, 236], ["a polyprotein", "PROBLEM", 20, 33], ["the viral non-structural proteins", "PROBLEM", 65, 98], ["methyltransferase", "TREATMENT", 109, 126], ["papain", "TREATMENT", 128, 134], ["cysteine protease", "TREATMENT", 140, 157], ["macro domain", "TREATMENT", 159, 171], ["helicase", "TREATMENT", 173, 181], ["RNA-dependent RNA polymerase (RdRp", "PROBLEM", 186, 220], ["these enzymes", "TEST", 223, 236], ["viral replication", "TREATMENT", 253, 270], ["polyprotein", "OBSERVATION", 22, 33], ["viral non-structural proteins", "OBSERVATION", 69, 98], ["viral replication", "OBSERVATION", 253, 270]]], ["Phylogenetic tree based on nucleotide sequences of complete capsid protein from different hepatitis E virus (HEV) and HEV-related viruses.", [["hepatitis E", "DISEASE", 90, 101], ["nucleotide", "CHEMICAL", 27, 37], ["hepatitis E virus", "ORGANISM", 90, 107], ["HEV", "ORGANISM", 109, 112], ["HEV-related viruses", "ORGANISM", 118, 137], ["capsid protein", "PROTEIN", 60, 74], ["hepatitis E virus", "SPECIES", 90, 107], ["hepatitis E virus", "SPECIES", 90, 107], ["HEV", "SPECIES", 109, 112], ["HEV", "SPECIES", 118, 121], ["Phylogenetic tree", "PROBLEM", 0, 17], ["nucleotide sequences", "TEST", 27, 47], ["complete capsid protein", "PROBLEM", 51, 74], ["different hepatitis E virus", "PROBLEM", 80, 107], ["HEV-related viruses", "PROBLEM", 118, 137], ["tree", "OBSERVATION_MODIFIER", 13, 17], ["capsid protein", "OBSERVATION", 60, 74], ["hepatitis", "OBSERVATION", 90, 99]]], ["Phylogenetic tree was inferred using the maximum likelihood method.", [["Phylogenetic tree", "PROBLEM", 0, 17], ["tree", "OBSERVATION_MODIFIER", 13, 17]]], ["A bootstrap analysis of 1000 replicates was included, and the results displayed on the interior branches.", [["interior branches", "MULTI-TISSUE_STRUCTURE", 87, 104], ["A bootstrap analysis", "TEST", 0, 20], ["interior", "ANATOMY_MODIFIER", 87, 95], ["branches", "ANATOMY_MODIFIER", 96, 104]]], ["The tree is drawn to scale, with branch lengths measured in the number of substitutions per site.", [["branch lengths", "PROBLEM", 33, 47], ["tree", "OBSERVATION_MODIFIER", 4, 8], ["branch", "OBSERVATION_MODIFIER", 33, 39], ["lengths", "OBSERVATION_MODIFIER", 40, 47], ["substitutions", "OBSERVATION", 74, 87], ["site", "OBSERVATION_MODIFIER", 92, 96]]], ["Evolutionary analyses were conducted in MEGA6.", [["MEGA6", "DNA", 40, 45], ["Evolutionary analyses", "TEST", 0, 21]]], ["Accession numbers are shown in brackets.", [["brackets", "OBSERVATION", 31, 39]]], ["Hepatitis E virus found in bovids and molluscs is not presented here.", [["Hepatitis E", "DISEASE", 0, 11], ["Hepatitis E virus", "ORGANISM", 0, 17], ["Hepatitis E virus", "SPECIES", 0, 17], ["Hepatitis E virus", "SPECIES", 0, 17], ["Hepatitis E virus", "PROBLEM", 0, 17]]], ["Genotypes HEV-3 and HEV-4 are, respectively, coloured in orange and blue.", [["HEV-3", "ORGANISM", 10, 15], ["HEV-4", "ORGANISM", 20, 25], ["HEV-", "SPECIES", 20, 24], ["HEV-3", "SPECIES", 10, 15], ["HEV-4", "SPECIES", 20, 25], ["Genotypes HEV", "TEST", 0, 13], ["HEV", "TEST", 20, 23]]], ["[Colour figure can be viewed at wileyonlinelibrary.com].StructureOpen reading frames 2 encodes the structural capsid protein and has a size of approximately 660 aa for genotypes 1-3 and 675 aa for members of genotype 4.", [["StructureOpen reading frames 2", "DNA", 56, 86], ["structural capsid protein", "PROTEIN", 99, 124], ["genotypes", "TEST", 168, 177], ["genotype 4", "PROBLEM", 208, 218], ["capsid protein", "OBSERVATION", 110, 124], ["size", "OBSERVATION_MODIFIER", 135, 139]]], ["This protein is highly immunogenic and is responsible for various functions such as assembly and host interaction.", [["highly", "OBSERVATION_MODIFIER", 16, 22], ["immunogenic", "OBSERVATION", 23, 34]]], ["Due to the high aa homogeneity of this region and the presence of only one reported HEV serotype, it is used both for diagnostic tests and vaccine development (Tsarev et al., 1997; Zhang et al., 2001; Engle et al., 2002; Koff, 2007; Panda et al., 2007) .StructureOpen reading frames 3 encodes a small phosphorylated protein with a size of approximately 120 aa which binds to the hepatocellular cytoskeleton to form a complex together with the capsid protein.", [["hepatocellular cytoskeleton", "ANATOMY", 379, 406], ["HEV", "ORGANISM", 84, 87], ["hepatocellular cytoskeleton", "CELLULAR_COMPONENT", 379, 406], ["StructureOpen reading frames 3", "DNA", 254, 284], ["small phosphorylated protein", "PROTEIN", 295, 323], ["capsid protein", "PROTEIN", 443, 457], ["HEV", "SPECIES", 84, 87], ["the high aa homogeneity of this region", "PROBLEM", 7, 45], ["HEV serotype", "PROBLEM", 84, 96], ["diagnostic tests", "TEST", 118, 134], ["a small phosphorylated protein", "PROBLEM", 293, 323], ["the capsid protein", "PROBLEM", 439, 457], ["HEV serotype", "OBSERVATION", 84, 96], ["small", "OBSERVATION_MODIFIER", 295, 300], ["size", "OBSERVATION_MODIFIER", 331, 335], ["hepatocellular", "ANATOMY", 379, 393], ["capsid protein", "OBSERVATION", 443, 457]]], ["Other possible ORF3 functions may be related to the regulation of cell signalling pathway and infectivity in vivo (Graff et al., 2005; Jim enez de Oya et al., 2007; Panda et al., 2007; Khuroo, 2008) .StructureA fourth ORF (ORF4) was reported from HEV-C2 (ferret) and two HEV-C1 (rat) sequences (Johne et al., 2012; Raj et al., 2012) .", [["cell", "ANATOMY", 66, 70], ["ORF3", "GENE_OR_GENE_PRODUCT", 15, 19], ["cell", "CELL", 66, 70], ["ORF4", "GENE_OR_GENE_PRODUCT", 223, 227], ["HEV-C2", "ORGANISM", 247, 253], ["ferret", "ORGANISM", 255, 261], ["HEV-C1", "ORGANISM", 271, 277], ["rat", "ORGANISM", 279, 282], ["ORF3", "DNA", 15, 19], ["StructureA fourth ORF", "DNA", 200, 221], ["ORF4", "DNA", 223, 227], ["HEV-C1 (rat) sequences", "DNA", 271, 293], ["ferret", "SPECIES", 255, 261], ["rat", "SPECIES", 279, 282], ["HEV-C2 (ferret", "SPECIES", 247, 261], ["ORF3 functions", "PROBLEM", 15, 29], ["cell signalling pathway", "TREATMENT", 66, 89], ["StructureA fourth ORF (ORF4)", "TEST", 200, 228], ["may be related to", "UNCERTAINTY", 30, 47], ["C2", "ANATOMY", 251, 253]]], ["In these Orthohepviruses C, ORF4 has 183 aa and overlaps with the 5 0 end of ORF1.", [["Orthohepviruses C", "CELL", 9, 26], ["ORF4", "GENE_OR_GENE_PRODUCT", 28, 32], ["ORF1", "GENE_OR_GENE_PRODUCT", 77, 81], ["ORF4", "DNA", 28, 32], ["5 0 end", "DNA", 66, 73], ["ORF1", "DNA", 77, 81], ["ORF4", "TEST", 28, 32]]], ["Its function is not yet known, but it has been located into the methyltransferase domain.", [["methyltransferase domain", "PROTEIN", 64, 88], ["methyltransferase domain", "OBSERVATION", 64, 88]]], ["Two additional ORFs were reported for one sequence found in rats, however, without the presence of a conventional start codon (Johne et al., 2012) .", [["rats", "ORGANISM", 60, 64], ["ORFs", "DNA", 15, 19], ["start codon", "DNA", 114, 125], ["rats", "SPECIES", 60, 64], ["Two additional ORFs", "TEST", 0, 19], ["one sequence", "TEST", 38, 50]]], ["A HEVrelated sequence found in moose has been partially sequenced.", [["HEVrelated sequence", "DNA", 2, 21], ["moose", "SPECIES", 31, 36], ["A HEVrelated sequence", "TEST", 0, 21]]], ["It contains a 3 0 end with poly A tail, ORF2, ORF3 and partial ORF1 (Lin et al., 2013) .", [["poly A tail", "GENE_OR_GENE_PRODUCT", 27, 38], ["ORF2", "GENE_OR_GENE_PRODUCT", 40, 44], ["ORF3", "GENE_OR_GENE_PRODUCT", 46, 50], ["poly A tail", "DNA", 27, 38], ["ORF2", "DNA", 40, 44], ["ORF3", "DNA", 46, 50], ["ORF1", "DNA", 63, 67], ["poly A tail", "TREATMENT", 27, 38], ["tail", "ANATOMY", 34, 38], ["partial", "OBSERVATION_MODIFIER", 55, 62], ["ORF1", "OBSERVATION_MODIFIER", 63, 67]]], ["More details regarding the genome organization of the different HEV and HEV-related viruses are available in Fig. 2 .Direct and Indirect Detection of HEV-Related Viruses in AnimalsHepatitis E virus and HEV-related strains have been genetically detected in naturally infected domestic and wild animals (Fig. 3 ).", [["Hepatitis E", "DISEASE", 180, 191], ["HEV", "ORGANISM", 64, 67], ["HEV-related viruses", "ORGANISM", 72, 91], ["HEV-Related Viruses", "ORGANISM", 150, 169], ["Animals", "ORGANISM", 173, 180], ["Hepatitis E virus", "ORGANISM", 180, 197], ["HEV", "ORGANISM", 202, 205], ["Hepatitis E virus", "SPECIES", 180, 197], ["HEV", "SPECIES", 64, 67], ["HEV", "SPECIES", 72, 75], ["Hepatitis E virus", "SPECIES", 180, 197], ["the different HEV", "PROBLEM", 50, 67], ["HEV-related viruses", "PROBLEM", 72, 91], ["Indirect Detection", "TEST", 128, 146], ["HEV", "PROBLEM", 150, 153], ["Related Viruses", "PROBLEM", 154, 169], ["Hepatitis E virus", "PROBLEM", 180, 197], ["HEV-related strains", "PROBLEM", 202, 221], ["different", "OBSERVATION_MODIFIER", 54, 63], ["HEV", "OBSERVATION", 64, 67], ["HEV", "OBSERVATION", 150, 153], ["Viruses", "OBSERVATION", 162, 169]]], ["In addition, antibodies against HEV have also been detected in many animal species such as dog, cat, sheep, goat, horse, rodents, cattle, duck, pigeon and non-human primates (Arankalle et al., 2001; Vitral et al., 2005; Mochizuki et al., 2006; Zhang et al., 2008a; Pavio et al., 2010) .", [["HEV", "ORGANISM", 32, 35], ["dog", "ORGANISM", 91, 94], ["cat", "ORGANISM", 96, 99], ["sheep", "ORGANISM", 101, 106], ["goat", "ORGANISM", 108, 112], ["horse", "ORGANISM", 114, 119], ["rodents", "ORGANISM", 121, 128], ["cattle", "ORGANISM", 130, 136], ["duck", "ORGANISM", 138, 142], ["pigeon", "ORGANISM", 144, 150], ["non-human", "ORGANISM", 155, 164], ["primates", "ORGANISM", 165, 173], ["antibodies", "PROTEIN", 13, 23], ["dog", "SPECIES", 91, 94], ["cat", "SPECIES", 96, 99], ["sheep", "SPECIES", 101, 106], ["goat", "SPECIES", 108, 112], ["horse", "SPECIES", 114, 119], ["cattle", "SPECIES", 130, 136], ["duck", "SPECIES", 138, 142], ["pigeon", "SPECIES", 144, 150], ["HEV", "SPECIES", 32, 35], ["dog", "SPECIES", 91, 94], ["sheep", "SPECIES", 101, 106], ["goat", "SPECIES", 108, 112], ["cattle", "SPECIES", 130, 136], ["antibodies", "TREATMENT", 13, 23], ["HEV", "PROBLEM", 32, 35]]], ["The antibody presence in these species raises a puzzling question and suggests that these animals may have been exposed to the HEV or to an antigenically related agent.HEV infection of non-human primatesThe first study reporting the infection of non-human primates with genotype 1 HEV (previously called ET-NAN-BH) showed that the cynomolgus monkey was susceptible to infection and suitable for use in experimental infection studies (Bradley et al., 1987) .", [["HEV infection", "DISEASE", 168, 181], ["infection", "DISEASE", 233, 242], ["infection", "DISEASE", 368, 377], ["infection", "DISEASE", 415, 424], ["animals", "ORGANISM", 90, 97], ["HEV", "ORGANISM", 127, 130], ["HEV", "ORGANISM", 168, 171], ["non-human", "ORGANISM", 185, 194], ["primates", "ORGANISM", 195, 203], ["non-human", "ORGANISM", 246, 255], ["primates", "ORGANISM", 256, 264], ["genotype 1 HEV", "ORGANISM", 270, 284], ["cynomolgus", "ORGANISM", 331, 341], ["monkey", "ORGANISM", 342, 348], ["cynomolgus monkey", "SPECIES", 331, 348], ["HEV", "SPECIES", 127, 130], ["HEV", "SPECIES", 168, 171], ["HEV", "SPECIES", 281, 284], ["cynomolgus monkey", "SPECIES", 331, 348], ["The antibody", "TEST", 0, 12], ["HEV infection of non-human primates", "PROBLEM", 168, 203], ["The first study", "TEST", 203, 218], ["the infection", "PROBLEM", 229, 242], ["the cynomolgus monkey", "PROBLEM", 327, 348], ["infection", "PROBLEM", 368, 377], ["experimental infection studies", "TEST", 402, 432], ["infection", "OBSERVATION", 172, 181], ["infection", "OBSERVATION", 233, 242], ["infection", "OBSERVATION", 368, 377], ["infection", "OBSERVATION", 415, 424]]], ["Several other species such as tamarins, rhesus monkey, three-striped night monkey and the common chimpanzee were also successfully infected with HEV (Bradley et al., 1987; Gupta et al., 1990; Ticehurst et al., 1992; McCaustland et al., 2000) .", [["tamarins", "ORGANISM", 30, 38], ["rhesus monkey", "ORGANISM", 40, 53], ["night monkey", "ORGANISM", 69, 81], ["chimpanzee", "ORGANISM", 97, 107], ["HEV", "ORGANISM", 145, 148], ["tamarins", "SPECIES", 30, 38], ["rhesus monkey", "SPECIES", 40, 53], ["striped night monkey", "SPECIES", 61, 81], ["chimpanzee", "SPECIES", 97, 107], ["rhesus monkey", "SPECIES", 40, 53], ["striped night monkey", "SPECIES", 61, 81], ["HEV", "SPECIES", 145, 148], ["Several other species", "PROBLEM", 0, 21], ["species", "OBSERVATION", 14, 21]]], ["Recently, it was demonstrated that the cynomolgus monkey is susceptible to infection with human and swine genotype 3 HEV from Argentina, Brazil and the Netherlands (de Carvalho et al., 2013) .", [["infection", "DISEASE", 75, 84], ["cynomolgus monkey", "ORGANISM", 39, 56], ["human", "ORGANISM", 90, 95], ["swine genotype 3 HEV", "ORGANISM", 100, 120], ["cynomolgus monkey", "SPECIES", 39, 56], ["human", "SPECIES", 90, 95], ["swine", "SPECIES", 100, 105], ["cynomolgus monkey", "SPECIES", 39, 56], ["human", "SPECIES", 90, 95], ["swine", "SPECIES", 100, 105], ["HEV", "SPECIES", 117, 120], ["infection", "PROBLEM", 75, 84], ["cynomolgus monkey", "OBSERVATION", 39, 56], ["infection", "OBSERVATION", 75, 84]]], ["These studies were very important in understanding different aspects of HEV infection in humans.", [["HEV infection", "DISEASE", 72, 85], ["HEV", "ORGANISM", 72, 75], ["humans", "ORGANISM", 89, 95], ["humans", "SPECIES", 89, 95], ["HEV", "SPECIES", 72, 75], ["humans", "SPECIES", 89, 95], ["These studies", "TEST", 0, 13], ["HEV infection in humans", "PROBLEM", 72, 95], ["HEV", "OBSERVATION_MODIFIER", 72, 75], ["infection", "OBSERVATION", 76, 85]]], ["Naturally occurring anti-HEV antibodies were reported in both free-living and captive non-human primates, and their role as reservoir has been discussed (Arankalle et al., 1994; Hirano et al., 2003b) .", [["non-human", "ORGANISM", 86, 95], ["primates", "ORGANISM", 96, 104], ["anti-HEV antibodies", "PROTEIN", 20, 39], ["Naturally occurring anti-HEV antibodies", "PROBLEM", 0, 39], ["anti-HEV antibodies", "OBSERVATION", 20, 39]]], ["However, neither HEV nor HEVrelated viruses have been found naturally in non-human primates (Meng, 2011) .HEV infection of SuidaeSince the first sequence was reported in swine in 1997 in the USA (Meng et al., 1997) , HEV genotypes 3 and 4 have been detected and seem to be enzootic in domestic pigs across the five continents (Fig. 3) .HEV infection of SuidaeIn Japan, HEV was detected in wild boar for the first time in 2004 (Sonoda et al., 2004) .", [["HEV infection", "DISEASE", 106, 119], ["HEV infection", "DISEASE", 336, 349], ["HEV", "ORGANISM", 17, 20], ["HEVrelated viruses", "ORGANISM", 25, 43], ["non-human primates", "ORGANISM", 73, 91], ["HEV", "ORGANISM", 106, 109], ["HEV genotypes 3", "GENE_OR_GENE_PRODUCT", 217, 232], ["4", "GENE_OR_GENE_PRODUCT", 237, 238], ["pigs", "ORGANISM", 294, 298], ["HEV", "ORGANISM", 336, 339], ["SuidaeIn Japan", "ORGANISM", 353, 367], ["HEV", "ORGANISM", 369, 372], ["boar", "ORGANISM", 394, 398], ["swine", "SPECIES", 170, 175], ["pigs", "SPECIES", 294, 298], ["HEV", "SPECIES", 17, 20], ["HEV", "SPECIES", 106, 109], ["swine", "SPECIES", 170, 175], ["pigs", "SPECIES", 294, 298], ["HEV", "SPECIES", 336, 339], ["HEV", "SPECIES", 369, 372], ["HEVrelated viruses", "PROBLEM", 25, 43], ["HEV infection", "PROBLEM", 106, 119], ["HEV genotypes", "TEST", 217, 230], ["viruses", "OBSERVATION", 36, 43], ["infection", "OBSERVATION", 110, 119], ["seem to be", "UNCERTAINTY", 262, 272], ["enzootic", "OBSERVATION_MODIFIER", 273, 281], ["infection", "OBSERVATION", 340, 349]]], ["The majority of HEV strains detected from wild boar belong to genotype 3 (Meng, 2010b) .", [["HEV", "ORGANISM", 16, 19], ["wild boar", "ORGANISM", 42, 51], ["boar", "SPECIES", 47, 51], ["HEV", "SPECIES", 16, 19], ["HEV strains", "PROBLEM", 16, 27], ["HEV strains", "OBSERVATION", 16, 27]]], ["In contrast to domestic swine, high detection rates of HEV RNA have been reported not only in young animals but also in adult wild boar (de Deus et al., 2008; Martelli et al., 2008; Oliveira-Filho et al., 2014) .", [["HEV", "ORGANISM", 55, 58], ["boar", "ORGANISM", 131, 135], ["HEV RNA", "RNA", 55, 62], ["swine", "SPECIES", 24, 29], ["boar", "SPECIES", 131, 135], ["swine", "SPECIES", 24, 29], ["HEV", "SPECIES", 55, 58], ["high detection rates of HEV RNA", "PROBLEM", 31, 62]]], ["In addition, it seems that viral genetic heterogeneity is higher in wild boar populations.", [["boar", "ORGANISM", 73, 77], ["viral genetic heterogeneity", "PROBLEM", 27, 54], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["genetic heterogeneity", "OBSERVATION", 33, 54], ["higher", "OBSERVATION_MODIFIER", 58, 64], ["boar populations", "OBSERVATION", 73, 89]]], ["In Japan, sequences from both genotypes 3 and 4 have been detected in wild boar as well as sequences belonging to the genotypes HEV-5 and HEV-6 (Sato et al., 2011; Smith et al., 2014) .HEV infection of CervidaeMolecular and serological evidence of HEV and HEVrelated viruses in cervids has been reported in Sika deer, red deer, tufted deer, Reeve's muntjac, roe deer and moose (Tei et al., 2003; Matsuura et al., 2007; Yu et al., 2007; Zhang et al., 2008b; Reuter et al., 2009; Boadella et al., 2010; Forg ach et al., 2010; Rutjes et al., 2010; Lin et al., 2013) .", [["cervids", "ANATOMY", 278, 285], ["HEV infection", "DISEASE", 185, 198], ["HEV and HEVrelated viruses", "DISEASE", 248, 274], ["cervids", "DISEASE", 278, 285], ["4", "GENE_OR_GENE_PRODUCT", 46, 47], ["boar", "ORGANISM", 75, 79], ["HEV-5", "ORGANISM", 128, 133], ["HEV-6", "ORGANISM", 138, 143], ["HEV", "ORGANISM", 185, 188], ["HEV", "ORGANISM", 248, 251], ["HEVrelated viruses", "ORGANISM", 256, 274], ["cervids", "CANCER", 278, 285], ["Sika deer", "ORGANISM", 307, 316], ["red deer", "ORGANISM", 318, 326], ["tufted deer", "ORGANISM", 328, 339], ["roe deer", "ORGANISM", 358, 366], ["genotypes 3 and 4", "DNA", 30, 47], ["deer", "SPECIES", 312, 316], ["deer", "SPECIES", 322, 326], ["tufted deer", "SPECIES", 328, 339], ["roe deer", "SPECIES", 358, 366], ["HEV-5", "SPECIES", 128, 133], ["HEV-6", "SPECIES", 138, 143], ["HEV", "SPECIES", 185, 188], ["HEV", "SPECIES", 248, 251], ["Sika deer", "SPECIES", 307, 316], ["red deer", "SPECIES", 318, 326], ["tufted deer", "SPECIES", 328, 339], ["roe deer", "SPECIES", 358, 366], ["the genotypes HEV", "TEST", 114, 131], ["HEV", "TEST", 138, 141], ["HEV infection of CervidaeMolecular", "PROBLEM", 185, 219], ["HEV", "PROBLEM", 248, 251], ["HEVrelated viruses", "PROBLEM", 256, 274], ["infection", "OBSERVATION", 189, 198], ["HEV", "OBSERVATION", 248, 251], ["viruses", "OBSERVATION", 267, 274]]], ["The first report of HEV-related sequences in deer demonstrated a close phylogenetic relationship with genotype 3.", [["HEV", "ORGANISM", 20, 23], ["deer", "ORGANISM", 45, 49], ["HEV-related sequences", "DNA", 20, 41], ["HEV", "SPECIES", 20, 23], ["deer", "SPECIES", 45, 49]]], ["In contrast to the other viruses found in cervids, the HEV-related virus detected in Swedish moose does not cluster within genotypes HEV-1 to HEV-7.", [["cervids", "ANATOMY", 42, 49], ["cervids", "CANCER", 42, 49], ["HEV-related virus", "ORGANISM", 55, 72], ["HEV-1", "ORGANISM", 133, 138], ["HEV-7", "ORGANISM", 142, 147], ["HEV-1", "SPECIES", 133, 138], ["HEV-related virus", "SPECIES", 55, 72], ["Swedish moose", "SPECIES", 85, 98], ["HEV-1", "SPECIES", 133, 138], ["HEV-7", "SPECIES", 142, 147], ["the other viruses", "PROBLEM", 15, 32], ["the HEV-related virus", "PROBLEM", 51, 72], ["genotypes HEV", "TEST", 123, 136], ["HEV", "TEST", 142, 145], ["viruses", "OBSERVATION", 25, 32], ["HEV", "OBSERVATION", 55, 58]]], ["Phylogenetic analysis based on the complete capsid protein indicates that the virus found in moose clusters in a separate branch (Fig. 1) .HEV infection of BovidaeAntibodies against HEV have been detected in cattle in several studies (Arankalle et al., 2001; Wang et al., 2002; Vitral et al., 2005; Zhang et al., 2008a) .", [["HEV infection", "DISEASE", 139, 152], ["BovidaeAntibodies", "CHEMICAL", 156, 173], ["HEV", "ORGANISM", 139, 142], ["BovidaeAntibodies", "GENE_OR_GENE_PRODUCT", 156, 173], ["HEV", "ORGANISM", 182, 185], ["capsid protein", "PROTEIN", 44, 58], ["cattle", "SPECIES", 208, 214], ["HEV", "SPECIES", 139, 142], ["HEV", "SPECIES", 182, 185], ["cattle", "SPECIES", 208, 214], ["Phylogenetic analysis", "TEST", 0, 21], ["the complete capsid protein", "TEST", 31, 58], ["the virus", "PROBLEM", 74, 83], ["HEV infection of BovidaeAntibodies", "PROBLEM", 139, 173], ["HEV", "PROBLEM", 182, 185], ["moose clusters", "OBSERVATION", 93, 107], ["branch", "ANATOMY_MODIFIER", 122, 128], ["Fig", "OBSERVATION_MODIFIER", 130, 133], ["infection", "OBSERVATION", 143, 152]]], ["However, only one study from China has genetic confirmation, obtained through the amplification of a 189 bp sequence of ORF2 from eight cow faeces.", [["ORF2", "GENE_OR_GENE_PRODUCT", 120, 124], ["cow", "ORGANISM", 136, 139], ["faeces", "ORGANISM_SUBDIVISION", 140, 146], ["189 bp sequence", "DNA", 101, 116], ["ORF2", "DNA", 120, 124], ["cow", "SPECIES", 136, 139], ["cow", "SPECIES", 136, 139], ["one study", "TEST", 14, 23], ["genetic confirmation", "TEST", 39, 59], ["a 189 bp sequence of ORF2", "TREATMENT", 99, 124]]], ["These sequences showed homology of 96-100% to each other and 76-86%, 82-84%, 79-85% and 84-96% homology with genotypes 1-4, respectively.", [["genotypes 1-4", "DNA", 109, 122], ["These sequences", "TEST", 0, 15], ["homology", "TEST", 23, 31], ["genotypes", "TEST", 109, 118]]], ["Accordingly, the HEV sequences found in bovines were assigned to genotype 4 (Hu and Ma, 2010) .", [["HEV", "ORGANISM", 17, 20], ["bovines", "ORGANISM", 40, 47], ["HEV sequences", "DNA", 17, 30], ["HEV", "SPECIES", 17, 20], ["bovines", "SPECIES", 40, 47], ["the HEV sequences", "TEST", 13, 30], ["genotype", "TEST", 65, 73]]], ["The same short HEV ORF2 sequence of 189 bp was amplified from six faecal samples of sheep by the same research group in China.", [["faecal samples", "ANATOMY", 66, 80], ["HEV", "ORGANISM", 15, 18], ["sheep", "ORGANISM", 84, 89], ["HEV ORF2 sequence", "DNA", 15, 32], ["sheep", "SPECIES", 84, 89], ["HEV", "SPECIES", 15, 18], ["sheep", "SPECIES", 84, 89], ["HEV ORF2 sequence", "TEST", 15, 32], ["bp", "TEST", 40, 42]]], ["These sequences showed homology of 99-100% between themselves and 79-85%, 81-83%, 79-84% and 85-95% homology with genotypes 1, 2, 3 and 4, respectively, and clustered into genotype 4 (Wang and Ma, 2010) .", [["3", "GENE_OR_GENE_PRODUCT", 130, 131], ["genotypes 1, 2, 3 and 4", "DNA", 114, 137], ["These sequences", "TEST", 0, 15], ["homology", "TEST", 23, 31], ["genotypes", "TEST", 114, 123]]], ["However, additional studies must be conducted to confirm the presence of viruses in these animal species, and longer sequences need to be isolated to confirm the genotype assignment.", [["additional studies", "TEST", 9, 27], ["viruses", "PROBLEM", 73, 80], ["viruses", "OBSERVATION", 73, 80]]], ["Recently, full genome sequences closely related to HEV-4 were detected in yak in China ( Fig. 1 ; Xu et al., 2014) .HEV infection of CamelidaeRecently, HEV-related virus was recovered in the faeces of three dromedary camels in Dubai.", [["faeces", "ANATOMY", 191, 197], ["HEV infection", "DISEASE", 116, 129], ["HEV-4", "ORGANISM", 51, 56], ["HEV", "ORGANISM", 116, 119], ["HEV-related virus", "ORGANISM", 152, 169], ["faeces", "ORGANISM_SUBDIVISION", 191, 197], ["HEV-related virus", "SPECIES", 152, 169], ["HEV-4", "SPECIES", 51, 56], ["yak", "SPECIES", 74, 77], ["HEV", "SPECIES", 116, 119], ["HEV-related virus", "SPECIES", 152, 169], ["HEV", "TEST", 51, 54], ["HEV infection of CamelidaeRecently", "PROBLEM", 116, 150], ["HEV-related virus", "PROBLEM", 152, 169], ["infection", "OBSERVATION", 120, 129], ["dromedary camels", "OBSERVATION", 207, 223]]], ["The isolates were called DcHEV (178 and 180C) and show more than 20% nucleotide divergence from the other HEVs (Woo et al., 2014) .HEV infection of CamelidaeThese viruses are most similar to viruses in the genus, Orthohepevirus A, and have been placed within this genus as genotype HEV-7 (Smith et al., 2014) .HEV infection of LeporidaeIn 2009, HEV-related sequences were found in Chinese farmed rabbits.", [["nucleotide", "CHEMICAL", 69, 79], ["HEV infection", "DISEASE", 131, 144], ["HEV infection", "DISEASE", 310, 323], ["nucleotide", "CHEMICAL", 69, 79], ["HEV", "ORGANISM", 131, 134], ["Orthohepevirus A", "ORGANISM", 213, 229], ["HEV-7", "ORGANISM", 282, 287], ["HEV", "ORGANISM", 310, 313], ["HEV", "ORGANISM", 345, 348], ["rabbits", "ORGANISM", 396, 403], ["HEVs", "CELL_TYPE", 106, 110], ["HEV-related sequences", "DNA", 345, 366], ["rabbits", "SPECIES", 396, 403], ["HEV", "SPECIES", 131, 134], ["Orthohepevirus A", "SPECIES", 213, 229], ["HEV-7", "SPECIES", 282, 287], ["HEV", "SPECIES", 310, 313], ["Chinese farmed rabbits", "SPECIES", 381, 403], ["HEV infection of Camelidae", "PROBLEM", 131, 157], ["These viruses", "PROBLEM", 157, 170], ["genotype HEV", "TEST", 273, 285], ["HEV infection", "PROBLEM", 310, 323], ["LeporidaeIn", "TREATMENT", 327, 338], ["HEV-related sequences", "TEST", 345, 366], ["infection", "OBSERVATION", 135, 144], ["viruses", "OBSERVATION", 163, 170], ["viruses", "OBSERVATION", 191, 198], ["genus", "ANATOMY", 206, 211], ["infection", "OBSERVATION", 314, 323]]], ["Phylogenetic analysis based on the complete genome sequence suggests that they were genetically closely related to human and porcine genotype HEV-3.", [["human", "ORGANISM", 115, 120], ["porcine genotype HEV-3", "ORGANISM", 125, 147], ["human", "SPECIES", 115, 120], ["porcine", "SPECIES", 125, 132], ["human", "SPECIES", 115, 120], ["Phylogenetic analysis", "TEST", 0, 21], ["the complete genome sequence", "TEST", 31, 59], ["human and porcine genotype HEV", "TREATMENT", 115, 145]]], ["The sequences of rabbit HEV have about 85% nucleotide homology between themselves and 74%, 73%, 78-79%, 74-75% and 46-47% homology with genotypes 1-4 of mammals and avian HEV, respectively.", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 43, 53], ["rabbit HEV", "ORGANISM", 17, 27], ["mammals", "ORGANISM", 153, 160], ["avian HEV", "ORGANISM", 165, 174], ["rabbit", "SPECIES", 17, 23], ["avian", "SPECIES", 165, 170], ["rabbit HEV", "SPECIES", 17, 27], ["HEV", "SPECIES", 171, 174], ["rabbit HEV", "TEST", 17, 27], ["nucleotide homology", "TEST", 43, 62], ["genotypes", "TEST", 136, 145]]], ["Later on, more sequences were reported in China, the USA and France, including closely related sequences found in humans (Cossaboom et al., 2011 (Cossaboom et al., , 2012 Izopet et al., 2012; Han et al., 2014) .HEV infection of LeporidaeThe sequences found in rabbits clustered in a new distinct branch related to genotype 3 and were initially suggested to form another genotype (Zhao et al., 2009; Geng et al., 2011; Izopet et al., 2012) .", [["HEV infection", "DISEASE", 211, 224], ["humans", "ORGANISM", 114, 120], ["HEV", "ORGANISM", 211, 214], ["rabbits", "ORGANISM", 260, 267], ["humans", "SPECIES", 114, 120], ["rabbits", "SPECIES", 260, 267], ["humans", "SPECIES", 114, 120], ["HEV", "SPECIES", 211, 214], ["rabbits", "SPECIES", 260, 267], ["HEV infection of Leporidae", "PROBLEM", 211, 237], ["The sequences", "TEST", 237, 250], ["infection", "OBSERVATION", 215, 224], ["new", "OBSERVATION_MODIFIER", 283, 286], ["distinct", "OBSERVATION_MODIFIER", 287, 295], ["branch", "OBSERVATION_MODIFIER", 296, 302]]], ["Further studies have shown that the HEV strains found in rabbits cluster at the edge of genotype 3 sequence space and could indeed represent a new genotype or a new genotype HEV-3 clade (Oliveira-Filho et al., 2013; Smith et al., 2013) .", [["HEV strains", "ORGANISM", 36, 47], ["rabbits", "ORGANISM", 57, 64], ["HEV-3", "ORGANISM", 174, 179], ["rabbits", "SPECIES", 57, 64], ["HEV", "SPECIES", 36, 39], ["rabbits", "SPECIES", 57, 64], ["Further studies", "TEST", 0, 15], ["the HEV strains", "PROBLEM", 32, 47], ["a new genotype", "PROBLEM", 141, 155], ["a new genotype HEV", "PROBLEM", 159, 177], ["new", "OBSERVATION_MODIFIER", 143, 146]]], ["According to the ICTV Hepevirus study group, the HEV strains found in rabbits are considered a distant variant in genotype HEV-3 (Smith et al., 2014) .HEV infection of MuridaeThe presence of antibodies against HEV has been reported in different rodent species (Kabrane-Lazizi et al., 1999; Favorov et al., 2000; Arankalle et al., 2001; Hirano et al., 2003a; Easterbrook et al., 2007) .", [["HEV infection", "DISEASE", 151, 164], ["HEV", "ORGANISM", 49, 52], ["rabbits", "ORGANISM", 70, 77], ["HEV-3", "ORGANISM", 123, 128], ["HEV", "ORGANISM", 151, 154], ["Muridae", "ORGANISM", 168, 175], ["HEV", "ORGANISM", 210, 213], ["antibodies", "PROTEIN", 191, 201], ["rabbits", "SPECIES", 70, 77], ["HEV", "SPECIES", 49, 52], ["rabbits", "SPECIES", 70, 77], ["HEV-3", "SPECIES", 123, 128], ["HEV", "SPECIES", 151, 154], ["HEV", "SPECIES", 210, 213], ["the ICTV Hepevirus study", "TEST", 13, 37], ["the HEV strains", "PROBLEM", 45, 60], ["a distant variant", "PROBLEM", 93, 110], ["genotype HEV", "TEST", 114, 126], ["HEV infection of Muridae", "PROBLEM", 151, 175], ["antibodies", "PROBLEM", 191, 201], ["HEV", "PROBLEM", 210, 213], ["distant variant", "OBSERVATION", 95, 110], ["infection", "OBSERVATION", 155, 164]]], ["Hepatitis E virus antigens were detected in different organs after experimental infection of Wistar rats with human virus (genotype 1) (Maneerat et al., 1996) .", [["organs", "ANATOMY", 54, 60], ["infection", "DISEASE", 80, 89], ["Hepatitis E virus", "ORGANISM", 0, 17], ["organs", "ORGAN", 54, 60], ["Wistar rats", "ORGANISM", 93, 104], ["human", "ORGANISM", 110, 115], ["Hepatitis E virus antigens", "PROTEIN", 0, 26], ["Hepatitis E virus", "SPECIES", 0, 17], ["rats", "SPECIES", 100, 104], ["human", "SPECIES", 110, 115], ["Hepatitis E virus", "SPECIES", 0, 17], ["human virus", "SPECIES", 110, 121], ["Hepatitis E virus antigens", "TEST", 0, 26], ["experimental infection", "PROBLEM", 67, 89], ["human virus (genotype", "TREATMENT", 110, 131], ["infection", "OBSERVATION", 80, 89]]], ["Nevertheless, none of the abovementioned studies succeeded in recovering viral genome.HEV infection of MuridaeIn 2008, fragments of HEV-related viruses were sequenced from faeces of Rattus norvegicus from Germany.", [["HEV infection", "DISEASE", 86, 99], ["HEV", "ORGANISM", 86, 89], ["HEV-related viruses", "ORGANISM", 132, 151], ["faeces", "ORGANISM_SUBDIVISION", 172, 178], ["Rattus norvegicus", "ORGANISM", 182, 199], ["viral genome", "DNA", 73, 85], ["Rattus norvegicus", "SPECIES", 182, 199], ["HEV", "SPECIES", 86, 89], ["Rattus norvegicus", "SPECIES", 182, 199], ["the abovementioned studies", "TEST", 22, 48], ["HEV infection of MuridaeIn", "PROBLEM", 86, 112], ["HEV-related viruses", "PROBLEM", 132, 151], ["viral genome", "OBSERVATION", 73, 85], ["infection", "OBSERVATION", 90, 99]]], ["The HEV-related sequences detected in rats have a sequence homology of about 60% and 50% with human and avian HEV strains, respectively.", [["HEV", "ORGANISM", 4, 7], ["rats", "ORGANISM", 38, 42], ["human", "ORGANISM", 94, 99], ["avian HEV", "ORGANISM", 104, 113], ["HEV-related sequences", "DNA", 4, 25], ["rats", "SPECIES", 38, 42], ["human", "SPECIES", 94, 99], ["HEV", "SPECIES", 4, 7], ["human", "SPECIES", 94, 99], ["HEV", "SPECIES", 110, 113], ["a sequence homology", "TEST", 48, 67], ["HEV strains", "OBSERVATION", 110, 121]]], ["Subsequently, the complete genomes of the two HEV strains from rats were determined and it was suggested that they might belong to a new species within Hepeviridae (Johne et al., 2010) .", [["HEV", "ORGANISM", 46, 49], ["rats", "ORGANISM", 63, 67], ["rats", "SPECIES", 63, 67], ["HEV", "SPECIES", 46, 49], ["the two HEV strains", "PROBLEM", 38, 57]]], ["Since then, new HEV-C1 sequences have been reported in Germany, USA, China, Vietnam and Indonesia (Johne et al., 2012; Li et al., 2013b,d) and specific HEV-C1 sequences were included in the species Orthohepevirus C genotype HEV-C1 (Smith et al., 2014) .", [["HEV-C1", "ORGANISM", 16, 22], ["HEV-C1", "ORGANISM", 152, 158], ["Orthohepevirus C", "ORGANISM", 198, 214], ["HEV-C1", "ORGANISM", 224, 230], ["HEV-C1 sequences", "DNA", 16, 32], ["HEV-C1 sequences", "DNA", 152, 168], ["new HEV-C1 sequences", "TEST", 12, 32], ["Li et al.", "TEST", 119, 128], ["specific HEV-C1 sequences", "TEST", 143, 168], ["the species", "TEST", 186, 197], ["C1", "ANATOMY", 228, 230]]], ["Recently, several liver tissue samples from Rattus rattus and R. norvegicus in museum collections were tested and found to contain HEV genotype 3 (Lack et al., 2012) .HEV infection of SoricidaeSequences closely related to HEV-C1 were detected from Asian musk shrews which shared the environment with wild rats in China (Guan et al., 2013) .HEV infection of MustelidaeThe first HEV-related virus found in Mustelidae was reported in the Netherlands in 2012.", [["liver tissue samples", "ANATOMY", 18, 38], ["HEV infection", "DISEASE", 167, 180], ["HEV infection", "DISEASE", 340, 353], ["HEV-related virus", "DISEASE", 377, 394], ["liver tissue samples", "TISSUE", 18, 38], ["Rattus rattus", "ORGANISM", 44, 57], ["R. norvegicus", "ORGANISM", 62, 75], ["museum", "ORGANISM", 79, 85], ["HEV", "ORGANISM", 167, 170], ["HEV-C1", "ORGANISM", 222, 228], ["musk shrews", "ORGANISM", 254, 265], ["rats", "ORGANISM", 305, 309], ["HEV", "ORGANISM", 340, 343], ["Mustelidae", "ORGANISM", 357, 367], ["HEV-related virus", "ORGANISM", 377, 394], ["Mustelidae", "ORGANISM", 404, 414], ["Rattus rattus", "SPECIES", 44, 57], ["R. norvegicus", "SPECIES", 62, 75], ["rats", "SPECIES", 305, 309], ["HEV-related virus", "SPECIES", 377, 394], ["Rattus rattus", "SPECIES", 44, 57], ["R. norvegicus", "SPECIES", 62, 75], ["HEV", "SPECIES", 167, 170], ["HEV-C1", "SPECIES", 222, 228], ["Asian musk shrews", "SPECIES", 248, 265], ["HEV", "SPECIES", 340, 343], ["several liver tissue samples", "TEST", 10, 38], ["Rattus rattus", "TEST", 44, 57], ["HEV genotype", "TEST", 131, 143], ["HEV infection of SoricidaeSequences", "PROBLEM", 167, 202], ["HEV infection of Mustelidae", "PROBLEM", 340, 367], ["related virus", "PROBLEM", 381, 394], ["liver", "ANATOMY", 18, 23], ["infection", "OBSERVATION", 171, 180], ["C1", "ANATOMY", 226, 228], ["infection", "OBSERVATION", 344, 353]]], ["Two years later, HEV was detected in a ferret breeding colony in the USA and in Japan (Li et al., 2014) .", [["colony", "ANATOMY", 55, 61], ["HEV", "ORGANISM", 17, 20], ["ferret", "ORGANISM", 39, 45], ["HEV", "SPECIES", 17, 20], ["ferret", "SPECIES", 39, 45], ["HEV", "PROBLEM", 17, 20]]], ["Phylogenetic analysis based on complete genomic sequences showed that HEV-related sequences found in ferrets were separate from genotypes 1 to 4 and clustered in a separate branch near to sequences found in rats (HEV-C1) (Raj et al., 2012; Li et al., 2015) .", [["HEV", "ORGANISM", 70, 73], ["ferrets", "ORGANISM", 101, 108], ["rats", "ORGANISM", 207, 211], ["HEV-C1", "ORGANISM", 213, 219], ["HEV-related sequences", "DNA", 70, 91], ["genotypes 1 to 4", "DNA", 128, 144], ["ferrets", "SPECIES", 101, 108], ["rats", "SPECIES", 207, 211], ["HEV", "SPECIES", 70, 73], ["Phylogenetic analysis", "TEST", 0, 21], ["complete genomic sequences", "TEST", 31, 57], ["HEV-related sequences", "PROBLEM", 70, 91], ["branch", "ANATOMY_MODIFIER", 173, 179], ["C1", "ANATOMY", 217, 219]]], ["Recently, partial genomic sequences of HEV-related viruses, genetically close to viruses found in ferrets (HEV-C2), were detected in 4 farmed mink from Denmark in 2013 (Krog et al., 2013) .HEV infection of HerpestidaeThe only HEV-related virus in Herpestidae was detected in 2006, in a mongoose from Japan (Nakamura et al., 2006) .", [["HEV infection", "DISEASE", 189, 202], ["Herpestidae", "CHEMICAL", 206, 217], ["HEV-related viruses", "ORGANISM", 39, 58], ["ferrets", "ORGANISM", 98, 105], ["HEV-C2", "ORGANISM", 107, 113], ["mink", "ORGANISM", 142, 146], ["HEV", "ORGANISM", 189, 192], ["Herpestidae", "GENE_OR_GENE_PRODUCT", 206, 217], ["HEV-related virus", "ORGANISM", 226, 243], ["Herpestidae", "ORGANISM", 247, 258], ["ferrets", "SPECIES", 98, 105], ["ferrets", "SPECIES", 98, 105], ["mink", "SPECIES", 142, 146], ["HEV", "SPECIES", 189, 192], ["partial genomic sequences", "PROBLEM", 10, 35], ["HEV-related viruses", "PROBLEM", 39, 58], ["viruses", "PROBLEM", 81, 88], ["HEV infection of Herpestidae", "PROBLEM", 189, 217], ["HEV-related virus", "PROBLEM", 226, 243], ["HEV", "OBSERVATION", 39, 42], ["viruses", "OBSERVATION", 51, 58], ["C2", "ANATOMY", 111, 113], ["infection", "OBSERVATION", 193, 202], ["HEV", "OBSERVATION_MODIFIER", 226, 229], ["-related", "OBSERVATION_MODIFIER", 229, 237], ["virus", "OBSERVATION", 238, 243]]], ["The whole genome sequence of this strain was determined: it was HEV genotype 3 closely related to a Japanese porcine HEV sequence.HEV infection of CanidaeIn 2013, fragments of HEV-related virus were sequenced from faeces of two foxes in the Netherlands.", [["HEV infection", "DISEASE", 130, 143], ["porcine", "ORGANISM", 109, 116], ["HEV", "ORGANISM", 117, 120], ["HEV", "ORGANISM", 130, 133], ["HEV-related virus", "ORGANISM", 176, 193], ["faeces", "ORGANISM_SUBDIVISION", 214, 220], ["Japanese porcine HEV sequence", "DNA", 100, 129], ["porcine", "SPECIES", 109, 116], ["HEV-related virus", "SPECIES", 176, 193], ["HEV", "SPECIES", 64, 67], ["Japanese porcine HEV", "SPECIES", 100, 120], ["HEV", "SPECIES", 130, 133], ["HEV-related virus", "SPECIES", 176, 193], ["this strain", "PROBLEM", 29, 40], ["HEV genotype 3", "PROBLEM", 64, 78], ["a Japanese porcine HEV sequence", "TREATMENT", 98, 129], ["HEV infection of CanidaeIn", "PROBLEM", 130, 156], ["HEV-related virus", "PROBLEM", 176, 193], ["infection", "OBSERVATION", 134, 143], ["related virus", "OBSERVATION_MODIFIER", 180, 193]]], ["These fragments were related to HEV-C1, but it is unknown, whether this virus circulates naturally in foxes or if detection is due to the consumption of prey such as rats (Bodewes et al., 2013) .HEV infection of ChiropteraIn 2012, a study analysed 3869 bat faecal and blood samples across five continents to detect HEV-related sequences.", [["fragments", "ANATOMY", 6, 15], ["faecal", "ANATOMY", 257, 263], ["blood samples", "ANATOMY", 268, 281], ["HEV infection", "DISEASE", 195, 208], ["HEV-C1", "ORGANISM", 32, 38], ["rats", "ORGANISM", 166, 170], ["HEV", "ORGANISM", 195, 198], ["faecal", "ORGANISM_SUBSTANCE", 257, 263], ["blood samples", "ORGANISM_SUBSTANCE", 268, 281], ["HEV-related sequences", "DNA", 315, 336], ["rats", "SPECIES", 166, 170], ["HEV-C1", "SPECIES", 32, 38], ["HEV", "SPECIES", 195, 198], ["HEV", "SPECIES", 315, 318], ["These fragments", "PROBLEM", 0, 15], ["HEV-C1", "PROBLEM", 32, 38], ["this virus circulates", "PROBLEM", 67, 88], ["a study", "TEST", 231, 238], ["bat faecal", "TEST", 253, 263], ["blood samples", "TEST", 268, 281], ["fragments", "OBSERVATION", 6, 15], ["C1", "ANATOMY", 36, 38], ["infection", "OBSERVATION", 199, 208]]], ["This study included 85 species of bats.", [["bats", "ORGANISM", 34, 38], ["This study", "TEST", 0, 10]]], ["Viruses were detected in 3 bat families (Hipposideridae, Vespertilionidae and Phyllostomidae) from Africa, Central America and Europe.", [["Viruses", "PROBLEM", 0, 7], ["Hipposideridae", "TREATMENT", 41, 55], ["Vespertilionidae and Phyllostomidae", "TREATMENT", 57, 92], ["Central America", "OBSERVATION", 107, 122]]], ["There was a high genetic diversity between HEVrelated viruses found in bats, comparable to that observed between sequences found in Orthohepevirus A (Drexler et al., 2012) .", [["HEVrelated viruses", "ORGANISM", 43, 61], ["Orthohepevirus A", "SPECIES", 132, 148], ["a high genetic diversity", "PROBLEM", 10, 34], ["HEVrelated viruses", "PROBLEM", 43, 61], ["high", "OBSERVATION_MODIFIER", 12, 16], ["genetic diversity", "OBSERVATION", 17, 34], ["viruses", "OBSERVATION", 54, 61]]], ["Currently, all the HEV sequences found in bats have been assigned to the new species Orthohepevirus D (Table 1; Smith et al., 2014) .HEV Infection of BirdsIn 1999, a virus related to HEV associated to big liver and spleen disease (BLS) was identified in chickens from Australia.", [["liver", "ANATOMY", 205, 210], ["spleen", "ANATOMY", 215, 221], ["HEV", "DISEASE", 183, 186], ["liver and spleen disease", "DISEASE", 205, 229], ["HEV", "ORGANISM", 19, 22], ["HEV", "ORGANISM", 133, 136], ["HEV", "ORGANISM", 183, 186], ["liver", "ORGAN", 205, 210], ["spleen", "ORGAN", 215, 221], ["chickens", "ORGANISM", 254, 262], ["HEV sequences", "DNA", 19, 32], ["chickens", "SPECIES", 254, 262], ["HEV", "SPECIES", 19, 22], ["HEV", "SPECIES", 133, 136], ["HEV", "SPECIES", 183, 186], ["chickens", "SPECIES", 254, 262], ["the HEV sequences", "TEST", 15, 32], ["a virus", "PROBLEM", 164, 171], ["HEV", "PROBLEM", 183, 186], ["big liver and spleen disease", "PROBLEM", 201, 229], ["Infection", "OBSERVATION", 137, 146], ["liver", "ANATOMY", 205, 210], ["spleen", "ANATOMY", 215, 221], ["disease", "OBSERVATION", 222, 229]]], ["This virus has about 62% homology with HEV nucleotide sequences from genotypes 1-4 (Payne et al., 1999) .", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 43, 53], ["HEV nucleotide sequences", "DNA", 39, 63], ["HEV", "SPECIES", 39, 42], ["This virus", "PROBLEM", 0, 10], ["HEV nucleotide sequences", "TEST", 39, 63], ["genotypes", "TEST", 69, 78]]], ["In 2001, another virus was detected from bile samples of White Leghorn chickens from the USA with hepatosplenomegaly (HS) syndrome (Haqshenas et al., 2001) .", [["bile samples", "ANATOMY", 41, 53], ["hepatosplenomegaly", "DISEASE", 98, 116], ["HS) syndrome", "DISEASE", 118, 130], ["bile samples", "ORGANISM_SUBSTANCE", 41, 53], ["chickens", "ORGANISM", 71, 79], ["chickens", "SPECIES", 71, 79], ["White Leghorn chickens", "SPECIES", 57, 79], ["another virus", "PROBLEM", 9, 22], ["White Leghorn chickens", "PROBLEM", 57, 79], ["hepatosplenomegaly (HS) syndrome", "PROBLEM", 98, 130], ["bile", "ANATOMY", 41, 45], ["White Leghorn chickens", "OBSERVATION", 57, 79], ["hepatosplenomegaly", "OBSERVATION", 98, 116]]], ["Later, the virus was designated avian HEV, and the viruses causing both BLS and HS were found to be distinct variant strains of the same virus (Meng, 2010a) .", [["avian HEV", "ORGANISM", 32, 41], ["avian HEV", "SPECIES", 32, 41], ["HEV", "SPECIES", 38, 41], ["the virus", "PROBLEM", 7, 16], ["the viruses", "PROBLEM", 47, 58], ["distinct variant strains", "PROBLEM", 100, 124]]], ["Since then, they have been found to be circulating among North American, European and Asian chicken flocks Sun et al., 2004a; Peralta et al., 2009; Kwon et al., 2012; Zhao et al., 2013; Hsu and Tsai, 2014) .", [["chicken", "ORGANISM", 92, 99], ["chicken", "SPECIES", 92, 99], ["Asian chicken", "SPECIES", 86, 99]]], ["Currently, all strains found in chicken are considered as belonging to the same specie Orthohepevirus B.HEV Infection of BirdsContrary to other animal species where HEV infections are usually asymptomatic, Orthohepeviruse B infection is associated with symptomatic disease.", [["HEV infections", "DISEASE", 165, 179], ["Orthohepeviruse B infection", "DISEASE", 206, 233], ["chicken", "ORGANISM", 32, 39], ["Orthohepevirus B.HEV", "ORGANISM", 87, 107], ["HEV", "ORGANISM", 165, 168], ["Orthohepeviruse B", "ORGANISM", 206, 223], ["chicken", "SPECIES", 32, 39], ["chicken", "SPECIES", 32, 39], ["HEV", "SPECIES", 165, 168], ["all strains", "PROBLEM", 11, 22], ["animal species", "PROBLEM", 144, 158], ["HEV infections", "PROBLEM", 165, 179], ["asymptomatic", "PROBLEM", 192, 204], ["Orthohepeviruse B infection", "PROBLEM", 206, 233], ["symptomatic disease", "PROBLEM", 253, 272], ["Infection", "OBSERVATION", 108, 117], ["infections", "OBSERVATION", 169, 179], ["infection", "OBSERVATION", 224, 233]]], ["Besides the enlargement of spleen and liver, both ovarian regression and presence of red fluid in the abdomen are commonly associated with the HS syndrome (Payne et al., 1999; Haqshenas et al., 2001) .", [["spleen", "ANATOMY", 27, 33], ["liver", "ANATOMY", 38, 43], ["ovarian", "ANATOMY", 50, 57], ["red fluid", "ANATOMY", 85, 94], ["abdomen", "ANATOMY", 102, 109], ["enlargement of spleen and liver", "DISEASE", 12, 43], ["spleen", "ORGAN", 27, 33], ["liver", "ORGAN", 38, 43], ["ovarian", "ORGAN", 50, 57], ["abdomen", "ORGAN", 102, 109], ["the enlargement of spleen and liver", "PROBLEM", 8, 43], ["both ovarian regression", "PROBLEM", 45, 68], ["red fluid in the abdomen", "PROBLEM", 85, 109], ["the HS syndrome", "PROBLEM", 139, 154], ["enlargement", "OBSERVATION", 12, 23], ["spleen", "ANATOMY", 27, 33], ["liver", "ANATOMY", 38, 43], ["both", "ANATOMY_MODIFIER", 45, 49], ["ovarian", "ANATOMY", 50, 57], ["regression", "OBSERVATION", 58, 68], ["red", "OBSERVATION_MODIFIER", 85, 88], ["fluid", "OBSERVATION", 89, 94], ["abdomen", "ANATOMY", 102, 109], ["syndrome", "OBSERVATION", 146, 154]]], ["Experimental infection studies have also described several other clinical signs such as anorexia and diarrhoea (Billam et al., 2005) .", [["infection", "DISEASE", 13, 22], ["anorexia", "DISEASE", 88, 96], ["diarrhoea", "DISEASE", 101, 110], ["Experimental infection studies", "PROBLEM", 0, 30], ["several other clinical signs", "PROBLEM", 51, 79], ["anorexia", "PROBLEM", 88, 96], ["diarrhoea", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 13, 22]]], ["In addition, it was suggested that heterogeneity into the distinct strains may be related to different pathogeneses (Billam et al., 2009) .HEV Infection of BirdsOrthohepevirus B shares several antigenic epitopes with HEV found in humans and swine, although at least one specific epitope has been reported among the viruses found in birds Guo et al., 2006) .", [["HEV", "ORGANISM", 139, 142], ["BirdsOrthohepevirus B", "ORGANISM", 156, 177], ["HEV", "ORGANISM", 217, 220], ["humans", "ORGANISM", 230, 236], ["swine", "ORGANISM", 241, 246], ["antigenic epitopes", "PROTEIN", 193, 211], ["humans", "SPECIES", 230, 236], ["swine", "SPECIES", 241, 246], ["HEV", "SPECIES", 139, 142], ["HEV", "SPECIES", 217, 220], ["humans", "SPECIES", 230, 236], ["swine", "SPECIES", 241, 246], ["heterogeneity into the distinct strains", "PROBLEM", 35, 74], ["different pathogeneses", "PROBLEM", 93, 115], ["HEV Infection of BirdsOrthohepevirus B", "PROBLEM", 139, 177], ["several antigenic epitopes", "PROBLEM", 185, 211], ["HEV", "PROBLEM", 217, 220], ["distinct strains", "OBSERVATION", 58, 74], ["may be related to", "UNCERTAINTY", 75, 92], ["different", "OBSERVATION_MODIFIER", 93, 102], ["pathogeneses", "OBSERVATION", 103, 115], ["Infection", "OBSERVATION", 143, 152]]], ["Further experimental infections have demonstrated that the Orthohepevirus B can infect and produce low viremia in turkeys, but is not infectious for rhesus monkeys (Huang et al., 2004; Sun et al., 2004b) .HEV infection of FishIn 1988, a new virus, infecting trout without causing disease, was isolated and named cutthroat trout virus (CTV; Hedrick et al., 1991) .", [["infections", "DISEASE", 21, 31], ["Orthohepevirus B", "CHEMICAL", 59, 75], ["viremia", "DISEASE", 103, 110], ["HEV infection", "DISEASE", 205, 218], ["FishIn 1988", "CHEMICAL", 222, 233], ["Orthohepevirus B", "ORGANISM", 59, 75], ["turkeys", "ORGANISM", 114, 121], ["rhesus", "ORGANISM", 149, 155], ["monkeys", "ORGANISM", 156, 163], ["HEV", "ORGANISM", 205, 208], ["trout", "ORGANISM", 258, 263], ["cutthroat trout virus", "ORGANISM", 312, 333], ["turkeys", "SPECIES", 114, 121], ["rhesus monkeys", "SPECIES", 149, 163], ["trout", "SPECIES", 258, 263], ["cutthroat trout", "SPECIES", 312, 327], ["virus", "SPECIES", 328, 333], ["Orthohepevirus B", "SPECIES", 59, 75], ["turkeys", "SPECIES", 114, 121], ["rhesus monkeys", "SPECIES", 149, 163], ["HEV", "SPECIES", 205, 208], ["trout", "SPECIES", 258, 263], ["cutthroat trout virus", "SPECIES", 312, 333], ["Further experimental infections", "PROBLEM", 0, 31], ["low viremia in turkeys", "PROBLEM", 99, 121], ["HEV infection of FishIn", "PROBLEM", 205, 228], ["a new virus", "PROBLEM", 235, 246], ["disease", "PROBLEM", 280, 287], ["infections", "OBSERVATION", 21, 31], ["low", "OBSERVATION_MODIFIER", 99, 102], ["viremia", "OBSERVATION", 103, 110], ["not", "UNCERTAINTY", 130, 133], ["infectious", "OBSERVATION_MODIFIER", 134, 144], ["infection", "OBSERVATION", 209, 218]]], ["After two decades, the complete genome of this virus was obtained and the organization was shown to be similar to HEV.", [["HEV", "ORGANISM", 114, 117], ["HEV", "SPECIES", 114, 117], ["this virus", "PROBLEM", 42, 52]]], ["Phylogenetic analysis based on partial RdRp aa sequences indicates proximity to the Hepeviridae family (Batts et al., 2011) , and currently, it has been assigned as the sole species into the genus Piscihepevirus (Smith et al., 2014) .HEV infection of Bivalve MolluscsThe presence of HEV RNA was reported on several occasions in bivalve molluscs Crossan et al., 2012; Donia et al., 2012) .", [["HEV infection", "DISEASE", 234, 247], ["HEV", "ORGANISM", 234, 237], ["HEV", "ORGANISM", 283, 286], ["RdRp aa sequences", "DNA", 39, 56], ["HEV RNA", "RNA", 283, 290], ["HEV", "SPECIES", 234, 237], ["HEV", "SPECIES", 283, 286], ["Phylogenetic analysis", "TEST", 0, 21], ["partial RdRp aa sequences", "TEST", 31, 56], ["HEV infection of Bivalve Molluscs", "PROBLEM", 234, 267], ["HEV RNA", "PROBLEM", 283, 290], ["genus Piscihepevirus", "ANATOMY", 191, 211], ["infection", "OBSERVATION", 238, 247], ["Bivalve Molluscs", "OBSERVATION", 251, 267], ["HEV RNA", "OBSERVATION", 283, 290]]], ["However, this is most likely due to passive filtration of HEV from contaminated water rather than to HEV replication occurring in molluscs.", [["HEV", "ORGANISM", 58, 61], ["HEV", "ORGANISM", 101, 104], ["HEV", "SPECIES", 58, 61], ["HEV", "SPECIES", 101, 104], ["passive filtration", "TREATMENT", 36, 54], ["HEV", "PROBLEM", 58, 61], ["HEV replication", "TREATMENT", 101, 116], ["most likely due to", "UNCERTAINTY", 17, 35], ["passive", "OBSERVATION_MODIFIER", 36, 43], ["filtration", "OBSERVATION", 44, 54], ["HEV", "OBSERVATION", 58, 61], ["replication", "OBSERVATION", 105, 116]]], ["Indeed, experimental bio accumulation of HEV has been demonstrated in oysters (Grodzki et al., 2014) .Zoonotic Concerns of HEV and HEV-Related VirusesBefore the first detection of HEV in swine, the occurrence of hepatitis E was associated with lack of access to clean water and contamination of drinking water due to unreliable sewage systems and hepatitis E was considered a disease of developing countries (Viswanathan, 1957; Aggarwal and Naik, 2009 ).", [["HEV", "DISEASE", 180, 183], ["hepatitis E", "DISEASE", 212, 223], ["hepatitis E", "DISEASE", 347, 358], ["HEV", "ORGANISM", 41, 44], ["HEV", "ORGANISM", 123, 126], ["HEV-Related Viruses", "ORGANISM", 131, 150], ["HEV", "ORGANISM", 180, 183], ["swine", "SPECIES", 187, 192], ["HEV", "SPECIES", 41, 44], ["HEV", "SPECIES", 123, 126], ["HEV", "SPECIES", 131, 134], ["HEV", "SPECIES", 180, 183], ["swine", "SPECIES", 187, 192], ["HEV", "PROBLEM", 41, 44], ["HEV", "PROBLEM", 123, 126], ["HEV", "PROBLEM", 131, 134], ["Related Viruses", "PROBLEM", 135, 150], ["HEV", "PROBLEM", 180, 183], ["hepatitis E", "PROBLEM", 212, 223], ["unreliable sewage systems", "PROBLEM", 317, 342], ["hepatitis E", "PROBLEM", 347, 358], ["HEV", "OBSERVATION", 41, 44], ["HEV", "OBSERVATION", 123, 126], ["Viruses", "OBSERVATION", 143, 150], ["hepatitis", "OBSERVATION", 212, 221]]], ["Due to this, from the late eighties to the early nineties, it was improbable that clinicians would diagnose autochthonous hepatitis E in industrialized countries (Scharschmidt, 1995) .", [["hepatitis E", "DISEASE", 122, 133]]], ["However, the presence of HEV antibodies in healthy individuals and blood donors in Europe and North America could not always be associated with travel to an endemic region (Skaug et al., 1994) .", [["blood", "ANATOMY", 67, 72], ["HEV", "ORGANISM", 25, 28], ["blood donors", "ORGANISM", 67, 79], ["HEV antibodies", "PROTEIN", 25, 39], ["HEV", "SPECIES", 25, 28], ["HEV antibodies in healthy individuals", "PROBLEM", 25, 62], ["HEV antibodies", "OBSERVATION", 25, 39]]], ["Thus, several autochthonous cases were reported in the USA, Europe, Australia and New Zealand (Mast et al., 1996) .Zoonotic Concerns of HEV and HEV-Related VirusesLater on, the viruses were revealed to be present in domestic swine and wild boar populations in both developing and developed countries (Meng et al., 1997; Meng, 2010a; Thiry et al., 2014) .", [["HEV", "ORGANISM", 136, 139], ["HEV", "ORGANISM", 144, 147], ["boar", "ORGANISM", 240, 244], ["swine", "SPECIES", 225, 230], ["boar", "SPECIES", 240, 244], ["HEV", "SPECIES", 136, 139], ["HEV", "SPECIES", 144, 147], ["swine", "SPECIES", 225, 230], ["HEV", "PROBLEM", 136, 139], ["HEV", "PROBLEM", 144, 147], ["the viruses", "PROBLEM", 173, 184], ["wild boar populations", "PROBLEM", 235, 256], ["several", "OBSERVATION_MODIFIER", 6, 13], ["autochthonous", "OBSERVATION_MODIFIER", 14, 27], ["New", "OBSERVATION_MODIFIER", 82, 85], ["HEV", "OBSERVATION", 136, 139]]], ["The genetic proximity raised the possibility of an animal reservoir and phylogenetic analysis clearly revealed that the autochthonous cases occurred more frequently than had been previously recognized in developed countries (Clemente-Casares et al., 2003) .Zoonotic Concerns of HEV and HEV-Related VirusesNowadays, viruses from the Hepeviridae family and HEV-related viruses are recognized to be present in mammals, avian and fish.", [["HEV", "ORGANISM", 278, 281], ["HEV-Related Viruses", "ORGANISM", 286, 305], ["Hepeviridae", "GENE_OR_GENE_PRODUCT", 332, 343], ["HEV-related viruses", "ORGANISM", 355, 374], ["avian", "ORGANISM", 416, 421], ["fish", "ORGANISM_SUBDIVISION", 426, 430], ["HEV", "SPECIES", 278, 281], ["HEV", "SPECIES", 286, 289], ["an animal reservoir", "TREATMENT", 48, 67], ["phylogenetic analysis", "TEST", 72, 93], ["the autochthonous cases", "PROBLEM", 116, 139], ["HEV", "PROBLEM", 278, 281], ["HEV", "PROBLEM", 286, 289], ["Related Viruses", "PROBLEM", 290, 305], ["viruses", "PROBLEM", 315, 322], ["related viruses", "PROBLEM", 359, 374], ["autochthonous", "OBSERVATION_MODIFIER", 120, 133], ["HEV", "OBSERVATION", 278, 281]]], ["Evidence suggesting zoonotic infections has been reported from strains circulating in domestic swine, wild boars, deer and rabbits (Meng et al., 1997; Hsieh et al., 1999; Tei et al., 2003; Izopet et al., 2012) .", [["zoonotic infections", "DISEASE", 20, 39], ["swine", "ORGANISM", 95, 100], ["boars", "ORGANISM", 107, 112], ["deer", "ORGANISM", 114, 118], ["rabbits", "ORGANISM", 123, 130], ["swine", "SPECIES", 95, 100], ["boars", "SPECIES", 107, 112], ["deer", "SPECIES", 114, 118], ["rabbits", "SPECIES", 123, 130], ["swine", "SPECIES", 95, 100], ["deer", "SPECIES", 114, 118], ["rabbits", "SPECIES", 123, 130], ["zoonotic infections", "PROBLEM", 20, 39], ["suggesting", "UNCERTAINTY", 9, 19], ["zoonotic", "OBSERVATION_MODIFIER", 20, 28], ["infections", "OBSERVATION", 29, 39]]], ["To date, limited information is available concerning the ability of these viruses to infect different species.Strong Evidence of Foodborne Transmission of HEVIn 2003, zoonotic transmission was reported for the first time.", [["zoonotic transmission", "DISEASE", 167, 188], ["these viruses", "PROBLEM", 68, 81], ["Foodborne", "OBSERVATION", 129, 138]]], ["Accordingly, four human cases were linked to the consumption of uncooked wild boar liver and Sika deer meat in Japan.", [["liver", "ANATOMY", 83, 88], ["meat", "ANATOMY", 103, 107], ["human", "ORGANISM", 18, 23], ["boar", "ORGANISM", 78, 82], ["liver", "ORGAN", 83, 88], ["human", "SPECIES", 18, 23], ["boar", "SPECIES", 78, 82], ["Sika deer", "SPECIES", 93, 102], ["meat", "SPECIES", 103, 107], ["human", "SPECIES", 18, 23], ["Sika deer", "SPECIES", 93, 102], ["liver", "ANATOMY", 83, 88]]], ["Confirmation was only possible from the deer meat, as no wild boar liver remained to be tested (Matsuda et al., 2003; Tei et al., 2003) .", [["meat", "ANATOMY", 45, 49], ["liver", "ANATOMY", 67, 72], ["deer", "ORGANISM", 40, 44], ["meat", "ORGANISM_SUBDIVISION", 45, 49], ["boar", "ORGANISM", 62, 66], ["liver", "ORGAN", 67, 72], ["deer", "SPECIES", 40, 44], ["boar", "SPECIES", 62, 66], ["liver", "ANATOMY", 67, 72]]], ["A nucleotide homology of 99.7-100% was observed between fragments of 326 nucleotides obtained from the patients who consumed raw deer sushi or sashimi and from the frozen deer meat used to prepare these meals (Tei et al., 2003) .Strong Evidence of Foodborne Transmission of HEVIn 2004, another study showed 99.7% homology between the full viral genome sequences found in wild boar and deer hunted in the same forest as the Sika deer consumed by the four patients above .", [["meat", "ANATOMY", 176, 180], ["nucleotide", "CHEMICAL", 2, 12], ["sashimi", "CHEMICAL", 143, 150], ["nucleotide", "CHEMICAL", 2, 12], ["nucleotides", "CHEMICAL", 73, 84], ["patients", "ORGANISM", 103, 111], ["deer", "ORGANISM", 171, 175], ["meat", "ORGANISM_SUBDIVISION", 176, 180], ["boar", "ORGANISM", 376, 380], ["deer", "ORGANISM", 385, 389], ["patients", "ORGANISM", 454, 462], ["viral genome sequences", "DNA", 339, 361], ["patients", "SPECIES", 103, 111], ["deer", "SPECIES", 129, 133], ["deer", "SPECIES", 171, 175], ["boar", "SPECIES", 376, 380], ["deer", "SPECIES", 385, 389], ["deer", "SPECIES", 428, 432], ["patients", "SPECIES", 454, 462], ["raw deer sushi", "SPECIES", 125, 139], ["deer", "SPECIES", 171, 175], ["deer", "SPECIES", 385, 389], ["Sika deer", "SPECIES", 423, 432], ["A nucleotide homology", "TEST", 0, 21], ["sashimi", "TREATMENT", 143, 150], ["the frozen deer meat", "TREATMENT", 160, 180], ["another study", "TEST", 286, 299]]], ["Another report from Japan in 2005 demonstrated transmission via ingestion of wild boar meat.", [["meat", "ANATOMY", 87, 91], ["boar", "ORGANISM", 82, 86], ["meat", "ORGANISM_SUBDIVISION", 87, 91], ["boar", "SPECIES", 82, 86], ["boar", "SPECIES", 82, 86]]], ["Phylogenetic analysis based on the complete capsid sequences showed 99.95% homology between HEV genotype 3 sequences obtained from the patient serum and the frozen wild boar meat consumed by them (Li et al., 2005) .Strong Evidence of Foodborne Transmission of HEVRecently, high homology between sequences detected in consumed pork meat and an acute hepatitis E patient was observed in Spain (Riveiro-Barciela et al., 2015) .", [["serum", "ANATOMY", 143, 148], ["meat", "ANATOMY", 174, 178], ["pork meat", "ANATOMY", 326, 335], ["acute hepatitis E", "DISEASE", 343, 360], ["patient", "ORGANISM", 135, 142], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["boar", "ORGANISM", 169, 173], ["meat", "ORGANISM_SUBDIVISION", 174, 178], ["patient", "ORGANISM", 361, 368], ["capsid sequences", "DNA", 44, 60], ["HEV genotype 3 sequences", "DNA", 92, 116], ["patient", "SPECIES", 135, 142], ["boar", "SPECIES", 169, 173], ["pork", "SPECIES", 326, 330], ["patient", "SPECIES", 361, 368], ["boar", "SPECIES", 169, 173], ["pork", "SPECIES", 326, 330], ["Phylogenetic analysis", "TEST", 0, 21], ["the complete capsid sequences", "TEST", 31, 60], ["HEV genotype 3 sequences", "TEST", 92, 116], ["the patient serum", "TEST", 131, 148], ["high homology between sequences", "PROBLEM", 273, 304], ["an acute hepatitis E", "PROBLEM", 340, 360], ["Foodborne", "OBSERVATION", 234, 243], ["acute", "OBSERVATION_MODIFIER", 343, 348], ["hepatitis", "OBSERVATION", 349, 358]]], ["Another strong evidence of HEV foodborne transmission was reported in a patient who consumed figatelli (raw pig liver sausage) in France (Renou et al., 2014) .HEV Transmission through Direct Contact or Indirect EvidenceEpidemiological investigations or clinical evidence has pointed out the consumption of wild boar or domestic pig meat as sources of several human HEV infections with genotypes HEV-3 and HEV-4 (Matsuda et al., 2003; Tamada et al., 2004; Wichmann et al., 2008) .", [["liver", "ANATOMY", 112, 117], ["meat", "ANATOMY", 332, 336], ["HEV foodborne transmission", "DISEASE", 27, 53], ["figatelli", "CHEMICAL", 93, 102], ["HEV infections", "DISEASE", 365, 379], ["HEV", "ORGANISM", 27, 30], ["patient", "ORGANISM", 72, 79], ["pig", "ORGANISM", 108, 111], ["liver", "ORGAN", 112, 117], ["boar", "ORGANISM", 311, 315], ["pig", "ORGANISM", 328, 331], ["meat", "ORGANISM_SUBDIVISION", 332, 336], ["human", "ORGANISM", 359, 364], ["HEV", "ORGANISM", 365, 368], ["HEV-3", "ORGANISM", 395, 400], ["HEV-4", "ORGANISM", 405, 410], ["patient", "SPECIES", 72, 79], ["pig", "SPECIES", 108, 111], ["boar", "SPECIES", 311, 315], ["pig", "SPECIES", 328, 331], ["human", "SPECIES", 359, 364], ["HEV", "SPECIES", 27, 30], ["pig", "SPECIES", 108, 111], ["HEV", "SPECIES", 159, 162], ["boar", "SPECIES", 311, 315], ["pig", "SPECIES", 328, 331], ["human", "SPECIES", 359, 364], ["HEV", "SPECIES", 365, 368], ["HEV-3", "SPECIES", 395, 400], ["HEV foodborne transmission", "PROBLEM", 27, 53], ["Indirect EvidenceEpidemiological investigations", "TEST", 202, 249], ["domestic pig meat", "TREATMENT", 319, 336], ["several human HEV infections", "PROBLEM", 351, 379], ["genotypes HEV", "TEST", 385, 398], ["strong evidence of", "UNCERTAINTY", 8, 26], ["HEV", "OBSERVATION_MODIFIER", 27, 30], ["foodborne", "OBSERVATION", 31, 40], ["liver", "ANATOMY", 112, 117], ["infections", "OBSERVATION", 369, 379]]], ["In addition, a number of studies have reported the presence of HEV in pig and wild boar meat products with sequences either similar or closely related to the ones found in humans (Feagins et al., 2007; Colson et al., 2010 Colson et al., , 2012 Wenzel et al., 2011; Moal et al., 2012) .HEV Transmission through Direct Contact or Indirect EvidenceGeographically, human-swine co-exposure could be related to a higher incidence in humans (Bouquet et al., 2011) .", [["HEV", "ORGANISM", 63, 66], ["pig", "ORGANISM", 70, 73], ["boar", "ORGANISM", 83, 87], ["humans", "ORGANISM", 172, 178], ["HEV", "ORGANISM", 285, 288], ["human", "ORGANISM", 361, 366], ["swine", "ORGANISM", 367, 372], ["humans", "ORGANISM", 427, 433], ["pig", "SPECIES", 70, 73], ["boar", "SPECIES", 83, 87], ["humans", "SPECIES", 172, 178], ["human", "SPECIES", 361, 366], ["swine", "SPECIES", 367, 372], ["humans", "SPECIES", 427, 433], ["HEV", "SPECIES", 63, 66], ["pig", "SPECIES", 70, 73], ["boar", "SPECIES", 83, 87], ["humans", "SPECIES", 172, 178], ["HEV", "SPECIES", 285, 288], ["human-swine", "SPECIES", 361, 372], ["humans", "SPECIES", 427, 433], ["HEV in pig", "TREATMENT", 63, 73], ["HEV", "OBSERVATION", 63, 66]]], ["Alternatively, if the area with a high incidence of human cases is far from regions with high pig density, eating habits could be a likely explanation (Matsuda et al., 2003; Wibawa et al., 2004; Colson et al., 2010; Bouquet et al., 2011) .HEV Transmission through Direct Contact or Indirect EvidenceCompared to unexposed groups, the HEV antibody prevalence is higher in diverse population groups with higher occupational exposure to HEV.", [["human", "ORGANISM", 52, 57], ["pig", "ORGANISM_SUBDIVISION", 94, 97], ["HEV", "ORGANISM", 239, 242], ["HEV", "ORGANISM", 333, 336], ["HEV", "ORGANISM", 433, 436], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["pig", "SPECIES", 94, 97], ["HEV", "SPECIES", 239, 242], ["HEV", "SPECIES", 333, 336], ["HEV", "SPECIES", 433, 436], ["human cases", "PROBLEM", 52, 63], ["high pig density", "PROBLEM", 89, 105], ["the HEV antibody prevalence", "TEST", 329, 356], ["high", "OBSERVATION_MODIFIER", 34, 38], ["high", "OBSERVATION_MODIFIER", 89, 93], ["pig density", "OBSERVATION_MODIFIER", 94, 105], ["higher", "OBSERVATION_MODIFIER", 360, 366]]], ["These groups include swine workers (butchers, farmers) and veterinarians.", [["swine", "ORGANISM", 21, 26], ["swine", "SPECIES", 21, 26], ["swine", "SPECIES", 21, 26]]], ["Regardless of exposure, no increase of associated hepatic disease was observed in these populations (Galiana et al., 2008; Chang et al., 2009; Pourpongporn et al., 2009; Krumbholz et al., 2012 Krumbholz et al., , 2014 .", [["hepatic", "ANATOMY", 50, 57], ["hepatic disease", "DISEASE", 50, 65], ["hepatic", "ORGAN", 50, 57], ["associated hepatic disease", "PROBLEM", 39, 65], ["no", "UNCERTAINTY", 24, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["hepatic", "ANATOMY", 50, 57], ["disease", "OBSERVATION", 58, 65]]], ["HEV was detected in both the bile of slaughtered pigs and effluent from the slaughterhouse, indicating that pigs can shed HEV at the time of slaughter (Casas et al., 2011; dos Santos et al., 2011) .", [["bile", "ANATOMY", 29, 33], ["HEV", "ORGANISM", 0, 3], ["bile", "MULTI-TISSUE_STRUCTURE", 29, 33], ["pigs", "ORGANISM", 49, 53], ["pigs", "ORGANISM", 108, 112], ["HEV", "ORGANISM", 122, 125], ["pigs", "SPECIES", 49, 53], ["pigs", "SPECIES", 108, 112], ["HEV", "SPECIES", 0, 3], ["pigs", "SPECIES", 49, 53], ["pigs", "SPECIES", 108, 112], ["HEV", "SPECIES", 122, 125], ["HEV", "PROBLEM", 0, 3], ["both", "ANATOMY_MODIFIER", 20, 24], ["bile", "ANATOMY", 29, 33], ["effluent", "OBSERVATION_MODIFIER", 58, 66]]], ["Indeed, a hepatitis E case has already been reported in a slaughterhouse worker (P erez-Gracia et al., 2007) .Role of Animals as HEV ReservoirsThe phylogenetic relationship of human zoonotic genotype HEV sequences with those of swine and wild boar (HEV-3 and HEV-4) suggests their involvement in the transmission cycle of HEV infection in humans.", [["hepatitis E", "DISEASE", 10, 21], ["HEV infection", "DISEASE", 322, 335], ["HEV", "ORGANISM", 129, 132], ["human", "ORGANISM", 176, 181], ["HEV", "ORGANISM", 200, 203], ["swine", "ORGANISM", 228, 233], ["wild boar", "ORGANISM", 238, 247], ["HEV-3", "ORGANISM", 249, 254], ["HEV-4", "ORGANISM", 259, 264], ["HEV", "ORGANISM", 322, 325], ["humans", "ORGANISM", 339, 345], ["human zoonotic genotype HEV sequences", "DNA", 176, 213], ["human", "SPECIES", 176, 181], ["swine", "SPECIES", 228, 233], ["boar", "SPECIES", 243, 247], ["humans", "SPECIES", 339, 345], ["HEV", "SPECIES", 129, 132], ["human", "SPECIES", 176, 181], ["HEV", "SPECIES", 200, 203], ["swine", "SPECIES", 228, 233], ["HEV-3", "SPECIES", 249, 254], ["HEV-4", "SPECIES", 259, 264], ["HEV", "SPECIES", 322, 325], ["humans", "SPECIES", 339, 345], ["HEV Reservoirs", "TREATMENT", 129, 143], ["HEV sequences", "TEST", 200, 213], ["HEV", "TEST", 249, 252], ["HEV", "TEST", 259, 262], ["HEV infection in humans", "PROBLEM", 322, 345], ["HEV Reservoirs", "OBSERVATION", 129, 143], ["HEV", "OBSERVATION_MODIFIER", 322, 325], ["infection", "OBSERVATION", 326, 335]]], ["Rabbits may also represent a reservoir of HEV for humans (Izopet et al., 2012) .", [["Rabbits", "ORGANISM", 0, 7], ["HEV", "ORGANISM", 42, 45], ["humans", "ORGANISM", 50, 56], ["Rabbits", "SPECIES", 0, 7], ["humans", "SPECIES", 50, 56], ["HEV", "SPECIES", 42, 45], ["humans", "SPECIES", 50, 56], ["may also represent", "UNCERTAINTY", 8, 26], ["reservoir", "OBSERVATION", 29, 38]]], ["In addition, cynomolgus macaques and pigs have been experimentally infected with rabbit HEV (Cossaboom et al., 2012; Liu et al., 2013) .", [["cynomolgus macaques", "ORGANISM", 13, 32], ["pigs", "ORGANISM", 37, 41], ["rabbit", "ORGANISM", 81, 87], ["HEV", "ORGANISM", 88, 91], ["cynomolgus macaques", "SPECIES", 13, 32], ["pigs", "SPECIES", 37, 41], ["rabbit", "SPECIES", 81, 87], ["cynomolgus macaques", "SPECIES", 13, 32], ["pigs", "SPECIES", 37, 41], ["rabbit", "SPECIES", 81, 87], ["HEV", "SPECIES", 88, 91], ["cynomolgus macaques", "TREATMENT", 13, 32], ["pigs", "TREATMENT", 37, 41], ["cynomolgus macaques", "OBSERVATION", 13, 32], ["infected", "OBSERVATION_MODIFIER", 67, 75]]], ["It is important to note that human HEV does not formally need a reservoir as faecal-oral transmission is effective in maintaining the infection within a human population, as occurs in non-industrialized regions.", [["faecal", "ANATOMY", 77, 83], ["oral", "ANATOMY", 84, 88], ["infection", "DISEASE", 134, 143], ["human", "ORGANISM", 29, 34], ["HEV", "ORGANISM", 35, 38], ["faecal", "ORGANISM_SUBDIVISION", 77, 83], ["oral", "ORGANISM_SUBDIVISION", 84, 88], ["human", "ORGANISM", 153, 158], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 29, 34], ["HEV", "SPECIES", 35, 38], ["human", "SPECIES", 153, 158], ["a reservoir", "TREATMENT", 62, 73], ["faecal-oral transmission", "TREATMENT", 77, 101], ["the infection", "PROBLEM", 130, 143], ["infection", "OBSERVATION", 134, 143]]], ["However, secondary reservoirs in pigs and wild boar contribute to the maintenance of the infection (HEV genotypes 3 and 4) in developed countries with a high sanitary level.", [["infection", "DISEASE", 89, 98], ["pigs", "ORGANISM", 33, 37], ["wild boar", "ORGANISM", 42, 51], ["pigs", "SPECIES", 33, 37], ["pigs", "SPECIES", 33, 37], ["HEV", "SPECIES", 100, 103], ["secondary reservoirs in pigs and wild boar", "PROBLEM", 9, 51], ["the infection", "PROBLEM", 85, 98], ["HEV genotypes", "TEST", 100, 113], ["secondary", "OBSERVATION_MODIFIER", 9, 18], ["reservoirs", "OBSERVATION_MODIFIER", 19, 29], ["wild boar", "OBSERVATION", 42, 51], ["infection", "OBSERVATION", 89, 98]]], ["In addition, the presence of the virus in other wild species such as deer may contribute to the maintenance of the virus in the natural environment.Role of Animals as HEV ReservoirsRodents have long been believed to be a potential reservoir of human HEV.", [["deer", "ORGANISM", 69, 73], ["HEV ReservoirsRodents", "ORGANISM", 167, 188], ["human", "ORGANISM", 244, 249], ["HEV", "ORGANISM", 250, 253], ["human", "SPECIES", 244, 249], ["deer", "SPECIES", 69, 73], ["HEV", "SPECIES", 167, 170], ["human", "SPECIES", 244, 249], ["HEV", "SPECIES", 250, 253], ["the virus", "PROBLEM", 29, 38], ["the virus", "PROBLEM", 111, 120], ["virus", "OBSERVATION", 33, 38], ["virus", "OBSERVATION", 115, 120]]], ["However, the susceptibility of rats to human HEV genotypes is very controversial.", [["rats", "ORGANISM", 31, 35], ["human", "ORGANISM", 39, 44], ["HEV", "ORGANISM", 45, 48], ["rats", "SPECIES", 31, 35], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["human HEV genotypes", "TEST", 39, 58]]], ["HEV-C1 does not infect rhesus monkeys (Purcell et al., 2011) , and laboratory rats do not appear to be susceptible to genotypes 1, 3 and 4 (Li et al., 2013a,c) , although one study reported partial genotype 3 sequences in rat liver specimens (Lack et al., 2012) .", [["liver specimens", "ANATOMY", 226, 241], ["HEV-C1", "ORGANISM", 0, 6], ["rhesus", "ORGANISM", 23, 29], ["monkeys", "ORGANISM", 30, 37], ["rats", "ORGANISM", 78, 82], ["rat", "ORGANISM", 222, 225], ["liver", "ORGAN", 226, 231], ["partial genotype 3 sequences", "DNA", 190, 218], ["rhesus monkeys", "SPECIES", 23, 37], ["rats", "SPECIES", 78, 82], ["rat", "SPECIES", 222, 225], ["rhesus monkeys", "SPECIES", 23, 37], ["rat", "SPECIES", 222, 225], ["laboratory rats", "TEST", 67, 82], ["genotypes", "TEST", 118, 127], ["Li et al.", "TEST", 140, 149], ["one study", "TEST", 171, 180], ["partial genotype 3 sequences", "PROBLEM", 190, 218], ["C1", "ANATOMY", 4, 6], ["liver", "ANATOMY", 226, 231]]], ["Viruses found in birds could not be transmitted experimentally to primates (Huang et al., 2004) .", [["birds", "ORGANISM", 17, 22], ["primates", "ORGANISM", 66, 74], ["Viruses", "PROBLEM", 0, 7]]], ["The transmission of rat or avian HEV to humans cannot be completely ruled out, but these species are not currently considered to be reservoirs of human HEV.", [["rat", "ORGANISM", 20, 23], ["avian HEV", "ORGANISM", 27, 36], ["humans", "ORGANISM", 40, 46], ["human", "ORGANISM", 146, 151], ["HEV", "ORGANISM", 152, 155], ["rat", "SPECIES", 20, 23], ["avian HEV", "SPECIES", 27, 36], ["humans", "SPECIES", 40, 46], ["human", "SPECIES", 146, 151], ["rat", "SPECIES", 20, 23], ["HEV", "SPECIES", 33, 36], ["humans", "SPECIES", 40, 46], ["human", "SPECIES", 146, 151], ["HEV", "SPECIES", 152, 155]]], ["The possibility that bats may play a role as a reservoir of HEV in mammals, as reported for many viruses such as coronaviruses or paramyxoviruses, was examined.", [["bats", "ORGANISM", 21, 25], ["HEV", "ORGANISM", 60, 63], ["coronaviruses", "ORGANISM", 113, 126], ["HEV", "SPECIES", 60, 63], ["many viruses", "PROBLEM", 92, 104], ["coronaviruses", "PROBLEM", 113, 126], ["paramyxoviruses", "PROBLEM", 130, 145]]], ["Phylogenetic analysis suggested that viruses found in bats belong to the Hepeviridae family and seem to be the most divergent mammalian hepeviruses described so far.", [["Hepeviridae", "GENE_OR_GENE_PRODUCT", 73, 84], ["hepeviruses", "CANCER", 136, 147], ["Phylogenetic analysis", "TEST", 0, 21], ["viruses", "PROBLEM", 37, 44], ["viruses", "OBSERVATION", 37, 44]]], ["Therefore, it is unlikely that bats transmit the virus to humans (Drexler et al., 2012) .", [["bats", "ORGANISM", 31, 35], ["humans", "ORGANISM", 58, 64], ["humans", "SPECIES", 58, 64], ["humans", "SPECIES", 58, 64]]], ["It is also unlikely that the transmission from trout to humans occurs due to the phylogenetic gaps found between HEV and CTV sequences.", [["trout", "ORGANISM", 47, 52], ["humans", "ORGANISM", 56, 62], ["HEV", "ORGANISM", 113, 116], ["CTV", "CANCER", 121, 124], ["HEV and CTV sequences", "DNA", 113, 134], ["humans", "SPECIES", 56, 62], ["trout", "SPECIES", 47, 52], ["humans", "SPECIES", 56, 62], ["HEV", "SPECIES", 113, 116], ["the phylogenetic gaps", "PROBLEM", 77, 98], ["HEV and CTV sequences", "TEST", 113, 134], ["also unlikely", "UNCERTAINTY", 6, 19]]], ["The human susceptibility for moose and dromedary camel HEV-related viruses is still unknown and transmission to humans cannot be excluded.Hypothesis on HEV OriginThe origin of HEV in animals and in humans is still unknown.", [["human", "ORGANISM", 4, 9], ["dromedary camel HEV", "ORGANISM", 39, 58], ["humans", "ORGANISM", 112, 118], ["HEV", "ORGANISM", 152, 155], ["HEV", "ORGANISM", 176, 179], ["humans", "ORGANISM", 198, 204], ["human", "SPECIES", 4, 9], ["camel", "SPECIES", 49, 54], ["humans", "SPECIES", 112, 118], ["humans", "SPECIES", 198, 204], ["human", "SPECIES", 4, 9], ["moose", "SPECIES", 29, 34], ["humans", "SPECIES", 112, 118], ["HEV", "SPECIES", 152, 155], ["HEV", "SPECIES", 176, 179], ["humans", "SPECIES", 198, 204], ["The human susceptibility", "TEST", 0, 24], ["moose and dromedary camel HEV-related viruses", "PROBLEM", 29, 74], ["HEV", "PROBLEM", 176, 179], ["cannot be excluded", "UNCERTAINTY", 119, 137], ["HEV Origin", "OBSERVATION_MODIFIER", 152, 162], ["origin", "ANATOMY_MODIFIER", 166, 172], ["HEV", "OBSERVATION", 176, 179]]], ["The presence of animal reservoirs can be considered at two non-mutually exclusive levels: animals as reservoirs for hepevirus ancestors of human HEV or current reservoirs interacting with human populations for zoonotic transmission.Hypothesis on HEV OriginThe role played by animals in the emergence of HEV in humans is still uncertain.", [["zoonotic transmission", "DISEASE", 210, 231], ["HEV", "DISEASE", 303, 306], ["human", "ORGANISM", 139, 144], ["HEV", "ORGANISM", 145, 148], ["human", "ORGANISM", 188, 193], ["HEV", "ORGANISM", 246, 249], ["HEV", "ORGANISM", 303, 306], ["humans", "ORGANISM", 310, 316], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 188, 193], ["humans", "SPECIES", 310, 316], ["human", "SPECIES", 139, 144], ["HEV", "SPECIES", 145, 148], ["human", "SPECIES", 188, 193], ["HEV", "SPECIES", 246, 249], ["HEV", "SPECIES", 303, 306], ["humans", "SPECIES", 310, 316], ["animal reservoirs", "TREATMENT", 16, 33], ["animal reservoirs", "OBSERVATION", 16, 33], ["HEV Origin", "OBSERVATION_MODIFIER", 246, 256]]], ["If the ancestor of genotypes 1-4 is hypothesized to be a human virus transmitted from humans to suids, animals would be the recent onset reservoirs with a role of maintenance of infection and reinfection of other mammals including humans.", [["infection", "DISEASE", 178, 187], ["1-4", "ORGANISM", 29, 32], ["human", "ORGANISM", 57, 62], ["humans", "ORGANISM", 86, 92], ["humans", "ORGANISM", 231, 237], ["human", "SPECIES", 57, 62], ["humans", "SPECIES", 86, 92], ["humans", "SPECIES", 231, 237], ["human virus", "SPECIES", 57, 68], ["humans", "SPECIES", 86, 92], ["humans", "SPECIES", 231, 237], ["genotypes", "TEST", 19, 28], ["a human virus", "PROBLEM", 55, 68], ["infection", "PROBLEM", 178, 187], ["infection", "OBSERVATION", 178, 187]]], ["For instance, the presence of HEV more specific to wild boar (Sato et al., 2011; may be indicative of the existence of a specific viral evolution, reflecting the maintenance of viral infection in this animal population.Hypothesis on HEV OriginThe difference between HEV sequences from wild boars and domestic pigs might be related to a dissimilarity in the structure of the two animal populations that could be explained by a higher turnover in domestic pig populations than in wild boar, despite a possible conservation of viruses in reproductive pig herds in sows and boars.", [["viral infection", "DISEASE", 177, 192], ["HEV", "ORGANISM", 30, 33], ["boar", "ORGANISM", 56, 60], ["HEV", "ORGANISM", 233, 236], ["HEV", "ORGANISM", 266, 269], ["wild boars", "ORGANISM", 285, 295], ["domestic pigs", "ORGANISM", 300, 313], ["pig", "ORGANISM", 454, 457], ["wild boar", "ORGANISM", 478, 487], ["pig", "ORGANISM", 548, 551], ["sows", "ORGANISM_SUBDIVISION", 561, 565], ["boars", "ORGANISM_SUBDIVISION", 570, 575], ["boars", "SPECIES", 290, 295], ["pigs", "SPECIES", 309, 313], ["pig", "SPECIES", 454, 457], ["pig", "SPECIES", 548, 551], ["sows", "SPECIES", 561, 565], ["HEV", "SPECIES", 30, 33], ["HEV", "SPECIES", 233, 236], ["HEV", "SPECIES", 266, 269], ["pig", "SPECIES", 454, 457], ["pig", "SPECIES", 548, 551], ["HEV", "PROBLEM", 30, 33], ["a specific viral evolution", "PROBLEM", 119, 145], ["viral infection", "PROBLEM", 177, 192], ["HEV sequences", "TEST", 266, 279], ["wild boars", "TREATMENT", 285, 295], ["domestic pigs", "TREATMENT", 300, 313], ["viruses", "PROBLEM", 524, 531], ["HEV", "OBSERVATION", 30, 33], ["may be indicative of", "UNCERTAINTY", 81, 101], ["viral", "OBSERVATION_MODIFIER", 177, 182], ["infection", "OBSERVATION", 183, 192], ["HEV Origin", "OBSERVATION_MODIFIER", 233, 243], ["viruses", "OBSERVATION", 524, 531]]], ["This might lead to a lower capacity of the virus to evolve in the domestic swine population.", [["swine", "ORGANISM", 75, 80], ["swine", "SPECIES", 75, 80], ["swine", "SPECIES", 75, 80], ["a lower capacity of the virus", "PROBLEM", 19, 48], ["lower capacity", "OBSERVATION_MODIFIER", 21, 35], ["virus", "OBSERVATION", 43, 48]]], ["Instead, environmental and behavioural differences of the wild boar may allow a greater stabilization of the virus in this population and promote selection and maintenance of new viruses.", [["boar", "ORGANISM", 63, 67], ["the wild boar", "TREATMENT", 54, 67], ["the virus", "PROBLEM", 105, 114], ["this population", "TREATMENT", 118, 133], ["new viruses", "PROBLEM", 175, 186], ["new", "OBSERVATION_MODIFIER", 175, 178], ["viruses", "OBSERVATION", 179, 186]]], ["A similar evolution may have occurred with the rabbit strain, starting from a related genotype 3 ancestor, but with a separate evolution in the rabbit population.", [["rabbit", "ORGANISM", 47, 53], ["rabbit", "ORGANISM", 144, 150], ["rabbit", "SPECIES", 47, 53], ["rabbit", "SPECIES", 144, 150], ["rabbit", "SPECIES", 47, 53], ["rabbit", "SPECIES", 144, 150], ["the rabbit strain", "PROBLEM", 43, 60], ["may have occurred", "UNCERTAINTY", 20, 37], ["rabbit strain", "OBSERVATION", 47, 60]]], ["The higher HEV prevalence in domestic swine than in wild animals could be explained by the continuous exchange of viruses between the human and the swine populations.", [["human", "ORGANISM", 134, 139], ["swine", "SPECIES", 38, 43], ["human", "SPECIES", 134, 139], ["swine", "SPECIES", 148, 153], ["HEV", "SPECIES", 11, 14], ["swine", "SPECIES", 38, 43], ["human", "SPECIES", 134, 139], ["swine", "SPECIES", 148, 153], ["the swine populations", "TREATMENT", 144, 165], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["HEV", "OBSERVATION_MODIFIER", 11, 14], ["prevalence", "OBSERVATION_MODIFIER", 15, 25], ["domestic swine", "OBSERVATION_MODIFIER", 29, 43]]], ["In addition, the intensive contact among confined populations or farmed swine may increase the potential for infection.Hypothesis on HEV OriginThe roots of sequences from genotypes HEV-1 to HEV-4 and HEV-C1 rat were calculated (Fig. 4) , and results suggested the ancestor to be of animal origin (Purdy and Khudyakov, 2010) .", [["roots", "ANATOMY", 147, 152], ["infection", "DISEASE", 109, 118], ["swine", "ORGANISM", 72, 77], ["HEV", "ORGANISM", 133, 136], ["roots", "ORGAN", 147, 152], ["HEV-1", "ORGANISM", 181, 186], ["HEV-4", "ORGANISM", 190, 195], ["HEV-C1 rat", "ORGANISM", 200, 210], ["swine", "SPECIES", 72, 77], ["HEV-1", "SPECIES", 181, 186], ["HEV-4", "SPECIES", 190, 195], ["HEV-C1 rat", "SPECIES", 200, 210], ["swine", "SPECIES", 72, 77], ["HEV", "SPECIES", 133, 136], ["HEV-1", "SPECIES", 181, 186], ["HEV-4", "SPECIES", 190, 195], ["HEV-C1 rat", "SPECIES", 200, 210], ["infection", "PROBLEM", 109, 118], ["genotypes HEV", "TEST", 171, 184], ["HEV", "TEST", 190, 193], ["HEV-C1 rat", "TEST", 200, 210], ["infection", "OBSERVATION", 109, 118], ["HEV Origin", "OBSERVATION_MODIFIER", 133, 143], ["C1 rat", "ANATOMY", 204, 210]]], ["This Bayesian analysis considered neither recombination events nor host species evolution.", [["This Bayesian analysis", "TEST", 0, 22], ["host species", "OBSERVATION", 67, 79]]], ["However, hosts of Orthohepevirus C variants have been detected from Carnivora, Rodentia and Soricomorpha, and Orthohepevirus A variants have been detected from Artiodactyla, Carnivora, Lagomorpha and Primates.", [["Orthohepevirus C", "ORGANISM", 18, 34], ["Soricomorpha", "GENE_OR_GENE_PRODUCT", 92, 104], ["Orthohepevirus A", "GENE_OR_GENE_PRODUCT", 110, 126], ["Orthohepevirus C variants", "PROBLEM", 18, 43], ["Soricomorpha", "TREATMENT", 92, 104], ["Lagomorpha", "TREATMENT", 185, 195]]], ["Such diversification of host orders suggests that HEV did not co-evolve with its hosts, but is more likely an opportunistic pathogen (Smith et al., 2014) .", [["HEV", "ORGANISM", 50, 53], ["HEV", "SPECIES", 50, 53], ["an opportunistic pathogen", "PROBLEM", 107, 132], ["more likely", "UNCERTAINTY", 95, 106], ["opportunistic", "OBSERVATION_MODIFIER", 110, 123]]], ["The division that might have led to the ancestors of human and swine hepevirus occurred at about the same time.", [["human", "ORGANISM", 53, 58], ["swine hepevirus", "ORGANISM", 63, 78], ["human", "SPECIES", 53, 58], ["swine", "SPECIES", 63, 68], ["human", "SPECIES", 53, 58], ["swine", "SPECIES", 63, 68]]], ["The appearance of the HEV-C1 suggests that mammalian HEV could have been adapted to different mammalian species over time (Purdy and Khudyakov, 2010) .", [["HEV-C1", "ORGANISM", 22, 28], ["mammalian HEV", "ORGANISM", 43, 56], ["HEV", "SPECIES", 53, 56], ["mammalian HEV", "PROBLEM", 43, 56], ["HEV", "OBSERVATION", 22, 25], ["C1", "ANATOMY", 26, 28], ["mammalian HEV", "OBSERVATION", 43, 56]]], ["There is evidence that genotype 1 or an anthropotropic ancestor of genotype 1 has been responsible for acute hepatitis infections among adults since the last decade of the 18th century (Teo, 2012) .", [["acute hepatitis infections", "DISEASE", 103, 129], ["genotype 1", "PROBLEM", 23, 33], ["genotype 1", "PROBLEM", 67, 77], ["acute hepatitis infections", "PROBLEM", 103, 129], ["responsible for", "UNCERTAINTY", 87, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["hepatitis", "OBSERVATION", 109, 118]]], ["This indicates that either estimates for the time for the most recent common ancestor for genotype 1 are underestimated or genotype 1 has gone through an evolutionary bottleneck and the ancestor is a survivor of that bottleneck.", [["genotype 1", "PROBLEM", 90, 100], ["genotype 1", "PROBLEM", 123, 133]]], ["The further discovery of other mammalian HEV-related viruses may help to improve the understanding of Hepeviridae evolution.", [["mammalian HEV", "ORGANISM", 31, 44], ["Hepeviridae", "GENE_OR_GENE_PRODUCT", 102, 113], ["other mammalian HEV-related viruses", "PROBLEM", 25, 60], ["Hepeviridae evolution", "PROBLEM", 102, 123], ["HEV", "OBSERVATION", 41, 44]]], ["However, the lack of fossil viruses, preventing a confirmation of statistical analyses conducted so far (Purdy and Khudyakov, 2010) , poses a challenge regarding the elucidation of the HEV (and HEV-related viruses) origin.", [["HEV", "ORGANISM", 185, 188], ["HEV-related viruses", "ORGANISM", 194, 213], ["HEV", "SPECIES", 185, 188], ["fossil viruses", "PROBLEM", 21, 35], ["statistical analyses", "TEST", 66, 86], ["a challenge", "TREATMENT", 140, 151], ["the HEV", "PROBLEM", 181, 188], ["fossil viruses", "OBSERVATION", 21, 35], ["HEV", "OBSERVATION", 185, 188]]], ["Therefore, Hepeviridae origin analysis will remain speculative but allows a clarification of the current situation.ConclusionSince the first characterized hepatitis E epidemic in 1955, several outbreaks have been described and the discovery of HEV-related viruses has increased significantly during the last 15 years.", [["hepatitis E", "DISEASE", 155, 166], ["HEV-related viruses", "ORGANISM", 244, 263], ["Hepeviridae origin analysis", "TEST", 11, 38], ["hepatitis E epidemic", "PROBLEM", 155, 175], ["HEV-related viruses", "PROBLEM", 244, 263], ["hepatitis", "OBSERVATION", 155, 164], ["HEV", "OBSERVATION", 244, 247], ["viruses", "OBSERVATION", 256, 263], ["increased", "OBSERVATION_MODIFIER", 268, 277]]], ["Rather than representing a true emergence, this trend is probably due to the increasing interest in public health and food safety as well as the use of improved diagnostic tools.", [["a true emergence", "PROBLEM", 25, 41], ["probably due to", "UNCERTAINTY", 57, 72], ["increasing", "OBSERVATION_MODIFIER", 77, 87]]], ["As their discovery, the taxonomy of the Hepeviridae family has been in perpetual evolution due to the introduction of newly identified viruses.ConclusionThe high HEV prevalence in animals worldwide raises the question of transmission to humans.", [["Hepeviridae", "GENE_OR_GENE_PRODUCT", 40, 51], ["HEV", "ORGANISM", 162, 165], ["humans", "ORGANISM", 237, 243], ["Hepeviridae family", "PROTEIN", 40, 58], ["humans", "SPECIES", 237, 243], ["HEV", "SPECIES", 162, 165], ["humans", "SPECIES", 237, 243], ["newly identified viruses", "PROBLEM", 118, 142], ["viruses", "OBSERVATION", 135, 142], ["high", "OBSERVATION_MODIFIER", 157, 161], ["HEV prevalence", "OBSERVATION", 162, 176]]], ["Indeed, studies have shown transmission of HEV via deer, swine and wild boar meat in Europe and Japan.", [["meat", "ANATOMY", 77, 81], ["HEV", "ORGANISM", 43, 46], ["deer", "ORGANISM", 51, 55], ["swine", "ORGANISM", 57, 62], ["boar", "ORGANISM", 72, 76], ["meat", "ORGANISM_SUBDIVISION", 77, 81], ["deer", "SPECIES", 51, 55], ["swine", "SPECIES", 57, 62], ["boar", "SPECIES", 72, 76], ["HEV", "SPECIES", 43, 46], ["deer", "SPECIES", 51, 55], ["swine", "SPECIES", 57, 62], ["boar", "SPECIES", 72, 76], ["HEV", "PROBLEM", 43, 46]]], ["High seroprevalence rates and similarities between the nucleotide sequences studied also raise the question of possible transmission between pigs and wild boar; particularly, when contact between these animals is possible, for example in the context of out-door breeding pigs.", [["nucleotide", "CHEMICAL", 55, 65], ["nucleotide", "CHEMICAL", 55, 65], ["pigs", "ORGANISM", 141, 145], ["boar", "ORGANISM", 155, 159], ["pigs", "ORGANISM", 271, 275], ["pigs", "SPECIES", 141, 145], ["boar", "SPECIES", 155, 159], ["pigs", "SPECIES", 271, 275], ["pigs", "SPECIES", 141, 145], ["High seroprevalence rates", "PROBLEM", 0, 25], ["the nucleotide sequences", "TEST", 51, 75], ["transmission between pigs and wild boar", "PROBLEM", 120, 159]]], ["Even if zoonotic transmission from different animal species is accepted in non-endemic regions, strong molecular evidence is scarce and the human susceptibility for bat, rat, ferret, dromedary camel and moose HEV-related viruses is still unknown.ConclusionOrigins of the virus and pathways of spread through time are still largely unknown due, among other things, to the lack of fossil records.", [["human", "ORGANISM", 140, 145], ["rat", "ORGANISM", 170, 173], ["ferret", "ORGANISM", 175, 181], ["dromedary camel", "ORGANISM", 183, 198], ["moose HEV-related viruses", "ORGANISM", 203, 228], ["human", "SPECIES", 140, 145], ["rat", "SPECIES", 170, 173], ["ferret", "SPECIES", 175, 181], ["camel", "SPECIES", 193, 198], ["moose HEV", "SPECIES", 203, 212], ["human", "SPECIES", 140, 145], ["rat", "SPECIES", 170, 173], ["ferret", "SPECIES", 175, 181], ["zoonotic transmission", "PROBLEM", 8, 29], ["different animal species", "PROBLEM", 35, 59], ["moose HEV-related viruses", "PROBLEM", 203, 228], ["the virus", "PROBLEM", 267, 276], ["virus", "OBSERVATION", 271, 276]]], ["Research to date cannot show the exact roles of humans and animals in Hepeviridae evolutionary history.AcknowledgementsWe thank Annette Dougall and Louisa Ludwig for the careful English correction of the manuscript.", [["humans", "ORGANISM", 48, 54], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54]]], ["It has not been formally disseminated by the Centers for Disease Control and Prevention/ Agency for Toxic Substances and Disease Registry.", [["Toxic Substances and Disease", "DISEASE", 100, 128], ["Disease Control", "TREATMENT", 57, 72], ["Toxic Substances", "PROBLEM", 100, 116]]], ["It does not represent and should not be construed to represent any agency determination or policy.", [["does not represent", "UNCERTAINTY", 3, 21]]], ["Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention.", [["Human", "ORGANISM", 114, 119], ["Human", "SPECIES", 114, 119], ["Disease Control", "TREATMENT", 176, 191]]], ["The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.", [["Disease Control", "TREATMENT", 131, 146]]]], "4c09b3a929b4f3b8a846627f3969fc0f403c9503": [["IntroductionRabies is spreading at an alarming rate in some regions of the developing world [1] [2] [3] .", [["IntroductionRabies", "DISEASE", 0, 18], ["spreading", "OBSERVATION_MODIFIER", 22, 31]]], ["Collaborative efforts among human and animal healthcare professionals are required to monitor this situation and allow a timely and proportioned therapeutic response, limiting unnecessary use of valuable vaccines.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["valuable vaccines", "TREATMENT", 195, 212]]], ["The combination of rabies awareness campaigns, improved vaccine coverage and disease surveillance has already resulted in the successful elimi-nation of canine rabies in North America [4] .", [["canine rabies", "DISEASE", 153, 166], ["rabies", "ORGANISM", 19, 25], ["canine", "ORGANISM", 153, 159], ["canine", "SPECIES", 153, 159], ["rabies", "SPECIES", 19, 25], ["canine", "SPECIES", 153, 159], ["rabies awareness campaigns", "PROBLEM", 19, 45], ["improved vaccine coverage", "TREATMENT", 47, 72], ["disease surveillance", "TEST", 77, 97]]], ["However, vaccines need to be efficacious enough to elicit a response that will confer protection and diagnostic techniques are needed to ensure that adequate levels of virus-neutralising antibodies (VNAbs) have been achieved in response to vaccination.", [["neutralising antibodies", "GENE_OR_GENE_PRODUCT", 174, 197], ["neutralising antibodies", "PROTEIN", 174, 197], ["VNAbs", "PROTEIN", 199, 204], ["vaccines", "TREATMENT", 9, 17], ["diagnostic techniques", "TEST", 101, 122], ["virus-neutralising antibodies", "TREATMENT", 168, 197], ["vaccination", "TREATMENT", 240, 251]]], ["The problem with current tests is that they are not easily used in endemic areas within developing countries because they need to be set up in containment laboratories since highly pathogenic zoonotic viruses are required to perform the assay, or such assays are prohibitively expensive.", [["current tests", "TEST", 17, 30], ["highly pathogenic zoonotic viruses", "PROBLEM", 174, 208], ["the assay", "TEST", 233, 242], ["such assays", "TEST", 247, 258]]], ["Those that are e.g., ELISA-based assays, do not have the sensitivity or specificity of the fluorescent antibody virus neutralisation (FAVN) assay that is widely used within Office international des \u00e9pizooties (OIE) rabies reference laboratories.", [["ELISA-based assays", "TEST", 21, 39], ["the sensitivity", "TEST", 53, 68], ["the fluorescent antibody virus neutralisation", "TEST", 87, 132]]], ["Therefore, in addition to the need for further implementation and development of improved anti-rabies biologicals, improved techniques to assess seroconversion are required before canine rabies is success- The owners were invited to bring their dogs to two sessions.", [["rabies", "DISEASE", 187, 193], ["canine rabies", "ORGANISM", 180, 193], ["dogs", "ORGANISM", 245, 249], ["canine", "SPECIES", 180, 186], ["further implementation", "TREATMENT", 39, 61], ["improved anti-rabies biologicals", "TREATMENT", 81, 113], ["seroconversion", "PROBLEM", 145, 159]]], ["During the first, samples were collected for baseline measurements, a rabies vaccine was administered and a welfare assessment conducted.", [["samples", "ANATOMY", 18, 25], ["rabies", "SPECIES", 70, 76], ["a rabies vaccine", "TREATMENT", 68, 84], ["a welfare assessment", "TEST", 106, 126]]], ["Twenty-one days later (* the revisit to BS village was 20 days postvaccination) the dogs had further samples collected.", [["samples", "ANATOMY", 101, 108], ["dogs", "ORGANISM", 84, 88], ["dogs", "SPECIES", 84, 88], ["further samples", "TEST", 93, 108]]], ["(C) While all samples were processed using the same protocol, the levels of haemolysis and serum collected were variable but did not affect results.Introductionfully eliminated in developing countries as it has been in North America.IntroductionWithin the Lyssavirus genus, classical rabies viruses (genotype 1) are not the only pathogen to cause morbidity and mortality in mammalian populations.", [["samples", "ANATOMY", 14, 21], ["serum", "ANATOMY", 91, 96], ["haemolysis", "DISEASE", 76, 86], ["rabies viruses", "DISEASE", 284, 298], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["Lyssavirus genus", "ORGANISM", 256, 272], ["rabies viruses", "ORGANISM", 284, 298], ["mammalian populations", "CELL", 374, 395], ["rabies viruses", "SPECIES", 284, 298], ["the same protocol", "TEST", 43, 60], ["the levels of haemolysis", "TEST", 62, 86], ["serum collected", "TEST", 91, 106], ["classical rabies viruses", "PROBLEM", 274, 298], ["morbidity", "PROBLEM", 347, 356], ["Lyssavirus genus", "OBSERVATION", 256, 272], ["mammalian populations", "OBSERVATION", 374, 395]]], ["Clearly, infection by lyssaviruses of the other genotypes (2) (3) (4) (5) (6) (7) can result in a clinical manifestation that is indistinguishable from rabies.", [["infection", "DISEASE", 9, 18], ["rabies", "DISEASE", 152, 158], ["rabies", "ORGANISM", 152, 158], ["rabies", "SPECIES", 152, 158], ["infection", "PROBLEM", 9, 18], ["the other genotypes (2) (3) (4) (5) (6) (7)", "PROBLEM", 38, 81], ["a clinical manifestation", "PROBLEM", 96, 120], ["infection", "OBSERVATION", 9, 18]]], ["The other genotypes are distributed geographically predominantly within African, European and Australian bat populations [5] .", [["distributed", "OBSERVATION_MODIFIER", 24, 35], ["geographically", "OBSERVATION_MODIFIER", 36, 50], ["predominantly", "OBSERVATION_MODIFIER", 51, 64]]], ["Recently, additional variants that are more divergent than genotypes 1-7 have been isolated suggesting further genotypes may yet exist [6] [7] [8] [9] [10] .", [["1-7", "GENE_OR_GENE_PRODUCT", 69, 72], ["[6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 135, 155], ["genotypes 1-7", "DNA", 59, 72], ["further genotypes", "PROBLEM", 103, 120]]], ["Isolates representing genotypes 1, 2 and 4-7 have been identified in insectivorous, fruit or vampire bats [5] .", [["fruit", "ANATOMY", 84, 89], ["7", "GENE_OR_GENE_PRODUCT", 43, 44], ["genotypes 1, 2 and 4-7", "DNA", 22, 44], ["Isolates", "TEST", 0, 8], ["genotypes", "TEST", 22, 31]]], ["Mokola virus (MOKV, genotype 3) along with Lagos bat virus (LBV, genotype 2) and Duvenhage virus (DUVV, genotype 4) comprises the African lyssaviruses.", [["Mokola virus", "ORGANISM", 0, 12], ["MOKV", "GENE_OR_GENE_PRODUCT", 14, 18], ["Lagos bat virus", "ORGANISM", 43, 58], ["LBV, genotype 2", "ORGANISM", 60, 75], ["Duvenhage virus", "ORGANISM", 81, 96], ["Mokola virus", "SPECIES", 0, 12], ["Lagos bat virus", "SPECIES", 43, 58], ["Duvenhage virus", "SPECIES", 81, 96], ["Mokola virus", "SPECIES", 0, 12], ["MOKV", "SPECIES", 14, 18], ["Lagos bat virus", "SPECIES", 43, 58], ["LBV", "SPECIES", 60, 63], ["Duvenhage virus", "SPECIES", 81, 96], ["DUVV", "SPECIES", 98, 102], ["Mokola virus (MOKV, genotype", "TREATMENT", 0, 28], ["Lagos bat virus (LBV, genotype", "TREATMENT", 43, 73], ["Duvenhage virus (DUVV, genotype 4", "TREATMENT", 81, 114]]], ["Interestingly, only a few clinical isolates representing these genotypes have been identified to date [11] .", [["a few clinical isolates", "PROBLEM", 20, 43], ["these genotypes", "PROBLEM", 57, 72], ["few", "OBSERVATION_MODIFIER", 22, 25]]], ["Recently, surveillance programs and greater access to serosurveillance techniques have resulted in the discovery of a high seroprevalence against LBV in East and West African megachiroptera [12, 13] and a common presence of LBV in South African bats collected for routine surveillance [11] .IntroductionThese reports and others [2, 14] emphasise that the potential for increased incidence levels of rabies and related lyssavirus infections is a concern in Africa, mainly because of the lack of awareness of these infections in the population.", [["rabies", "DISEASE", 399, 405], ["lyssavirus infections", "DISEASE", 418, 439], ["infections", "DISEASE", 513, 523], ["West African megachiroptera", "ORGANISM", 162, 189], ["LBV", "CANCER", 224, 227], ["rabies", "ORGANISM", 399, 405], ["African megachiroptera", "SPECIES", 167, 189], ["LBV", "SPECIES", 146, 149], ["African megachiroptera", "SPECIES", 167, 189], ["LBV", "SPECIES", 224, 227], ["African bats", "SPECIES", 237, 249], ["rabies", "SPECIES", 399, 405], ["surveillance programs", "TEST", 10, 31], ["serosurveillance techniques", "TREATMENT", 54, 81], ["routine surveillance", "TEST", 264, 284], ["increased incidence levels of rabies", "PROBLEM", 369, 405], ["related lyssavirus infections", "PROBLEM", 410, 439], ["these infections", "PROBLEM", 507, 523], ["lyssavirus infections", "OBSERVATION", 418, 439], ["infections", "OBSERVATION", 513, 523]]], ["However, there is also poor accessibility to vaccines and post-exposure treatments for those exposed to these viruses and there are difficulties with undertaking (sero)surveillance measures in many countries within Africa [15] .", [["vaccines", "TREATMENT", 45, 53], ["post-exposure treatments", "TREATMENT", 58, 82], ["these viruses", "PROBLEM", 104, 117], ["difficulties with undertaking (sero)surveillance measures", "PROBLEM", 132, 189], ["poor accessibility", "OBSERVATION", 23, 41], ["viruses", "OBSERVATION", 110, 117]]], ["While the most important factor in reducing rabies prevalence is the implementation of vaccination campaigns, it was highlighted at the recent Southern and Eastern African Rabies Group meeting that poor infrastructure becomes a major barrier when attempting to control rabies in Africa [16] .", [["rabies", "DISEASE", 44, 50], ["rabies", "DISEASE", 269, 275], ["rabies", "ORGANISM", 44, 50], ["rabies", "SPECIES", 44, 50], ["rabies", "SPECIES", 269, 275], ["vaccination campaigns", "TREATMENT", 87, 108], ["poor infrastructure", "PROBLEM", 198, 217]]], ["These views are shared by the OIE and World Health Organization (WHO), that list the development of novel diagnostics as an urgent requirement [17, 18] .IntroductionSerological techniques that can be employed to study naturally occurring or vaccine-induced humoral responses to rabies virus infection include the FAVN assay [19] , rapid fluorescent focus inhibition test (RFFIT) [20] and enzyme linked immunosorbant assay (ELISA) [21] .", [["rabies virus infection", "DISEASE", 278, 300], ["rabies virus", "ORGANISM", 278, 290], ["rabies virus", "SPECIES", 278, 290], ["rabies virus", "SPECIES", 278, 290], ["vaccine", "TREATMENT", 241, 248], ["humoral responses", "PROBLEM", 257, 274], ["rabies virus infection", "PROBLEM", 278, 300], ["the FAVN assay", "TEST", 309, 323], ["rapid fluorescent focus inhibition test", "TEST", 331, 370], ["enzyme linked immunosorbant assay", "TEST", 388, 421]]], ["Variations of these assays have been described previously [22, 23] .", [["these assays", "TEST", 14, 26]]], ["The routinely used FAVN assay and RFFIT are the current assays of choice with OIE/WHO reference laboratories but must be performed in BSL3/SAPO4 high containment facilities because live virus is handled as part of the assay.", [["BSL3", "GENE_OR_GENE_PRODUCT", 134, 138], ["SAPO4", "GENE_OR_GENE_PRODUCT", 139, 144], ["FAVN assay", "TREATMENT", 19, 29], ["live virus", "PROBLEM", 181, 191]]], ["While a modified RFFIT that combines green fluorescent protein (GFP) with live recombinant virus can remove the need for expensive conjugates, work with recombinant virus still requires the use of high containment facilities [23] .", [["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 37, 62], ["GFP", "GENE_OR_GENE_PRODUCT", 64, 67], ["live recombinant virus", "ORGANISM", 74, 96], ["recombinant virus", "ORGANISM", 153, 170], ["RFFIT", "PROTEIN", 17, 22], ["green fluorescent protein", "PROTEIN", 37, 62], ["GFP", "PROTEIN", 64, 67], ["green fluorescent protein (GFP", "PROBLEM", 37, 67], ["live recombinant virus", "TREATMENT", 74, 96], ["expensive conjugates", "TREATMENT", 121, 141], ["recombinant virus", "PROBLEM", 153, 170]]], ["With the recent addition to the above mentioned set of neutralisation assays of the ELISA-based method that uses plates coated with whole, inactivated virus, the need for live virus has been eliminated.", [["neutralisation assays", "TEST", 55, 76], ["the ELISA", "TEST", 80, 89], ["plates coated", "TREATMENT", 113, 126], ["whole, inactivated virus", "PROBLEM", 132, 156], ["live virus", "PROBLEM", 171, 181]]], ["Since both non-neutralising and neutralising antibodies are detected, the level of circulating, protective VNAbs alone cannot be determined.", [["VNAbs", "GENE_OR_GENE_PRODUCT", 107, 112], ["neutralising antibodies", "PROTEIN", 32, 55], ["VNAbs", "PROTEIN", 107, 112], ["neutralising antibodies", "TEST", 32, 55], ["protective VNAbs", "TREATMENT", 96, 112]]], ["There are also issues with low sensitivity when using the ELISA.IntroductionWe recently described the use of surrogate viruses known as lentiviral pseudotypes as replacements for live or inactivated whole virus to accurately determine anti-rabies VNAb responses in vaccine recipients.", [["lentiviral", "ORGANISM", 136, 146], ["VNAb", "GENE_OR_GENE_PRODUCT", 247, 251], ["recipients", "ORGANISM", 273, 283], ["VNAb", "PROTEIN", 247, 251], ["low sensitivity", "PROBLEM", 27, 42], ["surrogate viruses", "TREATMENT", 109, 126], ["lentiviral pseudotypes", "TREATMENT", 136, 158], ["replacements", "TREATMENT", 162, 174], ["live", "TREATMENT", 179, 183], ["inactivated whole virus", "PROBLEM", 187, 210], ["low sensitivity", "OBSERVATION_MODIFIER", 27, 42]]], ["The samples tested were taken from vaccinated humans, dogs and cats in the United Kingdom (UK) [24] .", [["samples", "ANATOMY", 4, 11], ["humans", "ORGANISM", 46, 52], ["dogs", "ORGANISM", 54, 58], ["cats", "ORGANISM", 63, 67], ["humans", "SPECIES", 46, 52], ["dogs", "SPECIES", 54, 58], ["cats", "SPECIES", 63, 67], ["humans", "SPECIES", 46, 52], ["The samples", "TEST", 0, 11]]], ["Here we report the results of the largest virus neutralisation study published to date using the surrogate lentiviral pseudotypes rather than the live native or recombinant rabies virus with field serum samples from Tanzanian dogs.", [["serum samples", "ANATOMY", 197, 210], ["lentiviral", "ORGANISM", 107, 117], ["recombinant", "ORGANISM", 161, 172], ["rabies virus", "ORGANISM", 173, 185], ["serum samples", "ORGANISM_SUBSTANCE", 197, 210], ["dogs", "ORGANISM", 226, 230], ["rabies virus", "SPECIES", 173, 185], ["dogs", "SPECIES", 226, 230], ["rabies virus", "SPECIES", 173, 185], ["the largest virus neutralisation study", "TEST", 30, 68], ["the surrogate lentiviral pseudotypes", "TREATMENT", 93, 129], ["recombinant rabies virus", "PROBLEM", 161, 185], ["field serum samples", "TEST", 191, 210], ["Tanzanian dogs", "TREATMENT", 216, 230]]], ["We further increase the utility of our pseudotype neutralisation assay for laboratories undertaking vaccine trials and serosurveillance in resource-limited, rabies endemic countries by exploring the use of lacZ as a reporter gene and incorporating the glycoproteins of a further three lyssavirus \"Primary\" refers to dogs that had never received a rabies vaccination prior to this study, \"booster\" refers to dogs that had previously received \u22651 rabies vaccination and \"no record\" means there was no vaccination history available or taken. a One sample was missing on arrival in the UK. b One sample vial was empty on arrival in the UK.Introductiongenotypes, in addition to genotype 1, which will allow improved serosurveillance for lyssaviruses other than classical rabies.", [["lyssaviruses", "DISEASE", 731, 743], ["rabies", "DISEASE", 765, 771], ["rabies", "ORGANISM", 157, 163], ["lacZ", "GENE_OR_GENE_PRODUCT", 206, 210], ["dogs", "ORGANISM", 316, 320], ["dogs", "ORGANISM", 407, 411], ["lacZ", "DNA", 206, 210], ["reporter gene", "DNA", 216, 229], ["dogs", "SPECIES", 316, 320], ["dogs", "SPECIES", 407, 411], ["rabies", "SPECIES", 347, 353], ["rabies", "SPECIES", 444, 450], ["rabies", "SPECIES", 765, 771], ["our pseudotype neutralisation assay", "TEST", 35, 70], ["vaccine trials", "TREATMENT", 100, 114], ["lacZ", "TREATMENT", 206, 210], ["a reporter gene", "TREATMENT", 214, 229], ["a rabies vaccination", "TREATMENT", 345, 365], ["this study", "TEST", 375, 385], ["\u22651 rabies vaccination", "TREATMENT", 441, 462], ["Introductiongenotypes", "TREATMENT", 634, 655], ["lyssaviruses", "PROBLEM", 731, 743], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["empty", "OBSERVATION", 607, 612]]], ["This report describes a highly sensitive yet flexible platform that can be adapted to allow the evaluation of vaccine and antiviral drugs against highly pathogenic viruses without the need for high level containment facilities or expensive reagents and equipment.Study areaDogs enrolled in this study were selected from domestic animals living in four villages (Ngarawani, Runga'bure, Nyamburi and Bisarara) within 20 km of the Serengeti National Park perimeter in the Serengeti District, northwestern Tanzania (Fig. 1A) .", [["the evaluation", "TEST", 92, 106], ["vaccine", "TREATMENT", 110, 117], ["antiviral drugs", "TREATMENT", 122, 137], ["highly pathogenic viruses", "PROBLEM", 146, 171], ["high level containment facilities", "TREATMENT", 193, 226], ["expensive reagents", "TREATMENT", 230, 248], ["Study areaDogs", "TEST", 263, 277], ["this study", "TEST", 290, 300], ["Ngarawani", "TREATMENT", 362, 371], ["Runga'bure", "TREATMENT", 373, 383], ["Nyamburi", "TREATMENT", 385, 393]]], ["In each case the dog owner's consent was sought before enrolling their dog in the study.", [["dog", "ORGANISM", 17, 20], ["dog", "ORGANISM", 71, 74], ["dog", "SPECIES", 17, 20], ["dog", "SPECIES", 17, 20], ["the study", "TEST", 78, 87]]], ["This project was part of the annual vaccination campaign undertaken by the Viral Transmission Dynamics Project, which works to prevent the spread of diseases through animal populations in the Serengeti region.Vaccination historyA detailed medical history of each dog enrolled in this study, which included any prior vaccinations, was taken at the first visit.", [["dog", "ORGANISM", 263, 266], ["the annual vaccination campaign", "TREATMENT", 25, 56], ["diseases", "PROBLEM", 149, 157], ["this study", "TEST", 279, 289], ["any prior vaccinations", "TREATMENT", 306, 328], ["diseases", "OBSERVATION", 149, 157], ["Serengeti", "ANATOMY", 192, 201], ["region", "ANATOMY_MODIFIER", 202, 208]]], ["Sixty-six and a half percent (n = 125) of the dogs had not been vaccinated against rabies prior to this study (referred to as \"primary\"), 27.2% (n = 52) had received at least one rabies vaccine previously (\"booster\") and there was no vaccination history available or taken for 7.3% (n = 14; \"no record\"; Table 1 ).", [["rabies", "DISEASE", 83, 89], ["dogs", "ORGANISM", 46, 50], ["rabies", "ORGANISM", 83, 89], ["rabies", "ORGANISM", 179, 185], ["dogs", "SPECIES", 46, 50], ["rabies", "SPECIES", 83, 89], ["rabies", "SPECIES", 179, 185], ["this study", "TEST", 99, 109]]], ["The Nobivac \u00ae rabies virus vaccine (donated by Intervet Schering-Plough Animal Health) was administered to all dogs in a single dose inoculation given subcutaneously.", [["subcutaneously", "ANATOMY", 151, 165], ["Nobivac \u00ae rabies virus", "ORGANISM", 4, 26], ["dogs", "ORGANISM", 111, 115], ["rabies virus vaccine", "SPECIES", 14, 34], ["dogs", "SPECIES", 111, 115], ["Nobivac \u00ae rabies virus", "SPECIES", 4, 26], ["The Nobivac \u00ae rabies virus vaccine", "TREATMENT", 0, 34], ["a single dose inoculation", "TREATMENT", 119, 144]]], ["It comprises an inactivated vaccine containing >2 IU rabies virus (Pasteur strain).Serum samplesAt the first visit, a blood sample was taken from each dog before the rabies virus vaccine was administered.", [["Serum samples", "ANATOMY", 83, 96], ["blood sample", "ANATOMY", 118, 130], ["IU", "ORGANISM", 50, 52], ["rabies virus", "ORGANISM", 53, 65], ["Pasteur strain", "ORGANISM", 67, 81], ["Serum samples", "ORGANISM_SUBSTANCE", 83, 96], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["dog", "ORGANISM", 151, 154], ["rabies virus", "ORGANISM", 166, 178], ["rabies virus", "SPECIES", 53, 65], ["rabies virus", "SPECIES", 53, 65], ["rabies virus", "SPECIES", 166, 178], ["an inactivated vaccine", "TREATMENT", 13, 35], ["Serum samples", "TEST", 83, 96], ["a blood sample", "TEST", 116, 130], ["the rabies virus vaccine", "TREATMENT", 162, 186]]], ["The overall study protocol is shown in Fig. 1B .Serum samplesBlood was drawn from the cephalic or jugular vein, stored on ice, and processed at the end of each day (centrifugation at 3000 rpm for 10 min).", [["Serum samples", "ANATOMY", 48, 61], ["Blood", "ANATOMY", 61, 66], ["cephalic", "ANATOMY", 86, 94], ["jugular vein", "ANATOMY", 98, 110], ["1B", "GENE_OR_GENE_PRODUCT", 44, 46], ["Serum samples", "ORGANISM_SUBSTANCE", 48, 61], ["Blood", "ORGANISM_SUBSTANCE", 61, 66], ["cephalic", "ORGANISM_SUBDIVISION", 86, 94], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 98, 110], ["The overall study protocol", "TEST", 0, 26], ["Serum samples", "TEST", 48, 61], ["Blood", "TEST", 61, 66], ["ice", "TREATMENT", 122, 125], ["cephalic", "ANATOMY", 86, 94], ["jugular vein", "ANATOMY", 98, 110]]], ["Serum was prepared, inactivated at 57 \u2022 C for 30 min and then frozen for transport.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5]]], ["In total, 321 samples were taken from the enrolled dogs, blinded and sent to University College London (UCL) and Veterinary Laboratories Agency (VLA) for testing.", [["samples", "ANATOMY", 14, 21], ["dogs", "ORGANISM", 51, 55], ["dogs", "SPECIES", 51, 55], ["testing", "TEST", 154, 161]]], ["The OIE standard reference dog serum diluted to 0.5 international units/ml (IU/ml) with PBS was used as a positive control.Serum samplesRabbit anti-sera raised against LBV isolate RV1 (n = 2) and DUVV isolate RV131 (n = 4) were used in neutralisation assays with African lyssavirus pseudotypes.", [["serum", "ANATOMY", 31, 36], ["Serum", "ANATOMY", 123, 128], ["RV131", "CHEMICAL", 209, 214], ["dog", "ORGANISM", 27, 30], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["Serum", "ORGANISM_SUBSTANCE", 123, 128], ["dog", "SPECIES", 27, 30], ["dog", "SPECIES", 27, 30], ["LBV", "SPECIES", 168, 171], ["DUVV", "SPECIES", 196, 200], ["African lyssavirus pseudotypes", "SPECIES", 263, 293], ["PBS", "TREATMENT", 88, 91], ["a positive control", "TREATMENT", 104, 122], ["Serum samplesRabbit anti-sera", "TEST", 123, 152], ["DUVV isolate", "TEST", 196, 208], ["neutralisation assays", "TEST", 236, 257], ["African lyssavirus pseudotypes", "PROBLEM", 263, 293]]], ["Anti-sera to MOKV were not available but anti-LBV serum is known to cross-neutralise MOKV.", [["serum", "ANATOMY", 50, 55], ["MOKV", "GENE_OR_GENE_PRODUCT", 13, 17], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["MOKV", "GENE_OR_GENE_PRODUCT", 85, 89], ["MOKV", "PROTEIN", 13, 17], ["MOKV", "PROTEIN", 85, 89], ["MOKV", "SPECIES", 13, 17], ["anti-LBV", "SPECIES", 41, 49], ["anti-LBV serum", "TEST", 41, 55]]], ["One serum raised against uninfected tissue culture supernatant and another against Australian bat lyssavirus (RV634) were used in the same panel as the LBV and DUVV sera.Infection and neutralisation assaysHuman embryonic kidney 293T cells [25] were used for production of the lentiviral pseudotypes (lyssavirus surrogates).", [["serum", "ANATOMY", 4, 9], ["tissue culture supernatant", "ANATOMY", 36, 62], ["LBV", "ANATOMY", 152, 155], ["sera", "ANATOMY", 165, 169], ["embryonic kidney 293T cells", "ANATOMY", 211, 238], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["bat lyssavirus", "ORGANISM", 94, 108], ["RV634", "ORGANISM", 110, 115], ["LBV", "CANCER", 152, 155], ["DUVV", "ORGANISM", 160, 164], ["sera", "ORGANISM_SUBSTANCE", 165, 169], ["Human", "ORGANISM", 205, 210], ["embryonic kidney 293T cells", "CELL", 211, 238], ["lentiviral", "ORGANISM", 276, 286], ["Human embryonic kidney 293T cells", "CELL_LINE", 205, 238], ["Human", "SPECIES", 205, 210], ["Australian bat lyssavirus", "SPECIES", 83, 108], ["RV634", "SPECIES", 110, 115], ["LBV", "SPECIES", 152, 155], ["DUVV", "SPECIES", 160, 164], ["Human", "SPECIES", 205, 210], ["One serum", "TEST", 0, 9], ["uninfected tissue culture supernatant", "PROBLEM", 25, 62], ["Australian bat lyssavirus", "TEST", 83, 108], ["the LBV and DUVV sera", "TREATMENT", 148, 169], ["Infection", "PROBLEM", 170, 179], ["neutralisation assays", "TEST", 184, 205], ["the lentiviral pseudotypes", "TREATMENT", 272, 298], ["uninfected tissue", "OBSERVATION_MODIFIER", 25, 42], ["kidney", "ANATOMY", 221, 227], ["293T cells", "OBSERVATION", 228, 238], ["lentiviral pseudotypes", "OBSERVATION", 276, 298]]], ["Neutralisation assays were undertaken on baby hamster kidney 21 cells clone 13 (BHK; [26] ).", [["hamster kidney 21 cells", "ANATOMY", 46, 69], ["BHK", "ANATOMY", 80, 83], ["hamster kidney 21 cells clone", "CELL", 46, 75], ["BHK", "CELL", 80, 83], ["baby hamster kidney 21 cells clone 13", "CELL_LINE", 41, 78], ["BHK", "CELL_LINE", 80, 83], ["hamster", "SPECIES", 46, 53], ["hamster", "SPECIES", 46, 53], ["Neutralisation assays", "TEST", 0, 21], ["kidney", "ANATOMY", 54, 60]]], ["The NP2 human glioma cell line expressing CD4 and CXCR4 was used as target cells for HIV-1 pseudotypes [27] .FAVN assaysLive virus experiments were undertaken using a restricted version of the FAVN that is identical to the existing FAVN assay [19] but with serum samples diluted 3-fold to a final titre of 1:81, roughly equivalent to 5.92 IU/ml.Pseudotype assaysStandard plasmids and the transfection protocol for lentiviral pseudotype (lyssavirus surrogate) production have been described elsewhere [24] .", [["glioma cell line", "ANATOMY", 14, 30], ["cells", "ANATOMY", 75, 80], ["serum samples", "ANATOMY", 257, 270], ["plasmids", "ANATOMY", 371, 379], ["NP2", "CELL", 4, 7], ["human", "ORGANISM", 8, 13], ["glioma cell line", "CELL", 14, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["CXCR4", "GENE_OR_GENE_PRODUCT", 50, 55], ["cells", "CELL", 75, 80], ["HIV-1 pseudotypes", "ORGANISM", 85, 102], ["FAVN", "SIMPLE_CHEMICAL", 193, 197], ["serum samples", "ORGANISM_SUBSTANCE", 257, 270], ["lentiviral pseudotype", "ORGANISM", 414, 435], ["NP2 human glioma cell line", "CELL_LINE", 4, 30], ["CD4", "PROTEIN", 42, 45], ["CXCR4", "PROTEIN", 50, 55], ["plasmids", "DNA", 371, 379], ["human", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 85, 90], ["human", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 85, 90], ["FAVN assaysLive virus", "SPECIES", 109, 130], ["The NP2 human glioma cell line", "TREATMENT", 0, 30], ["CXCR4", "TEST", 50, 55], ["HIV", "TEST", 85, 88], ["FAVN assaysLive virus experiments", "PROBLEM", 109, 142], ["the existing FAVN assay", "TEST", 219, 242], ["serum samples", "TEST", 257, 270], ["a final titre", "TEST", 289, 302], ["Pseudotype assays", "TEST", 345, 362], ["Standard plasmids", "TREATMENT", 362, 379], ["the transfection protocol", "TREATMENT", 384, 409], ["lentiviral pseudotype (lyssavirus surrogate", "TREATMENT", 414, 457], ["glioma cell line", "OBSERVATION", 14, 30]]], ["Additionally, glycoprotein (G) gene sequences from LBV (LBV.SA2004; accession number EF547428), MOKV (MOKV.98/071 RA361; accession number GQ500108) and DUVV (DUVV.RSA2006; accession number EU623444) were amplified by PCR using specific primers (detailed in Supplementary Table S1 ).", [["SA2004", "CHEMICAL", 60, 66], ["RSA2006", "CHEMICAL", 163, 170], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 14, 30], ["glycoprotein (G) gene sequences", "DNA", 14, 45], ["DUVV", "PROTEIN", 152, 156], ["DUVV", "PROTEIN", 158, 162], ["RSA2006", "DNA", 163, 170], ["LBV", "SPECIES", 51, 54], ["LBV", "SPECIES", 56, 59], ["DUVV", "SPECIES", 152, 156], ["glycoprotein (G) gene sequences", "TREATMENT", 14, 45], ["DUVV (DUVV", "TREATMENT", 152, 162], ["specific primers", "TREATMENT", 227, 243]]], ["Pseudotypes containing the HIV-1 envelope gp160 gene were generated using pSVIIIenv [28] .", [["HIV-1", "ORGANISM", 27, 32], ["gp160", "GENE_OR_GENE_PRODUCT", 42, 47], ["HIV-1 envelope gp160 gene", "DNA", 27, 52], ["HIV-1", "SPECIES", 27, 32], ["HIV-1", "SPECIES", 27, 32], ["Pseudotypes", "PROBLEM", 0, 11], ["the HIV", "TEST", 23, 30]]], ["G gene sequence analysis was undertaken using ClustalW [29] and Treeview [30] .Pseudotype assaysInfection and neutralisation assays using lyssavirus pseudotypes were performed as previously described [24] with the following three modifications: (1) plates were centrifuged at 500 rpm for 10 s after the virus was added and once more following addition of BHK cells; (2) to ensure the OIE standard reference dog serum recorded an IC 100 at a 1:40 dilution, approximately 30\u00d7 TCID 50 of pseudotype was used; (3) serum was diluted 5-fold to a final titre of 1:640.Pseudotype assays2.5.", [["BHK cells", "ANATOMY", 355, 364], ["serum", "ANATOMY", 411, 416], ["serum", "ANATOMY", 510, 515], ["G", "GENE_OR_GENE_PRODUCT", 0, 1], ["lyssavirus pseudotypes", "ORGANISM", 138, 160], ["BHK cells", "CELL", 355, 364], ["dog", "ORGANISM", 407, 410], ["serum", "ORGANISM_SUBSTANCE", 411, 416], ["pseudotype", "ORGANISM", 485, 495], ["serum", "ORGANISM_SUBSTANCE", 510, 515], ["BHK cells", "CELL_LINE", 355, 364], ["dog", "SPECIES", 407, 410], ["dog", "SPECIES", 407, 410], ["G gene sequence analysis", "TEST", 0, 24], ["Pseudotype assaysInfection", "PROBLEM", 79, 105], ["neutralisation assays", "TEST", 110, 131], ["lyssavirus pseudotypes", "PROBLEM", 138, 160], ["plates", "TEST", 249, 255], ["the virus", "PROBLEM", 299, 308], ["BHK cells", "TREATMENT", 355, 364], ["pseudotype", "TREATMENT", 485, 495], ["serum", "TEST", 510, 515], ["a final titre", "TEST", 538, 551], ["Pseudotype assays2.5", "TREATMENT", 561, 581], ["Infection", "OBSERVATION", 96, 105]]], ["Pseudotype reporter genes 2.5.1.\u02c7-GalactosidasePseudotype assaysTo enable pseudotype particle detection using the appropriate \u2424-galactosidase (\u2424-gal) substrates, we constructed pCSLZW, which contains the lacZ gene from pMFG-nls-lacZ (a kind gift from Dr. Yasuhiro Takeuchi; [31] ) cloned into pCSGW (primers detailed in Supplementary Table S1 ).", [["\u2424-gal", "GENE_OR_GENE_PRODUCT", 143, 148], ["pCSLZW", "GENE_OR_GENE_PRODUCT", 177, 183], ["lacZ", "GENE_OR_GENE_PRODUCT", 204, 208], ["pMFG-nls", "GENE_OR_GENE_PRODUCT", 219, 227], ["lacZ", "GENE_OR_GENE_PRODUCT", 228, 232], ["pCSGW", "GENE_OR_GENE_PRODUCT", 293, 298], ["Pseudotype reporter genes 2.5", "DNA", 0, 29], ["\u2424-galactosidase (\u2424-gal) substrates", "DNA", 126, 160], ["pCSLZW", "DNA", 177, 183], ["lacZ gene", "DNA", 204, 213], ["pMFG", "DNA", 219, 223], ["nls", "DNA", 224, 227], ["lacZ", "DNA", 228, 232], ["pCSGW", "DNA", 293, 298], ["Pseudotype reporter genes", "TEST", 0, 25], ["GalactosidasePseudotype assays", "PROBLEM", 34, 64], ["pseudotype particle detection", "TEST", 74, 103], ["the appropriate \u2424-galactosidase (\u2424-gal) substrates", "TREATMENT", 110, 160]]], ["Where \u2424-gal was the reporter protein, \u2424-gal-pseudotype-infected cells were detected Strong correlation between FAVN and pseudotype neutralising antibody titres using Tanzanian dog sera.", [["cells", "ANATOMY", 64, 69], ["sera", "ANATOMY", 180, 184], ["\u2424-gal", "GENE_OR_GENE_PRODUCT", 6, 11], ["\u2424-gal", "GENE_OR_GENE_PRODUCT", 38, 43], ["cells", "CELL", 64, 69], ["FAVN", "GENE_OR_GENE_PRODUCT", 111, 115], ["dog", "ORGANISM", 176, 179], ["sera", "ORGANISM_SUBSTANCE", 180, 184], ["\u2424-gal", "PROTEIN", 6, 11], ["\u2424-gal-pseudotype-infected cells", "CELL_LINE", 38, 69], ["FAVN", "PROTEIN", 111, 115], ["dog", "SPECIES", 176, 179], ["dog", "SPECIES", 176, 179], ["the reporter protein", "TEST", 16, 36], ["\u2424-gal", "TEST", 38, 43], ["infected cells", "PROBLEM", 55, 69], ["FAVN", "TEST", 111, 115], ["pseudotype neutralising antibody titres", "TREATMENT", 120, 159], ["Tanzanian dog sera", "TREATMENT", 166, 184], ["infected cells", "OBSERVATION", 55, 69]]], ["(A) Neutralising titres achieved with the pseudotype assay increase concordantly with those detected in the FAVN assay.", [["A) Neutralising titres", "TREATMENT", 1, 23], ["the pseudotype assay", "TEST", 38, 58]]], ["The distribution, according to VNAb titres determined by the (B) pseudotype and (C) FAVN assays, of sera collected at the first visit from primary (dogs that had not received a previous rabies vaccination-black columns), booster (dogs that had received \u22651 rabies vaccination previously-grey columns) or dogs with no vaccination record (white columns) is shown.", [["sera", "ANATOMY", 100, 104], ["VNAb", "GENE_OR_GENE_PRODUCT", 31, 35], ["sera", "ORGANISM_SUBSTANCE", 100, 104], ["dogs", "ORGANISM", 148, 152], ["dogs", "ORGANISM", 230, 234], ["dogs", "ORGANISM", 303, 307], ["dogs", "SPECIES", 148, 152], ["dogs", "SPECIES", 230, 234], ["dogs", "SPECIES", 303, 307], ["VNAb titres", "TEST", 31, 42], ["pseudotype and (C) FAVN assays", "PROBLEM", 65, 95], ["sera", "TEST", 100, 104], ["a previous rabies vaccination", "TREATMENT", 175, 204], ["\u22651 rabies vaccination", "TREATMENT", 253, 274], ["dogs", "PROBLEM", 303, 307], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["Similar analyses for samples collected at the second visit are shown in (D) and (E) for the pseudotype and FAVN assays, respectively.", [["samples", "ANATOMY", 21, 28], ["pseudotype", "ORGANISM", 92, 102], ["samples", "TEST", 21, 28], ["the pseudotype and FAVN assays", "TEST", 88, 118]]], ["The dotted line marks the level of VNAb that was achieved by the OIE positive control serum.", [["serum", "ANATOMY", 86, 91], ["VNAb", "GENE_OR_GENE_PRODUCT", 35, 39], ["serum", "ORGANISM_SUBSTANCE", 86, 91], ["VNAb", "PROTEIN", 35, 39], ["dotted", "OBSERVATION_MODIFIER", 4, 10], ["line", "OBSERVATION", 11, 15]]], ["Percents of samples with an inadequate or adequate VNAb response are given left and right of the dotted line, respectively.", [["samples", "ANATOMY", 12, 19], ["left", "ANATOMY", 75, 79], ["samples", "CANCER", 12, 19], ["samples", "TEST", 12, 19], ["left", "ANATOMY_MODIFIER", 75, 79], ["right", "ANATOMY_MODIFIER", 84, 89], ["dotted line", "OBSERVATION", 97, 108]]], ["Vaccination history was available for 169 dogs (first visit: primary n = 119, booster n = 50, no record n = 13; second visit: primary n = 84, booster n = 37, no record n = 1).", [["dogs", "ORGANISM", 42, 46], ["dogs", "SPECIES", 42, 46]]], ["(F) Results from the pseudotype neutralisation and FAVN assays reveal a high degree of concordance (Sn: sensitivity and Sp: specificity) and a strong correlation (r) between titres.", [["pseudotype", "ORGANISM", 21, 31], ["the pseudotype neutralisation", "TEST", 17, 46], ["FAVN assays", "TEST", 51, 62], ["high degree", "OBSERVATION_MODIFIER", 72, 83]]], ["Sn and Sp are relative to the 0.5 IU/ml threshold and r/p values were calculated using Pearson's product-moment correlation.", [["Sn", "CHEMICAL", 0, 2], ["Sn", "GENE_OR_GENE_PRODUCT", 0, 2], ["Sp", "GENE_OR_GENE_PRODUCT", 7, 9], ["Sn", "PROTEIN", 0, 2], ["Sp", "PROTEIN", 7, 9], ["r/p values", "TEST", 54, 64], ["Pearson's product", "TEST", 87, 104]]], ["Arrows indicate VNAb titres for which there were no serum samples containing that level of antibodies.Pseudotype assaysusing 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside (Xgal; Sigma), chlorophenol red-beta-d-galactopyranoside (CPRG; Sigma) or o-nitrophenyl-b-d-galactopyranoside (ONPG; Sigma).", [["serum samples", "ANATOMY", 52, 65], ["5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside", "CHEMICAL", 125, 176], ["Xgal", "CHEMICAL", 178, 182], ["chlorophenol red-beta-d-galactopyranoside", "CHEMICAL", 192, 233], ["CPRG", "CHEMICAL", 235, 239], ["o-nitrophenyl-b-d-galactopyranoside", "CHEMICAL", 251, 286], ["5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside", "CHEMICAL", 125, 176], ["Xgal", "CHEMICAL", 178, 182], ["chlorophenol red-beta-d-galactopyranoside", "CHEMICAL", 192, 233], ["CPRG", "CHEMICAL", 235, 239], ["o-nitrophenyl-b-d-galactopyranoside", "CHEMICAL", 251, 286], ["ONPG", "CHEMICAL", 288, 292], ["VNAb", "GENE_OR_GENE_PRODUCT", 16, 20], ["serum samples", "ORGANISM_SUBSTANCE", 52, 65], ["5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside", "SIMPLE_CHEMICAL", 125, 176], ["Xgal", "SIMPLE_CHEMICAL", 178, 182], ["Sigma", "SIMPLE_CHEMICAL", 184, 189], ["chlorophenol red-beta-d-galactopyranoside", "SIMPLE_CHEMICAL", 192, 233], ["CPRG", "SIMPLE_CHEMICAL", 235, 239], ["Sigma", "SIMPLE_CHEMICAL", 241, 246], ["o-nitrophenyl-b-d-galactopyranoside", "SIMPLE_CHEMICAL", 251, 286], ["ONPG", "SIMPLE_CHEMICAL", 288, 292], ["antibodies", "PROTEIN", 91, 101], ["VNAb titres", "PROBLEM", 16, 27], ["serum samples", "TEST", 52, 65], ["Pseudotype assaysusing", "TEST", 102, 124], ["bromo", "TEST", 127, 132], ["chloro", "TREATMENT", 135, 141], ["-indolyl", "TREATMENT", 143, 151], ["galactopyranoside", "TREATMENT", 159, 176], ["chlorophenol red-beta", "TREATMENT", 192, 213], ["galactopyranoside (CPRG", "TREATMENT", 216, 239], ["o-nitrophenyl", "TREATMENT", 251, 264]]], ["Detection using the X-gal substrate was accomplished by fixing the infected cell monolayer and then staining the cells with substrate buffer (10 mM deoxycholic acid, 5 mM potassium ferrocy-nate, 5 mM potassium ferricynate, 4.3 mM magnesium chloride and 0.02% (v/v) NP40) containing 1 mg/ml X-gal.", [["cell monolayer", "ANATOMY", 76, 90], ["cells", "ANATOMY", 113, 118], ["deoxycholic acid", "CHEMICAL", 148, 164], ["potassium ferrocy-nate", "CHEMICAL", 171, 193], ["potassium", "CHEMICAL", 200, 209], ["magnesium chloride", "CHEMICAL", 230, 248], ["deoxycholic acid", "CHEMICAL", 148, 164], ["potassium ferrocy-nate", "CHEMICAL", 171, 193], ["potassium ferricynate", "CHEMICAL", 200, 221], ["magnesium chloride", "CHEMICAL", 230, 248], ["NP40", "CHEMICAL", 265, 269], ["X-gal", "GENE_OR_GENE_PRODUCT", 20, 25], ["cell monolayer", "CELL", 76, 90], ["cells", "CELL", 113, 118], ["deoxycholic acid", "SIMPLE_CHEMICAL", 148, 164], ["potassium ferrocy-nate", "SIMPLE_CHEMICAL", 171, 193], ["potassium ferricynate", "SIMPLE_CHEMICAL", 200, 221], ["magnesium chloride", "SIMPLE_CHEMICAL", 230, 248], ["X-gal", "GENE_OR_GENE_PRODUCT", 290, 295], ["X-gal substrate", "DNA", 20, 35], ["Detection", "TEST", 0, 9], ["the X-gal substrate", "TREATMENT", 16, 35], ["the infected cell monolayer", "PROBLEM", 63, 90], ["substrate buffer", "TREATMENT", 124, 140], ["mM deoxycholic acid", "TEST", 145, 164], ["potassium", "TEST", 171, 180], ["ferrocy", "TEST", 181, 188], ["nate", "TEST", 189, 193], ["potassium", "TEST", 200, 209], ["ferricynate", "TEST", 210, 221], ["mM magnesium chloride", "TREATMENT", 227, 248], ["infected cell monolayer", "OBSERVATION", 67, 90]]], ["For CPRG and ONPG substrates, nuclei were lysed and 50 l of reaction buffer (120 mM Na 2 HPO 4 \u00b72H 2 O, 80 mM NaH 2 PO 4 \u00b7H 2 O, 2 mM MgCl 2 , 100 mM \u2424mercaptoethanol) was added containing CPRG or ONPG at a final concentration of 29.2 and 1.3 mg/ml, respectively.", [["nuclei", "ANATOMY", 30, 36], ["Na", "CHEMICAL", 84, 86], ["HPO 4 \u00b72H 2 O", "CHEMICAL", 89, 102], ["NaH 2 PO 4 \u00b7H 2 O", "CHEMICAL", 110, 127], ["MgCl 2", "CHEMICAL", 134, 140], ["\u2424mercaptoethanol", "CHEMICAL", 150, 166], ["CPRG", "CHEMICAL", 189, 193], ["ONPG", "CHEMICAL", 197, 201], ["Na 2 HPO", "CHEMICAL", 84, 92], ["2H 2 O", "CHEMICAL", 96, 102], ["NaH 2 PO 4 \u00b7H 2 O", "CHEMICAL", 110, 127], ["MgCl 2", "CHEMICAL", 134, 140], ["\u2424mercaptoethanol", "CHEMICAL", 150, 166], ["CPRG", "CHEMICAL", 189, 193], ["ONPG", "CHEMICAL", 197, 201], ["CPRG", "SIMPLE_CHEMICAL", 4, 8], ["ONPG", "SIMPLE_CHEMICAL", 13, 17], ["nuclei", "CELLULAR_COMPONENT", 30, 36], ["2H 2 O", "SIMPLE_CHEMICAL", 96, 102], ["MgCl 2", "SIMPLE_CHEMICAL", 134, 140], ["\u2424mercaptoethanol", "SIMPLE_CHEMICAL", 150, 166], ["CPRG", "SIMPLE_CHEMICAL", 189, 193], ["ONPG", "SIMPLE_CHEMICAL", 197, 201], ["CPRG", "PROTEIN", 4, 8], ["CPRG and ONPG substrates", "TREATMENT", 4, 28], ["reaction buffer", "TREATMENT", 60, 75], ["2 mM MgCl", "TREATMENT", 129, 138], ["100 mM \u2424mercaptoethanol)", "TREATMENT", 143, 167], ["CPRG", "TREATMENT", 189, 193], ["ONPG", "TREATMENT", 197, 201]]], ["This reaction was Table 2 Distribution of sera according to FAVN neutralising antibody titre.Pseudotype assaysPercentages given are the proportion in that category out of the total number for the column. a Samples that were positive by FAVN assay but negative by the pseudotype assay.Pseudotype assaysinhibited, after 1-2 h at 37 \u2022 C, by adding stop solution (1 M sodium carbonate).GFP and luciferaseGFP and luciferase reporter genes were employed to detect GFP-positive cells, which were visualised using a fluorescent microscope and FACSCalibur (BD Biosciences) and luciferase expression, which was detected using the Bright-Glo reagent and GloMax 96 microplate luminometer (Promega).Serum samples analysedOf the 191 dogs enrolled in this study, the mean age was 1.94 years and 51.3% were female (Table 1 ).", [["sera", "ANATOMY", 42, 46], ["cells", "ANATOMY", 471, 476], ["Serum samples", "ANATOMY", 686, 699], ["sodium carbonate", "CHEMICAL", 364, 380], ["sodium carbonate", "CHEMICAL", 364, 380], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["sodium carbonate", "SIMPLE_CHEMICAL", 364, 380], ["GFP", "GENE_OR_GENE_PRODUCT", 382, 385], ["luciferaseGFP", "GENE_OR_GENE_PRODUCT", 390, 403], ["luciferase", "GENE_OR_GENE_PRODUCT", 408, 418], ["GFP", "GENE_OR_GENE_PRODUCT", 458, 461], ["cells", "CELL", 471, 476], ["luciferase", "GENE_OR_GENE_PRODUCT", 568, 578], ["Serum samples", "ORGANISM_SUBSTANCE", 686, 699], ["dogs", "ORGANISM", 719, 723], ["FAVN", "PROTEIN", 60, 64], ["GFP and luciferaseGFP and luciferase reporter genes", "DNA", 382, 433], ["GFP-positive cells", "CELL_LINE", 458, 476], ["luciferase", "PROTEIN", 568, 578], ["dogs", "SPECIES", 719, 723], ["This reaction", "PROBLEM", 0, 13], ["sera", "TEST", 42, 46], ["neutralising antibody titre", "TEST", 65, 92], ["Pseudotype assays", "TEST", 93, 110], ["a Samples", "TEST", 204, 213], ["FAVN assay", "TEST", 236, 246], ["the pseudotype assay", "TEST", 263, 283], ["Pseudotype assaysinhibited", "PROBLEM", 284, 310], ["1 M sodium carbonate", "TREATMENT", 360, 380], ["GFP", "TEST", 382, 385], ["luciferaseGFP", "TEST", 390, 403], ["luciferase reporter genes", "TEST", 408, 433], ["GFP", "TEST", 458, 461], ["positive cells", "PROBLEM", 462, 476], ["a fluorescent microscope", "TEST", 506, 530], ["BD Biosciences", "TEST", 548, 562], ["luciferase expression", "TEST", 568, 589], ["the Bright-Glo reagent", "TREATMENT", 616, 638], ["GloMax", "TREATMENT", 643, 649], ["Serum samples", "TEST", 686, 699], ["this study", "TEST", 736, 746], ["column", "ANATOMY", 196, 202], ["positive cells", "OBSERVATION", 462, 476]]], ["In total, 321 samples were taken during both visits (Table 1) .", [["samples", "ANATOMY", 14, 21]]], ["However, in transport one sample disappeared (#27) and one leaked so no serum remained (#192).", [["sample", "ANATOMY", 26, 32], ["serum", "ANATOMY", 72, 77], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["serum", "TEST", 72, 77], ["no", "UNCERTAINTY", 69, 71]]], ["Of the remaining 319 samples, the volume in 12 was too small to test in the FAVN assay and a further three samples could not initially be tested in the pseudotype assays because of contamination and toxicity.", [["samples", "ANATOMY", 21, 28], ["samples", "ANATOMY", 107, 114], ["toxicity", "DISEASE", 199, 207], ["pseudotype", "ORGANISM", 152, 162], ["the volume", "TEST", 30, 40], ["the FAVN assay", "TEST", 72, 86], ["the pseudotype assays", "TEST", 148, 169], ["contamination", "PROBLEM", 181, 194], ["toxicity", "PROBLEM", 199, 207], ["contamination", "OBSERVATION", 181, 194]]], ["The remaining 304 samples were tested in both assay types.Serum samples analysedWhile the serum process times were kept as constant as possible there were varying degrees of haemolysis and volumes of sera produced varied with each collection (Fig. 1C) .", [["samples", "ANATOMY", 18, 25], ["Serum samples", "ANATOMY", 58, 71], ["serum", "ANATOMY", 90, 95], ["sera", "ANATOMY", 200, 204], ["haemolysis", "DISEASE", 174, 184], ["samples", "CANCER", 18, 25], ["Serum samples", "ORGANISM_SUBSTANCE", 58, 71], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["sera", "ORGANISM_SUBSTANCE", 200, 204], ["The remaining 304 samples", "TEST", 0, 25], ["Serum samples", "TEST", 58, 71], ["the serum process", "TEST", 86, 103], ["varying degrees of haemolysis", "PROBLEM", 155, 184], ["volumes of sera", "PROBLEM", 189, 204], ["haemolysis", "OBSERVATION", 174, 184]]], ["Haemolysis did not affect the results obtained with either the FAVN or the pseudotype assays.Sensitivity and specificity of CVS-11 pseudotypes using Tanzanian canine seraSera that failed to achieve an antibody titre of 1:10 by the pseudotype assay, the lowest recordable result from the dilutions that were used, were given an arbitrary titre of 1:5 for this analysis.", [["Haemolysis", "DISEASE", 0, 10], ["pseudotypes", "ORGANISM", 131, 142], ["canine", "ORGANISM", 159, 165], ["canine", "SPECIES", 159, 165], ["canine", "SPECIES", 159, 165], ["Haemolysis", "PROBLEM", 0, 10], ["the pseudotype assays", "TEST", 71, 92], ["Sensitivity", "TEST", 93, 104], ["CVS", "TEST", 124, 127], ["Tanzanian canine seraSera", "TREATMENT", 149, 174], ["an antibody titre", "TEST", 198, 215], ["the pseudotype assay", "TEST", 227, 247], ["the dilutions", "TEST", 283, 296], ["an arbitrary titre", "TEST", 324, 342], ["this analysis", "TEST", 354, 367]]], ["The OIE positive control serum routinely neutralised 100% of CVS-11 pseudotype particles at a dilution of 1:40 (in this study the OIE mean dilution = 37.5 and standard deviation = \u00b114.4) and 100% of live CVS-11 at a dilution of 15.59, normally equivalent to 0.5 IU/ml, for the FAVN assay (in this study the OIE mean dilution = 17.2 and standard deviation = \u00b1 4.0).", [["serum", "ANATOMY", 25, 30], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["pseudotype", "ORGANISM", 68, 78], ["The OIE", "TEST", 0, 7], ["CVS", "TEST", 61, 64], ["this study", "TEST", 115, 125], ["mean dilution", "TEST", 134, 147], ["standard deviation", "TEST", 159, 177], ["live CVS", "TEST", 199, 207], ["a dilution", "TEST", 214, 224], ["the FAVN assay", "TEST", 273, 287], ["this study", "TEST", 292, 302], ["the OIE mean dilution", "TEST", 303, 324], ["standard deviation", "TEST", 336, 354]]], ["The lowest titre a serum sample was given by the FAVN assay in this study is 0.07 IU/ml.", [["serum sample", "ANATOMY", 19, 31], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["a serum sample", "TEST", 17, 31], ["the FAVN assay", "TEST", 45, 59], ["this study", "TEST", 63, 73]]], ["Any dogs with VNAb levels that attained an IC 100 at a dilution of greater than or equal to 1:40 (by pseudotype assay) or a titre of 0.5 IU/ml (by FAVN assay) were considered positive (also referred to as \"adequate\" in this study).Sensitivity and specificity of CVS-11 pseudotypes using Tanzanian canine seraWhen results from the FAVN and pseudotype assays were compared, we observed a concurrent increase in VNAb titres reported by the pseudotype assay as the FAVN titre increased ( Fig. 2A ).", [["dogs", "ORGANISM", 4, 8], ["pseudotypes", "ORGANISM", 269, 280], ["canine", "ORGANISM", 297, 303], ["pseudotype", "ORGANISM", 339, 349], ["VNAb", "GENE_OR_GENE_PRODUCT", 409, 413], ["VNAb", "PROTEIN", 409, 413], ["dogs", "SPECIES", 4, 8], ["canine", "SPECIES", 297, 303], ["canine", "SPECIES", 297, 303], ["VNAb levels", "TEST", 14, 25], ["pseudotype assay", "TEST", 101, 117], ["this study", "TEST", 219, 229], ["Sensitivity", "TEST", 231, 242], ["CVS", "TEST", 262, 265], ["Tanzanian canine seraWhen", "TEST", 287, 312], ["the FAVN", "TEST", 326, 334], ["pseudotype assays", "TEST", 339, 356], ["a concurrent increase in VNAb titres", "PROBLEM", 384, 420], ["the pseudotype assay", "TEST", 433, 453], ["the FAVN titre", "TEST", 457, 471], ["increase", "OBSERVATION_MODIFIER", 397, 405]]], ["There were 17 discordant samples, classified as negative by the pseudotype assay but positive with the FAVN assay ( Table 2) .", [["samples", "ANATOMY", 25, 32], ["samples", "CANCER", 25, 32], ["pseudotype", "ORGANISM", 64, 74], ["17 discordant samples", "PROBLEM", 11, 32], ["the pseudotype assay", "TEST", 60, 80], ["the FAVN assay", "TEST", 99, 113]]], ["As a result, the average titre of samples classified as borderline positive by the FAVN assay (0.5 IU/ml) is 1:25, a borderline negative result with the pseudotype assay.", [["samples", "ANATOMY", 34, 41], ["the average titre of samples", "TEST", 13, 41], ["the FAVN assay", "TEST", 79, 93], ["the pseudotype assay", "TEST", 149, 169]]], ["While these discordant samples reduced the sensitivity of the pseudotype neutralisation assay to 94.4%, the specificity of the assay was 100% (n = 304).", [["samples", "ANATOMY", 23, 30], ["samples", "CANCER", 23, 30], ["pseudotype", "ORGANISM", 62, 72], ["the pseudotype neutralisation assay", "TEST", 58, 93], ["the assay", "TEST", 123, 132]]], ["The majority of the discrepancies clustered around 0.5 IU/ml, the titre achieved using the OIE positive control serum and currently used to classify VNAb responses as inadequate (levels below that achieved by the OIE positive control serum) or adequate (levels greater than or equal to that achieved by the OIE positive control serum).", [["serum", "ANATOMY", 112, 117], ["serum", "ANATOMY", 234, 239], ["serum", "ANATOMY", 328, 333], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["VNAb", "SIMPLE_CHEMICAL", 149, 153], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["serum", "ORGANISM_SUBSTANCE", 328, 333], ["the titre", "TREATMENT", 62, 71], ["serum", "TEST", 234, 239], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["Twelve of the discordant results (71%) were in the lowest dilution classified as positive by the FAVN assay (0.5 IU/ml), one (5.9%) fell within the 0.66 IU/ml category, three (17.6%) in the 0.87 IU/ml category and one (5.9%) scored 1.14 IU/ml by the FAVN assay (Table 3 ).", [["the lowest dilution", "TEST", 47, 66], ["the FAVN assay", "TEST", 93, 107], ["category", "TEST", 201, 209], ["the FAVN assay", "TEST", 246, 260]]], ["There were no discrepant results achieved using the FAVN or pseudotype assays and samples from the second visit.Sensitivity and specificity of CVS-11 pseudotypes using Tanzanian canine seraPrior to vaccination at the first visit, results using the pseudotype assay classified 89.9% of the dogs that had never been vaccinated Table 3 Titres recorded for discordant sera using the FAVN and pseudotype assays.", [["samples", "ANATOMY", 82, 89], ["sera", "ANATOMY", 364, 368], ["pseudotype", "ORGANISM", 60, 70], ["pseudotypes", "ORGANISM", 150, 161], ["canine", "ORGANISM", 178, 184], ["dogs", "ORGANISM", 289, 293], ["sera", "ORGANISM_SUBSTANCE", 364, 368], ["canine", "SPECIES", 178, 184], ["dogs", "SPECIES", 289, 293], ["canine", "SPECIES", 178, 184], ["the FAVN", "TREATMENT", 48, 56], ["pseudotype assays", "TEST", 60, 77], ["Sensitivity", "TEST", 112, 123], ["CVS", "TEST", 143, 146], ["Tanzanian canine seraPrior", "TREATMENT", 168, 194], ["the pseudotype assay", "TEST", 244, 264], ["the FAVN", "TREATMENT", 375, 383], ["pseudotype assays", "TEST", 388, 405], ["no", "UNCERTAINTY", 11, 13]]], ["1.14 20 a Vaccination history was not available for this dog (\"no record\"). b Serum samples taken from dogs with no rabies vaccination history prior to this study (\"primary\").", [["Serum samples", "ANATOMY", 78, 91], ["dog", "ORGANISM", 57, 60], ["Serum samples", "ORGANISM_SUBSTANCE", 78, 91], ["dogs", "ORGANISM", 103, 107], ["dogs", "SPECIES", 103, 107], ["rabies", "SPECIES", 116, 122], ["Serum samples", "TEST", 78, 91], ["this study", "TEST", 152, 162]]], ["Radial tree and panels showing degree of glycoprotein identity and viral titre of lyssavirus pseudotypes.", [["Radial tree", "ANATOMY", 0, 11], ["Radial tree", "MULTI-TISSUE_STRUCTURE", 0, 11], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 41, 53], ["lyssavirus pseudotypes", "ORGANISM", 82, 104], ["Radial tree and panels", "TEST", 0, 22], ["degree of glycoprotein identity", "PROBLEM", 31, 62], ["viral titre of lyssavirus pseudotypes", "PROBLEM", 67, 104], ["tree", "ANATOMY_MODIFIER", 7, 11], ["glycoprotein identity", "OBSERVATION", 41, 62], ["viral titre", "OBSERVATION", 67, 78], ["lyssavirus pseudotypes", "OBSERVATION", 82, 104]]], ["The envelope G genes from LBV, MOKV and DUVV were cloned into pI.18 and titres were compared with that achieved by pseudotypes bearing the CVS-11 G. Identity of the full-length G amino acid sequence was used to construct the tree.", [["amino acid", "CHEMICAL", 179, 189], ["amino acid", "CHEMICAL", 179, 189], ["envelope G", "GENE_OR_GENE_PRODUCT", 4, 14], ["LBV", "GENE_OR_GENE_PRODUCT", 26, 29], ["MOKV", "GENE_OR_GENE_PRODUCT", 31, 35], ["DUVV", "GENE_OR_GENE_PRODUCT", 40, 44], ["pI.18", "GENE_OR_GENE_PRODUCT", 62, 67], ["G", "SIMPLE_CHEMICAL", 177, 178], ["amino acid", "AMINO_ACID", 179, 189], ["envelope G genes", "DNA", 4, 20], ["LBV", "DNA", 26, 29], ["MOKV", "DNA", 31, 35], ["DUVV", "DNA", 40, 44], ["pI.18", "DNA", 62, 67], ["LBV", "SPECIES", 26, 29], ["MOKV", "SPECIES", 31, 35], ["DUVV", "SPECIES", 40, 44], ["The envelope G genes", "TREATMENT", 0, 20], ["DUVV", "TREATMENT", 40, 44], ["the CVS", "TEST", 135, 142], ["the full-length G amino acid sequence", "TREATMENT", 161, 198], ["tree", "ANATOMY_MODIFIER", 225, 229]]], ["Viral titres were assessed using GFP carrying pseudotypes and are given in IFU/ml.", [["Viral", "ORGANISM", 0, 5], ["GFP", "GENE_OR_GENE_PRODUCT", 33, 36], ["Viral titres", "TEST", 0, 12], ["GFP carrying pseudotypes", "TREATMENT", 33, 57]]], ["The branch lengths and scale correspond to the number of amino acid substitutions per site.Sensitivity and specificity of CVS-11 pseudotypes using Tanzanian canine sera(\"primary\") as having inadequate levels of VNAbs (Fig. 2B) .", [["sera", "ANATOMY", 164, 168], ["amino acid", "CHEMICAL", 57, 67], ["amino acid", "CHEMICAL", 57, 67], ["amino acid", "AMINO_ACID", 57, 67], ["pseudotypes", "ORGANISM", 129, 140], ["canine", "ORGANISM", 157, 163], ["sera", "ORGANISM_SUBSTANCE", 164, 168], ["VNAbs", "PROTEIN", 211, 216], ["canine", "SPECIES", 157, 163], ["canine", "SPECIES", 157, 163], ["amino acid substitutions", "TREATMENT", 57, 81], ["Sensitivity", "TEST", 91, 102], ["specificity", "TEST", 107, 118], ["CVS", "TEST", 122, 125], ["branch", "OBSERVATION_MODIFIER", 4, 10], ["lengths", "OBSERVATION_MODIFIER", 11, 18], ["amino", "OBSERVATION", 57, 62], ["acid substitutions", "OBSERVATION", 63, 81]]], ["This compares to 81.5% as determined by the FAVN assay (Fig. 2C ).", [["the FAVN assay", "TEST", 40, 54]]], ["There was a roughly equal split of inadequate vs adequate levels of VNAbs (48% vs 52%) for the dogs that had received one or more rabies vaccination(s) previously (\"booster\") when tested using the pseudotype assay (Fig. 2B ).", [["dogs", "ORGANISM", 95, 99], ["rabies", "ORGANISM", 130, 136], ["dogs", "SPECIES", 95, 99], ["rabies", "SPECIES", 130, 136], ["VNAbs", "TEST", 68, 73], ["the pseudotype assay", "TEST", 193, 213], ["roughly", "OBSERVATION_MODIFIER", 12, 19], ["equal", "OBSERVATION_MODIFIER", 20, 25], ["split", "OBSERVATION_MODIFIER", 26, 31]]], ["The discrepant results described above caused this balance to shift in favour of adequate VNAb levels (36% vs 64%) when the same sera were analysed by the FAVN assay (Fig. 2C ).", [["sera", "ANATOMY", 129, 133], ["VNAb", "GENE_OR_GENE_PRODUCT", 90, 94], ["sera", "ORGANISM_SUBSTANCE", 129, 133], ["VNAb", "PROTEIN", 90, 94], ["this balance", "PROBLEM", 46, 58], ["the same sera", "TEST", 120, 133], ["the FAVN assay", "TEST", 151, 165]]], ["In sera from the second visit both assays detected three dogs (2.5%) that failed to achieve a level of VNAbs that was greater than the OIE control serum despite receiving the vaccination (Fig. 2D and E) .", [["sera", "ANATOMY", 3, 7], ["serum", "ANATOMY", 147, 152], ["sera", "ORGANISM_SUBSTANCE", 3, 7], ["dogs", "ORGANISM", 57, 61], ["VNAbs", "GENE_OR_GENE_PRODUCT", 103, 108], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["VNAbs", "PROTEIN", 103, 108], ["dogs", "SPECIES", 57, 61], ["assays", "TEST", 35, 41], ["VNAbs", "TREATMENT", 103, 108], ["the vaccination", "TREATMENT", 171, 186]]], ["None of the three dogs had been given a rabies vaccination prior to this study and their level of circulating VNAbs was inadequate at both visits.", [["dogs", "ORGANISM", 18, 22], ["rabies", "ORGANISM", 40, 46], ["VNAbs", "GENE_OR_GENE_PRODUCT", 110, 115], ["dogs", "SPECIES", 18, 22], ["rabies", "SPECIES", 40, 46], ["a rabies vaccination", "TREATMENT", 38, 58], ["this study", "TEST", 68, 78]]], ["Analysis of all results showed that the titres recorded for each serum by FAVN and pseudotype assays correlated strongly (r = 0.915, p < 0.001 [Pearson's product-moment correlation]; Fig. 2F ).African lyssavirus pseudotypes for surveillanceWe cloned the G gene sequences of LBV, MOKV and DUVV into our expression plasmid and tested their ability to be incorporated into lentiviral pseudotype particles.", [["serum", "ANATOMY", 65, 70], ["plasmid", "ANATOMY", 313, 320], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["FAVN", "GENE_OR_GENE_PRODUCT", 74, 78], ["pseudotype", "ORGANISM", 83, 93], ["African lyssavirus pseudotypes", "ORGANISM", 193, 223], ["G", "GENE_OR_GENE_PRODUCT", 254, 255], ["lentiviral", "ORGANISM", 370, 380], ["G gene sequences", "DNA", 254, 270], ["LBV", "DNA", 274, 277], ["MOKV", "DNA", 279, 283], ["DUVV", "DNA", 288, 292], ["expression plasmid", "DNA", 302, 320], ["African lyssavirus pseudotypes", "SPECIES", 193, 223], ["LBV", "SPECIES", 274, 277], ["MOKV", "SPECIES", 279, 283], ["DUVV", "SPECIES", 288, 292], ["Analysis", "TEST", 0, 8], ["the titres", "TEST", 36, 46], ["each serum", "TEST", 60, 70], ["FAVN", "TEST", 74, 78], ["pseudotype assays", "TEST", 83, 100], ["p", "TEST", 133, 134], ["Pearson's product", "TEST", 144, 161], ["African lyssavirus pseudotypes", "TREATMENT", 193, 223], ["surveillanceWe", "TREATMENT", 228, 242], ["DUVV", "TREATMENT", 288, 292], ["our expression plasmid", "TREATMENT", 298, 320], ["lentiviral pseudotype particles", "TREATMENT", 370, 401], ["lentiviral pseudotype", "OBSERVATION", 370, 391]]], ["Using GFP as a marker for infection of BHK cells we observed comparable titres for LBV and MOKV pseudotypes as we achieved using CVS-11 (3.3 \u00d7 10 5 , 3.6 \u00d7 10 5 and 3.2 \u00d7 10 5 IFU/ml, respectively; Fig. 3 ).", [["BHK cells", "ANATOMY", 39, 48], ["infection", "DISEASE", 26, 35], ["GFP", "GENE_OR_GENE_PRODUCT", 6, 9], ["BHK cells", "CELL", 39, 48], ["LBV", "GENE_OR_GENE_PRODUCT", 83, 86], ["MOKV pseudotypes", "ORGANISM", 91, 107], ["GFP", "PROTEIN", 6, 9], ["BHK cells", "CELL_LINE", 39, 48], ["BHK", "SPECIES", 39, 42], ["LBV", "SPECIES", 83, 86], ["MOKV", "SPECIES", 91, 95], ["GFP", "TREATMENT", 6, 9], ["infection of BHK cells", "PROBLEM", 26, 48], ["LBV", "TREATMENT", 83, 86], ["MOKV pseudotypes", "TREATMENT", 91, 107], ["CVS", "TEST", 129, 132]]], ["The titre recorded for pseudotypes expressing the DUVV G was 1.5-fold higher at 5.2 \u00d7 10 5 IFU/ml.", [["DUVV G", "GENE_OR_GENE_PRODUCT", 50, 56], ["DUVV G", "PROTEIN", 50, 56], ["DUVV", "SPECIES", 50, 54], ["The titre", "TEST", 0, 9], ["pseudotypes", "PROBLEM", 23, 34], ["the DUVV G", "TEST", 46, 56]]], ["To test the specificity of these African lyssavirus pseudotypes, neutralisation assays were run with sera raised against LBV (RV1; serum nos.", [["sera", "ANATOMY", 101, 105], ["serum", "ANATOMY", 131, 136], ["lyssavirus pseudotypes", "ORGANISM", 41, 63], ["sera", "ORGANISM_SUBSTANCE", 101, 105], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["African lyssavirus pseudotypes", "SPECIES", 33, 63], ["LBV", "SPECIES", 121, 124], ["RV1", "SPECIES", 126, 129], ["these African lyssavirus pseudotypes", "PROBLEM", 27, 63], ["neutralisation assays", "TEST", 65, 86], ["sera", "TEST", 101, 105], ["LBV (RV1", "TEST", 121, 129]]], ["1 and 2) and DUVV (RV131; serum nos.", [["serum", "ANATOMY", 26, 31], ["DUVV", "SIMPLE_CHEMICAL", 13, 17], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["DUVV", "SPECIES", 13, 17], ["DUVV", "TEST", 13, 17], ["serum nos", "TEST", 26, 35]]], ["Neutralising titres with the pseudotypes correlated strongly with the titres observed using the FAVN assay (Table 4 ).", [["Neutralising titres", "TREATMENT", 0, 19], ["the pseudotypes", "TREATMENT", 25, 40], ["the titres", "TEST", 66, 76], ["the FAVN assay", "TEST", 92, 106]]], ["Anti-LBV sera cross-neutralised MOKV in both the FAVN and pseudotype assays.", [["sera", "ANATOMY", 9, 13], ["sera", "ORGANISM_SUBSTANCE", 9, 13], ["MOKV", "GENE_OR_GENE_PRODUCT", 32, 36], ["MOKV", "PROTEIN", 32, 36], ["Anti-LBV", "SPECIES", 0, 8], ["pseudotype assays", "TEST", 58, 75], ["FAVN", "ANATOMY", 49, 53]]], ["However, the FAVN assay failed to detect anti-DUVV VNAb in serum 4 and 111 and only low levels in serum 3 (IC 100 = 8) compared to the pseudotype assay, which recorded IC 100 titres of 160, 8 and 28 for sera 3, 4 and 111, respectively ( Table 4 ).", [["serum", "ANATOMY", 59, 64], ["serum", "ANATOMY", 98, 103], ["sera", "ANATOMY", 203, 207], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["serum", "ORGANISM_SUBSTANCE", 98, 103], ["pseudotype", "ORGANISM", 135, 145], ["FAVN", "PROTEIN", 13, 17], ["anti-DUVV VNAb", "PROTEIN", 41, 55], ["anti-DUVV", "SPECIES", 41, 50], ["the FAVN assay", "TEST", 9, 23], ["anti-DUVV VNAb in serum", "TEST", 41, 64], ["serum", "TEST", 98, 103], ["IC", "TEST", 107, 109], ["the pseudotype assay", "TEST", 131, 151], ["IC", "TEST", 168, 170], ["sera", "TEST", 203, 207], ["low levels", "OBSERVATION_MODIFIER", 84, 94]]], ["The negative control and Australian bat lyssavirus (ABLV) sera did not achieve an IC 100 against any genotype, in either assay, and no cross-neutralisation of DUVV by the LBV sera was observed (Table 4 ).Utility of rabies (CVS-11) pseudotypes carrying the lacZ reporter geneTo broaden the lyssavirus pseudotype platform, we cloned the lacZ gene as a reporter.", [["sera", "ANATOMY", 58, 62], ["sera", "ANATOMY", 175, 179], ["DUVV", "CHEMICAL", 159, 163], ["rabies", "DISEASE", 215, 221], ["bat lyssavirus", "ORGANISM", 36, 50], ["ABLV", "ORGANISM", 52, 56], ["sera", "ORGANISM_SUBSTANCE", 58, 62], ["DUVV", "SIMPLE_CHEMICAL", 159, 163], ["LBV", "ORGANISM", 171, 174], ["sera", "ORGANISM_SUBSTANCE", 175, 179], ["rabies", "ORGANISM", 215, 221], ["CVS-11", "ORGANISM", 223, 229], ["pseudotypes", "ORGANISM", 231, 242], ["lacZ reporter gene", "GENE_OR_GENE_PRODUCT", 256, 274], ["lacZ", "GENE_OR_GENE_PRODUCT", 335, 339], ["lacZ reporter gene", "DNA", 256, 274], ["lacZ gene", "DNA", 335, 344], ["Australian bat lyssavirus", "SPECIES", 25, 50], ["ABLV", "SPECIES", 52, 56], ["DUVV", "SPECIES", 159, 163], ["LBV", "SPECIES", 171, 174], ["Australian bat lyssavirus", "TEST", 25, 50], ["an IC", "TEST", 79, 84], ["the LBV sera", "TEST", 167, 179], ["CVS", "TEST", 223, 226], ["pseudotypes", "TREATMENT", 231, 242], ["the lyssavirus pseudotype platform", "TREATMENT", 285, 319], ["negative", "OBSERVATION", 4, 12]]], ["Using a panel of 33 serum samples selected to contain low, medium and high VNAb titres, we ran parallel assays and determined that using lacZ as the reporter gene, instead of luciferase, did not alter the high correlation (r = 0.918, p < 0.001 [Pearson's product-moment correlation]; Fig. 4A ) or sensitivity and specificity with respect to the titres achieved using the FAVN assay.Utility of rabies (CVS-11) pseudotypes carrying the lacZ reporter geneWhile the flexibility to use different read-outs is a key requirement of any assay to be used in Africa, it must also be robust, able to withstand fluctuations in temperatures.", [["serum samples", "ANATOMY", 20, 33], ["rabies", "DISEASE", 393, 399], ["serum samples", "ORGANISM_SUBSTANCE", 20, 33], ["VNAb", "GENE_OR_GENE_PRODUCT", 75, 79], ["lacZ", "GENE_OR_GENE_PRODUCT", 137, 141], ["luciferase", "GENE_OR_GENE_PRODUCT", 175, 185], ["rabies", "ORGANISM", 393, 399], ["CVS-11", "ORGANISM", 401, 407], ["pseudotypes", "ORGANISM", 409, 420], ["lacZ reporter gene", "GENE_OR_GENE_PRODUCT", 434, 452], ["lacZ", "DNA", 137, 141], ["reporter gene", "DNA", 149, 162], ["luciferase", "PROTEIN", 175, 185], ["lacZ reporter gene", "DNA", 434, 452], ["a panel", "TEST", 6, 13], ["serum samples", "TEST", 20, 33], ["lacZ", "TREATMENT", 137, 141], ["p", "TEST", 234, 235], ["Pearson's product", "TEST", 245, 262], ["sensitivity", "TEST", 297, 308], ["specificity", "TEST", 313, 324], ["the titres", "TEST", 341, 351], ["the FAVN assay", "TEST", 367, 381], ["CVS", "TEST", 401, 404], ["pseudotypes", "TREATMENT", 409, 420], ["any assay", "TEST", 525, 534], ["low", "OBSERVATION_MODIFIER", 54, 57]]], ["Therefore, we tested the stability of the pseudotype stocks stored under different conditions.", [["pseudotype", "ORGANISM", 42, 52], ["the pseudotype stocks", "TREATMENT", 38, 59], ["pseudotype stocks", "OBSERVATION", 42, 59]]], ["Freeze-thaw cycles of CVS-11 pseudotypes revealed an average decrease of 3.7% in viral titre per cycle, while pseudotypes bearing the VSV or HIV-1 envelope proteins lost 2.6% and 9.2%, respectively (Fig. 4B) .", [["VSV", "ORGANISM", 134, 137], ["HIV-1", "ORGANISM", 141, 146], ["VSV or HIV-1 envelope proteins", "PROTEIN", 134, 164], ["HIV-1", "SPECIES", 141, 146], ["VSV", "SPECIES", 134, 137], ["HIV-1", "SPECIES", 141, 146], ["CVS", "TEST", 22, 25], ["pseudotypes", "TEST", 29, 40], ["viral titre", "TEST", 81, 92], ["pseudotypes bearing the VSV", "PROBLEM", 110, 137], ["HIV", "TEST", 141, 144], ["envelope proteins", "TEST", 147, 164], ["average", "OBSERVATION_MODIFIER", 53, 60], ["decrease", "OBSERVATION_MODIFIER", 61, 69]]], ["Compared to the CVS-11 pseudotype stock stored at \u221280 \u2022 C, aliquots stored at room temperature (average of 23 \u2022 C) had a half-life of 1-2 weeks, which increased to 2-4 weeks for aliquots at +4 \u2022 C. Pseudotypes stored at \u221220 \u2022 C were relatively stable for over 6 months (Fig. 4C) .", [["pseudotype", "ORGANISM", 23, 33], ["the CVS", "TEST", 12, 19], ["Pseudotypes", "TEST", 198, 209], ["stable", "OBSERVATION_MODIFIER", 244, 250]]], ["This stability was similar to that observed with RV 131 (DUVV) pseudotypes bearing the VSV envelope glycoprotein and was 7-fold greater than the half-life of pseudotypes bearing the HIV envelope glycoprotein stored at +4 \u2022 C or room temperature (data not shown).", [["VSV", "ORGANISM", 87, 90], ["pseudotypes", "ORGANISM", 158, 169], ["VSV envelope glycoprotein", "PROTEIN", 87, 112], ["HIV envelope glycoprotein", "PROTEIN", 182, 207], ["HIV", "SPECIES", 182, 185], ["VSV", "SPECIES", 87, 90], ["HIV", "SPECIES", 182, 185], ["RV", "TEST", 49, 51], ["pseudotypes bearing the VSV envelope glycoprotein", "PROBLEM", 63, 112], ["pseudotypes", "PROBLEM", 158, 169], ["the HIV envelope glycoprotein", "PROBLEM", 178, 207], ["room temperature", "TEST", 228, 244]]], ["The inclusion of lacZ as a reporter gene increased the applicability of our pseudotype system in resource-limited laboratories as it allows the determination of VNAb titres without the need for expensive regents or equipment.", [["lacZ", "GENE_OR_GENE_PRODUCT", 17, 21], ["VNAb", "GENE_OR_GENE_PRODUCT", 161, 165], ["lacZ", "DNA", 17, 21], ["reporter gene", "DNA", 27, 40], ["VNAb", "PROTEIN", 161, 165], ["The inclusion of lacZ", "TREATMENT", 0, 21], ["VNAb titres", "TREATMENT", 161, 172], ["expensive regents or equipment", "TREATMENT", 194, 224]]], ["Cells were infected with lacZbased pseudotypes and subsequently stained with one of three \u2424-gal substrates.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["\u2424-gal substrates", "PROTEIN", 90, 106], ["lacZbased pseudotypes", "PROBLEM", 25, 46]]], ["Punctate blue staining of infected cell nuclei was achieved in the presence of X-gal (Fig. 5 , far left panels).", [["cell nuclei", "ANATOMY", 35, 46], ["Punctate blue", "CHEMICAL", 0, 13], ["Punctate blue", "CHEMICAL", 0, 13], ["cell nuclei", "CELL", 35, 46], ["X-gal", "GENE_OR_GENE_PRODUCT", 79, 84], ["Punctate blue staining of infected cell nuclei", "PROBLEM", 0, 46], ["X-gal (Fig.", "TEST", 79, 90], ["blue staining", "OBSERVATION", 9, 22], ["infected cell nuclei", "OBSERVATION", 26, 46]]], ["We also adapted the assay to allow the \u2424-gal colorimetric substrates CPRG and ONPG to be used (Fig. 5 , second left and middle panels).", [["CPRG", "SIMPLE_CHEMICAL", 69, 73], ["ONPG", "SIMPLE_CHEMICAL", 78, 82], ["ONPG", "PROTEIN", 78, 82], ["the assay", "TEST", 16, 25], ["the \u2424-gal colorimetric substrates CPRG", "TREATMENT", 35, 73], ["ONPG", "TREATMENT", 78, 82], ["middle panels", "ANATOMY", 120, 133]]], ["These changes, and resulting VNAb titres, were recorded using a microplate reader, reading at 550 nm (CPRG) or 405 nm (ONPG), or simply by eye.", [["eye", "ANATOMY", 139, 142], ["VNAb", "GENE_OR_GENE_PRODUCT", 29, 33], ["eye", "ORGAN", 139, 142], ["resulting VNAb titres", "PROBLEM", 19, 40], ["a microplate reader", "TREATMENT", 62, 81], ["eye", "ANATOMY", 139, 142]]], ["The incorporation of lacZ is an additional option to the much used GFP and luciferase reporter genes, which allow a more high-throughput approach but at a far greater expense (Fig. 5 , second right and far right panels, respectively).DiscussionWhile mass culling of stray dogs has previously been shown to be ineffective in controlling the spread of rabies [33, 34] , this practice is once again being adopted by a number of countries.", [["rabies", "DISEASE", 350, 356], ["lacZ", "GENE_OR_GENE_PRODUCT", 21, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 67, 70], ["luciferase", "GENE_OR_GENE_PRODUCT", 75, 85], ["dogs", "ORGANISM", 272, 276], ["lacZ", "DNA", 21, 25], ["GFP and luciferase reporter genes", "DNA", 67, 100], ["dogs", "SPECIES", 272, 276], ["rabies", "SPECIES", 350, 356], ["lacZ", "TREATMENT", 21, 25], ["right", "ANATOMY_MODIFIER", 192, 197], ["right", "ANATOMY_MODIFIER", 206, 211]]], ["On the contrary, dog vaccination programs have been enormously successful in controlling canine rabies [35] [36] [37] , and improved diagnostics to enable rapid serosurveillance in countries undertaking these programs are therefore important.", [["rabies", "DISEASE", 96, 102], ["dog", "ORGANISM", 17, 20], ["canine", "ORGANISM", 89, 95], ["canine", "SPECIES", 89, 95], ["dog", "SPECIES", 17, 20], ["canine", "SPECIES", 89, 95], ["dog vaccination programs", "TREATMENT", 17, 41]]], ["The assay reported here offers a practical, effective and robust solution for rapid lyssavirus serosurveillance.", [["lyssavirus", "SPECIES", 84, 94], ["The assay", "TEST", 0, 9], ["rapid lyssavirus serosurveillance", "TREATMENT", 78, 111]]], ["Using lentiviral pseudotypes we can accurately measure the concentration of VNAbs and, coupled with the use of lacZ as the reporter gene for pseudotype particle production, removes the need for high containment laboratories and expensive equipment or reagents.", [["lentiviral", "ORGANISM", 6, 16], ["VNAbs", "GENE_OR_GENE_PRODUCT", 76, 81], ["lacZ", "GENE_OR_GENE_PRODUCT", 111, 115], ["VNAbs", "PROTEIN", 76, 81], ["lacZ", "DNA", 111, 115], ["reporter gene", "DNA", 123, 136], ["lentiviral pseudotypes", "TREATMENT", 6, 28], ["VNAbs", "TREATMENT", 76, 81], ["lacZ", "TREATMENT", 111, 115], ["pseudotype particle production", "PROBLEM", 141, 171], ["high containment laboratories", "TREATMENT", 194, 223], ["expensive equipment", "TREATMENT", 228, 247]]], ["This allows the assay to be undertaken in laboratories previously unable to use the existing FAVN.", [["FAVN", "CANCER", 93, 97], ["FAVN", "PROTEIN", 93, 97], ["the assay", "TEST", 12, 21], ["the existing FAVN", "TREATMENT", 80, 97]]], ["Furthermore, the assay is not just restricted to lyssavirus serosurveillance as other highly pathogenic viruses that have been pseudotyped could be incorporated into this platform [24, [38] [39] [40] [41] .DiscussionTo our knowledge this is the largest study published to date using pseudotypes in a diagnostic format for serosurveillance.", [["pseudotyped", "ORGANISM", 127, 138], ["[38] [39] [40", "SIMPLE_CHEMICAL", 185, 198], ["the assay", "TEST", 13, 22], ["lyssavirus serosurveillance", "TREATMENT", 49, 76], ["other highly pathogenic viruses", "PROBLEM", 80, 111], ["pseudotyped", "PROBLEM", 127, 138], ["pseudotypes", "PROBLEM", 283, 294]]], ["Of the 319 samples received, titres for three could not be determined using the pseudotype assay: one had low level contamination and two caused cellular cytotoxicity in the assay.", [["samples", "ANATOMY", 11, 18], ["cellular", "ANATOMY", 145, 153], ["samples", "CANCER", 11, 18], ["cellular", "CELL", 145, 153], ["titres", "TREATMENT", 29, 35], ["the pseudotype assay", "TEST", 76, 96], ["low level contamination", "PROBLEM", 106, 129], ["cellular cytotoxicity in the assay", "PROBLEM", 145, 179], ["cellular cytotoxicity", "OBSERVATION", 145, 166]]], ["These issues were overcome using higher concentrations of antibiotics and increasing the number of BHK cells used 2-fold, to 2 \u00d7 10 4 per assay.", [["BHK cells", "ANATOMY", 99, 108], ["BHK cells", "CELL", 99, 108], ["BHK cells", "CELL_LINE", 99, 108], ["higher concentrations of antibiotics", "TREATMENT", 33, 69], ["BHK cells", "TREATMENT", 99, 108]]], ["In comparison, there were 12 samples that could not be titrated with the FAVN assay because of insufficient serum volume.", [["samples", "ANATOMY", 29, 36], ["serum", "ANATOMY", 108, 113], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["the FAVN assay", "TEST", 69, 83], ["insufficient serum volume", "PROBLEM", 95, 120]]], ["While serum volume varied between samples, there was sufficient volume for each sample to run duplicate pseudotype neutralisation assays.", [["serum", "ANATOMY", 6, 11], ["samples", "ANATOMY", 34, 41], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["serum volume", "TEST", 6, 18], ["samples", "TEST", 34, 41], ["pseudotype neutralisation assays", "TEST", 104, 136], ["pseudotype neutralisation", "OBSERVATION", 104, 129]]], ["This highlights another major advantage of using pseudotypes as surrogate viruses in neutralisation assays, only small serum vol- Fig. 5 .", [["serum", "ANATOMY", 119, 124], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["pseudotypes", "TREATMENT", 49, 60], ["neutralisation assays", "TEST", 85, 106], ["small serum vol", "TEST", 113, 128], ["small", "OBSERVATION_MODIFIER", 113, 118]]], ["Repertoire of reporter genes that can be carried within pseudotypes.", [["reporter genes", "DNA", 14, 28]]], ["We have expanded the range of reporter genes to enable the neutralisation assay to be performed in a much greater number of laboratories than previously possible.", [["reporter genes", "DNA", 30, 44], ["the neutralisation assay", "TEST", 55, 79]]], ["LacZ-based pseudotypes can be detected with X-gal, CPRG or ONPG \u2424-gal substrates that turn blue, red or yellow in the presence of the enzyme, respectively.", [["LacZ", "GENE_OR_GENE_PRODUCT", 0, 4], ["X-gal", "GENE_OR_GENE_PRODUCT", 44, 49], ["CPRG", "SIMPLE_CHEMICAL", 51, 55], ["ONPG \u2424-gal", "GENE_OR_GENE_PRODUCT", 59, 69], ["LacZ", "PROTEIN", 0, 4], ["X-gal, CPRG or ONPG \u2424-gal substrates", "DNA", 44, 80], ["enzyme", "PROTEIN", 134, 140], ["LacZ-based pseudotypes", "PROBLEM", 0, 22], ["CPRG", "TREATMENT", 51, 55], ["ONPG \u2424-gal substrates", "TREATMENT", 59, 80], ["the enzyme", "TEST", 130, 140], ["pseudotypes", "OBSERVATION", 11, 22]]], ["GFP appears as green cytoplasmic staining while the oxidation of the luciferase substrate results in light emission that can be detected in a luminometer.Discussion[VNAb]: virus-neutralising antibody concentration.", [["cytoplasmic", "ANATOMY", 21, 32], ["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytoplasmic", "ORGANISM_SUBSTANCE", 21, 32], ["luciferase", "GENE_OR_GENE_PRODUCT", 69, 79], ["virus-", "ORGANISM", 172, 178], ["GFP", "PROTEIN", 0, 3], ["luciferase substrate", "PROTEIN", 69, 89], ["GFP", "TEST", 0, 3], ["green cytoplasmic staining", "PROBLEM", 15, 41], ["the luciferase substrate", "TEST", 65, 89], ["virus-neutralising antibody concentration", "TREATMENT", 172, 213], ["green cytoplasmic staining", "OBSERVATION", 15, 41]]], ["The arrow indicates zero luciferase activity. umes (5-10-fold less than live virus assays) are required for each assay.DiscussionAn additional important benefit of pseudotypes is the flexibility to choose the reporter gene depending on the operator's requirements.", [["luciferase", "GENE_OR_GENE_PRODUCT", 25, 35], ["luciferase", "PROTEIN", 25, 35], ["reporter gene", "DNA", 209, 222], ["zero luciferase activity", "PROBLEM", 20, 44], ["umes", "TEST", 46, 50], ["pseudotypes", "TREATMENT", 164, 175], ["zero", "OBSERVATION", 20, 24], ["luciferase activity", "OBSERVATION", 25, 44]]], ["For this study, luciferase-based CVS-11 pseudotypes were used, which allowed high-throughput screening of the samples.", [["samples", "ANATOMY", 110, 117], ["luciferase", "GENE_OR_GENE_PRODUCT", 16, 26], ["pseudotypes", "ORGANISM", 40, 51], ["luciferase", "PROTEIN", 16, 26], ["this study", "TEST", 4, 14], ["luciferase", "TEST", 16, 26], ["CVS", "TEST", 33, 36], ["pseudotypes", "PROBLEM", 40, 51], ["the samples", "TEST", 106, 117]]], ["This permitted many plates to be analysed in a short period, however, both the luciferase reagent and the plate reader are expensive.", [["luciferase", "GENE_OR_GENE_PRODUCT", 79, 89], ["luciferase", "PROTEIN", 79, 89], ["many plates", "TREATMENT", 15, 26], ["the luciferase reagent", "TREATMENT", 75, 97]]], ["In contrast, the reagent for the lacZ reporter system is over 30 times less expensive than that for luciferase and 3 times less expensive than the fluorescein isothiocyanate conjugate used in the FAVN assay.", [["fluorescein isothiocyanate", "CHEMICAL", 147, 173], ["fluorescein isothiocyanate", "CHEMICAL", 147, 173], ["lacZ", "GENE_OR_GENE_PRODUCT", 33, 37], ["luciferase", "GENE_OR_GENE_PRODUCT", 100, 110], ["fluorescein isothiocyanate conjugate", "SIMPLE_CHEMICAL", 147, 183], ["luciferase", "PROTEIN", 100, 110], ["the lacZ reporter system", "TREATMENT", 29, 53], ["luciferase", "TEST", 100, 110], ["the fluorescein isothiocyanate conjugate", "TREATMENT", 143, 183]]], ["Additionally, as neutralisation assays using pseudotypes are safer, not requiring BSL3/SAPO 4 facilities, the overall cost of using them is many fold lower compared to performing the FAVN assay, thereby allowing expansion of rabies serosurveillance in resourcelimited laboratories.", [["pseudotypes", "ORGANISM", 45, 56], ["rabies", "ORGANISM", 225, 231], ["rabies", "SPECIES", 225, 231], ["neutralisation assays", "TEST", 17, 38], ["pseudotypes", "PROBLEM", 45, 56], ["BSL3/SAPO", "TREATMENT", 82, 91], ["many fold lower", "PROBLEM", 140, 155], ["the FAVN assay", "TEST", 179, 193]]], ["In addition, since pseudotypes carrying the lacZ reporter can be detected using X-gal, CPRG or ONPG, the flexibility of the assay is further increased.", [["lacZ", "GENE_OR_GENE_PRODUCT", 44, 48], ["X-gal", "GENE_OR_GENE_PRODUCT", 80, 85], ["CPRG", "GENE_OR_GENE_PRODUCT", 87, 91], ["ONPG", "GENE_OR_GENE_PRODUCT", 95, 99], ["lacZ reporter", "DNA", 44, 57], ["X-gal", "DNA", 80, 85], ["CPRG", "DNA", 87, 91], ["ONPG", "DNA", 95, 99], ["pseudotypes", "PROBLEM", 19, 30], ["CPRG", "TREATMENT", 87, 91], ["ONPG", "TREATMENT", 95, 99], ["the assay", "TEST", 120, 129], ["increased", "OBSERVATION_MODIFIER", 141, 150]]], ["With colorimetric substrates it is possible to record VNAb titres by simply looking at the assay plate and recording the colour change.", [["VNAb", "SIMPLE_CHEMICAL", 54, 58], ["VNAb", "PROTEIN", 54, 58], ["colorimetric substrates", "TREATMENT", 5, 28]]], ["Neutralisation assays using pseudotypes with lacZ as the reporter can also be used for semi-high-throughput screening when using an ELI-SPOT (X-gal staining) or microplate reader (CPRG and ONPG staining).", [["lacZ", "GENE_OR_GENE_PRODUCT", 45, 49], ["X-gal", "GENE_OR_GENE_PRODUCT", 142, 147], ["lacZ", "DNA", 45, 49], ["Neutralisation assays", "TEST", 0, 21], ["pseudotypes with lacZ", "TREATMENT", 28, 49], ["an ELI-SPOT (X-gal staining", "TEST", 129, 156], ["microplate reader (CPRG and ONPG staining", "TREATMENT", 161, 202]]], ["However, the flexibility offered by packaging lacZ, GFP or luciferase into the pseudotype particle alone makes this assay an attractive option for use in any laboratory undertaking lyssavirus serosurveillance.DiscussionThe stability of pseudotypes reported here also makes this assay suitable for use in countries where the infrastructure and coldchain may be unreliable.", [["lacZ", "GENE_OR_GENE_PRODUCT", 46, 50], ["GFP", "GENE_OR_GENE_PRODUCT", 52, 55], ["luciferase", "GENE_OR_GENE_PRODUCT", 59, 69], ["pseudotypes", "ORGANISM", 236, 247], ["packaging lacZ", "DNA", 36, 50], ["GFP", "DNA", 52, 55], ["luciferase", "PROTEIN", 59, 69], ["lyssavirus", "SPECIES", 181, 191], ["packaging lacZ", "TREATMENT", 36, 50], ["the pseudotype particle", "TREATMENT", 75, 98], ["pseudotypes", "PROBLEM", 236, 247], ["this assay", "TEST", 273, 283], ["pseudotype particle", "OBSERVATION", 79, 98]]], ["If the stocks of pseudotype particles were to be thawed and re-frozen or to be stored at temperatures below \u221280 \u2022 C, they would still be viable for use in subsequent neutralisation assays.", [["pseudotype", "ORGANISM", 17, 27], ["pseudotype particles", "PROBLEM", 17, 37], ["subsequent neutralisation assays", "TEST", 155, 187]]], ["This is a major advantage over live virus, where the virus titre decreases rapidly on freeze-thaw or storage above \u221280 \u2022 C. However, where possible stocks of pseudotypes should be maintained at \u221280 \u2022 C and stored in aliquots to reduce the number of times each vial is thawed.", [["live virus", "ORGANISM", 31, 41], ["pseudotypes", "ORGANISM", 158, 169], ["live virus", "PROBLEM", 31, 41], ["the virus titre", "PROBLEM", 49, 64], ["stocks of pseudotypes", "PROBLEM", 148, 169], ["decreases", "OBSERVATION_MODIFIER", 65, 74], ["rapidly", "OBSERVATION_MODIFIER", 75, 82]]], ["A future consideration is to freeze dry the pseudotype particles to avoid cold-chain storage and to increase ease of transport.DiscussionThe number of inadequate versus adequate vaccine responders, detected by both types of assays, was comparable at either visit for collection of serum.", [["serum", "ANATOMY", 281, 286], ["pseudotype", "ORGANISM", 44, 54], ["serum", "ORGANISM_SUBSTANCE", 281, 286], ["the pseudotype particles", "TREATMENT", 40, 64], ["cold-chain storage", "PROBLEM", 74, 92], ["assays", "TEST", 224, 230], ["collection of serum", "TEST", 267, 286]]], ["However, 17 discordant results were observed between the pseudotype and FAVN assays, which can partially be explained by the fact that they were all close to the 0.5 IU/ml threshold.", [["pseudotype", "ORGANISM", 57, 67], ["the pseudotype and FAVN assays", "PROBLEM", 53, 83]]], ["Assay variability with the FAVN assay means that samples scoring 0.5 IU/ml had a variable range of 0.38-0.66 IU/ml if the test was repeated.", [["samples", "ANATOMY", 49, 56], ["Assay variability", "TEST", 0, 17], ["the FAVN assay", "TEST", 23, 37], ["the test", "TEST", 118, 126]]], ["Twelve out of these 17 samples that had a 0.5 IU/ml titre in the FAVN assay might have been classified as negative if re-tested, which would result in a new sensitiv-ity score of 98.3%.", [["samples", "ANATOMY", 23, 30], ["samples", "CANCER", 23, 30], ["a 0.5 IU/ml titre", "TREATMENT", 40, 57], ["the FAVN assay", "TEST", 61, 75], ["a new sensitiv-ity score", "PROBLEM", 151, 175]]], ["Conversely, it is also possible that the scores of 0.38-0.66 IU/ml obtained with the FAVN assay and the corresponding titres achieved using the pseudotype assay could change if re-tested.", [["the scores", "TEST", 37, 47], ["the FAVN assay", "TEST", 81, 95], ["the corresponding titres", "TREATMENT", 100, 124], ["the pseudotype assay", "TREATMENT", 140, 160]]], ["It is worth noting the 17 dogs that were classified as having inadequate VNAb responses using the pseudotype assay, in disagreement with the FAVN results, were sampled before vaccination in this trial.", [["dogs", "ORGANISM", 26, 30], ["VNAb", "GENE_OR_GENE_PRODUCT", 73, 77], ["dogs", "SPECIES", 26, 30], ["the pseudotype assay", "TEST", 94, 114], ["vaccination", "TREATMENT", 175, 186]]], ["In addition, 10 out of the 17 samples were from dogs with no history of previous rabies vaccination and 6 had been vaccinated \u22651 year before the study began, therefore their levels of VNAbs could have decreased over time.", [["samples", "ANATOMY", 30, 37], ["rabies", "DISEASE", 81, 87], ["samples", "CANCER", 30, 37], ["dogs", "ORGANISM", 48, 52], ["rabies", "ORGANISM", 81, 87], ["VNAbs", "GENE_OR_GENE_PRODUCT", 184, 189], ["VNAbs", "PROTEIN", 184, 189], ["dogs", "SPECIES", 48, 52], ["rabies", "SPECIES", 81, 87], ["previous rabies vaccination", "TREATMENT", 72, 99], ["the study", "TEST", 141, 150], ["decreased", "OBSERVATION_MODIFIER", 201, 210]]], ["These discordant results coupled with neutralisation data showing DUVV pseudotypes can detect VNAb in anti-DUVV serum not detected by the FAVN assay suggests that the pseudotype assay may be more specific and sensitive for detection of seroconversion than the FAVN assay when a 0.5 IU/ml cut-off is used.", [["serum", "ANATOMY", 112, 117], ["DUVV pseudotypes", "ORGANISM", 66, 82], ["VNAb", "GENE_OR_GENE_PRODUCT", 94, 98], ["anti-DUVV", "ORGANISM_SUBSTANCE", 102, 111], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["pseudotype", "ORGANISM", 167, 177], ["VNAb", "PROTEIN", 94, 98], ["DUVV", "SPECIES", 66, 70], ["anti-DUVV", "SPECIES", 102, 111], ["neutralisation data", "TEST", 38, 57], ["DUVV pseudotypes", "PROBLEM", 66, 82], ["VNAb in anti-DUVV serum", "TEST", 94, 117], ["the FAVN assay", "TEST", 134, 148], ["the pseudotype assay", "TEST", 163, 183], ["seroconversion", "PROBLEM", 236, 250], ["the FAVN assay", "TEST", 256, 270], ["a 0.5 IU/ml cut", "TREATMENT", 276, 291]]], ["However, to confirm this observation further studies are required using analogous viral isolates and serum, and larger sample sizes.DiscussionThe introduction of the LBV, MOKV and DUVV G as binding antigens into our pseudotype platform, coupled with existing CVS-11, EBLV-1 and EBLV-2 pseudotypes, means that serum can now be screened to detect VNAbs against six different lyssavirus genotypes.", [["serum", "ANATOMY", 101, 106], ["sample", "ANATOMY", 119, 125], ["serum", "ANATOMY", 309, 314], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["MOKV", "SIMPLE_CHEMICAL", 171, 175], ["DUVV G", "GENE_OR_GENE_PRODUCT", 180, 186], ["EBLV-1", "ORGANISM", 267, 273], ["EBLV-2 pseudotypes", "ORGANISM", 278, 296], ["serum", "ORGANISM_SUBSTANCE", 309, 314], ["VNAbs", "GENE_OR_GENE_PRODUCT", 345, 350], ["LBV", "PROTEIN", 166, 169], ["MOKV", "PROTEIN", 171, 175], ["DUVV G", "PROTEIN", 180, 186], ["binding antigens", "PROTEIN", 190, 206], ["VNAbs", "PROTEIN", 345, 350], ["this observation further studies", "TEST", 20, 52], ["analogous viral isolates", "TEST", 72, 96], ["serum", "TEST", 101, 106], ["the LBV", "TEST", 162, 169], ["our pseudotype platform", "TEST", 212, 235], ["CVS", "TEST", 259, 262], ["EBLV", "TEST", 267, 271], ["EBLV", "TEST", 278, 282], ["pseudotypes", "PROBLEM", 285, 296], ["serum", "TEST", 309, 314], ["VNAbs", "TEST", 345, 350], ["six different lyssavirus genotypes", "PROBLEM", 359, 393], ["larger", "OBSERVATION_MODIFIER", 112, 118], ["sizes", "OBSERVATION_MODIFIER", 126, 131]]], ["This is of particular importance because large proportions of these assays are performed on sera from bats, from which only small volumes of serum are available.DiscussionAt a time when emerging infectious disease outbreaks are becoming more frequent and have the potential to spread faster through international travel, technological advances in infectious disease research are making assays more rapid facilitating more automation.", [["sera", "ANATOMY", 92, 96], ["serum", "ANATOMY", 141, 146], ["infectious disease", "DISEASE", 195, 213], ["infectious disease", "DISEASE", 347, 365], ["sera", "ORGANISM_SUBSTANCE", 92, 96], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["these assays", "TEST", 62, 74], ["emerging infectious disease outbreaks", "PROBLEM", 186, 223], ["small", "OBSERVATION_MODIFIER", 124, 129], ["infectious", "OBSERVATION", 195, 205]]], ["However, countries where the outbreaks are most likely to occur are often unable to utilise these new techniques.", [["most likely", "UNCERTAINTY", 43, 54]]], ["We have addressed these limitations by developing an assay that can be used for infectious disease serosurveillance and for monitoring vaccine responses within low-containment laboratories.", [["an assay", "TEST", 50, 58], ["infectious disease serosurveillance", "TREATMENT", 80, 115], ["monitoring vaccine responses", "TEST", 124, 152]]], ["Neutralisation assays based on pseudotypes as a source of target antigen are a useful platform to use at the start of a new outbreak, not only for rabies, but also other enveloped RNA viruses such as SARS coronaviruses, influenza and Ebola viruses.", [["rabies", "DISEASE", 147, 153], ["SARS coronaviruses", "DISEASE", 200, 218], ["influenza and Ebola viruses", "DISEASE", 220, 247], ["SARS coronaviruses", "ORGANISM", 200, 218], ["Ebola viruses", "ORGANISM", 234, 247], ["Ebola", "SPECIES", 234, 239], ["rabies", "SPECIES", 147, 153], ["SARS coronaviruses", "SPECIES", 200, 218], ["Ebola viruses", "SPECIES", 234, 247], ["Neutralisation assays", "TEST", 0, 21], ["pseudotypes", "PROBLEM", 31, 42], ["target antigen", "PROBLEM", 58, 72], ["rabies", "PROBLEM", 147, 153], ["RNA viruses", "PROBLEM", 180, 191], ["SARS coronaviruses", "PROBLEM", 200, 218], ["influenza", "PROBLEM", 220, 229], ["Ebola viruses", "PROBLEM", 234, 247], ["Ebola viruses", "OBSERVATION", 234, 247]]], ["Incorporating the lyssaviral envelope protein (G) into the pseudotype platform creates an assay that allows rapid screening and vaccine evaluation to be performed within weeks of the start of an epidemic.", [["lyssaviral envelope protein", "PROTEIN", 18, 45], ["the lyssaviral envelope protein", "TREATMENT", 14, 45], ["rapid screening", "TEST", 108, 123], ["vaccine evaluation", "TEST", 128, 146]]]], "00a172302a68e534862468c0d37c4991dc16f57b": [["However, the COVID-19 global pandemic makes the content of this book more relevant than ever today.", [["the COVID", "TEST", 9, 18]]], ["Readers of this book will be introduced to research into the sociopolitical nature of mathematics education and the role of mathematics education research in promoting equity and social justice in the field.", [["mathematics education", "TREATMENT", 86, 107]]]]}